Early Recognition of Spondyloarthritis in Patients at Risk by Karreman, M.C. (Maren)


Early	Recognition	of	Spondyloarthritis	in	
Patients	at	Risk	
	
	
	
	
	
	
M.C.	Karreman	 	
Early	recognition	of	Spondyloarthritis	in	Patients	at	Risk	
	
	
	
Vroegherkenning	van	spondyloartritis	in	patiënten	met	een	
verhoogd	risico	
	
	
	
Proefschrift	
	
	
ter	verkrijging	van	de	graad	van	doctor	aan	de	
Erasmus	Universiteit	Rotterdam	
op	gezag	van	de	
rector	magnificus	
	
	
prof.dr.	R.C.M.E.	Engels	
	
	
en	volgens	besluit	van	het	College	voor	Promoties.	
De	openbare	verdediging	zal	plaatsvinden	op		
	
	
12-09-2018	om	15.30uur	
	
	
Maren	Charlotte	Karreman	
geboren	te	Rotterdam		
	
	
	
	
	
	
	
	
	
	
Colofon
ISBN   978-94-6332-389-5   
Cover design & Lay-out: Loes Kema, GVO drukkers & vormgevers
Printed by:  GVO drukkers & vormgevers B.V., Ede, the Netherlands
Copyright © 2018 Maren Karreman
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system 
or transmitted in any form or by any means without prior permission of the author.
Financial support for the publication of this thesis was kindly provided by the Erasmus 
University Medical Center Rotterdam, Maasstad Hospital Rotterdam, Dutch arthritis 
foundation, TDIOR B.V.,  Chipsoft B.V., Pfizer B.V., UCB Pharma B.V. & Sobi B.V.
Early	recognition	of	Spondyloarthritis	in	Patients	at	Risk	
	
	
	
Vroegherkenning	van	spondyloartritis	in	patiënten	met	een	
verhoogd	risico	
	
	
	
Proefschrift	
	
	
ter	verkrijging	van	de	graad	van	doctor	aan	de	
Erasmus	Universiteit	Rotterdam	
op	gezag	van	de	
rector	magnificus	
	
	
prof.dr.	R.C.M.E.	Engels	
	
	
en	volgens	besluit	van	het	College	voor	Promoties.	
De	openbare	verdediging	zal	plaatsvinden	op		
	
	
12-09-2018	om	15.30uur	
	
	
Maren	Charlotte	Karreman	
geboren	te	Rotterdam		
	
	
	
	
	
	
	
	
	
	
Promotiecommissie:	
	
Promotor:	 	 Prof.	dr.	J.M.W.	Hazes	
	
Overige	leden:	 	 Prof.	P.J.E.	Bindels	
Dr.	I.E.	van	der	Horst-Bruinsma	
Prof.	E.P.	Prens	
	
Co-promotoren:	 Dr.	J.J.	Luime	
Dr.	A.E.A.M.	Weel	
	
	
	 	
Promotiecommissie:	
	
Promotor:	 	 Prof.	dr.	J.M.W.	Hazes	
	
Overige	leden:	 	 Prof.	P.J.E.	Bindels	
Dr.	I.E.	van	der	Horst-Bruinsma	
Prof.	E.P.	Prens	
	
Co-promotoren:	 Dr.	J.J.	Luime	
Dr.	A.E.A.M.	Weel	
	
	
	 	
Contents	
	
Chapter	1.		 	 General	Introduction	
	
Part	I.	Prevalence	and	Burden	of	Spondyloarthritis	in	Patients	at	Risk	
	
Chapter	2.		 	 Prevalence	of	Psoriatic	Arthritis	in	Primary	Care	Patients	with	Psoriasis	
	
Chapter	3.	 Adding	Ultrasound	to	Clinical	Examination	reduced	Frequency	of	Enthesitis	in	
Primary	Care	Psoriasis	Patients	with	Musculoskeletal	Complaints	
	
Chapter	4.	 The	Prevalence	and	Incidence	of	Axial	and	Peripheral	Spondyloarthritis	in	
Inflammatory	Bowel	Disease:	A	Systematic	Review	and	Meta-Analysis	
	
Chapter	5.	 Musculoskeletal	Complaints	cause	Significant	Burden	in	Patients	with	
Inflammatory	Bowel	Disease:	A	Survey	among	Patients	
	
Part	II.	Awareness	and	Early	Recognition	of	Spondyloarthritis	in	Patients	at	Risk	
	
Chapter	6.		 Awareness	of	Spondyloarthritis	in	General	Practitioners	and	their	Patients:	A	
Cross-sectional	Survey	in	Primary	Care	
	
Chapter	7.	 Performance	of	Screeningtools	for	Psoriatic	Arthritis:	A	Cross-sectional	Study	
in	Primary	Care	
	
Chapter	8.		 Which	Tool	to	use	when	screening	for	Psoriatic	Arthritis	in	Psoriasis	Patients	
in	a	Primary	Care	Setting?	
	
Part	III.	General	Discussion,	Summary	&	Addendum	
	
Chapter	9.		 General	Discussion	
	
Chapter	10.	 Summary	
	 Nederlandse	Samenvatting	
	
Addendum	 About	the	Author	
	 PhD	Portfolio	
	 List	of	Publications	
	 Dankwoord	
	 	
7
27
43
57
91
111
125
141
155
169
179
25
109
153

Chapter 1.
General Introduction
Spondyloarthritis	
Spondyloarthritis	(SpA)	is	an	umbrella	term	for	a	group	of	inflammatory	rheumatic	diseases	with	signs	
and	symptoms	that	have	an	overlapping	genetic	and	pathophysiologic	etiology.1		
	
SpA	can	manifest	itself	through	pain	and	stiffness	of	the	joints,	tendons	and	/or	lower	back.	Due	to	
inflammation	of	the	axial	skeleton,	peripheral	joints	or	entheses	the	main	clinical	manifestations	are	
respectively	sacroiliitis,	arthritis,	dactylitis	and/or	enthesitis.		But	also	extra-articular	manifestations	
like	uveitis,	psoriasis	and	inflammatory	bowel	disease	(IBD)	can	occur.	Multiple	combinations	of	these	
features	are	possible,	leading	to	a	wide	range	of	different	phenotypes	of	SpA.	
	
Van	Tubergen,	nat	rev	rheum	2015	
	
SpA	can	be	considered	a	condition	in	itself,	but	in	practice	several	subtypes	are	used	like	ankylosing	
spondylitis	 (AS),	non-radiographic	axial	 SpA	 (nr-axSpA),	psoriatic	 arthritis	 (PsA),	 SpA	 related	 to	 IBD	
(IBD-SpA),	reactive	arthritis	(ReA)	and	undifferentiated	SpA	(uSpA).2	Until	the	1950s	it	was	believed	
that	 there	was	no	distinction	between	the	different	 types	of	arthritis	 like	 rheumatoid	arthritis	and	
spondyloarthritis.	Afterwards,	 the	discussion	started	 that	SpA	may	be	an	entirely	different	disease	
than	rheumatoid	arthritis.	In	1976,	Moll	&	Wright	were	the	first	to	describe	the	unified	concept	of	SpA	
characterized	 as	 seronegative	 arthritides,	 with	 overlapping	 clinical,	 serological	 and	 radiological	
features.3		After	the	concept	of	SpA	was	established,	the	development	of	classification	criteria	started.	
Many	 different	 sets	 of	 classification	 criteria	 for	 the	 different	 subtypes	 (i.e.	 ankylosing	 spondylitis,	
psoriatic	arthritis)	were	developed	over	the	years.	For	SpA	in	general	the	AMOR	criteria	were	set	up	
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in	1990,	 followed	by	 the	ESSG	criteria	 in	1991.4,5	The	AMOR	criteria	consist	of	a	 scoring	system	of	
different	signs	and	symptoms	of	SpA,	which	can	contribute	either	1,	2	or	3	points	to	the	required	6	for	
classifying	 SpA.4	 To	 fulfil	 the	 ESSG	 criteria	 a	 patient	 must	 have	 inflammatory	 back	 pain	 and/or	
peripheral	arthritis,	 in	combination	with	one	other	SpA	feature.5	These	criteria	seemed	to	perform	
reasonable	in	different	cohorts,	but	the	main	problem	was	the	low	sensitivity	for	early	SpA.	In	addition,	
no	 distinction	 is	 made	 between	 axial	 or	 peripheral	 manifestations,	 which	 is	 important	 as	 these	
different	manifestations	have	different	epidemiology,	symptoms	and	treatment	options.	Recently,	the	
ASAS	(Assessment	of	SpondyloArthritis	international	Society)	group	proposed	another	classification	of	
SpA.	These	criteria	do	not	look	at	the	different	subtypes	of	SpA,	but	focus	on	the	predominant	clinical	
manifestation,	which	 can	 be	 either	 axial	 or	 peripheral.6,7	 Besides	 inflammatory	 axial	 or	 peripheral	
symptoms,	patients	must	have	other	SpA	features	to	classify	as	having	SpA.		
	
Ethiopathogenesis	
The	prevalence	of	SpA	has	been	widely	studied	and	the	reported	prevalences	in	the	general	population	
range	from	0.2%	in	South-East	Asia	to	1.61%	in	Northern	Arctic	communities	as	demonstrated	in	a	
recent	meta-analysis.8	The	prevalence	of	SpA	is	hereby	comparable	with	the	prevalence	of	rheumatoid	
arthritis.	The	prevalence	of	SpA	is	strongly	dependent	on	the	prevalence	of	HLA-B27	across	the	world,	
which	partly	explains	the	spread	in	prevalence.	Besides	this	important	etiological	factor,	several	other	
factors	like	study	design,	population	selection	and	the	use	of	different	classification	criteria	also	play	
an	important	role	in	the	spread	in	prevalence.	
	
The	pathophysiology	of	SpA	is	complex	and	has	not	yet	been	fully	revealed.	Although	SpA	can	manifest	
in	multiple	forms,	the	genetics	and	pathogenesis	overlap	to	a	greater	or	lesser	extent.9			
Multiple	factors	are	likely	relevant	in	the	development	of	SpA,	among	which	environmental	factors	
and	genetic	factors.	These	genetic	factors	contribute	to	a	great	extent	to	the	hereditability	of	SpA,	
with	 studies	 showing	 contribution	 of	 these	 genetic	 factors	 of	 up	 to	 90%	 of	 the	 susceptibility	 to	
ankylosing	spondylitis.10		The	most	well-known	and	important	genetic	factor	in	SpA	is	HLA-B27.9	The	
presence	of	HLA-B27	differs	across	the	world	and	therefore	partly	explains	the	geographic	variation	in	
SpA	prevalence.8	The	link	between	SpA	and	HLA-B27	is	strongest	in	axial	SpA,	demonstrated	by	the	
fact	that	approximately	80-90%	of	Northern	European	patients	with	axial	SpA	are	HLA-B27	positive.	
The	other	way	around,	if	a	patient	is	HLA-B27	positive	the	risk	of	developing	SpA	is	approximately	5-
7%,	HLA-B27	is	therefore	included	in	the	ASAS	classification	criteria	as	well	as	in	several	referral	tools	
for	axial	SpA.11-14	However,	the	prevalence	of	HLA-B27	is	 lower	in	patients	with	early	axial	SpA	and	
decreases	towards	20%	in	psoriasis	patients	with	peripheral	arthritis.		Besides	HLA-B27,	several	other	
potential	genetic	determinants	have	been	identified,	such	as	IL23R,	IL1A,	IL1R2	and	ERAP1.15	However,	
the	contribution	of	these	factors	seems	to	be	low	and	the	evidence	is	still	scarce.	
Another	well-established	important	factor	in	the	pathogenesis	of	SpA	is	Tumor	Necrosis	Factor	(TNF).	
TNF-α	plays	a	role	in	the	development	of	synovitis,	but	also	in	extra-articular	manifestations	like	gut	
inflammation	and	psoriasis.	16-18	Over	the	last	years,	knowledge	about	the	role	of	interleukin-23	(IL-
23)	en	interleukin-17	(IL-17)	has	exponentially	increased.	18	IL-23,	which	is	produced	by	dendritic	cells	
and	macrophages,	induces	amongst	others	the	production	of	IL-17	and	IL-22.These	two	cytokines	are	
physiologically	 important	for	gut	homeostasis,	but	have	a	pathological	role	in	the	joint.	 It	has	been	
demonstrated	 that	 the	 link	between	SpA	and	gut	 inflammation	works	both	ways.	Multiple	 studies	
have	demonstrated	the	presence	of	microscopic	gut	inflammation	in	patients	with	SpA.	The	other	way	
around	it	also	seems	that	the	gut	has	an	important	role	in	the	etiopathogenesis	of	SpA.17IL-17	and	IL-
22	are	also	important	in	the	development	of	enthesitis	and	osteoproliferation.17,18			
	
Risk	Groups	
As	mentioned	earlier,	SpA	can	manifest	with	musculoskeletal	complaints,	like	inflammatory	back	pain	
or	arthritis.	However,	in	some	patients	skin	(i.e.	psoriasis)	or	bowel	(i.e.	IBD)	symptoms	occur	before	
the	onset	of	musculoskeletal	complaints.	These	groups	of	patients	are	therefore	at	risk	of	developing	
certain	subtypes	of	SpA;	namely	psoriatic	arthritis	(PsA)	in	patients	with	psoriasis	and	IBD-associated	
SpA	in	patients	with	IBD.	These	subgroups	of	patients	at	risk	are	the	focus	of	this	thesis	and	will	be	
described	separately.	
	
Psoriasis	and	Psoriatic	Arthritis	
Clinical	Manifestations	
Psoriasis	 is	a	chronic	 immune-mediated	disease	of	 the	skin,	 leading	to	characteristic	erythematous	
plaques.19	It	affects	men	and	women	equally	and	can	occur	at	any	age	with	peak	incidence	between	
20-30	 years	 of	 age	 and	 50-60	 years	 of	 age.20	 Psoriasis	 can	 be	 accompanied	 by	 a	 number	 of	
comorbidities,	 including	cardiovascular	disease,	depression	and	as	described	 in	this	 thesis	psoriatic	
arthritis	 (PsA).21	 In	 most	 cases,	 psoriasis	 precedes	 the	 development	 of	 PsA	 by	 approximately	 12	
years.16		
PsA	affects	men	and	woman	equally	and	typically	presents	between	30	and	50	years	of	age.22	It	can	
manifest	with	peripheral	arthritis,	but	also	with	enthesitis	or	sacroiliitis.16,22	Peripheral	arthritis	usually	
occurs	 in	 an	 asymmetrical	 distribution	 and	mostly	 in	 the	 larger	 joints,	 but	 there	 is	 also	 a	 subtype	
mimicking	 rheumatoid	 arthritis	 with	 polyarthritis	 of	 the	 small	 joints.22	 Enthesitis,	 defined	 as	 an	
inflammation	of	the	insertion	of	the	tendon	to	the	bone,	can	occur	at	any	site	were	tendons	attach	to	
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the	bone,	but	 the	most	known	 location	 is	 the	Achilles	 tendon.	Another	subtype	of	PsA	 is	 the	axial	
subtype,	with	inflammation	of	the	sacroiliac	joints,	like	ankylosing	spondylitis.	It	has	been	described	
that	 certain	 factors	 in	 psoriasis	 patients	 are	 associated	 with	 the	 development	 of	 PsA.	 These	
characteristics	 include	 psoriasis	 of	 the	 nail,	 scalp	 or	 intergluteal	 as	 well	 as	 certain	 environmental	
factors	 like	 infections,	 heavy	 lifting	 and	 injuries.23,24	 Over	 the	 years,	multiple	 sets	 of	 classification	
criteria	have	been	developed	and	used	for	PsA.	One	of	the	first	is	by	Moll	&	Wright,	who	divided	PsA	
into	five	clinical	patterns;	asymmetrical	oligoarthritis,	symmetrical	polyarthritis,	distal	interphalangeal	
arthritis,	 arthritis	 mutilans	 and	 spinal	 column	 involvement.25	 As	 the	 pattern	 of	 involvement	 may	
change	over	time,	this	classification	proved	not	very	useful.22	In	2006	the	now	widely	used	CASPAR	
criteria	were	 introduced.26	 To	 fulfil	 these	 classification	 criteria,	 a	 patient	must	 have	 inflammatory	
articular,	 entheseal	 or	 spinal	 disease.	 On	 top	 of	 this,	 at	 least	 3	 out	 of	 the	 following	 6	 points	 are	
required:	the	presence	of	psoriasis	(current	(2	points)	or	history),	presence	of	psoriatic	nail	dystrophy,	
absence	of	rheumatoid	factor,	dactylitis	(diagnosed	by	rheumatologist)	and	radiographic	evidence	of	
juxtaarticular	 new	 bone	 formation.	 The	 difficulty	 with	 these	 criteria	 is	 that	 the	 stem	 elements	
(inflammatory	articular,	entheseal	or	spinal	disease)	are	not	defined.	Whereas	this	might	be	less	of	a	
problem	for	articular	and	spinal	disease,	the	definition	of	inflammatory	entheseal	disease	is	not	clear.	
Although	 the	 CASPAR	 criteria	 are	widely	 used	 in	 research,	 in	 clinical	 practice	 the	 diagnosis	 of	 the	
rheumatologist	based	on	clinical	manifestations	is	still	the	gold	standard.	
	
Epidemiology	
The	estimated	prevalence	of	 psoriasis	 is	 approximately	 3%,	with	higher	 prevalences	 in	 Caucasians	
compared	to	other	ethnicities.27	The	prevalence	of	PsA	in	the	general	population	is	reported	to	range	
from	0.01%	in	the	Middle	East	to	0.19%	in	Europe.8,28	The	prevalence	of	PsA	in	patients	with	psoriasis	
has	also	been	frequently	studied	and	ranges	from	6	to	42%.28	Most	prevalence	studies	were	performed	
in	secondary	care,	whereas	in	a	country	like	the	Netherlands	with	an	extensive	primary	health	care	
system,	the	prevalence	in	primary	care	is	very	important,	but	lacking.	
	
Burden	of	Disease	
Numerous	studies	have	been	performed	regarding	the	burden	of	disease	of	both	psoriasis	and	PsA.	
Psoriasis	negatively	affects	quality	of	life,	as	to	be	expected	this	quality	of	life	depends	partly	on	the	
severity	of	the	skin	involvement.29		In	addition	to	the	risk	psoriasis	patients	have	at	developing	PsA,	a	
number	of	other	comorbidities	can	occur	among	which	cardiovascular	problems	 like	hypertension,	
hyperlipidemia	and	diabetes	mellitus.30	The	presence	of	PsA	besides	the	psoriasis	reduces	the	quality	
of	life	further	than	psoriasis	alone.22,29,31	A	few	studies	have	compared	the	burden	of	disease	between	
PsA,	rheumatoid	arthritis	and	axial	SpA	and	showed	comparable	or	worse	quality	of	life	for	patients	
with	 PsA	or	 axial	 SpA	 compared	with	 rheumatoid	 arthritis.32,33	 Besides	 the	 reduced	quality	 of	 life,	
inability	to	work	has	also	been	recognized	as	a	problem	in	both	psoriasis	and	PsA	patients.34-36	As	PsA	
is	an	erosive	disease,	patients	are	at	risk	for	developing	serious	joint	damage.	Over	the	last	couple	of	
years	it	has	become	more	and	more	apparent	that	early	treatment	can	prevent	this	major	damage	
and	lead	to	better	functional	outcome.37,38	With	regard	to	the	economic	burden	of	psoriasis	and	PsA,	
it	is	apparent	that	these	diseases	will	be	accompanied	by	certain	costs.	These	costs	increase	with	the	
treatment	and	management	(including	the	use	of	biologics)	of	more	severe	disease.39,40	
	
Treatment	
With	regard	to	treatment	both	the	skin	manifestations	and	musculoskeletal	manifestations	have	to	
be	taken	into	account.	As	there	is	a	certain	overlap	in	pathogenesis,	some	treatments	are	effective	for	
both	psoriasis	and	PsA.	However,	both	manifestations	of	psoriatic	disease	also	have	their	own	specific	
treatments.	 Specific	 treatment	 for	 psoriasis	 includes	 topical	 treatment	 (including	 steroids),	
phototherapy	and	oral	retinoids.41	For	severe	psoriasis	or	psoriasis	in	combination	with	PsA,	DMARDS	
like	methotrexate	 and	 biologicals	 such	 as	 anti-TNF	 can	 be	 used.	 If	 patients	 suffer	 from	 comorbid	
psoriasis	and	PSA,	one	should	attempt	to	use	treatment	modalities	that	address	both	skin	and	joint	
manifestations.	The	treatment	recommendations	for	PsA	are	quite	similar	with	those	of	psoriasis	in	
the	advanced	steps,	but	begin	with	PsA	specific	treatment.	The	treatment	goals	in	PsA	are	to	achieve	
a	state	of	minimal	disease	activity,	maintaining	 functional	ability	and	quality	of	 life	and	preventing	
joint	 erosions.	 Treatment	 should	be	monitored	 regularly	 and	 adjusted	where	necessary,	 based	on	
shared	decision	making	with	the	patient.42		The	first	step	in	PsA	treatment	are	NSAIDs.	Intra-articular	
corticosteroids	could	be	used	as	adjunctive	therapy,	even	as	systemic	corticosteroids	at	the	lowest	
dose	possible.	In	patients	with	many	swollen	joints,	high	levels	of	CRP/ESR	or	relevant	extra-articular	
manifestations,	NSAIDs	will	not	be	sufficient.	It	is	therefore	recommended	to	initiate	DMARDs	early	
on	 in	 these	patients,	with	a	preference	 for	methotrexate	 in	 case	of	 skin	 involvement.42	 If	 the	 first	
DMARD	fails,	the	next	step	is	to	prescribe	another	DMARD	before	switching	to	biologicals.	For	patients	
with	predominantly	axial	or	entheseal	disease,	DMARDs	have	no	proven	efficacy.	If	NSAIDs	fail	in	these	
patients,	biologicals	are	the	treatment	of	choice.		
	
Inflammatory	Bowel	Disease-Spondyloarthritis		
Clinical	Manifestations	
IBD	is	a	chronic	relapsing-remitting	disease	of	the	gastro-intestinal	tract	and	comprises	both	Crohn’s	
disease	 (CD)	 and	ulcerative	 colitis	 (UC).43	 CD	 is	 characterized	by	 transmural	 inflammation	 and	 can	
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the	bone,	but	 the	most	known	 location	 is	 the	Achilles	 tendon.	Another	subtype	of	PsA	 is	 the	axial	
subtype,	with	inflammation	of	the	sacroiliac	joints,	like	ankylosing	spondylitis.	It	has	been	described	
that	 certain	 factors	 in	 psoriasis	 patients	 are	 associated	 with	 the	 development	 of	 PsA.	 These	
characteristics	 include	 psoriasis	 of	 the	 nail,	 scalp	 or	 intergluteal	 as	 well	 as	 certain	 environmental	
factors	 like	 infections,	 heavy	 lifting	 and	 injuries.23,24	 Over	 the	 years,	multiple	 sets	 of	 classification	
criteria	have	been	developed	and	used	for	PsA.	One	of	the	first	is	by	Moll	&	Wright,	who	divided	PsA	
into	five	clinical	patterns;	asymmetrical	oligoarthritis,	symmetrical	polyarthritis,	distal	interphalangeal	
arthritis,	 arthritis	 mutilans	 and	 spinal	 column	 involvement.25	 As	 the	 pattern	 of	 involvement	 may	
change	over	time,	this	classification	proved	not	very	useful.22	In	2006	the	now	widely	used	CASPAR	
criteria	were	 introduced.26	 To	 fulfil	 these	 classification	 criteria,	 a	 patient	must	 have	 inflammatory	
articular,	 entheseal	 or	 spinal	 disease.	 On	 top	 of	 this,	 at	 least	 3	 out	 of	 the	 following	 6	 points	 are	
required:	the	presence	of	psoriasis	(current	(2	points)	or	history),	presence	of	psoriatic	nail	dystrophy,	
absence	of	rheumatoid	factor,	dactylitis	(diagnosed	by	rheumatologist)	and	radiographic	evidence	of	
juxtaarticular	 new	 bone	 formation.	 The	 difficulty	 with	 these	 criteria	 is	 that	 the	 stem	 elements	
(inflammatory	articular,	entheseal	or	spinal	disease)	are	not	defined.	Whereas	this	might	be	less	of	a	
problem	for	articular	and	spinal	disease,	the	definition	of	inflammatory	entheseal	disease	is	not	clear.	
Although	 the	 CASPAR	 criteria	 are	widely	 used	 in	 research,	 in	 clinical	 practice	 the	 diagnosis	 of	 the	
rheumatologist	based	on	clinical	manifestations	is	still	the	gold	standard.	
	
Epidemiology	
The	estimated	prevalence	of	 psoriasis	 is	 approximately	 3%,	with	higher	 prevalences	 in	 Caucasians	
compared	to	other	ethnicities.27	The	prevalence	of	PsA	in	the	general	population	is	reported	to	range	
from	0.01%	in	the	Middle	East	to	0.19%	in	Europe.8,28	The	prevalence	of	PsA	in	patients	with	psoriasis	
has	also	been	frequently	studied	and	ranges	from	6	to	42%.28	Most	prevalence	studies	were	performed	
in	secondary	care,	whereas	in	a	country	like	the	Netherlands	with	an	extensive	primary	health	care	
system,	the	prevalence	in	primary	care	is	very	important,	but	lacking.	
	
Burden	of	Disease	
Numerous	studies	have	been	performed	regarding	the	burden	of	disease	of	both	psoriasis	and	PsA.	
Psoriasis	negatively	affects	quality	of	life,	as	to	be	expected	this	quality	of	life	depends	partly	on	the	
severity	of	the	skin	involvement.29		In	addition	to	the	risk	psoriasis	patients	have	at	developing	PsA,	a	
number	of	other	comorbidities	can	occur	among	which	cardiovascular	problems	 like	hypertension,	
hyperlipidemia	and	diabetes	mellitus.30	The	presence	of	PsA	besides	the	psoriasis	reduces	the	quality	
of	life	further	than	psoriasis	alone.22,29,31	A	few	studies	have	compared	the	burden	of	disease	between	
PsA,	rheumatoid	arthritis	and	axial	SpA	and	showed	comparable	or	worse	quality	of	life	for	patients	
with	 PsA	or	 axial	 SpA	 compared	with	 rheumatoid	 arthritis.32,33	 Besides	 the	 reduced	quality	 of	 life,	
inability	to	work	has	also	been	recognized	as	a	problem	in	both	psoriasis	and	PsA	patients.34-36	As	PsA	
is	an	erosive	disease,	patients	are	at	risk	for	developing	serious	joint	damage.	Over	the	last	couple	of	
years	it	has	become	more	and	more	apparent	that	early	treatment	can	prevent	this	major	damage	
and	lead	to	better	functional	outcome.37,38	With	regard	to	the	economic	burden	of	psoriasis	and	PsA,	
it	is	apparent	that	these	diseases	will	be	accompanied	by	certain	costs.	These	costs	increase	with	the	
treatment	and	management	(including	the	use	of	biologics)	of	more	severe	disease.39,40	
	
Treatment	
With	regard	to	treatment	both	the	skin	manifestations	and	musculoskeletal	manifestations	have	to	
be	taken	into	account.	As	there	is	a	certain	overlap	in	pathogenesis,	some	treatments	are	effective	for	
both	psoriasis	and	PsA.	However,	both	manifestations	of	psoriatic	disease	also	have	their	own	specific	
treatments.	 Specific	 treatment	 for	 psoriasis	 includes	 topical	 treatment	 (including	 steroids),	
phototherapy	and	oral	retinoids.41	For	severe	psoriasis	or	psoriasis	in	combination	with	PsA,	DMARDS	
like	methotrexate	 and	 biologicals	 such	 as	 anti-TNF	 can	 be	 used.	 If	 patients	 suffer	 from	 comorbid	
psoriasis	and	PSA,	one	should	attempt	to	use	treatment	modalities	that	address	both	skin	and	joint	
manifestations.	The	treatment	recommendations	for	PsA	are	quite	similar	with	those	of	psoriasis	in	
the	advanced	steps,	but	begin	with	PsA	specific	treatment.	The	treatment	goals	in	PsA	are	to	achieve	
a	state	of	minimal	disease	activity,	maintaining	 functional	ability	and	quality	of	 life	and	preventing	
joint	 erosions.	 Treatment	 should	be	monitored	 regularly	 and	 adjusted	where	necessary,	 based	on	
shared	decision	making	with	the	patient.42		The	first	step	in	PsA	treatment	are	NSAIDs.	Intra-articular	
corticosteroids	could	be	used	as	adjunctive	therapy,	even	as	systemic	corticosteroids	at	the	lowest	
dose	possible.	In	patients	with	many	swollen	joints,	high	levels	of	CRP/ESR	or	relevant	extra-articular	
manifestations,	NSAIDs	will	not	be	sufficient.	It	is	therefore	recommended	to	initiate	DMARDs	early	
on	 in	 these	patients,	with	a	preference	 for	methotrexate	 in	 case	of	 skin	 involvement.42	 If	 the	 first	
DMARD	fails,	the	next	step	is	to	prescribe	another	DMARD	before	switching	to	biologicals.	For	patients	
with	predominantly	axial	or	entheseal	disease,	DMARDs	have	no	proven	efficacy.	If	NSAIDs	fail	in	these	
patients,	biologicals	are	the	treatment	of	choice.		
	
Inflammatory	Bowel	Disease-Spondyloarthritis		
Clinical	Manifestations	
IBD	is	a	chronic	relapsing-remitting	disease	of	the	gastro-intestinal	tract	and	comprises	both	Crohn’s	
disease	 (CD)	 and	ulcerative	 colitis	 (UC).43	 CD	 is	 characterized	by	 transmural	 inflammation	 and	 can	
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occur	in	any	part	of	the	gastro-intestinal	tract,	from	mouth	to	anus.	UC	is	characterized	by	mucosal	
inflammation	of	the	colon,	usually	starting	in	the	rectum	and	moving	up	in	the	colon	in	continuity.		IBD	
usually	manifests	 in	 young	 adults	 (<30	 years	 of	 age)	 and	 can	 be	 accompanied	 by	 a	 various	 extra-
intestinal	manifestations	in	multiple	organ	systems,	among	which	rheumatic	manifestations	as	IBD-
SpA.	As	with	PsA,	 IBD-SpA	will	mostly	occur	 in	patients	already	suffering	from	inflammatory	bowel	
disease	(IBD).	However,	the	concept	of	IBD-SpA	is	not	as	clear	as	the	concept	of	PsA.	Orchard	et	al	
made	a	classification	of	two	types	of	arthritis	in	patients	with	IBD.44	Type	1	represents	an	oligoarticular	
arthritis,	particularly	affecting	large	joint	of	the	lower	extremities	and	correlates	with	IBD	activity.	Type	
2	has	a	polyarticular,	symmetrical	distribution	mostly	affecting	joints	of	the	upper	extremities	and	is	
less	likely	to	correlate	with	IBD	activity.	Although	this	distinction	is	still	used	by	gastroenterologists,	it	
is	 not	widely	 accepted	 in	 rheumatology.45	Rheumatologists	 classify	 IBD-SpA	according	 to	 the	most	
predominant	manifestation.	As	this	can	be	either	peripheral	(arthritis,	enthesitis,	dactylitis)	or	axial	
(sacroiliitis,	ankylosing	spondylitis),	criteria	are	used	accordingly.	In	practice,	this	means	that	multiple	
sets	of	criteria	are	used	like	the	ASAS	criteria,	the	ESSG	criteria	and	the	modified	New	York	criteria.5-
7,46	
	
Epidemiology	
Prevalence	of	CD	varies	from	1.5	to	213	cases	per	100,000	persons,	whereas	the	prevalence	of	UC	
varies	from	2.4	to	294	cases	per	100,000.47		
With	regard	to	IBD-SpA,	few	population-based	studies	are	available.	Two	European	studies	reported	
prevalences	of	0.02	and	0.09.48,49	The	prevalence	of	 IBD-SpA	 in	patients	with	 IBD	has	been	studies	
more	extensively,	with	a	reported	range	from	2	to	46%	in	patients	with	IBD.45,50		
	
Burden	of	Disease	
Over	the	years	the	quality	of	life	in	patients	with	IBD	has	been	extensively	studied.	While	some	studies	
show	 reduced	 quality	 of	 life51-54,	 other	 studies	 show	 no	 difference	 between	 IBD	 patients	 and	 the	
reference	 population.55,56	 As	 IBD	 can	 be	 accompanied	 by	 a	 large	 number	 of	 extra-intestinal	
manifestations,	which	all	can	have	impact	on	quality	of	life,	it	is	difficult	to	say	which	causes	the	reduce	
in	quality	of	life.	Until	now,	the	specific	impact	of	extra-intestinal	manifestations,	among	which	the	
large	group	of	rheumatic	manifestations,	has	not	been	fully	investigated.	However,	some	studies	have	
looked	at	the	influence	of	musculoskeletal	complaints	(MSC)	on	quality	of	life	and	show	lower	scores	
on	SF-36	and	IBDQ	for	patients	with	MSC.57,58	IBD	has	a	negative	impact	on	employment	status,	where	
patients	with	MSC	experience	higher	work	and	activity	impairment	than	IBD	patients	without	MSC.58,59	
With	regard	to	economic	burden,	the	health	expenditure	per	IBD	patient	can	be	even	greater	than	the	
costs	for	other	chronic	disease	like	diabetes,	hypertension	and	COPD.53	As	IBD	is	a	chronic	disease,	
patients	often	use	medication,	among	which	the	expensive	biologicals,	 for	 long	periods	of	 time.	 In	
addition,	 a	 lot	 of	 IBD	 patients	 need	 surgery	 or	 even	multiple	 surgeries.53	 It	 seems	 apparent	 that	
patients	who	also	 suffer	 from	SpA,	will	have	even	higher	 costs	as	 the	costs	 for	 the	 treatment	and	
monitoring	of	SpA	should	be	added.	
	
Treatment	
As	with	PsA,	some	of	the	treatment	for	IBD	will	be	effective	for	IBD-SpA	as	well,	but	both	diseases	also	
have	 their	own	 treatment	options.	Treatment	 for	 IBD	also	 follows	a	 step-up	strategy.	First	 step	of	
treatment	is	5-aminosalicylic	acid	(mesalazine	or	sulfalazine)	or	steroids.	The	following	steps	include	
immunusuppressants	 (e.g.	 azathioprine,	 cyclosporine,	 methotrexate),	 anti-TNFα	 (e.g.	 infliximab,	
adalumimab)	and	surgery.60,61	Although	treatment	for	IBD	has	improved	over	the	last	years,	surgery	
remains	unavoidable	for	part	of	the	patients.	For	UC	patients,	surgical	intervention	is	needed	in	10-
30%	of	patients,	while	for	patients	with	CD,	surgery	is	needed	in	up	to	80%	of	patients.62	For	patients	
with	IBD-SpA	it	is	desirable	to	find	a	treatment	strategy	suitable	for	both	the	IBD	and	the	SpA.		
The	European	Crohn’s	and	Colitis	Organisation	(ECCO)	recently	published	a	guideline	on	extraintestinal	
manifestations	of	IBD.63		These	guidelines	recommend	joint	management	with	the	rheumatologist	of	
IBD	patients	with	axial	or	peripheral	 involvement.	As	with	PsA,	 first	 choice	of	 treatment	would	be	
NSAIDs.	However,	 long-term	treatment	of	NSAIDs	should	be	avoided	 in	patients	with	 IBD	as	 it	can	
increase	the	risk	for	relapse	of	IBD.	Evidence	suggests	that	selective	COX-2	inhibitors	may	be	a	better	
option	 as	 they	 do	 not	 seem	 to	 cause	 relapse	 of	 IBD.50,63,64	 For	 patients	 with	 axial	 involvement,	
biologicals	(anti-TNFα)	are	the	first	choice	of	treatment	after	failure	of	or	intolerance	for	NSAIDs.	A	lot	
of	 the	 treatment	 options	 for	 IBD	 are	 also	 effective	 in	 peripheral	 arthritis.	 It	 is	 therefore	 said	 that	
effective	treatment	of	the	IBD	is	often	sufficient	to	treat	peripheral	arthritis.	However,	short-term	use	
of	systemic	corticosteroids	or	local	corticosteroids	injections	are	advised	for	symptom	relief.	Further	
treatment	options	are	DMARDs	(sulfasalazine,	methotrexate)	and	if	this	fails	biologicals.	With	regard	
to	biologicals	it	is	recommended	to	preferably	choose	a	biological	with	proven	effectiveness	for	both	
the	 IBD	and	SpA,	 like	 infliximab	and	adalumimab.	Etanercept	 is	effective	 in	SpA,	but	has	not	been	
found	effective	for	IBD.50	
	
Early	Recognition	of	SpA	
Early	recognition	of	SpA	is	important.65	SpA	is	a	chronic	and	potentially	disabling	disease	as	it	can	lead	
to	severe	joint	deformations	if	left	untreated.	These	complications	could	self-evidently	lead	to	reduced	
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occur	in	any	part	of	the	gastro-intestinal	tract,	from	mouth	to	anus.	UC	is	characterized	by	mucosal	
inflammation	of	the	colon,	usually	starting	in	the	rectum	and	moving	up	in	the	colon	in	continuity.		IBD	
usually	manifests	 in	 young	 adults	 (<30	 years	 of	 age)	 and	 can	 be	 accompanied	 by	 a	 various	 extra-
intestinal	manifestations	in	multiple	organ	systems,	among	which	rheumatic	manifestations	as	IBD-
SpA.	As	with	PsA,	 IBD-SpA	will	mostly	occur	 in	patients	already	suffering	from	inflammatory	bowel	
disease	(IBD).	However,	the	concept	of	IBD-SpA	is	not	as	clear	as	the	concept	of	PsA.	Orchard	et	al	
made	a	classification	of	two	types	of	arthritis	in	patients	with	IBD.44	Type	1	represents	an	oligoarticular	
arthritis,	particularly	affecting	large	joint	of	the	lower	extremities	and	correlates	with	IBD	activity.	Type	
2	has	a	polyarticular,	symmetrical	distribution	mostly	affecting	joints	of	the	upper	extremities	and	is	
less	likely	to	correlate	with	IBD	activity.	Although	this	distinction	is	still	used	by	gastroenterologists,	it	
is	 not	widely	 accepted	 in	 rheumatology.45	Rheumatologists	 classify	 IBD-SpA	according	 to	 the	most	
predominant	manifestation.	As	this	can	be	either	peripheral	(arthritis,	enthesitis,	dactylitis)	or	axial	
(sacroiliitis,	ankylosing	spondylitis),	criteria	are	used	accordingly.	In	practice,	this	means	that	multiple	
sets	of	criteria	are	used	like	the	ASAS	criteria,	the	ESSG	criteria	and	the	modified	New	York	criteria.5-
7,46	
	
Epidemiology	
Prevalence	of	CD	varies	from	1.5	to	213	cases	per	100,000	persons,	whereas	the	prevalence	of	UC	
varies	from	2.4	to	294	cases	per	100,000.47		
With	regard	to	IBD-SpA,	few	population-based	studies	are	available.	Two	European	studies	reported	
prevalences	of	0.02	and	0.09.48,49	The	prevalence	of	 IBD-SpA	 in	patients	with	 IBD	has	been	studies	
more	extensively,	with	a	reported	range	from	2	to	46%	in	patients	with	IBD.45,50		
	
Burden	of	Disease	
Over	the	years	the	quality	of	life	in	patients	with	IBD	has	been	extensively	studied.	While	some	studies	
show	 reduced	 quality	 of	 life51-54,	 other	 studies	 show	 no	 difference	 between	 IBD	 patients	 and	 the	
reference	 population.55,56	 As	 IBD	 can	 be	 accompanied	 by	 a	 large	 number	 of	 extra-intestinal	
manifestations,	which	all	can	have	impact	on	quality	of	life,	it	is	difficult	to	say	which	causes	the	reduce	
in	quality	of	life.	Until	now,	the	specific	impact	of	extra-intestinal	manifestations,	among	which	the	
large	group	of	rheumatic	manifestations,	has	not	been	fully	investigated.	However,	some	studies	have	
looked	at	the	influence	of	musculoskeletal	complaints	(MSC)	on	quality	of	life	and	show	lower	scores	
on	SF-36	and	IBDQ	for	patients	with	MSC.57,58	IBD	has	a	negative	impact	on	employment	status,	where	
patients	with	MSC	experience	higher	work	and	activity	impairment	than	IBD	patients	without	MSC.58,59	
With	regard	to	economic	burden,	the	health	expenditure	per	IBD	patient	can	be	even	greater	than	the	
costs	for	other	chronic	disease	like	diabetes,	hypertension	and	COPD.53	As	IBD	is	a	chronic	disease,	
patients	often	use	medication,	among	which	the	expensive	biologicals,	 for	 long	periods	of	 time.	 In	
addition,	 a	 lot	 of	 IBD	 patients	 need	 surgery	 or	 even	multiple	 surgeries.53	 It	 seems	 apparent	 that	
patients	who	also	 suffer	 from	SpA,	will	have	even	higher	 costs	as	 the	costs	 for	 the	 treatment	and	
monitoring	of	SpA	should	be	added.	
	
Treatment	
As	with	PsA,	some	of	the	treatment	for	IBD	will	be	effective	for	IBD-SpA	as	well,	but	both	diseases	also	
have	 their	own	 treatment	options.	Treatment	 for	 IBD	also	 follows	a	 step-up	strategy.	First	 step	of	
treatment	is	5-aminosalicylic	acid	(mesalazine	or	sulfalazine)	or	steroids.	The	following	steps	include	
immunusuppressants	 (e.g.	 azathioprine,	 cyclosporine,	 methotrexate),	 anti-TNFα	 (e.g.	 infliximab,	
adalumimab)	and	surgery.60,61	Although	treatment	for	IBD	has	improved	over	the	last	years,	surgery	
remains	unavoidable	for	part	of	the	patients.	For	UC	patients,	surgical	intervention	is	needed	in	10-
30%	of	patients,	while	for	patients	with	CD,	surgery	is	needed	in	up	to	80%	of	patients.62	For	patients	
with	IBD-SpA	it	is	desirable	to	find	a	treatment	strategy	suitable	for	both	the	IBD	and	the	SpA.		
The	European	Crohn’s	and	Colitis	Organisation	(ECCO)	recently	published	a	guideline	on	extraintestinal	
manifestations	of	IBD.63		These	guidelines	recommend	joint	management	with	the	rheumatologist	of	
IBD	patients	with	axial	or	peripheral	 involvement.	As	with	PsA,	 first	 choice	of	 treatment	would	be	
NSAIDs.	However,	 long-term	treatment	of	NSAIDs	should	be	avoided	 in	patients	with	 IBD	as	 it	can	
increase	the	risk	for	relapse	of	IBD.	Evidence	suggests	that	selective	COX-2	inhibitors	may	be	a	better	
option	 as	 they	 do	 not	 seem	 to	 cause	 relapse	 of	 IBD.50,63,64	 For	 patients	 with	 axial	 involvement,	
biologicals	(anti-TNFα)	are	the	first	choice	of	treatment	after	failure	of	or	intolerance	for	NSAIDs.	A	lot	
of	 the	 treatment	 options	 for	 IBD	 are	 also	 effective	 in	 peripheral	 arthritis.	 It	 is	 therefore	 said	 that	
effective	treatment	of	the	IBD	is	often	sufficient	to	treat	peripheral	arthritis.	However,	short-term	use	
of	systemic	corticosteroids	or	local	corticosteroids	injections	are	advised	for	symptom	relief.	Further	
treatment	options	are	DMARDs	(sulfasalazine,	methotrexate)	and	if	this	fails	biologicals.	With	regard	
to	biologicals	it	is	recommended	to	preferably	choose	a	biological	with	proven	effectiveness	for	both	
the	 IBD	and	SpA,	 like	 infliximab	and	adalumimab.	Etanercept	 is	effective	 in	SpA,	but	has	not	been	
found	effective	for	IBD.50	
	
Early	Recognition	of	SpA	
Early	recognition	of	SpA	is	important.65	SpA	is	a	chronic	and	potentially	disabling	disease	as	it	can	lead	
to	severe	joint	deformations	if	left	untreated.	These	complications	could	self-evidently	lead	to	reduced	
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quality	 of	 life	 and	 reduced	 work	 participation.66,67	 Over	 the	 last	 couple	 of	 years	 various	 effective	
treatments	for	SpA	have	become	available.	Evidence	suggests	that	short	disease	duration	is	one	of	the	
predictors	of	good	response	to	these	treatments.37,38,67	In	order	to	achieve	this	early	recognition,	two	
important	factors	are	awareness	and	screening.	
	
Awareness	
In	 order	 to	 recognize	 a	 disease	 like	 SpA	early,	 patients	 at	 risk	 as	well	 as	 physicians	 treating	 these	
patients	should	be	aware	of	the	increased	risk	of	SpA.	In	countries	with	a	primary	healthcare	system,	
like	the	Netherlands,	patients	who	experience	MSC	will	visit	their	general	practitioner	(GP).	MSC	are	
a	very	common	complaint	in	the	general	population,	and	account	for	about	20%	of	consultations	in	
primary	care.68,69	Some	of	these	complaints	will	have	an	inflammatory	cause,	like	SpA.	However,	the	
prevalence	 of	 SpA	 is	 relatively	 low	 in	 the	 general	 population,	 so	GPs	will	 not	 see	 it	 often	 in	 their	
practice.	Making	GPs	aware	of	the	concept	of	SpA,	including	knowledge	about	the	patientgroups	at	
risk	(e.g.	psoriasis,	IBD),	could	aid	the	recognition.	In	the	United	Kingdom,	which	also	has	an	extensive	
primary	health	care	system,	campaigns	for	improvement	of	awareness	for	rheumatoid	arthritis	have	
been	set	up.70,71	In	the	Netherlands,	a	guideline	for	general	practitioners	has	been	set	up	to	aid	them	
in	the	workup	of	patients	with	inflammatory	arthritis.72	However,	the	focus	on	early	recognition	and	
awareness	of	SpA	lags	behind.	As	awareness	and	knowledge	are	very	broad	concepts,	it	is	necessary	
to	assess	the	current	status	of	GPs	to	detect	where	the	gaps	are	in	this	knowledge	and	awareness.	The	
other	way	around,	it	may	also	be	beneficial	if	patients	with	psoriasis	or	IBD	are	aware	themselves	that	
they	could	develop	SpA.	As	with	awareness	for	GPs,	it	needs	to	be	assessed	if	patients	with	psoriasis	
and	IBD	are	aware	and	in	addition	if	increasing	this	awareness	could	really	lead	to	decreasing	delay	in	
consulting	a	physician	about	these	complaints.	
	
Screening	
Another	way	 to	aid	early	 recognition,	 is	 screening.	The	concept	of	 screening	 is	 to	 identify	possible	
disease	 in	patients	without	 signs	or	 symptoms.	 This	 has	been	widely	 implemented	 in	 for	 example	
oncology,	 with	 international	 successful	 screening	 programs	 for	 breastcancer,	 cervical	 cancer	 and	
bowel	cancer.	Screening	becomes	more	and	more	important	as	a	lot	of	diseases	can	be	better	treated	
or	even	cured	in	the	early	phases	of	the	disease.	As	both	PsA	and	IBD-SpA	are	in	most	cases	preceded	
by	psoriasis	respectively	 IBD,	 implementing	screening	methods	can	be	very	beneficial.16,45	Over	the	
last	years,	multiple	screeningtools	have	been	developed	to	screen	psoriasis	patients	for	the	presence	
of	 PsA.73-76	 Most	 of	 these	 tools	 were	 developed	 in	 secondary	 care	 settings	 and	 show	 moderate	
performance	with	regard	to	sensitivity	and	specificity.77-79	With	regard	to	the	healthcare	organization	
in	the	Netherlands,	it	is	valuable	to	gain	insight	in	the	performance	in	primary	care.	To	date,	the	use	
of	screeningtools	has	not	been	implemented	in	standard	daily	practice.	In	contrast	with	the	extensive	
research	in	screening	for	PsA,	no	screeningtools	have	been	developed	to	screen	IBD	patients	for	the	
presence	of	IBD-SpA.	
	
SENSOR	&	AppSpA	Studies	
The	studies	that	are	described	in	this	thesis	used	data	from	two	large	primary	care	projects:	SENSOR	
(ScrEeNing	arthritiS	in	psORiasis)	and	AppSpA	(Awareness	in	Patients	and	Primary	care	physicians	of	
SPondyloArthritis).	
The	SENSOR	study	was	set	up	in	2013	in	a	primary	care	setting,	where	GPs	were	invited	to	participate.	
Participating	GPs	selected	their	patients	with	psoriasis	out	of	their	databases	based	on	ICPC	coding	
(International	Classification	of	Primary	Care),	which	is	the	standard	for	coding	symptoms	and	diseases	
in	primary	care	in	the	Netherlands.	All	patients	with	ICPC	S91	for	psoriasis	were	selected	and	invited	
to	participate.	Patients	were	eligible	to	participate	if	they	had	psoriasis,	were	18	years	or	older	and	
suffered	 from	 any	 kind	 of	 MSC.	 All	 eligible	 patients	 willing	 to	 participate,	 completed	 a	 set	 of	
questionnaires	and	were	subsequently	invited	for	clinical	evaluation	by	a	trained	research	assistant.	
Clinical	 evaluation	 focused	 on	 skin,	 joints,	 entheses	 and	 lower	 back.	 If	 there	 were	 indications	 of	
underlying	inflammatory	rheumatic	disease,	patients	were	advised	to	consult	a	rheumatologist,	where	
a	diagnosis	of	PsA	could	be	considered.	
The	AppSpA	study	was	set	up	in	2014	and	also	focused	on	primary	care.	This	study	consisted	of	two	
parts;	namely	a	GP-part	and	a	patient-part.	The	GP-part	focused	on	awareness	and	knowledge	of	SpA	
and	 was	 assessed	 with	 a	 survey.	 GPs	 from	 various	 regions	 in	 the	 Netherlands	 were	 invited	 to	
participate	and	complete	the	survey.	The	patient	part	also	consisted	of	a	survey	and	included	patients	
at	risk	for	SpA,	i.e.	patients	with	psoriasis	or	IBD.	This	aim	of	this	survey	was	to	assess	the	burden	of	
disease	for	psoriasis	and	IBD	patients	with	and	without	MSC.	GPs	were	recruited	to	select	patients	
with	psoriasis	or	IBD	aged	18-55	years	out	of	their	database	(ICPC	S91	for	psoriasis	and	D94	for	IBD)	
and	 invite	 them	 to	 participate.	 In	 addition,	 patients	 were	 recruited	 via	 the	 Dutch	 patients’	
organizations	 for	 psoriasis	 and	 IBD.	 If	 patients	 were	 willing	 to	 participate	 they	 received	 a	 set	 of	
questionnaires	concerning	their	IBD,	presence	of	musculoskeletal	complaints,	quality	of	life	and	work	
participation.		
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quality	 of	 life	 and	 reduced	 work	 participation.66,67	 Over	 the	 last	 couple	 of	 years	 various	 effective	
treatments	for	SpA	have	become	available.	Evidence	suggests	that	short	disease	duration	is	one	of	the	
predictors	of	good	response	to	these	treatments.37,38,67	In	order	to	achieve	this	early	recognition,	two	
important	factors	are	awareness	and	screening.	
	
Awareness	
In	 order	 to	 recognize	 a	 disease	 like	 SpA	early,	 patients	 at	 risk	 as	well	 as	 physicians	 treating	 these	
patients	should	be	aware	of	the	increased	risk	of	SpA.	In	countries	with	a	primary	healthcare	system,	
like	the	Netherlands,	patients	who	experience	MSC	will	visit	their	general	practitioner	(GP).	MSC	are	
a	very	common	complaint	in	the	general	population,	and	account	for	about	20%	of	consultations	in	
primary	care.68,69	Some	of	these	complaints	will	have	an	inflammatory	cause,	like	SpA.	However,	the	
prevalence	 of	 SpA	 is	 relatively	 low	 in	 the	 general	 population,	 so	GPs	will	 not	 see	 it	 often	 in	 their	
practice.	Making	GPs	aware	of	the	concept	of	SpA,	including	knowledge	about	the	patientgroups	at	
risk	(e.g.	psoriasis,	IBD),	could	aid	the	recognition.	In	the	United	Kingdom,	which	also	has	an	extensive	
primary	health	care	system,	campaigns	for	improvement	of	awareness	for	rheumatoid	arthritis	have	
been	set	up.70,71	In	the	Netherlands,	a	guideline	for	general	practitioners	has	been	set	up	to	aid	them	
in	the	workup	of	patients	with	inflammatory	arthritis.72	However,	the	focus	on	early	recognition	and	
awareness	of	SpA	lags	behind.	As	awareness	and	knowledge	are	very	broad	concepts,	it	is	necessary	
to	assess	the	current	status	of	GPs	to	detect	where	the	gaps	are	in	this	knowledge	and	awareness.	The	
other	way	around,	it	may	also	be	beneficial	if	patients	with	psoriasis	or	IBD	are	aware	themselves	that	
they	could	develop	SpA.	As	with	awareness	for	GPs,	it	needs	to	be	assessed	if	patients	with	psoriasis	
and	IBD	are	aware	and	in	addition	if	increasing	this	awareness	could	really	lead	to	decreasing	delay	in	
consulting	a	physician	about	these	complaints.	
	
Screening	
Another	way	 to	aid	early	 recognition,	 is	 screening.	The	concept	of	 screening	 is	 to	 identify	possible	
disease	 in	patients	without	 signs	or	 symptoms.	 This	 has	been	widely	 implemented	 in	 for	 example	
oncology,	 with	 international	 successful	 screening	 programs	 for	 breastcancer,	 cervical	 cancer	 and	
bowel	cancer.	Screening	becomes	more	and	more	important	as	a	lot	of	diseases	can	be	better	treated	
or	even	cured	in	the	early	phases	of	the	disease.	As	both	PsA	and	IBD-SpA	are	in	most	cases	preceded	
by	psoriasis	respectively	 IBD,	 implementing	screening	methods	can	be	very	beneficial.16,45	Over	the	
last	years,	multiple	screeningtools	have	been	developed	to	screen	psoriasis	patients	for	the	presence	
of	 PsA.73-76	 Most	 of	 these	 tools	 were	 developed	 in	 secondary	 care	 settings	 and	 show	 moderate	
performance	with	regard	to	sensitivity	and	specificity.77-79	With	regard	to	the	healthcare	organization	
in	the	Netherlands,	it	is	valuable	to	gain	insight	in	the	performance	in	primary	care.	To	date,	the	use	
of	screeningtools	has	not	been	implemented	in	standard	daily	practice.	In	contrast	with	the	extensive	
research	in	screening	for	PsA,	no	screeningtools	have	been	developed	to	screen	IBD	patients	for	the	
presence	of	IBD-SpA.	
	
SENSOR	&	AppSpA	Studies	
The	studies	that	are	described	in	this	thesis	used	data	from	two	large	primary	care	projects:	SENSOR	
(ScrEeNing	arthritiS	in	psORiasis)	and	AppSpA	(Awareness	in	Patients	and	Primary	care	physicians	of	
SPondyloArthritis).	
The	SENSOR	study	was	set	up	in	2013	in	a	primary	care	setting,	where	GPs	were	invited	to	participate.	
Participating	GPs	selected	their	patients	with	psoriasis	out	of	their	databases	based	on	ICPC	coding	
(International	Classification	of	Primary	Care),	which	is	the	standard	for	coding	symptoms	and	diseases	
in	primary	care	in	the	Netherlands.	All	patients	with	ICPC	S91	for	psoriasis	were	selected	and	invited	
to	participate.	Patients	were	eligible	to	participate	if	they	had	psoriasis,	were	18	years	or	older	and	
suffered	 from	 any	 kind	 of	 MSC.	 All	 eligible	 patients	 willing	 to	 participate,	 completed	 a	 set	 of	
questionnaires	and	were	subsequently	invited	for	clinical	evaluation	by	a	trained	research	assistant.	
Clinical	 evaluation	 focused	 on	 skin,	 joints,	 entheses	 and	 lower	 back.	 If	 there	 were	 indications	 of	
underlying	inflammatory	rheumatic	disease,	patients	were	advised	to	consult	a	rheumatologist,	where	
a	diagnosis	of	PsA	could	be	considered.	
The	AppSpA	study	was	set	up	in	2014	and	also	focused	on	primary	care.	This	study	consisted	of	two	
parts;	namely	a	GP-part	and	a	patient-part.	The	GP-part	focused	on	awareness	and	knowledge	of	SpA	
and	 was	 assessed	 with	 a	 survey.	 GPs	 from	 various	 regions	 in	 the	 Netherlands	 were	 invited	 to	
participate	and	complete	the	survey.	The	patient	part	also	consisted	of	a	survey	and	included	patients	
at	risk	for	SpA,	i.e.	patients	with	psoriasis	or	IBD.	This	aim	of	this	survey	was	to	assess	the	burden	of	
disease	for	psoriasis	and	IBD	patients	with	and	without	MSC.	GPs	were	recruited	to	select	patients	
with	psoriasis	or	IBD	aged	18-55	years	out	of	their	database	(ICPC	S91	for	psoriasis	and	D94	for	IBD)	
and	 invite	 them	 to	 participate.	 In	 addition,	 patients	 were	 recruited	 via	 the	 Dutch	 patients’	
organizations	 for	 psoriasis	 and	 IBD.	 If	 patients	 were	 willing	 to	 participate	 they	 received	 a	 set	 of	
questionnaires	concerning	their	IBD,	presence	of	musculoskeletal	complaints,	quality	of	life	and	work	
participation.		
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Objective	and	Outline	Thesis	
In	 summary,	 early	 recognition	 of	 patients	 at	 risk	 for	 SpA	 is	 important.	 Since	 patients	 with	
musculoskeletal	pain	will,	irrespective	of	having	PSO	or	IBD,	most	likely	visit	their	general	practitioner	
for	these	complaints,	the	primary	care	setting	seems	key.	
	
The	aims	of	this	thesis	are:	
- To	 get	 insight	 in	 the	 prevalence	 of	 PsA	 and	 ultrasound	 findings	 of	 enthesitis	 in	 psoriasis	
patients	in	a	primary	care	setting		
- To	give	an	overview	of	the	prevalence	of	axial	and	peripheral	SpA	in	IBD	patients		
- To	describe	the	burden	of	musculoskeletal	complaints	in	patients	with	IBD	
- To	evaluate	the	awareness	of	SpA	among	GPs	and	patients	with	IBD	or	PSO		
- To	assess	the	optimal	screening-strategy	for	PsA	in	a	primary	care	setting	
	
Part	I.	Prevalence	&	Burden	of	SpA	in	patients	at	risk	
In	 Chapter	 2	 we	 describe	 the	 results	 of	 a	 cross-sectional	 study	 estimating	 the	 prevalence	 of	
musculoskeletal	 complaints	 and	 PsA	 in	 primary	 care	 psoriasis	 patients.	 Chapter	 3	 focuses	 on	 an	
important	but	scarcely	studied	part	of	PsA,	namely	enthesitis.	 In	this	study	we	aimed	to	assess	the	
frequency	 of	 clinically	 relevant	 ultrasound	 inflammation	 at	 the	 entheses	 of	 primary	 care	 psoriasis	
patients.		
Chapter	4	focuses	on	the	prevalence	of	the	various	manifestations	of	SpA	in	patients	suffering	from	
IBD.	 We	 performed	 a	 systematic	 review	 and	 aimed	 to	 give	 pooled	 estimates	 for	 both	 the	 axial	
manifestations	and	the	peripheral	manifestations	of	SpA	in	IBD	patients.	In	Chapter	5	we	looked	at	
patients	with	IBD	with	or	without	musculoskeletal	complaints.	The	aim	of	this	study	was	to	assess	the	
impact	of	musculoskeletal	complaints	on	quality	of	life	and	work	participation	in	patients	with	IBD.	
	
Part	II.	Early	Recognition	
The	second	part	of	this	thesis	 focusses	on	early	recognition	of	SpA	 in	patients	at	risk,	by	means	of	
awareness	 and	 screening.	 Chapter	 6	 describes	 the	 current	 practice	 of	 Dutch	 GPs	 with	 regard	 to	
inflammatory	musculoskeletal	complaints.	With	this	survey	we	aimed	to	gain	insight	in	the	knowledge	
and	awareness	of	GPs	with	regard	to	SpA	and	patients	with	psoriasis	or	IBD	at	risk	for	SpA.	Besides	the	
GPs,	 we	 also	 looked	 into	 the	 awareness	 of	 the	 patients	 themselves.	 Chapter	 7	 describes	 the	
performance	of	different	in	secondary	care	validated	screeningtools	for	PsA	in	a	primary	care	setting.	
Finally,	Chapter	8	describes	the	performance	of	a	newly	developed	screeningtool	for	PsA,	consisting	
of	the	best	performing	items	of	previous	screeningtools.	This	screeningtool	was	initially	developed	in	
a	secondary	care	setting	and	we	assess	its	performance	in	our	primary	care	setting.	 	
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Objective	and	Outline	Thesis	
In	 summary,	 early	 recognition	 of	 patients	 at	 risk	 for	 SpA	 is	 important.	 Since	 patients	 with	
musculoskeletal	pain	will,	irrespective	of	having	PSO	or	IBD,	most	likely	visit	their	general	practitioner	
for	these	complaints,	the	primary	care	setting	seems	key.	
	
The	aims	of	this	thesis	are:	
- To	 get	 insight	 in	 the	 prevalence	 of	 PsA	 and	 ultrasound	 findings	 of	 enthesitis	 in	 psoriasis	
patients	in	a	primary	care	setting		
- To	give	an	overview	of	the	prevalence	of	axial	and	peripheral	SpA	in	IBD	patients		
- To	describe	the	burden	of	musculoskeletal	complaints	in	patients	with	IBD	
- To	evaluate	the	awareness	of	SpA	among	GPs	and	patients	with	IBD	or	PSO		
- To	assess	the	optimal	screening-strategy	for	PsA	in	a	primary	care	setting	
	
Part	I.	Prevalence	&	Burden	of	SpA	in	patients	at	risk	
In	 Chapter	 2	 we	 describe	 the	 results	 of	 a	 cross-sectional	 study	 estimating	 the	 prevalence	 of	
musculoskeletal	 complaints	 and	 PsA	 in	 primary	 care	 psoriasis	 patients.	 Chapter	 3	 focuses	 on	 an	
important	but	scarcely	studied	part	of	PsA,	namely	enthesitis.	 In	this	study	we	aimed	to	assess	the	
frequency	 of	 clinically	 relevant	 ultrasound	 inflammation	 at	 the	 entheses	 of	 primary	 care	 psoriasis	
patients.		
Chapter	4	focuses	on	the	prevalence	of	the	various	manifestations	of	SpA	in	patients	suffering	from	
IBD.	 We	 performed	 a	 systematic	 review	 and	 aimed	 to	 give	 pooled	 estimates	 for	 both	 the	 axial	
manifestations	and	the	peripheral	manifestations	of	SpA	in	IBD	patients.	In	Chapter	5	we	looked	at	
patients	with	IBD	with	or	without	musculoskeletal	complaints.	The	aim	of	this	study	was	to	assess	the	
impact	of	musculoskeletal	complaints	on	quality	of	life	and	work	participation	in	patients	with	IBD.	
	
Part	II.	Early	Recognition	
The	second	part	of	this	thesis	 focusses	on	early	recognition	of	SpA	 in	patients	at	risk,	by	means	of	
awareness	 and	 screening.	 Chapter	 6	 describes	 the	 current	 practice	 of	 Dutch	 GPs	 with	 regard	 to	
inflammatory	musculoskeletal	complaints.	With	this	survey	we	aimed	to	gain	insight	in	the	knowledge	
and	awareness	of	GPs	with	regard	to	SpA	and	patients	with	psoriasis	or	IBD	at	risk	for	SpA.	Besides	the	
GPs,	 we	 also	 looked	 into	 the	 awareness	 of	 the	 patients	 themselves.	 Chapter	 7	 describes	 the	
performance	of	different	in	secondary	care	validated	screeningtools	for	PsA	in	a	primary	care	setting.	
Finally,	Chapter	8	describes	the	performance	of	a	newly	developed	screeningtool	for	PsA,	consisting	
of	the	best	performing	items	of	previous	screeningtools.	This	screeningtool	was	initially	developed	in	
a	secondary	care	setting	and	we	assess	its	performance	in	our	primary	care	setting.	 	
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Abstract	
	
Objective.	To	estimate	the	prevalence	of	PsA	in	primary	care	patients	diagnosed	with	psoriasis.	The	
second	objective	was	to	estimate	the	prevalence	of	MSC	in	primary	care	psoriasis	patients.	
	
Methods.	 We	 conducted	 a	 cross-sectional	 study	 in	 adult	 primary	 care	 patients	 with	 psoriasis.		
Responding	patients	reporting	pain	in	joints,	entheses	or	lower	back	were	checked	on	eligibility	by	a	
telephone	interview	and	invited	for	clinical	evaluation.	During	clinical	evaluation	skin,	nails,	joints	and	
entheses	 were	 assessed.	 Additionally,	 ultrasonography	 of	 the	 entheses	 was	 performed	 by	 an	
independent	trained	examiner	if	a	patient	had	at	least	one	tender	enthesis	(LEI/MASES).	A	patient	had	
PsA	if	fulfilling	the	CASPAR	criteria.	
	
Results.	 2564	 psoriasis	 patients	 from	 97	 GPs	 were	 invited.	 Of	 the	 1673	 responders	 (65.2%),	 841	
(50.3%)	 were	 willing	 to	 participate.	 823	 (32.1%)	 patients	 reported	 suffering	 from	 MSC	 of	 which	
eventually	 524	 were	 eligible	 and	 clinically	 evaluated.	 Sixty-four	 cases	 of	 established	 PsA	 were	
identified	and	another	17	cases	of	PsA	were	newly	diagnosed,	leading	to	a	prevalence	of	3.2%	(95%CI	
2.5%-3.9%)	among	primary	care	psoriasis	patients.	This	would	increase	towards	4.6%	(95%	CI	3.8%-
5.4%)	if	the	PsA	cases	based	on	enthesitis	are	also	taken	into	account.		
	
Conclusion.	 Among	 psoriasis	 patients	 in	 primary	 care	 the	 prevalence	 of	 PsA	 is	 conservatively	
estimated	to	be	3.2%	increasing	to	4.6%	if	enthesitis	is	taken	into	account.	The	prevalence	of	MSC	in	
psoriasis	patients	is	comparable	to	the	prevalence	in	general	population.	
	
	 	
Introduction	
Psoriatic	arthritis	(PsA)	is	the	second	most	frequent	inflammatory	arthritis	for	which	a		rheumatologist	
is	 consulted.1	 PsA	 is	well	 treatable	 and	an	 increasing	number	of	 studies	 show	 that	 early	diagnosis	
improves	the	outcome	substantially.2-6	In	most	cases	PsA	is	preceded	by	psoriasis,	which	affects	2-3%	
of	 the	 Western	 population.7-9	 Estimates	 of	 the	 prevalence	 of	 PsA	 among	 psoriasis	 patients	 are	
numerous	 and	 range	 widely	 (6-42%)	 and	most	 data	 stems	 from	 secondary	 dermatology	 care.10,11	
However,	most	psoriasis	patients	at	risk	for	PsA	will	visit	their	general	practitioner	(GP)	first	if	having	
musculoskeletal	complaints	(MSC),	enabling	early	referral	if	recognized	timely.	Therefore,	prevalence	
data	from	primary	care	is	important.	To	our	knowledge,	only	two	studies	have	reported	the	prevalence	
of	PsA	in	primary	care.	Both	studies	were	performed	in	the	UK	and	report	prevalences	of	9.0%	and	
13.8%.12,13	
The	 primary	 objective	 of	 this	 study	 was	 to	 give	 an	 estimate	 of	 the	 prevalence	 of	 PsA	 including	
enthesitis	 in	 primary	 care	 psoriasis	 patients	 and	 secondly	 to	 estimate	 the	 prevalence	 of	 MSC	 in	
psoriasis	patients.	
	
Methods	
Patients	
Between	June	2013	and	March	2014,	270	GPs	from	the	greater	Rotterdam	area	in	the	Netherlands	
were	invited	to	participate,	initially	by	a	personal	letter	and	if	they	did	not	respond	by	phone	call.	The	
participating	 GPs	 (n=97;	 36%)	 selected	 their	 psoriasis	 patients	 aged	 18	 years	 and	 over	 from	 their	
databases	using	ICPC	code	S91	(International	Classification	of	Primary	Care	code	for	psoriasis).14	In	the	
Netherlands,	the	ICPC	is	the	standard	for	coding	and	classification	of	signs	and	symptoms	in	general	
practice.	 The	 identified	 psoriasis	 patients	 received	 an	 invitation	 from	 their	 GP	 asking	 them	 to	
participate.	 Patients	were	asked	 to	 return	 the	 reply	 slip,	which	 contained	 two	questions.	 The	 first	
question	was	if	they	did	or	did	not	suffer	from	regular	joint	complaints,	back	complaints	or	tendon	
complaints.	 Secondly	 they	 were	 asked	 if	 they	 wanted	 to	 participate.	 In	 the	 accompanying	 letter,	
patients	were	asked	to	return	the	reply	slip,	regardless	of	whether	they	wanted	to	participate.	The	
patients	who	agreed	to	participate	were	called	by	a	trained	interviewer	to	verify		if	they	had	regular	
joint	and	tendon	complaints	or	chronic	low	back	pain	(with	chronic	defined	as	more	than	12	weeks	
and	 onset	 before	 the	 age	 of	 45).	 She	 also	 verified	whether	 they	 had	 a	 diagnosis	 of	 psoriasis	 and	
sufficient	knowledge	of	the	Dutch	language	to	complete	the	questionnaires.	Ethics	approval	from	the	
Dutch	Medical	Ethical	Committee	(M12-1275)	was	obtained	as	well	as	written	informed	consent	from	
all	participating	patients.	
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Abstract	
	
Objective.	To	estimate	the	prevalence	of	PsA	in	primary	care	patients	diagnosed	with	psoriasis.	The	
second	objective	was	to	estimate	the	prevalence	of	MSC	in	primary	care	psoriasis	patients.	
	
Methods.	 We	 conducted	 a	 cross-sectional	 study	 in	 adult	 primary	 care	 patients	 with	 psoriasis.		
Responding	patients	reporting	pain	in	joints,	entheses	or	lower	back	were	checked	on	eligibility	by	a	
telephone	interview	and	invited	for	clinical	evaluation.	During	clinical	evaluation	skin,	nails,	joints	and	
entheses	 were	 assessed.	 Additionally,	 ultrasonography	 of	 the	 entheses	 was	 performed	 by	 an	
independent	trained	examiner	if	a	patient	had	at	least	one	tender	enthesis	(LEI/MASES).	A	patient	had	
PsA	if	fulfilling	the	CASPAR	criteria.	
	
Results.	 2564	 psoriasis	 patients	 from	 97	 GPs	 were	 invited.	 Of	 the	 1673	 responders	 (65.2%),	 841	
(50.3%)	 were	 willing	 to	 participate.	 823	 (32.1%)	 patients	 reported	 suffering	 from	 MSC	 of	 which	
eventually	 524	 were	 eligible	 and	 clinically	 evaluated.	 Sixty-four	 cases	 of	 established	 PsA	 were	
identified	and	another	17	cases	of	PsA	were	newly	diagnosed,	leading	to	a	prevalence	of	3.2%	(95%CI	
2.5%-3.9%)	among	primary	care	psoriasis	patients.	This	would	increase	towards	4.6%	(95%	CI	3.8%-
5.4%)	if	the	PsA	cases	based	on	enthesitis	are	also	taken	into	account.		
	
Conclusion.	 Among	 psoriasis	 patients	 in	 primary	 care	 the	 prevalence	 of	 PsA	 is	 conservatively	
estimated	to	be	3.2%	increasing	to	4.6%	if	enthesitis	is	taken	into	account.	The	prevalence	of	MSC	in	
psoriasis	patients	is	comparable	to	the	prevalence	in	general	population.	
	
	 	
Introduction	
Psoriatic	arthritis	(PsA)	is	the	second	most	frequent	inflammatory	arthritis	for	which	a		rheumatologist	
is	 consulted.1	 PsA	 is	well	 treatable	 and	an	 increasing	number	of	 studies	 show	 that	 early	diagnosis	
improves	the	outcome	substantially.2-6	In	most	cases	PsA	is	preceded	by	psoriasis,	which	affects	2-3%	
of	 the	 Western	 population.7-9	 Estimates	 of	 the	 prevalence	 of	 PsA	 among	 psoriasis	 patients	 are	
numerous	 and	 range	 widely	 (6-42%)	 and	most	 data	 stems	 from	 secondary	 dermatology	 care.10,11	
However,	most	psoriasis	patients	at	risk	for	PsA	will	visit	their	general	practitioner	(GP)	first	if	having	
musculoskeletal	complaints	(MSC),	enabling	early	referral	if	recognized	timely.	Therefore,	prevalence	
data	from	primary	care	is	important.	To	our	knowledge,	only	two	studies	have	reported	the	prevalence	
of	PsA	in	primary	care.	Both	studies	were	performed	in	the	UK	and	report	prevalences	of	9.0%	and	
13.8%.12,13	
The	 primary	 objective	 of	 this	 study	 was	 to	 give	 an	 estimate	 of	 the	 prevalence	 of	 PsA	 including	
enthesitis	 in	 primary	 care	 psoriasis	 patients	 and	 secondly	 to	 estimate	 the	 prevalence	 of	 MSC	 in	
psoriasis	patients.	
	
Methods	
Patients	
Between	June	2013	and	March	2014,	270	GPs	from	the	greater	Rotterdam	area	in	the	Netherlands	
were	invited	to	participate,	initially	by	a	personal	letter	and	if	they	did	not	respond	by	phone	call.	The	
participating	 GPs	 (n=97;	 36%)	 selected	 their	 psoriasis	 patients	 aged	 18	 years	 and	 over	 from	 their	
databases	using	ICPC	code	S91	(International	Classification	of	Primary	Care	code	for	psoriasis).14	In	the	
Netherlands,	the	ICPC	is	the	standard	for	coding	and	classification	of	signs	and	symptoms	in	general	
practice.	 The	 identified	 psoriasis	 patients	 received	 an	 invitation	 from	 their	 GP	 asking	 them	 to	
participate.	 Patients	were	asked	 to	 return	 the	 reply	 slip,	which	 contained	 two	questions.	 The	 first	
question	was	if	they	did	or	did	not	suffer	from	regular	joint	complaints,	back	complaints	or	tendon	
complaints.	 Secondly	 they	 were	 asked	 if	 they	 wanted	 to	 participate.	 In	 the	 accompanying	 letter,	
patients	were	asked	to	return	the	reply	slip,	regardless	of	whether	they	wanted	to	participate.	The	
patients	who	agreed	to	participate	were	called	by	a	trained	interviewer	to	verify		if	they	had	regular	
joint	and	tendon	complaints	or	chronic	low	back	pain	(with	chronic	defined	as	more	than	12	weeks	
and	 onset	 before	 the	 age	 of	 45).	 She	 also	 verified	whether	 they	 had	 a	 diagnosis	 of	 psoriasis	 and	
sufficient	knowledge	of	the	Dutch	language	to	complete	the	questionnaires.	Ethics	approval	from	the	
Dutch	Medical	Ethical	Committee	(M12-1275)	was	obtained	as	well	as	written	informed	consent	from	
all	participating	patients.	
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Data	collection	
Data	was	collected	by	self-reported	questionnaires	and	clinical	evaluation.		
Questionnaires.	Patients	were	asked	 to	complete	 three	questionnaires	 related	 to	 their	 complaints.	
Indication	 of	 inflammatory	 back	 pain	 was	 assessed	 by	 the	 ASAS-IBP	 (ASAS	 questionnaire	 on	
Inflammatory	Back	Pain)15,	which	consists	of	five	yes-no	questions.	To	assess	the	presence	of	other	
MSC	 the	 PEST	 (Psoriasis	 Epidemiology	 Screening	 Tool)16	 and	 the	 EARP	 (Early	 Psoriatic	 Arthritis	
Screening	 Questionnaire)17	 were	 used.	 These	 are	 both	 validated	 questionnaires	 developed	 as	
screening	tools	for	PsA,	consisting	of	yes-no	questions	on	the	presence	of	particular	features	such	as	
joint	swelling	and	swelling	of	the	Achilles	tendon.	The	PEST	also	includes	a	manikin	for	stiff,	swollen	
or	painful	joints.		
Clinical	Evaluation.	A	trained	research	assistant	completed	a	detailed	history,	containing	information	
about	psoriasis	and	musculoskeletal	complaints,	presence	of	other	features	including	dactylitis,	uveitis	
and	inflammatory	bowel	disease	and	family	history.	Physical	examination	focused	on	the	skin,	nails,	
joints	and	entheses.	Psoriasis	severity	was	scored	by	the	psoriasis	area	and	severity	index	PASI18	This	
provides	a	quantitative	assessment	of	psoriasis	based	on	the	amount	of	body	surface	area	involved	
and	 the	degree	of	 severity	of	 erythema,	 induration	 and	 scaling	weighted	by	body	 area.	 The	 score	
ranges	 between	 0	 and	 72	 and	 a	 score	 above	 10	 is	 considered	 to	 represent	 moderate	 to	 severe	
psoriasis.	 The	nails	were	visually	 inspected	and	 if	 an	abnormality	was	observed	a	photograph	was	
taken,	which	was	evaluated	by	a	trained	dermatologist	who	was	unaware	of	clinical	presentation.	The	
joints	were	evaluated	by	manual	palpation	of	tenderness	and	swelling	using	the	66/68	joint	count.19	
The	enthesis	were	manually	evaluated	for	tenderness	using	the	LEI	(Leeds	Enthesitis	Index20	and	the	
MASES	 (Maastricht	Ankylosing	 Spondylitis	 Enthesitis	 Score)21.	 The	 LEI	 consists	 of	 6	 entheseal	 sites	
(lateral	epicondyle	of	 the	humerus,	medial	 condyle	of	 the	 femur	and	Achilles	 tendon	 insertion,	all	
bilaterally)	and	the	MASES	of	13	entheseal	sites	(1st	and	7th	costochondral	joint,	anterior	and	posterior	
superior	iliac	spine,	iliac	crest,	proximal	insertion	of	Achilles	tendon,	all	bilaterally	and	the	5th	lumbar	
spinous	processus),	the	score	is	the	sum	of	all	tender	sites.	
Ultrasound	evaluation	of	the	enthesis.	 If	clinical	evaluation	resulted	in	at	least	one	tender	enthesis,	
patients	were	referred	for	an	ultrasonographic	examination	by	an	independent	trained	examiner	using	
Esaote	Mylab60	(probe	LA	435).	The	six	entheses	included	in	the	MASEI	(Madrid	Sonographic	Enthesis	
Index)	22	were	examined	bilaterally:	olecranon	tuberosity,	superior	&	inferior	pole	of	the	patella,	tibial	
tuberosity,	superior	pole	(Achilles	tendon)	&	inferior	pole	(plantar	fascia)	of	the	calcaneus	plus	the	
lateral	 epicondyle	 tendon	 insertions	 (elbow).	US	 enthesitis	was	 defined	 as	 the	 presence	 of	 power	
Doppler	(PD)	signal	(<2mm	of	the	bony	cortex)	or	in	case	of	the	plantar	fascia	an	increased	thickness	
of	the	enthesis	(>4.4mm)	as	PD	signal	cannot	be	obtained	at	the	plantar	fascia.22,23	
	
Referral	to	rheumatologist	
Patients	 were	 advised	 to	 consult	 a	 rheumatologist	 if	 there	 were	 indications	 of	 underlying	
rheumatological	 disease.	 Referral	 criteria	 were	 set	 up	 and	 these	 included	 an	 evident	 history	 of	
dactylitis	or	arthritis	as	well	as	current	peripheral	or	axial	manifestations.	Peripheral	manifestations	
were	 defined	 as	 arthritis	 in	 one	 or	 more	 joints	 upon	 physical	 examination	 or	 enthesitis	 at	 US	
examination.	Possible	axial	manifestation	was	defined	as	low	back	pain	for	more	than	12	consecutive	
weeks	 with	 an	 onset	 before	 the	 age	 of	 45	 and	 two	 or	 more	 of	 the	 following;	 positive	 ASAS-IBP	
questionnaire	(4	out	of	5	positive),	positive	family	history	of	SpA,	good	response	to	NSAIDs	or	chronic	
low	back	pain	for	more	than	5	years.24	
	
Case	definition	
The	 diagnosis	 of	 PsA	was	 based	 on	 the	 CASPAR	 criteria,	 where	 patients	must	 have	 inflammatory	
articular	disease	in	the	joints,	spine	or	entheses.25	On	top	of	this,	at	least	3	out	of	the	following	6	points	
are	 required:	 the	 presence	 of	 psoriasis	 (current	 (2	 points)	 or	 history),	 presence	 of	 psoriatic	 nail	
dystrophy,	absence	of	rheumatoid	factor,	dactylitis	(diagnosed	by	rheumatologist)	and	radiographic	
evidence	of	juxtaarticular	new	bone	formation.	The	presence	of	peripheral	arthritis	and	axial	disease	
were	confirmed	by	a	rheumatologist.	For	enthesitis	there	is	no	commonly	accepted	clinical	definition,	
which	is	why	we	decided	to	use	a	combination	of	clinical	characteristics	and	positive	Power	Doppler	
signal	at	the	enthesis	(<2mm	of	the	bony	cortex).23	Clinical	characteristics	included	self-reported	pain	
at	the	enthesis	(either	on	PEST	or	EARP	questionnaire	or	in	the	history)	or	the	presence	of	a	tender	
enthesis	at	clinical	examination	(LEI/MASES).	We	did	not	accept	the	sole	presence	of	PD	as	study	data	
suggest	that	PD	could	be	present	in	non-clinical	cases.26-28		
	
Statistical	Analysis	
Descriptive	statistics	were	used	for	the	prevalence	of	PsA	and	MSC,	symptom	duration,	medication	
use	and	other	clinical	features	in	STATA	13.	Because	of	missing	information	in	different	phases	of	the	
patient	recruitment	on	both	the	prevalence	of	PsA	and	the	prevalence	of	MSC,	sensitivity	analysis	was	
performed.	We	evaluated	three	scenarios	in	which	we	assumed	what	would	have	been	the	frequency	
of	PsA	and	MSC	as	if	we	had	have	evaluated	the	patients	that	did	not	reply.	In	the	first	scenario,	we	
used	 our	 observed	 frequency	 of	MSC	 among	 the	 responders	 to	 apply	 to	 the	 non-responders	 and	
subsequently	we	applied	the	observed	frequency	of	PsA	within	the	MSC	to	the	non-responders.	In	the	
second	scenario,	we	used	for	the	non-responders	the	MSC	frequency	we	observed	from	the	patients	
who	returned	their	reply-slip	but	did	not	want	to	participate.	For	the	frequency	of	PsA	we	made	the	
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Data	collection	
Data	was	collected	by	self-reported	questionnaires	and	clinical	evaluation.		
Questionnaires.	Patients	were	asked	 to	complete	 three	questionnaires	 related	 to	 their	 complaints.	
Indication	 of	 inflammatory	 back	 pain	 was	 assessed	 by	 the	 ASAS-IBP	 (ASAS	 questionnaire	 on	
Inflammatory	Back	Pain)15,	which	consists	of	five	yes-no	questions.	To	assess	the	presence	of	other	
MSC	 the	 PEST	 (Psoriasis	 Epidemiology	 Screening	 Tool)16	 and	 the	 EARP	 (Early	 Psoriatic	 Arthritis	
Screening	 Questionnaire)17	 were	 used.	 These	 are	 both	 validated	 questionnaires	 developed	 as	
screening	tools	for	PsA,	consisting	of	yes-no	questions	on	the	presence	of	particular	features	such	as	
joint	swelling	and	swelling	of	the	Achilles	tendon.	The	PEST	also	includes	a	manikin	for	stiff,	swollen	
or	painful	joints.		
Clinical	Evaluation.	A	trained	research	assistant	completed	a	detailed	history,	containing	information	
about	psoriasis	and	musculoskeletal	complaints,	presence	of	other	features	including	dactylitis,	uveitis	
and	inflammatory	bowel	disease	and	family	history.	Physical	examination	focused	on	the	skin,	nails,	
joints	and	entheses.	Psoriasis	severity	was	scored	by	the	psoriasis	area	and	severity	index	PASI18	This	
provides	a	quantitative	assessment	of	psoriasis	based	on	the	amount	of	body	surface	area	involved	
and	 the	degree	of	 severity	of	 erythema,	 induration	 and	 scaling	weighted	by	body	 area.	 The	 score	
ranges	 between	 0	 and	 72	 and	 a	 score	 above	 10	 is	 considered	 to	 represent	 moderate	 to	 severe	
psoriasis.	 The	nails	were	visually	 inspected	and	 if	 an	abnormality	was	observed	a	photograph	was	
taken,	which	was	evaluated	by	a	trained	dermatologist	who	was	unaware	of	clinical	presentation.	The	
joints	were	evaluated	by	manual	palpation	of	tenderness	and	swelling	using	the	66/68	joint	count.19	
The	enthesis	were	manually	evaluated	for	tenderness	using	the	LEI	(Leeds	Enthesitis	Index20	and	the	
MASES	 (Maastricht	Ankylosing	 Spondylitis	 Enthesitis	 Score)21.	 The	 LEI	 consists	 of	 6	 entheseal	 sites	
(lateral	epicondyle	of	 the	humerus,	medial	 condyle	of	 the	 femur	and	Achilles	 tendon	 insertion,	all	
bilaterally)	and	the	MASES	of	13	entheseal	sites	(1st	and	7th	costochondral	joint,	anterior	and	posterior	
superior	iliac	spine,	iliac	crest,	proximal	insertion	of	Achilles	tendon,	all	bilaterally	and	the	5th	lumbar	
spinous	processus),	the	score	is	the	sum	of	all	tender	sites.	
Ultrasound	evaluation	of	the	enthesis.	 If	clinical	evaluation	resulted	in	at	least	one	tender	enthesis,	
patients	were	referred	for	an	ultrasonographic	examination	by	an	independent	trained	examiner	using	
Esaote	Mylab60	(probe	LA	435).	The	six	entheses	included	in	the	MASEI	(Madrid	Sonographic	Enthesis	
Index)	22	were	examined	bilaterally:	olecranon	tuberosity,	superior	&	inferior	pole	of	the	patella,	tibial	
tuberosity,	superior	pole	(Achilles	tendon)	&	inferior	pole	(plantar	fascia)	of	the	calcaneus	plus	the	
lateral	 epicondyle	 tendon	 insertions	 (elbow).	US	 enthesitis	was	 defined	 as	 the	 presence	 of	 power	
Doppler	(PD)	signal	(<2mm	of	the	bony	cortex)	or	in	case	of	the	plantar	fascia	an	increased	thickness	
of	the	enthesis	(>4.4mm)	as	PD	signal	cannot	be	obtained	at	the	plantar	fascia.22,23	
	
Referral	to	rheumatologist	
Patients	 were	 advised	 to	 consult	 a	 rheumatologist	 if	 there	 were	 indications	 of	 underlying	
rheumatological	 disease.	 Referral	 criteria	 were	 set	 up	 and	 these	 included	 an	 evident	 history	 of	
dactylitis	or	arthritis	as	well	as	current	peripheral	or	axial	manifestations.	Peripheral	manifestations	
were	 defined	 as	 arthritis	 in	 one	 or	 more	 joints	 upon	 physical	 examination	 or	 enthesitis	 at	 US	
examination.	Possible	axial	manifestation	was	defined	as	low	back	pain	for	more	than	12	consecutive	
weeks	 with	 an	 onset	 before	 the	 age	 of	 45	 and	 two	 or	 more	 of	 the	 following;	 positive	 ASAS-IBP	
questionnaire	(4	out	of	5	positive),	positive	family	history	of	SpA,	good	response	to	NSAIDs	or	chronic	
low	back	pain	for	more	than	5	years.24	
	
Case	definition	
The	 diagnosis	 of	 PsA	was	 based	 on	 the	 CASPAR	 criteria,	 where	 patients	must	 have	 inflammatory	
articular	disease	in	the	joints,	spine	or	entheses.25	On	top	of	this,	at	least	3	out	of	the	following	6	points	
are	 required:	 the	 presence	 of	 psoriasis	 (current	 (2	 points)	 or	 history),	 presence	 of	 psoriatic	 nail	
dystrophy,	absence	of	rheumatoid	factor,	dactylitis	(diagnosed	by	rheumatologist)	and	radiographic	
evidence	of	juxtaarticular	new	bone	formation.	The	presence	of	peripheral	arthritis	and	axial	disease	
were	confirmed	by	a	rheumatologist.	For	enthesitis	there	is	no	commonly	accepted	clinical	definition,	
which	is	why	we	decided	to	use	a	combination	of	clinical	characteristics	and	positive	Power	Doppler	
signal	at	the	enthesis	(<2mm	of	the	bony	cortex).23	Clinical	characteristics	included	self-reported	pain	
at	the	enthesis	(either	on	PEST	or	EARP	questionnaire	or	in	the	history)	or	the	presence	of	a	tender	
enthesis	at	clinical	examination	(LEI/MASES).	We	did	not	accept	the	sole	presence	of	PD	as	study	data	
suggest	that	PD	could	be	present	in	non-clinical	cases.26-28		
	
Statistical	Analysis	
Descriptive	statistics	were	used	for	the	prevalence	of	PsA	and	MSC,	symptom	duration,	medication	
use	and	other	clinical	features	in	STATA	13.	Because	of	missing	information	in	different	phases	of	the	
patient	recruitment	on	both	the	prevalence	of	PsA	and	the	prevalence	of	MSC,	sensitivity	analysis	was	
performed.	We	evaluated	three	scenarios	in	which	we	assumed	what	would	have	been	the	frequency	
of	PsA	and	MSC	as	if	we	had	have	evaluated	the	patients	that	did	not	reply.	In	the	first	scenario,	we	
used	 our	 observed	 frequency	 of	MSC	 among	 the	 responders	 to	 apply	 to	 the	 non-responders	 and	
subsequently	we	applied	the	observed	frequency	of	PsA	within	the	MSC	to	the	non-responders.	In	the	
second	scenario,	we	used	for	the	non-responders	the	MSC	frequency	we	observed	from	the	patients	
who	returned	their	reply-slip	but	did	not	want	to	participate.	For	the	frequency	of	PsA	we	made	the	
Chapter 2
32
same	assumption	as	 in	 the	 first	 scenario.	 The	 third	 scenario	equals	 the	 second	with	 regard	 to	 the	
observed	 frequency	of	MSC,	but	 the	 frequency	of	PsA	was	as	observed	among	clinically	evaluated	
patients	only.		
	
Results	
Source	population	
In	total,	97	GPs	participated,	representing	a	source	population	of	158	046	patients	aged	18	years	and	
over.	Out	of	these	158	046	patients,	2647	had	an	ICPC	code	S91	for	psoriasis	(1.7%)	(Figure	1).	In	the	
process	of	inviting	the	patients	for	clinical	evaluation,	83	(3.1%)	patients	reported	not	having	psoriasis	
and	were	excluded,	so	eventually	we	had	a	population	of	2564	psoriasis	patients	(mean	age	55.2	years	
(SD	17.5),	51.6%	male).	Figure	2	shows	the	distribution	of	psoriasis	per	age	category	and	gender.	
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tendons	and/or	lower	back	were	then	mentioned	by	78.4%	of	the	patients	(n=659)	and	subsequently	
invited	for	clinical	evaluation.	Of	these,	524	patients	were	actually	present	at	their	clinical	evaluation	
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Prevalence	of	musculoskeletal	complaints	
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reported	 having	 regular	MSC,	which	 leads	 to	 a	 prevalence	 of	 32.1%,	 assuming	 no	 additional	MSC	
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Figure	3.	Flow	diagram	of	sources	used	for	calculating	the	prevalence	of	musculoskeletal	
complaints	&	psoriatic	arthritis	in	a	primary	care	psoriasis	population	
	
	
	
Clinically	evaluated	patients	
The	mean	age	of	the	524	evaluated	patients	was	55.8	years	(SD	13.9)	and	50.0%	were	male.	Mean	
psoriasis	 duration	 was	 21.0±16.3	 years,	 with	 74%	 of	 the	 psoriasis	 diagnoses	 confirmed	 by	 a	
dermatologist.	 The	 remaining	 26%	 of	 psoriasis	 cases	 were	 confirmed	 by	 the	 GP.	 During	 clinical	
evaluation	81	patients	(15.5%)	had	nail	abnormalities	consistent	with	psoriatic	nail	dystrophy.	Median	
PASI	score	in	the	study	population	was	2.2	(IQR	1-4).	Table	1	provides	the	clinical	details	for	those	not	
suffering	from	PsA,	established	PsA,	new	PsA	and	enthesitis.		
	
	
	
	
	
Prevalence	of	PsA	
Established	PsA	
The	frequency	of	established	PsA	was	2.5%	(95%	CI	2.0-3.2%;	n=64).	As	with	information	about	MSC,	
information	about	an	established	diagnosis	of	PsA	was	also	derived	from	two	sources.	First,	we	had	
13	patients	who	did	not	want	to	participate	in	the	study	but	already	had	a	confirmed	diagnosis	of	PsA.	
Another	51	patients	with	a	confirmed	diagnosis	of	PsA	did	participate	in	the	study	(Figure	3).	
Newly	diagnosed	PsA	
Besides	the	established	cases,	PsA	was	also	newly	diagnosed	by	a	rheumatologist	in	17	cases.	Within	
the	PsA	cases	11	patients	(64.7%)	presented	solely	with	peripheral	arthritis.	Five	cases	(29.4%)	of	axial	
PsA	were	diagnosed	and	one	patient	(5.9%)	presented	with	a	combination	of	axial	PsA	and	peripheral	
arthritis.	Moreover,	we	also	identified	36	cases	of	enthesitis,	in	which	the	inflammatory	component	
was	confirmed	by	US.	Most	of	these	patients	refrained	from	further	evaluation	by	a	rheumatologist,	
but	according	to	the	CASPAR	criteria,	most	of	these	cases	will	classify	as	PsA.		
	
Overall	prevalence	&	sensitivity	analysis	
In	total	we	identified	81	cases	of	PsA,	of	which	17	(21%)	cases	were	newly	diagnosed.	This	leads	to	a	
prevalence	of	PsA	among	all	2564	primary	care	psoriasis	patients	of	3.2%	(95%	CI	2.5-3.9%)	(Figure	3).	
This	represents	the	situation	in	which	no	additional	cases	would	be	identified	in	the	non-responders	
and	in	patients	who	declined	participation.	It	is	questionable	whether	this	assumption	holds	true	and	
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dermatologist.	 The	 remaining	 26%	 of	 psoriasis	 cases	 were	 confirmed	 by	 the	 GP.	 During	 clinical	
evaluation	81	patients	(15.5%)	had	nail	abnormalities	consistent	with	psoriatic	nail	dystrophy.	Median	
PASI	score	in	the	study	population	was	2.2	(IQR	1-4).	Table	1	provides	the	clinical	details	for	those	not	
suffering	from	PsA,	established	PsA,	new	PsA	and	enthesitis.		
	
	
	
	
	
Prevalence	of	PsA	
Established	PsA	
The	frequency	of	established	PsA	was	2.5%	(95%	CI	2.0-3.2%;	n=64).	As	with	information	about	MSC,	
information	about	an	established	diagnosis	of	PsA	was	also	derived	from	two	sources.	First,	we	had	
13	patients	who	did	not	want	to	participate	in	the	study	but	already	had	a	confirmed	diagnosis	of	PsA.	
Another	51	patients	with	a	confirmed	diagnosis	of	PsA	did	participate	in	the	study	(Figure	3).	
Newly	diagnosed	PsA	
Besides	the	established	cases,	PsA	was	also	newly	diagnosed	by	a	rheumatologist	in	17	cases.	Within	
the	PsA	cases	11	patients	(64.7%)	presented	solely	with	peripheral	arthritis.	Five	cases	(29.4%)	of	axial	
PsA	were	diagnosed	and	one	patient	(5.9%)	presented	with	a	combination	of	axial	PsA	and	peripheral	
arthritis.	Moreover,	we	also	identified	36	cases	of	enthesitis,	in	which	the	inflammatory	component	
was	confirmed	by	US.	Most	of	these	patients	refrained	from	further	evaluation	by	a	rheumatologist,	
but	according	to	the	CASPAR	criteria,	most	of	these	cases	will	classify	as	PsA.		
	
Overall	prevalence	&	sensitivity	analysis	
In	total	we	identified	81	cases	of	PsA,	of	which	17	(21%)	cases	were	newly	diagnosed.	This	leads	to	a	
prevalence	of	PsA	among	all	2564	primary	care	psoriasis	patients	of	3.2%	(95%	CI	2.5-3.9%)	(Figure	3).	
This	represents	the	situation	in	which	no	additional	cases	would	be	identified	in	the	non-responders	
and	in	patients	who	declined	participation.	It	is	questionable	whether	this	assumption	holds	true	and	
Table 1 Characteristics of the 524 participating psoriasis patients
Axial 
manifestations 
& Peripheral 
Arthritis*
(n=17)
Enthesitis*
(n=36)
Established 
PsA 
patients* 
(n=51)
Psoriasis 
patients*
(n=420)
Mean Age, years (±SD) 47.4 (10.7) 58.0 (12.3) 56.1 (14.4) 55.9 (14.0)
Male sex, n (%) 8 (47.1) 17 (47.2) 21 (41.2) 216 (51.4)
Body Mass Index, mean (±SD) 27.9 (6.2) 30.0 (4.1) 28.2 (8.3) 27.8 (4.8)
Median Psoriasis Symptom Duration, years 
(IQR)
15 (4-30) 20 (11-37) 20 (12-33) 15 (8-30)
Psoriasis Diagnosis by Dermatologist, n (%) 13 (76.5) 31 (86.1) 42 (82.4) 302 (71.9)
Nail psoriasis, n (%) 5 (29.4) 2 (5.6) 10 (19.6) 64 (15.2)
PASI, median (IQR) 3 (1.3-4) 3.1 (1.7-4.4) 1 (0-3) 2.2 (1-4)
Median MSC Symptom Duration, years (IQR)
                                                                              Joints 12.5 (2-23) 10 (5-25) 12 (8-20) 8 (4-14)
Lower Back 18 (9-25) 33 (14-41) 8.5 (5-18) 12 (5-25)
LEI, median (IQR) 0 (0-1) 1 (1-2) 0 (0-1) 0 (0-0)
MASES, median (IQR) 0 (0-3) 2 (0-3) 0 (0-2) 0 (0-0)
PsA=Psoriatic Arthritis, PASI=Psoriasis Area&Severity Index, MSC=musculoskeletal complaints, LEI=Leeds 
Enthesitis Index, MASES= Maastricht Ankylosing Spondylitis Enthesitis Score
*Axial manifestations & arthritis are the patients who were diagnosed as having PsA by the rheumatologist. 
Enthesitis are the patients who would have a diagnosis of PsA based on the CASPAR criteria. Established 
PsA are the patients already diagnosed with PsA at the beginning of the study and psoriasis patients are the 
patients with MSC but without PsA.
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we	therefore	did	a	sensitivity	analysis	evaluating	three	scenarios.	In	the	first	scenario,	we	assumed	an	
equal	prevalence	of	MSC	for	the	responders	and	the	non-responders.	Among	the	1673	responders,	
823	suffered	from	MSC,	leading	to	a	prevalence	of	49.2%.	The	prevalence	of	PsA	among	the	patients	
suffering	 from	MSC	 was	 9.8%	 (81	 PsA	 cases	 in	 823	 patients	 with	MSC).	 We	 assumed	 that	 these	
prevalences	 we	 observed	 in	 the	 responders,	 would	 also	 apply	 to	 the	 891	 non-responders.	 This	
assumption	would	then	increase	the	prevalence	of	PsA	towards	4.8%	(95%	CI	4.1-5.7%).	In	the	second	
scenario,	we	used	the	observed	frequency	of	MSC	among	the	non-participants	who	returned	their	
reply	slip.	Among	the	832	patients	who	indicated	that	they	did	not	want	to	participate,	704	provided	
information	about	the	presence	of	MSC,	of	which	164	suffered	from	MSC	(23.3%)	(Figure	3).	In	this	
scenario,	when	assuming	equal	prevalence	of	PsA	as	in	the	first	scenario	(9.8%),	the	prevalence	of	PsA	
would	 increase	towards	3.9%	(95%	CI	3.2-4.8%).	 In	 the	third	and	 final	scenario,	we	used	the	same	
frequency	of	MSC	as	in	the	second	scenario	(23.3%),	but	varied	the	prevalence	of	PsA.	We	used	the	
frequency	of	PsA	we	observed	in	all	patients	who	were	clinically	evaluated,	this	leads	to	a	prevalence	
of	PsA	of	13.0%.	Applying	this	prevalence	of	PsA	on	the	non-responders,	the	prevalence	of	PsA	would	
increase	towards	4.2%	(95%CI	3.5-5.1%).	
	
Enthesitis	
111	patients	were	referred	for	US	evaluation	of	the	enthesis.	In	36	cases	a	combination	of	clinical	and	
US	 enthesitis	 was	 present.	 As	 the	 CASPAR	 criteria	 suggest	 that	 the	 sole	 presence	 of	 enthesitis	 is	
sufficient	to	have	inflammatory	articular	disease,	adding	the	patients	with	enthesitis	would	increase	
the	prevalence	to	4.6%	(95%	CI	3.8-5.4%).	The	three	scenarios	in	the	sensitivity	analysis	would	than	
lead	to	a	prevalence	of	7.0	(95%CI	6.1-8.0)	if	assuming	equal	prevalences	of	MSC	and	PsA,	5.7	(95%	CI	
4.9-6.7%)	if	the	MSC	frequency	in	the	non-participants	would	be	taken	into	account	and	6.2%	(95%CI	
5.3-7.2%)	if	varying	the	frequency	of	PsA	
	
Discussion	
In	this	large	primary	care	based	study	we	found	a	PsA	prevalence	of	3.2%	(95%	CI	2.5-3.9%)	among	
2564	 psoriasis	 patients,	 of	 which	 21%	 was	 newly	 diagnosed.	 The	 prevalence	 of	 musculoskeletal	
complaints	was	32.1%	(95%CI	30.3-33.9%).	In	these	estimates	we	assumed	that	no	additional	cases	
would	be	found	in	the	non-responders.	This	is	probably	a	harsh	assumption	and	we	therefore	did	a	
sensitivity	analysis	in	which	the	prevalence	increased	towards	7.0%	(95%CI	6.1-8.0%)	if	cases	would	
be	found	in	the	non-responders	as	well.		
Previous	 literature	 about	 the	 prevalence	 of	 PsA	 in	 primary	 care	 is	 scarce.12,13	 A	 higher	
prevalence	of	8.6%	(95%	CI	7.7-9.5%)	was	observed	by	Ogdie	et	al.13	One	of	the	explanations	for	this	
difference	 could	 be	 that	 they	 based	 the	 diagnosis	 of	 PsA	 on	medical	 codes	 in	 a	 population-based	
medical	records	database	rather	than	clinical	examination.	An	even	higher	prevalence	was	reported	
by	 Ibrahim	 et	 al	 (13.8%	 (95%CI	 7.1-24.1%)),	 but	 this	 study	 had	 substantial	 non-response.12	 The	
prevalence	would	 reduce	 towards	 1.9%	 if	 all	 initial	 patients	would	 be	 taken	 into	 account	 and	 no	
additional	cases	would	be	found	in	the	non-responders.	More	data	is	available	from	secondary	care,	
where	PsA	prevalence	figures	range	from	6%	to	42%	among	psoriasis	patients.10,29	This	wide	spread	is	
likely	 to	 be	 caused	 by	 the	 use	 of	many	 different	 criteria	 sets,	 self-reported	 patient	 diagnosis	 and	
diagnosis	by	the	dermatologist.		
Defining	 PsA	 has	 proven	 to	 be	 challenging	 due	 to	 its	 clinical	 heterogeneity.	 In	 2006,	 new	
classification	criteria	were	established,	the	CASPAR	criteria.25	Besides	peripheral	synovitis	and	axial	
disease,	 entheseal	 involvement	 was	 characterized	 as	 inflammatory	 articular	 disease.	 Enthesitis	 is	
established	 by	manual	 palpation	 in	which	 pain,	 redness	 and	 swelling	 are	 considered.	 No	 detailed	
definition	for	these	features	is	available	and	according	to	the	CASPAR	criteria,	left	to	the	discretion	of	
the	treating	physician.	If	the	enthesis	lies	deep	within	the	surrounding	tissue,	it	is	difficult	to	locate	
the	enthesis	and	observe	redness	and	swelling.	Pain	itself	is	no	sign	for	underlying	inflammation	as	it	
could	be	related	to	overuse,	metabolic	disease	or	ageing.27	To	overcome	these	difficulties,	we	chose	
to	combine	the	inflammatory	signs	on	US	with	clinical	symptoms,	as	we	think	this	 is	an	acceptable	
definition	for	enthesitis.	If	positive	for	this	definition	patients	classified	as	PsA	according	to	the	CASPAR	
criteria.		
The	prevalence	of	MSC	among	all	initially	invited	psoriasis	patients	was	32.1%,	running	up	to	
49.2%	among	the	patients	returning	their	reply	slip.	These	numbers	fall	well	into	the	MSC	estimates	
in	the	general	population	of	39.7%30	and	53.9%31	in	the	Netherlands.	It	seems	that	psoriasis	patients	
do	not	suffer	more	frequently	from	MSC	than	the	general	population.	
Our	study	has	certain	strengths	and	limitations.	One	of	the	strengths	of	this	study	is	the	large	
population	of	psoriasis	patients.	We	invited	2564	psoriasis	patients	out	of	primary	care	databases	and	
achieved	a	response	rate	of	65.2%.	This	is	a	high	response	rate	for	a	primary	care	study,	as	you	have	
to	depend	on	the	GPs	in	order	to	recruit	patients.	Patients	are	invited	for	the	study	via	the	GP,	so	you	
are	 not	 able	 to	 recruit	 patients	 yourself.	 Secondly,	 our	 study	 provides	 prevalence	 estimates	 for	
primary	care	and	as	mentioned	before	only	two	studies	reported	about	the	prevalence	in	a	primary	
care	 setting	 thus	 far.12,13	 Among	 the	 limitations	 are	 misclassification	 of	 psoriasis,	 ethnicity,	 self-
selection	of	patients,	selection	by	MSC	and	missed	cases.	Psoriasis	was	identified	by	applying	the	ICPC	
code	in	the	GP	databases.	Some	misclassification	(3.1%)	occurred,	possibly	related	to	the	GP	initially	
considering	the	skin	problem	to	be	psoriasis,	which	then	later	on	was	changed	without	updating	the	
ICPC	code.	Ethnic	and	geographic	variation	play	a	role	in	the	prevalence	of	psoriasis	and	also	in	PsA	
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we	therefore	did	a	sensitivity	analysis	evaluating	three	scenarios.	In	the	first	scenario,	we	assumed	an	
equal	prevalence	of	MSC	for	the	responders	and	the	non-responders.	Among	the	1673	responders,	
823	suffered	from	MSC,	leading	to	a	prevalence	of	49.2%.	The	prevalence	of	PsA	among	the	patients	
suffering	 from	MSC	 was	 9.8%	 (81	 PsA	 cases	 in	 823	 patients	 with	MSC).	 We	 assumed	 that	 these	
prevalences	 we	 observed	 in	 the	 responders,	 would	 also	 apply	 to	 the	 891	 non-responders.	 This	
assumption	would	then	increase	the	prevalence	of	PsA	towards	4.8%	(95%	CI	4.1-5.7%).	In	the	second	
scenario,	we	used	the	observed	frequency	of	MSC	among	the	non-participants	who	returned	their	
reply	slip.	Among	the	832	patients	who	indicated	that	they	did	not	want	to	participate,	704	provided	
information	about	the	presence	of	MSC,	of	which	164	suffered	from	MSC	(23.3%)	(Figure	3).	In	this	
scenario,	when	assuming	equal	prevalence	of	PsA	as	in	the	first	scenario	(9.8%),	the	prevalence	of	PsA	
would	 increase	towards	3.9%	(95%	CI	3.2-4.8%).	 In	 the	third	and	 final	 scenario,	we	used	the	same	
frequency	of	MSC	as	in	the	second	scenario	(23.3%),	but	varied	the	prevalence	of	PsA.	We	used	the	
frequency	of	PsA	we	observed	in	all	patients	who	were	clinically	evaluated,	this	leads	to	a	prevalence	
of	PsA	of	13.0%.	Applying	this	prevalence	of	PsA	on	the	non-responders,	the	prevalence	of	PsA	would	
increase	towards	4.2%	(95%CI	3.5-5.1%).	
	
Enthesitis	
111	patients	were	referred	for	US	evaluation	of	the	enthesis.	In	36	cases	a	combination	of	clinical	and	
US	 enthesitis	 was	 present.	 As	 the	 CASPAR	 criteria	 suggest	 that	 the	 sole	 presence	 of	 enthesitis	 is	
sufficient	to	have	inflammatory	articular	disease,	adding	the	patients	with	enthesitis	would	increase	
the	prevalence	to	4.6%	(95%	CI	3.8-5.4%).	The	three	scenarios	in	the	sensitivity	analysis	would	than	
lead	to	a	prevalence	of	7.0	(95%CI	6.1-8.0)	if	assuming	equal	prevalences	of	MSC	and	PsA,	5.7	(95%	CI	
4.9-6.7%)	if	the	MSC	frequency	in	the	non-participants	would	be	taken	into	account	and	6.2%	(95%CI	
5.3-7.2%)	if	varying	the	frequency	of	PsA	
	
Discussion	
In	this	large	primary	care	based	study	we	found	a	PsA	prevalence	of	3.2%	(95%	CI	2.5-3.9%)	among	
2564	 psoriasis	 patients,	 of	 which	 21%	 was	 newly	 diagnosed.	 The	 prevalence	 of	 musculoskeletal	
complaints	was	32.1%	(95%CI	30.3-33.9%).	In	these	estimates	we	assumed	that	no	additional	cases	
would	be	found	in	the	non-responders.	This	is	probably	a	harsh	assumption	and	we	therefore	did	a	
sensitivity	analysis	in	which	the	prevalence	increased	towards	7.0%	(95%CI	6.1-8.0%)	if	cases	would	
be	found	in	the	non-responders	as	well.		
Previous	 literature	 about	 the	 prevalence	 of	 PsA	 in	 primary	 care	 is	 scarce.12,13	 A	 higher	
prevalence	of	8.6%	(95%	CI	7.7-9.5%)	was	observed	by	Ogdie	et	al.13	One	of	the	explanations	for	this	
difference	 could	 be	 that	 they	 based	 the	 diagnosis	 of	 PsA	 on	medical	 codes	 in	 a	 population-based	
medical	records	database	rather	than	clinical	examination.	An	even	higher	prevalence	was	reported	
by	 Ibrahim	 et	 al	 (13.8%	 (95%CI	 7.1-24.1%)),	 but	 this	 study	 had	 substantial	 non-response.12	 The	
prevalence	would	 reduce	 towards	 1.9%	 if	 all	 initial	 patients	would	 be	 taken	 into	 account	 and	 no	
additional	cases	would	be	found	in	the	non-responders.	More	data	is	available	from	secondary	care,	
where	PsA	prevalence	figures	range	from	6%	to	42%	among	psoriasis	patients.10,29	This	wide	spread	is	
likely	 to	 be	 caused	 by	 the	 use	 of	many	 different	 criteria	 sets,	 self-reported	 patient	 diagnosis	 and	
diagnosis	by	the	dermatologist.		
Defining	 PsA	 has	 proven	 to	 be	 challenging	 due	 to	 its	 clinical	 heterogeneity.	 In	 2006,	 new	
classification	criteria	were	established,	the	CASPAR	criteria.25	Besides	peripheral	synovitis	and	axial	
disease,	 entheseal	 involvement	 was	 characterized	 as	 inflammatory	 articular	 disease.	 Enthesitis	 is	
established	 by	manual	 palpation	 in	which	 pain,	 redness	 and	 swelling	 are	 considered.	 No	 detailed	
definition	for	these	features	is	available	and	according	to	the	CASPAR	criteria,	left	to	the	discretion	of	
the	treating	physician.	If	the	enthesis	lies	deep	within	the	surrounding	tissue,	it	is	difficult	to	locate	
the	enthesis	and	observe	redness	and	swelling.	Pain	itself	is	no	sign	for	underlying	inflammation	as	it	
could	be	related	to	overuse,	metabolic	disease	or	ageing.27	To	overcome	these	difficulties,	we	chose	
to	combine	the	inflammatory	signs	on	US	with	clinical	symptoms,	as	we	think	this	 is	an	acceptable	
definition	for	enthesitis.	If	positive	for	this	definition	patients	classified	as	PsA	according	to	the	CASPAR	
criteria.		
The	prevalence	of	MSC	among	all	initially	invited	psoriasis	patients	was	32.1%,	running	up	to	
49.2%	among	the	patients	returning	their	reply	slip.	These	numbers	fall	well	into	the	MSC	estimates	
in	the	general	population	of	39.7%30	and	53.9%31	in	the	Netherlands.	It	seems	that	psoriasis	patients	
do	not	suffer	more	frequently	from	MSC	than	the	general	population.	
Our	study	has	certain	strengths	and	limitations.	One	of	the	strengths	of	this	study	is	the	large	
population	of	psoriasis	patients.	We	invited	2564	psoriasis	patients	out	of	primary	care	databases	and	
achieved	a	response	rate	of	65.2%.	This	is	a	high	response	rate	for	a	primary	care	study,	as	you	have	
to	depend	on	the	GPs	in	order	to	recruit	patients.	Patients	are	invited	for	the	study	via	the	GP,	so	you	
are	 not	 able	 to	 recruit	 patients	 yourself.	 Secondly,	 our	 study	 provides	 prevalence	 estimates	 for	
primary	care	and	as	mentioned	before	only	two	studies	reported	about	the	prevalence	in	a	primary	
care	 setting	 thus	 far.12,13	 Among	 the	 limitations	 are	 misclassification	 of	 psoriasis,	 ethnicity,	 self-
selection	of	patients,	selection	by	MSC	and	missed	cases.	Psoriasis	was	identified	by	applying	the	ICPC	
code	in	the	GP	databases.	Some	misclassification	(3.1%)	occurred,	possibly	related	to	the	GP	initially	
considering	the	skin	problem	to	be	psoriasis,	which	then	later	on	was	changed	without	updating	the	
ICPC	code.	Ethnic	and	geographic	variation	play	a	role	in	the	prevalence	of	psoriasis	and	also	in	PsA	
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prevalence.32	 For	 example,	 1%	of	 the	Asian	 psoriasis	 patients	 is	 affected	 by	 PsA	 versus	 10-42%	 in	
Europe	and	North-America.33	 In	our	 study	population	about	98%	were	 from	Caucasian	origin.	 This	
should	be	taken	into	account	when	interpreting	the	results.	Self-selection	related	to	symptoms	might	
have	been	an	 issue	as	we	observe	 that	 the	mean	age	of	 the	 responders	was	55.8±13.9	 years	 and	
people	of	older	age	tend	to	have	more	joint	complaints.	The	ideal	population	would	be	younger,	as	
we	know	that	 the	peak	 incidence	of	PsA	 is	between	30	and	50	years	of	age.	 It	 could	 therefore	be	
possible	that	we	missed	some	cases	among	the	younger	patients	who	did	not	participate.	In	addition,	
we	 only	 invited	 patients	with	 regular	 spells	 of	MSC.	 This	might	 have	 left	 us	with	missed	 cases	 as	
patients	 could	 suffer	 from	 symptom-free	 synovitis	 or	 enthesitis.	However,	we	 think	 the	 chance	of	
missing	a	substantial	number	of	cases	this	way	is	negligible.	Missed	established	PsA	cases	might	be	an	
issue,	although	we	explicitly	asked	to	contact	us	independent	of	symptom	state.			
In	conclusion,	we	conservatively	estimated	the	prevalence	of	PsA	among	psoriasis	patients	in	
primary	care	to	be	3.2%	increasing	to	4.6%	if	enthesitis	is	taken	into	account.	The	prevalence	of	MSC	
among	psoriasis	patients	is	comparable	with	the	prevalence	of	MSC	in	general	population.	 	
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prevalence.32	 For	 example,	 1%	of	 the	Asian	 psoriasis	 patients	 is	 affected	 by	 PsA	 versus	 10-42%	 in	
Europe	and	North-America.33	 In	our	 study	population	about	98%	were	 from	Caucasian	origin.	 This	
should	be	taken	into	account	when	interpreting	the	results.	Self-selection	related	to	symptoms	might	
have	been	an	 issue	as	we	observe	 that	 the	mean	age	of	 the	 responders	was	55.8±13.9	 years	 and	
people	of	older	age	tend	to	have	more	joint	complaints.	The	ideal	population	would	be	younger,	as	
we	know	that	 the	peak	 incidence	of	PsA	 is	between	30	and	50	years	of	age.	 It	 could	 therefore	be	
possible	that	we	missed	some	cases	among	the	younger	patients	who	did	not	participate.	In	addition,	
we	 only	 invited	 patients	with	 regular	 spells	 of	MSC.	 This	might	 have	 left	 us	with	missed	 cases	 as	
patients	 could	 suffer	 from	 symptom-free	 synovitis	 or	 enthesitis.	However,	we	 think	 the	 chance	of	
missing	a	substantial	number	of	cases	this	way	is	negligible.	Missed	established	PsA	cases	might	be	an	
issue,	although	we	explicitly	asked	to	contact	us	independent	of	symptom	state.			
In	conclusion,	we	conservatively	estimated	the	prevalence	of	PsA	among	psoriasis	patients	in	
primary	care	to	be	3.2%	increasing	to	4.6%	if	enthesitis	is	taken	into	account.	The	prevalence	of	MSC	
among	psoriasis	patients	is	comparable	with	the	prevalence	of	MSC	in	general	population.	 	
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Abstract	
	
Objective.	Part	of	the	psoriasis	patients	with	musculoskeletal	complaints	will	have	inflammation	of	
the	entheses.	Entheseal	inflammation	is	difficult	to	assess	by	clinical	examination	only.	Therefore,	we	
aimed	 to	 determine	 the	 frequency	 of	 clinically	 relevant	 ultrasound	 inflammation	 at	 the	 most	
commonly	assessed	entheses	(MASEI;	Madrid	Sonographic	Enthesis	Index)	in	primary	care	psoriasis	
patients	with	one	or	more	tender	entheses.		
	
Methods.	Adult	primary	care	psoriasis	patients	with	musculoskeletal	complaints	(tender	enthesis	or	
arthritis	at	physical	examination)	had	an	ultrasound	examination	of	seven	entheses	according	to	the	
MASEI.	Clinically	relevant	ultrasound	inflammation	was	defined	as	active	inflammation	on	ultrasound	
in	combination	with	at	least	one	clinical	feature	at	the	same	enthesis.	Active	ultrasound	inflammation	
contained	positive	power	Doppler	signal	or	 in	case	of	 the	plantar	aponeurosis	 increased	thickness.	
Structural	 changes	 entailed	 calcifications,	 enthesophytes,	 increased	 thickness,	 hypoechogeneicity	
indicating	irregular	fiber	structure	and	erosions.	Clinically,	an	enthesis	was	scored	positive	by	a	tender	
enthesis	 at	 clinical	 examination,	 reported	 pain	 in	 the	 history	 or	 self-reported	 pain	 in	 the	
questionnaires.		
	
Results.	 Of	 542	 primary	 care	 psoriasis	 patient,	 111	 patients	 had	 tender	 entheses	 and/or	 arthritis.	
These	 patients	 were	 both	 clinically	 and	 ultrasonographically	 evaluated.	 Active	 ultrasound	
inflammation	accompanied	with	pain	or	tenderness	at	the	enthesis	was	found	in	36%	of	the	patients	
(n=40).	Most	common	were	inflammation	at	the	knee	(n=11)	and	at	the	plantar	aponeurosis	(n=10).	
Structural	 changes	 were	 observed	 in	 95%	 of	 the	 psoriasis	 patients	 independent	 of	 their	 clinical	
manifestation.	
	
Conclusion.	 We	 found	 concurrent	 presence	 of	 ultrasound	 inflammatory	 changes	 and	 clinical	
symptoms	in	36%	of	the	primary	care	psoriasis	patients	who	had	tenderness	at	one	or	more	entheseal	
sites.		
	
Introduction	
Enthesitis	 is	an	 important	domain	 in	psoriatic	arthritis	 (PsA).	Since	 the	 introduction	of	 the	CASPAR	
classification	 criteria	 for	 PsA	 in	 2006,	 psoriasis	 patients	 can	 classify	 as	 PsA	with	 only	 enthesitis	 as	
inflammatory	articular	involvement.1	Increasing	attention	is	paid	to	its	assessment2,	3,	but	up	to	now	
no	 consensus	 has	 been	 achieved	 on	 its	 measurements	 in	 the	 diagnostic	 setting.	 In	 both	 the	
classification	criteria	for	PsA	and	spondyloarthritis	(SpA),	enthesitis	is	included.	The	CASPAR	criteria	
suggest	that	the	doctor	diagnoses	enthesitis	as	he	sees	fit.	The	ASAS	criteria	for	peripheral	SpA	include	
only	 the	 Achilles	 tendon	 and	 the	 plantar	 aponeurosis	 without	 being	 specific	 which	 clinical	
characteristics	need	to	present.4		
Enthesitis	is	defined	as	inflammation	at	tendon,	ligament,	joint	capsules	or	aponeurosis	insertion	sites	
to	bone.	Entheseal	pain	can	be	severe,	disabling	and	continuous,	and	can	last	for	several	years.5,	6	The	
ethiopathogenesis	is	poorly	understood	and	may	relate	to	mechanical	stress	on	top	of	the	immune	
response.7	 Clinical	 assessment	 of	 the	 entheses	 is	 difficult	 as	 inflammation	 is	 often	 not	 visible	 or	
palpable.	In	addition,	it	may	be	difficult	to	anatomically	locate	the	enthesis	if	it	lies	deep	within	the	
surrounding	tissue.8	The	location	of	several	entheseal	sites	overlaps	with	those	of	the	tender	points	
of	 fibromyalgia.9	 Furthermore,	 the	 presence	 of	 a	 tender	 enthesis	 is	 not	 necessarily	 indicative	 for	
underlying	 inflammatory	 disease	 as	 it	 could	 be	 related	 to	 overuse,	metabolic	 disease	 or	 ageing.10	
These	challenges	could	lead	to	clinically	false-positive	patients.		
To	resolve	the	difficulties	regarding	clinical	assessment	of	the	entheses,	inflammatory	characteristics	
at	 the	 enthesis	 can	 be	 visualized	 by	 ultrasound.11	 Especially	 the	 use	 of	 the	 power	 Doppler	mode	
improves	the	assessment	of	inflammation	at	the	entheses.12,	13	New	data	about	ultrasound	enthesitis	
emerged	in	patients	with	psoriasis,	PsA	and	healthy	controls.14-16	So	far,	studies	evaluated	enthesitis	
in	 patients	 with	 psoriasis	 who	 were	 referred	 from	 the	 dermatologist.16-20	 A	 significant	 higher	
prevalence	of	both	grayscale	 (GS)	 and	power	Doppler	 (PD)	ultrasound	enthesopathy	was	 found	 in	
patients	with	psoriasis	than	in	controls	(patients	with	dermatological	diseases	other	than	psoriasis).16-
18	In	patients	with	PsA	the	severity	of	ultrasound	abnormalities	was	even	higher	than	in	patients	with	
psoriasis.20	 Ultrasound	 abnormalities	 at	 the	 entheses	 were	 present	 in	 both	 symptomatic	 (true-
positive)	 and	asymptomatic	 (false-positive	or	 subclinical	 disease)	psoriasis	 patients	which	 suggests	
single	application	of	ultrasound	is	not	sufficient	to	detect	clinically	relevant	entheseal	inflammation.19,	
21	
Little	 data	 is	 available	 on	 the	 presence	 of	 PsA	 in	 primary	 care	 psoriasis	 patients.22,	 23	 In	 several	
countries	psoriasis	patients	are	treated	by	their	general	practitioner	and	this	might	mean	that	cases	
of	PsA	are	missed.	In	addition,	these	studies	did	not	include	ultrasound	to	assess	inflammation	at	the	
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Abstract	
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18	In	patients	with	PsA	the	severity	of	ultrasound	abnormalities	was	even	higher	than	in	patients	with	
psoriasis.20	 Ultrasound	 abnormalities	 at	 the	 entheses	 were	 present	 in	 both	 symptomatic	 (true-
positive)	 and	asymptomatic	 (false-positive	or	 subclinical	 disease)	psoriasis	 patients	which	 suggests	
single	application	of	ultrasound	is	not	sufficient	to	detect	clinically	relevant	entheseal	inflammation.19,	
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Little	 data	 is	 available	 on	 the	 presence	 of	 PsA	 in	 primary	 care	 psoriasis	 patients.22,	 23	 In	 several	
countries	psoriasis	patients	are	treated	by	their	general	practitioner	and	this	might	mean	that	cases	
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entheses.	In	a	large	primary	care	based	study	the	frequency	of	PsA	in	psoriasis	patients	was	estimated	
to	be	3.1%	for	arthritis	and	axial	disease,	increasing	to	4.6%	when	enthesitis	would	be	included.24	
In	this	study	we	describe	the	frequency	of	ultrasound	abnormalities	at	the	entheses	and	its	clinical	
information	 in	 primary	 care	 psoriasis	 patients	 who	 had	 at	 least	 one	 tender	 enthesis	 at	 clinical	
examination.	 We	 combined	 PD	 ultrasound	 and	 clinical	 information	 at	 the	 same	 enthesis	 to	
differentiate	between	active	inflammation	and	other	manifestations	of	enthesopathy.	
	
Materials	&	Methods	
Patients	
Adult	 patients	with	psoriasis	 (ICPC	 S91)	were	 identified	 from	97	 general	 practitioners	 (GPs)	 in	 the	
Rotterdam	area.	These	patients	were	invited	to	participate	in	the	SENSOR	study.	Details	of	this	cross-
sectional	study	can	be	found	in	Karreman	et	al.24	In	brief,	patients	who	reported	regular	episodes	of	
pain	in	joints,	entheses	or	the	lower	back	were	eligible	and	invited	for	clinical	evaluation	by	a	trained	
nurse.	 Patients	 were	 not	 recruited	 consecutively.	 Data	 collection	 included	 a	 detailed	 clinical	
examination	 (amongst	 others,	 swollen	 joint	 count,	 tender	 joint	 count,	 entheses	 evaluation),	
demographic	characteristics	and	symptom	history.		
Written	informed	consent	was	obtained	from	the	participants.	The	study	was	approved	by	the	medical	
ethic	committee	of	Catharina	Hospital,	Eindhoven,	the	Netherlands.	
	
Entheses	evaluation	
Clinical	examination	
Physical	examination	included	the	66/68	joint	count	for	PsA	and	entheseal	assessment	following	the	
Leeds	 Enthesitis	 Index	 (LEI)	 and	 the	Maastricht	 Ankylosing	 Spondylitis	 Enthesis	 Score	 (MASES).2,	 3	
Other	assessments	included	measurement	of	psoriasis	severity	by	the	PASI	and	body	mass	index.	If	
clinical	examination	indicated	a	painful	enthesis	on	the	LEI/MASES	or	indicated	an	arthritis,	ultrasound	
examination	of	the	entheses	was	performed.		
	
Ultrasound	examination	
An	independent	ultrasound	examiner	blinded	for	the	clinical	details	performed	the	ultrasound	using	
Esoate	MyLab60	(probe	LA	435).	The	six	entheses	of	the	Madrid	Sonographic	Enthesis	Index	(MASEI)25	
and	the	lateral	epicondyle	tendon	insertion	(elbow)	were	examined.	Each	tendon	was	examined	in	the	
longitudinal	plane.	Knee	entheses	were	examined	with	the	patient	 in	supine	position	and	the	knee	
flexed	at	20°.	The	Achilles	 tendon	and	 the	plantar	aponeurosis	were	examined	with	 the	patient	 in	
prone	position	and	the	feet	hanging	over	the	edge	of	the	examination	table	in	neutral	position.	To	
examine	the	lateral	aspect	of	the	elbow,	the	patient	was	positioned	with	the	elbow	flexed,	forearm	
extended	and	palm	down.	To	examine	the	olecranon,	the	patient	was	asked	to	raise	the	elbow	and	to	
keep	the	elbow	flexed	(90°)	with	the	hand	palm	resting	on	the	table.	According	to	the	MASEI	scoring	
system	 the	 following	 elemental	 lesions	 of	 enthesitis	 were	 evaluated	 at	 each	 site:	 calcifications,	
bursitis,	erosions,	PD	signal	 in	bursa	or	enthesis	 full	 tendon	(cortical	bone	profile,	 intratendon	and	
paratendon	on	the	enthesis	insertion)	and	thickness	and	structure.25	Ultrasound	abnormalities	were	
divided	 into	 ‘active	 inflammation’	 and	 ‘structural	 change’	 parameters.	 Active	 inflammatory	
components	on	ultrasound	included	the	presence	of	PD	signal	(<2mm	of	the	bony	cortex)15	or	in	case	
of	 the	 plantar	 aponeurosis	 an	 increased	 thickness	 (≥4.4mm).26	 Structural	 changes	 included	
calcifications,	erosions,	structure,	and	increased	thickness.	
	
Self-reported	pain	at	the	entheses	
Patients	 completed	online	 self-reported	questionnaires	 including	 the	EARP27	 and	PEST28.	 From	 the	
EARP	questionnaire	we	used	the	question	regarding	the	Achilles	tendon.	From	the	PEST	questionnaire	
we	 used	 those	 questions	 regarding	 pain	 of	 the	 heel,	 elbows,	 and	 knees.	 Patient	 history	 included	
questions	about	symptom	history	regarding	previous	episodes	of	entheseal	inflammatory	complaints,	
which	were	diagnosed	by	a	GP.	
	
Enthesitis	definition	
In	 this	 study	 we	 combined	 data	 from	 ultrasound	 and	 clinical	 examination,	 and	 patient-reported	
questionnaires	 to	 define	 active	 inflammation	 at	 the	 enthesis.	 We	 defined	 enthesitis	 as	 active	
inflammation	 on	 ultrasound	 (presence	 of	 PD	 signal	 and/or	 increased	 thickness	 of	 the	 plantar	
aponeurosis)	 in	combination	with	at	 least	one	clinical	 feature	at	the	same	enthesis:	 i)	tender	point	
LEI/MASES,	ii)	self-reported	pain	at	the	elbow,	knee,	Achilles	tendon	and	heel	from	the	EARP	or	PEST	
questionnaire,	 iii)	 self-reported	 entheseal	 complaints	 (defined	 as	 previous	 episodes	 of	 entheseal	
inflammatory	complaints,	diagnosed	by	a	GP).	
	
Statistical	analysis	
To	 determine	 differences	 in	 baseline	 characteristics	 and	 ultrasound	 findings	 between	 patients	
suspected	for	enthesitis	and	patients	suspected	for	arthritis	we	used	descriptive	statistics.	Depending	
on	 the	 distribution	 of	 the	 data	 we	 used	 the	 independent	 T-test	 or	Wilcoxon-Mann-Whitney	 test.	
Frequencies	were	compared	using	a	Chi-square	test.	Analyses	were	done	using	STATA	12.0.	
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Results	
In	 total,	 111	 patients	 of	 the	 total	 study	 population	with	 psoriasis	 (n=524)	who	 reported	 regularly	
musculoskeletal	 complaints	 were	 evaluated	 by	 ultrasound.	 Of	 these	 patients,	 88	 patients	 were	
referred	for	ultrasound	because	they	had	at	least	one	tender	enthesis	on	the	LEI/MASES.	The	other	
23	patients	were	referred	for	suspected	arthritis	and	also	underwent	an	evaluation	of	the	entheses	by	
ultrasound.	 Nine	 (8%)	 patients	 had	 a	 confirmed	 diagnosis	 of	 PsA	 by	 a	 rheumatologist.	 Patient	
characteristics	are	presented	in	Table	1.		
	
	
	
	
Entheses	evaluation	
Clinical	examination	
The	median	number	of	tender	entheses	on	the	LEI	was	2	(IQR:	0-3).	The	median	number	of	tender	
entheses	on	the	MASES	was	1	(IQR:	0-3).	Patients	suspected	for	enthesitis	had	more	tender	entheses	
on	both	the	LEI	and	the	MASES	(median	(IQR):	4	[1-7])	than	patients	suspected	for	arthritis	(median	
(IQR):	2	[0-4];	p<0.0001).	The	most	common	tender	entheses	were	found	at	the	lateral	epicondyle	of	
the	humerus	(52%)	and	at	the	medial	epicondyle	of	the	femur	(50%)	[Table	3].	
	
Ultrasound	examination	
In	 106	 (95%)	 patients	 (n=111)	we	detected	one	or	more	ultrasound	 abnormalities	 at	 the	 enthesis	
[Table	2].	There	was	no	difference	in	ultrasound	findings	between	patients	suspected	for	enthesitis	
and	patients	suspected	for	arthritis.		
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In	 50	 (45%)	 patients	 we	 found	 ultrasound	 abnormalities	 indicating	 inflammatory	 disease	 at	 the	
enthesis	[Table	3].	Thirty-five	(32%)	patients	were	PD	positive	on	ultrasound	of	whom	5	(5%)	also	had	
a	thickened	plantar	aponeurosis.	Fifteen	(14%)	patients	only	had	a	thickened	plantar	aponeurosis.		
	
	
	
	
Positive	PD	signal	was	found	most	often	at	the	lateral	epicondyle	of	the	humerus	(21	patients,	19%)	
and	at	the	insertion	of	the	quadriceps	tendon	at	the	superior	pole	of	the	patella	(13	patients,	12%).	In	
19	(17%)	patients	we	found	positive	PD	signal	at	more	than	one	enthesis.	Of	note,	we	did	not	find	any	
indication	of	inflammatory	disease	at	the	triceps	enthesis	at	the	olecranon.		
Structural	changes	of	the	enthesis	on	ultrasound	[Table	3]	were	very	common.	Increased	thickness	of	
the	 distal	 patella	 tendon	 at	 the	 tuberositas	 tibiae	 (69%),	 and	 calcifications	 at	 the	 enthesis	 of	 the	
quadriceps	tendon	(superior	pole	patella:	59%)	and	at	the	enthesis	of	the	Achilles	tendon	(63%)	were	
found	most	often.	Structural	changes	without	 indication	of	 inflammatory	disease	were	found	in	56	
(50%)	patients.		
	
Self-reported	pain	at	the	entheses	
In	 total,	105	patients	 (95%)	reported	pain	at	 	a	 location	relevant	 to	the	enthesis:	 the	elbow,	knee,	
Achilles	tendon,	or	heel.	Pain	in	the	knee	was	most	frequently	reported	(71%),	followed	by	the	heel	
(55%)	and	elbow	(49%).	Nineteen	(17%)	patients	reported	pain	at	the	Achilles	tendon	insertion.	
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Patients	who	had	clinical	symptoms	and	PD	at	one	of	their	enthesis	or	a	thickened	plantar	aponeurosis	
were	classified	as	having	ultrasound	confirmed	inflammatory	enthesitis.	Of	the	50	patients		
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found	most	often.	Structural	changes	without	 indication	of	 inflammatory	disease	were	found	in	56	
(50%)	patients.		
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In	 total,	105	patients	 (95%)	reported	pain	at	 	a	 location	relevant	 to	the	enthesis:	 the	elbow,	knee,	
Achilles	tendon,	or	heel.	Pain	in	the	knee	was	most	frequently	reported	(71%),	followed	by	the	heel	
(55%)	and	elbow	(49%).	Nineteen	(17%)	patients	reported	pain	at	the	Achilles	tendon	insertion.	
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were	classified	as	having	ultrasound	confirmed	inflammatory	enthesitis.	Of	the	50	patients		
	
	 	
Table 1 Baseline characteristics of primary care psoriasis patients (n=111)
Suspected for enthesitis 
(n=88)
Suspected for arthritis 
(n=23)
p-value
Women (%) 57 39 0.130
Age, years (mean, sd) 54 (13) 54 (14) 0.936
LEI (median, IQR) 2 (1-4) 0 (0-1) <0.001
MASES (median, IQR) 2 (0-4) 0 (0-1) <0.001
MASEI (median, IQR) 7 (5-12) 10 (5-13) 0.302
Power Doppler positive, n (%) 0.626
- 1 enthesis 14 (16) 2 (9)
- 2 entheses 12 (14) 3 (13)
- 3 entheses 3 (3) 1 (4)
LEI = Leeds Enthesitis Index (range: 0-6); MASES = Maastricht Ankylosing Spondylitis Enthesis Score (range: 
0-13); MASEI = Madrid Sonographic Enthesis Index (range: 0-136); sd = standard deviation; IQR = interquartile 
range
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Results	
In	 total,	 111	 patients	 of	 the	 total	 study	 population	with	 psoriasis	 (n=524)	who	 reported	 regularly	
musculoskeletal	 complaints	 were	 evaluated	 by	 ultrasound.	 Of	 these	 patients,	 88	 patients	 were	
referred	for	ultrasound	because	they	had	at	least	one	tender	enthesis	on	the	LEI/MASES.	The	other	
23	patients	were	referred	for	suspected	arthritis	and	also	underwent	an	evaluation	of	the	entheses	by	
ultrasound.	 Nine	 (8%)	 patients	 had	 a	 confirmed	 diagnosis	 of	 PsA	 by	 a	 rheumatologist.	 Patient	
characteristics	are	presented	in	Table	1.		
	
	
	
	
Entheses	evaluation	
Clinical	examination	
The	median	number	of	tender	entheses	on	the	LEI	was	2	(IQR:	0-3).	The	median	number	of	tender	
entheses	on	the	MASES	was	1	(IQR:	0-3).	Patients	suspected	for	enthesitis	had	more	tender	entheses	
on	both	the	LEI	and	the	MASES	(median	(IQR):	4	[1-7])	than	patients	suspected	for	arthritis	(median	
(IQR):	2	[0-4];	p<0.0001).	The	most	common	tender	entheses	were	found	at	the	lateral	epicondyle	of	
the	humerus	(52%)	and	at	the	medial	epicondyle	of	the	femur	(50%)	[Table	3].	
	
Ultrasound	examination	
In	 106	 (95%)	 patients	 (n=111)	we	detected	one	or	more	ultrasound	 abnormalities	 at	 the	 enthesis	
[Table	2].	There	was	no	difference	in	ultrasound	findings	between	patients	suspected	for	enthesitis	
and	patients	suspected	for	arthritis.		
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Table 2 Ultrasound abnormalities at the enthesis using the MASEI score (n=111)
Insertion PD signal Structure Thickness Bursitis Erosion Calcification
Lateral epicondyle tendon (elbow)* 21 (19) 19 (17) 51 (46) 35 (32) 47 (42)
Triceps tendon* 0 25 (23) 18 (16) 9 (8) 26 (23)
Quadriceps tendon* 13 (12) 12 (11) 53 (48) 3 (3) 66 (59)
Proximal patella tendon* 2 (2) 4 (4) 29 (26) 2 (1) 15 (14)
Distal patella tendon* 9 (8) 3 (3) 77 (69) 1 (1) 3 (3) 23 (21)
Achilles tendon* 4 (4) 1 (1) 12 (11) 0 1 (1) 70 (63)
Plantar aponeurosis * † 1 (1) 20 (18) 0 20 (18)
*n (%); MASEI = Madrid Sonographic Enthesis Index (range: 0-136); PD = power Doppler; † = not detectable
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With	 ultrasound	 abnormalities	 indicating	 inflammatory	 disease,	 the	 ultrasound	 findings	 were	
confirmed	by	clinical	information	in	40	patients	(36%).	These	patients	were	classified	as	having	active	
(ultrasound	confirmed	 inflammatory)	enthesitis.	Twenty-eight	patients	had	active	enthesitis	at	one	
enthesis.	These	were	found	at	the	knee	(n=11),	at	the	insertion	of	the	plantar	aponeurosis	(n=10),	at	
the	lateral	epicondyle	of	the	humerus	(n=6)	and	at	the	Achilles	tendon	(n=1).	Ten	patients	had	active	
enthesitis	at	two	entheses,	and	two	patients	had	active	enthesitis	at	three	entheses.	Thirty-two	cases	
were	referred	because	they	had	at	least	one	tender	enthesis	on	the	LEI/MASES.	The	other	eight	cases	
were	referred	for	suspected	arthritis.	
Ten	patients	had	inflammatory	ultrasound	abnormalities	while	they	did	not	report	clinical	problems.	
We	found	a	positive	PD	signal	in	five	patients.	The	PD	signal	was	found	at	the	enthesis	of	the	lateral	
epicondyle	of	the	humerus	(n=3),	at	the	entheses	of	the	knee	(n=1),	and	in	one	patient	both	at	the	
lateral	epicondyle	(humerus)	and	the	Achilles	enthesis.	The	plantar	aponeurosis	was	thickened	in	five	
patients	without	clinical	symptoms.		
Figure	 1	 shows	 the	 distribution	 of	 the	 ultrasound	 findings,	 both	 structural	 changes	 and	 active	
inflammation	combined	with	the	clinical	findings	at	each	entheseal	site.	
Five	 patients	 had	 a	 painful	 enthesis	 clinically	without	 having	 any	 ultrasound	 abnormalities.	 These	
patients	 all	 had	 a	 painful	 knee,	 combined	with	 a	 painful	 enthesis	 at	 the	 lateral	 epicondyle	 of	 the	
humerus	(n=4),	with	a	painful	heel	(n=2),	or	a	tender	Achilles	enthesis	(n=1).		
The	other	56	patients	had	a	painful	enthesis	with	structural	changes	on	ultrasound.		
	
	
	
	
Discussion	
In	 36%	of	 the	primary	 care	psoriasis	 patients	who	had	 tenderness	 at	 one	or	more	entheseal	 sites	
(n=111)	enthesitis	was	present,	defined	as	concurrent	presence	of	ultrasound	inflammatory	changes	
and	 clinical	 symptoms.	 Ultrasound	 assessment	 included	 five	 elemental	 lesions:	 the	 presence	 of	
calcifications,	 erosions,	 increased	 thickness,	 changes	 in	 fiber	 structure,	 and	positive	PD	 signal.	We	
indicated	the	first	4	lesions	as	‘structural	changes’	of	the	enthesis	which	were	present	in	95%	of	the	
patients,	while	we	named	positive	PD	signal	 the	 ‘inflammatory	component’,	present	 in	32%	of	 the	
patients.	One	exception	was	made	for	the	plantar	aponeurosis	as	ultrasound	was	not	able	to	elicit	any	
PD	signal	in	this	area.	Therefore,	increased	thickness	was	chosen	to	assess	inflammatory	changes	at	
the	enthesis	of	the	plantar	aponeurosis,	which	was	present	in	18%	of	the	patients.	In	total,	45%	of	the	
patients	(n=50)	had	ultrasound	inflammatory	changes.	Combined	with	clinical	information	at	the	same	
enthesis	this	led	to	36%	of	the	patients	(n=40)	having	enthesitis.	In	part	of	our	study	population	(9%;	
n=10)	 we	 found	 ultrasound	 inflammatory	 components,	 but	 these	 were	 not	 confirmed	 by	 clinical	
information.	 This	 could	 be	 related	 to	 subclinical	 disease,	 which	 could	 be	 predictive	 for	 the	
development	of	PsA	in	patients	with	psoriasis.21,	29-31		
Considerable	advances	have	been	made	in	the	use	of	ultrasound	to	evaluate	entheses.	Nevertheless,	
context	 of	 clinical	 information	 remains	 needed	 to	 differentiate	 between	 active	 inflammation	 and	
other	manifestations	of	enthesopathy.10	By	adding	ultrasound	to	the	clinical	evaluation	of	entheses	
we	were	able	to	visualize	the	presence	of	active	inflammatory	involvement	of	the	enthesis.	This	could	
help	 to	 differentiate	 patients	with	 non-inflammatory	 entheseal	 pain	 from	patients	with	 entheseal	
involvement	related	to	inflammation,	helping	physicians	to	make	informed	decisions	about	whom	to	
treat	 with	 anti-inflammatory	 drugs.	 First-line	 treatment	 recommendations	 for	 enthesitis	 in	 PsA	
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Table 3 Ultrasound and clinical findings per entheseal site (n=111)
Insertion US inflammatory 
(n,%)
US structural 
(n,%)
Tender point 
(n,%)
Self-reported 
(n,%)
Lateral epicondyle tendon (elbow) 21 (19) 62 (56) 58 (52) 54 (49)
Triceps tendon 0 49 (44) † 54 (49)
Quadriceps tendon 13 (12) 68 (61) 55 (50)* 79 (71)
Proximal patella tendon 2 (2) 37 (33)
Distal patella tendon 9 (8) 74 (67)
Achilles tendon 4 (4) 68 (61) 32 (29) 19 (17)
Plantar aponeurosis 20 (18) 16 (14) † 61 (55)
US = ultrasound; † = not included in LEI/MASES; * = medial epicondyle femur
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development	of	PsA	in	patients	with	psoriasis.21,	29-31		
Considerable	advances	have	been	made	in	the	use	of	ultrasound	to	evaluate	entheses.	Nevertheless,	
context	 of	 clinical	 information	 remains	 needed	 to	 differentiate	 between	 active	 inflammation	 and	
other	manifestations	of	enthesopathy.10	By	adding	ultrasound	to	the	clinical	evaluation	of	entheses	
we	were	able	to	visualize	the	presence	of	active	inflammatory	involvement	of	the	enthesis.	This	could	
help	 to	 differentiate	 patients	with	 non-inflammatory	 entheseal	 pain	 from	patients	with	 entheseal	
involvement	related	to	inflammation,	helping	physicians	to	make	informed	decisions	about	whom	to	
treat	 with	 anti-inflammatory	 drugs.	 First-line	 treatment	 recommendations	 for	 enthesitis	 in	 PsA	
	
Figure	1.	Distribution	of	the	ultrasound	findings,	both	structural	changes	(US	structural)	and	active	inflammation	
(US	inflammatory),	in	combination	with	the	clinical	findings	(	-	=	negative;	+	=	positive)	at	each	entheseal	site	(US	
=	ultrasound).		
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patients	are	NSAIDs.	After	insufficient	response	to	NSAIDs,	treatment	can	be	switched	to	biological	
agents.32,	33	Since	rheumatologists	are	quite	reserved	to	prescribe	biologic	agents	to	treat	enthesitis,	
ultrasound	 might	 give	 more	 certainty	 for	 detecting	 inflammatory	 disease	 at	 tender	 entheses.	
However,	further	research	regarding	the	treatment	of	ultrasound	confirmed	enthesitis	is	needed.		
One	of	the	difficulties	we	came	across	was	the	absence	of	general	accepted	definitions	for	both	the	
clinical	presentation	as	well	as	the	ultrasound	presentation	of	enthesitis.	The	OMERACT	Ultrasound	
Task	Force	recently	debated	the	latter,	but	they	did	not	come	to	a	definite	conclusion	what	would	be	
inflammatory.15	 The	 main	 reason	 for	 this	 was	 the	 discussion	 on	 entheseal	 thickness.	 Part	 of	 the	
ultrasound	examiners	felt	this	to	belong	to	inflammatory	changes	while	other	examiners	attributed	
this	to	structural	changes.	Both	could	be	true.	In	the	acute	phase,	increased	thickness	might	be	present	
due	to	 inflammation	as	shown	by	McGonagle	et	al	with	soft	tissue	and	bone	edema	at	the	plantar	
aponeurosis	 insertion	 on	 MRI	 appearances.34	 However,	 thickening	 could	 also	 be	 the	 result	 of	 a	
disorganized	repair	process	(scar	tissue)	in	which	no	inflammation	is	present	anymore.		
There	are	several	strengths	and	weaknesses	to	discuss	when	interpreting	the	results	of	our	study.	At	
first,	 for	 practical	 reasons	 we	 choose	 to	 apply	 ultrasound,	 rather	 than	MRI.	 Ultrasound	was	 easy	
accessible,	we	could	apply	it	to	different	locations	at	once	and	there	were	no	safety	issues.	It	has	the	
disadvantage	 that	 it	 is	 reader	 dependable,	 which	 was	 solved	 by	 one	 examiner	 for	 all	 patients.	
However,	ultrasound	cannot	depict	bone	edema	which	is	also	indicative	for	inflammatory	changes	like	
MRI	 does.	MRI	 is	 capable	 of	 detecting	 soft	 tissue	 changes	 associated	with	 surrounding	 soft	 tissue	
edema	 in	 the	 region	 adjacent	 to	 the	 enthesis.10	 However,	 application	 of	MRI	 would	 require	 long	
acquisition	time	to	evaluate	six	entheses	bilaterally.	There	have	been	recent	advances	in	whole	body	
MRI	but	issues	need	to	be	solved	such	as	field	of	view,	image	resolution	for	small	structures	and	body	
position.35	Secondly,	patient	position	during	the	ultrasound	examination	of	the	knee	entheses	was	not	
ideal.	In	our	study	maximum	flexion	of	the	knee	was	20°,	which	could	have	influenced	our	PD	signal	
at	the	entheseal	level	of	the	knee	entheses.	Previous	studies	found	an	severe	decrease	of	PD	signal	
when	the	knee	was	flexed	at	30°.36	Flexion	of	the	knee	could	increase	intratendinous	tension,	which	
facilitates	 collapse	 of	 the	microvessels.	 Thirdly,	 due	 to	 the	 aim	 of	 our	 initial	 study,	 which	was	 to	
estimate	the	prevalence	of	PsA	in	primary	care	psoriasis	patients,	we	did	not	include	control	patients.	
However,	 there	 is	a	 substantial	body	of	evidence	 that	 shows	 the	usefulness	of	 the	MASEI	 score	 in	
differentiating	 patients	 with	 PsA/SpA	 from	 healthy	 controls20,	 37,	 especially	 if	 using	 inflammatory	
changes	(PD	signal)	rather	than	structural	changes.21	This	stresses	our	choice	to	use	a	positive	PD	signal	
at	 the	enthesis	as	an	 indication	for	active	ultrasound	enthesitis.	A	strength	of	our	study	 is	 that	we	
included	 primary	 care	 patients	 with	 psoriasis	 with	 musculoskeletal	 complaints.	 Most	 studies	
evaluating	enthesitis	with	ultrasound	have	included	psoriasis	patients	in	secondary	care	referred	by	
the	dermatologist.16	Our	study	population	is	a	different	population	in	which	it	would	be	beneficial	to	
screen	for	PsA	and	to	improve	early	diagnosis	of	PsA.		
In	 conclusion,	 enthesitis	 defined	 as	 concurrent	 presence	 of	 ultrasound	 inflammatory	 changes	 and	
clinical	symptoms	was	present	in	36%	of	the	primary	care	psoriasis	patients	who	had	tenderness	at	
one	or	more	entheseal	sites.	Combining	clinical	data	and	ultrasound	at	the	same	enthesis	reduced	the	
frequency	of	entheseal	lesions	that	should	be	evaluated	by	the	rheumatologist	compared	to	clinical	
exam	only.	Consensus	needs	to	be	reached	to	find	a	generally	accepted	definition	for	enthesitis	which	
would	be	feasible	in	daily	clinical	work.			
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However,	ultrasound	cannot	depict	bone	edema	which	is	also	indicative	for	inflammatory	changes	like	
MRI	 does.	MRI	 is	 capable	 of	 detecting	 soft	 tissue	 changes	 associated	with	 surrounding	 soft	 tissue	
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at	the	entheseal	level	of	the	knee	entheses.	Previous	studies	found	an	severe	decrease	of	PD	signal	
when	the	knee	was	flexed	at	30°.36	Flexion	of	the	knee	could	increase	intratendinous	tension,	which	
facilitates	 collapse	 of	 the	microvessels.	 Thirdly,	 due	 to	 the	 aim	 of	 our	 initial	 study,	 which	was	 to	
estimate	the	prevalence	of	PsA	in	primary	care	psoriasis	patients,	we	did	not	include	control	patients.	
However,	 there	 is	a	 substantial	body	of	evidence	 that	 shows	 the	usefulness	of	 the	MASEI	 score	 in	
differentiating	 patients	 with	 PsA/SpA	 from	 healthy	 controls20,	 37,	 especially	 if	 using	 inflammatory	
changes	(PD	signal)	rather	than	structural	changes.21	This	stresses	our	choice	to	use	a	positive	PD	signal	
at	 the	enthesis	as	an	 indication	for	active	ultrasound	enthesitis.	A	strength	of	our	study	 is	 that	we	
included	 primary	 care	 patients	 with	 psoriasis	 with	 musculoskeletal	 complaints.	 Most	 studies	
evaluating	enthesitis	with	ultrasound	have	included	psoriasis	patients	in	secondary	care	referred	by	
the	dermatologist.16	Our	study	population	is	a	different	population	in	which	it	would	be	beneficial	to	
screen	for	PsA	and	to	improve	early	diagnosis	of	PsA.		
In	 conclusion,	 enthesitis	 defined	 as	 concurrent	 presence	 of	 ultrasound	 inflammatory	 changes	 and	
clinical	symptoms	was	present	in	36%	of	the	primary	care	psoriasis	patients	who	had	tenderness	at	
one	or	more	entheseal	sites.	Combining	clinical	data	and	ultrasound	at	the	same	enthesis	reduced	the	
frequency	of	entheseal	lesions	that	should	be	evaluated	by	the	rheumatologist	compared	to	clinical	
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Abstract	
	
Background	&	Aims.	Inflammatory	Bowel	Disease	is	a	chronic	disease	which	affects	up	to	0.5%	of	the	
population.	 Various	 extraintestinal	 manifestations	 occur,	 among	 which	 rheumatic	 manifestations,	
grouped	together	under	the	name	spondyloarthritis.	The	objective	of	the	systematic	review	and	meta-
analysis	was	 to	give	a	 systematic	overview	of	 the	prevalence	and	 incidence	of	 spondyloarthritis	 in	
patients	with	inflammatory	bowel	disease.		
	
Methods.	 We	 systematically	 searched	 Embase,	 Pubmed,	 OvidSP,	 Scopus	 and	 Web-of-science	
databases	from	inception	to	August	2016.	All	articles	that	addressed	the	prevalence	or	incidence	of	
the	 different	 features	 of	 spondyloarthritis	 in	 adult	 inflammatory	 bowel	 disease	 patients	 were	
included.	Methodological	quality	was	assessed	using	a	modified	quality	assessment	tool	developed	
for	prevalence	studies.	
	
Results.	71	studies	were	included	reporting	on	the	prevalence	of	sacroiliitis,	ankylosing	spondylitis,	
arthritis,	enthesitis	and	dactylitis.	Pooled	prevalences	were	calculated	for	sacroiliitis	(10%;	95%	CI	8-
12%),	ankylosing	spondylitis	(3%;	95%	CI	2-4%)	and	arthritis	(13%;	95%CI	12-15%).	Geographic	area,	
setting	 and	 use	 of	 different	 criteria	 contribute	 to	 the	 large	 heterogeneity.	 Few	 estimates	 were	
available	for	enthesitis	(prevalence	range	from	1	to	54%)	and	dactylitis	(prevalence	range	from	0	to	
6%).	Only	three	incidence	studies	were	identified,	which	report	cumulative	incidences	from	5	to	30	
years.	
	
Conclusions.	Spondyloarthritis	occurs	in	up	to	13%	of	patients	with	IBD.	Ankylosing	spondylitis	is	the	
least	common	(3%)	followed	by	sacroiliitis	(10%)	and	peripheral	arthritis	(13%).		
	
	 	
Introduction	
Inflammatory	Bowel	Disease	(IBD)	is	a	common	chronic	inflammatory	disease	of	the	gastro-intestinal	
tract,	 which	 encompasses	 both	 Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC).	 IBD	 can	 be	
accompanied	by	a	number	of	extra-intestinal	manifestations	(EIM)	in	multiple	organ	systems,	among	
which	 rheumatic	manifestations	 grouped	 together	 under	 the	 name	 spondyloarthritis	 (SpA),	which	
might	affect	2-46%	of	IBD	patients.1-4	SpA	can	lead	to	a	reduced	quality	of	life	as	well	as	work	disability,	
and	is	therefore	cause	of	significant	burden	on	patients	as	well	as	the	society	as	a	whole.5-8	Without	
treatment,	severe	joint	deformations	can	occur,	both	in	peripheral	joints	and	the	spine.	Detection	of	
patients	developing	SpA	is	therefore	important,	as	early	and	adequate	treatment	can	prevent	these	
complications.	
In	gastroenterology	a	distinction	is	made	between	type	1	and	type	2	arthritis.	Type	1	arthritis	parallels	
IBD	activity,	 usually	 affects	 five	 joints	or	 less	 and	 tends	 to	be	 self-limiting.	 Type	2	 arthritis	 usually	
affects	more	 than	 five	 joints	 and	does	not	 correlate	with	 IBD	activity.3	Although	 this	 distinction	 is	
widely	used	 in	gastroenterology	practice,	 it	 is	not	often	used	by	rheumatologists.	Rheumatologists	
tend	 to	 follow	 the	 recently	 developed	 ASAs	 criteria,	 which	make	 a	 distinction	 between	 axial	 and	
peripheral	manifestations.9,10	Both	axial	and	peripheral	manifestations	can	occur	in	patients	with	IBD.	
With	regard	to	the	axial	manifestations	of	SpA,	the	main	symptom	is	chronic	low	back	pain	induced	by	
inflammation	of	 the	sacroiliac	 joints,	 the	so-called	sacroiliitis	 (SI).	Ankylosing	spondylitis	 (AS)	 is	 the	
best	 known	 subtype,	 however	 it	 is	 the	 least	 frequent	 manifestation.	 In	 peripheral	 SpA,	 arthritis,	
enthesitis	and	dactylitis	are	the	main	symptoms.	Arthritis	can	be	observed	in	every	peripheral	joint,	
with	a	preference	for	the	large	joints.	Enthesitis	indicates	inflammation	of	the	tendon	insertion	to	the	
bone.	This	can	occur	in	every	location	of	tendon	insertions	to	bone,	but	best-known	locations	are	the	
Achilles	heel	and	the	fascia	plantaris.	Dactylitis	is	a	less	common	manifestation	of	SpA	and	indicates	
the	presence	of	inflammation	of	an	entire	digit,	the	so	called	sausage-fingers	or	–toes.	Patients	with	
IBD	are	at	increased	risk	for	developing	SpA	but	prevalence	estimates	based	on	the	recently	accepted	
definition	 of	 axial	 and	 peripheral	 joint	 manifestations	 are	 lacking.	 In	 this	 systematic	 review,	 we	
summarize	the	prevalence	and	incidence	of	the	various	axial	and	peripheral	joint	manifestations	of	
SpA	in	patients	with	IBD.	Secondly,	we	perform	a	meta-analysis	to	estimate	the	point	prevalence	of	
SI,	AS	and	peripheral	arthritis	in	patients	with	IBD.	
	
Methods	
This	systematic	review	was	reported	in	accordance	with	the	PRISMA	guidelines.11	
	
Literature	Search	
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Abstract	
	
Background	&	Aims.	Inflammatory	Bowel	Disease	is	a	chronic	disease	which	affects	up	to	0.5%	of	the	
population.	 Various	 extraintestinal	 manifestations	 occur,	 among	 which	 rheumatic	 manifestations,	
grouped	together	under	the	name	spondyloarthritis.	The	objective	of	the	systematic	review	and	meta-
analysis	was	 to	give	a	 systematic	overview	of	 the	prevalence	and	 incidence	of	 spondyloarthritis	 in	
patients	with	inflammatory	bowel	disease.		
	
Methods.	 We	 systematically	 searched	 Embase,	 Pubmed,	 OvidSP,	 Scopus	 and	 Web-of-science	
databases	from	inception	to	August	2016.	All	articles	that	addressed	the	prevalence	or	incidence	of	
the	 different	 features	 of	 spondyloarthritis	 in	 adult	 inflammatory	 bowel	 disease	 patients	 were	
included.	Methodological	quality	was	assessed	using	a	modified	quality	assessment	tool	developed	
for	prevalence	studies.	
	
Results.	71	studies	were	included	reporting	on	the	prevalence	of	sacroiliitis,	ankylosing	spondylitis,	
arthritis,	enthesitis	and	dactylitis.	Pooled	prevalences	were	calculated	for	sacroiliitis	(10%;	95%	CI	8-
12%),	ankylosing	spondylitis	(3%;	95%	CI	2-4%)	and	arthritis	(13%;	95%CI	12-15%).	Geographic	area,	
setting	 and	 use	 of	 different	 criteria	 contribute	 to	 the	 large	 heterogeneity.	 Few	 estimates	 were	
available	for	enthesitis	(prevalence	range	from	1	to	54%)	and	dactylitis	(prevalence	range	from	0	to	
6%).	Only	three	incidence	studies	were	identified,	which	report	cumulative	incidences	from	5	to	30	
years.	
	
Conclusions.	Spondyloarthritis	occurs	in	up	to	13%	of	patients	with	IBD.	Ankylosing	spondylitis	is	the	
least	common	(3%)	followed	by	sacroiliitis	(10%)	and	peripheral	arthritis	(13%).		
	
	 	
Introduction	
Inflammatory	Bowel	Disease	(IBD)	is	a	common	chronic	inflammatory	disease	of	the	gastro-intestinal	
tract,	 which	 encompasses	 both	 Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC).	 IBD	 can	 be	
accompanied	by	a	number	of	extra-intestinal	manifestations	(EIM)	in	multiple	organ	systems,	among	
which	 rheumatic	manifestations	 grouped	 together	 under	 the	 name	 spondyloarthritis	 (SpA),	which	
might	affect	2-46%	of	IBD	patients.1-4	SpA	can	lead	to	a	reduced	quality	of	life	as	well	as	work	disability,	
and	is	therefore	cause	of	significant	burden	on	patients	as	well	as	the	society	as	a	whole.5-8	Without	
treatment,	severe	joint	deformations	can	occur,	both	in	peripheral	joints	and	the	spine.	Detection	of	
patients	developing	SpA	is	therefore	important,	as	early	and	adequate	treatment	can	prevent	these	
complications.	
In	gastroenterology	a	distinction	is	made	between	type	1	and	type	2	arthritis.	Type	1	arthritis	parallels	
IBD	activity,	 usually	 affects	 five	 joints	or	 less	 and	 tends	 to	be	 self-limiting.	 Type	2	 arthritis	 usually	
affects	more	 than	 five	 joints	 and	does	not	 correlate	with	 IBD	activity.3	Although	 this	 distinction	 is	
widely	used	 in	gastroenterology	practice,	 it	 is	not	often	used	by	rheumatologists.	Rheumatologists	
tend	 to	 follow	 the	 recently	 developed	 ASAs	 criteria,	 which	make	 a	 distinction	 between	 axial	 and	
peripheral	manifestations.9,10	Both	axial	and	peripheral	manifestations	can	occur	in	patients	with	IBD.	
With	regard	to	the	axial	manifestations	of	SpA,	the	main	symptom	is	chronic	low	back	pain	induced	by	
inflammation	of	 the	sacroiliac	 joints,	 the	so-called	sacroiliitis	 (SI).	Ankylosing	spondylitis	 (AS)	 is	 the	
best	 known	 subtype,	 however	 it	 is	 the	 least	 frequent	 manifestation.	 In	 peripheral	 SpA,	 arthritis,	
enthesitis	and	dactylitis	are	the	main	symptoms.	Arthritis	can	be	observed	in	every	peripheral	joint,	
with	a	preference	for	the	large	joints.	Enthesitis	indicates	inflammation	of	the	tendon	insertion	to	the	
bone.	This	can	occur	in	every	location	of	tendon	insertions	to	bone,	but	best-known	locations	are	the	
Achilles	heel	and	the	fascia	plantaris.	Dactylitis	is	a	less	common	manifestation	of	SpA	and	indicates	
the	presence	of	inflammation	of	an	entire	digit,	the	so	called	sausage-fingers	or	–toes.	Patients	with	
IBD	are	at	increased	risk	for	developing	SpA	but	prevalence	estimates	based	on	the	recently	accepted	
definition	 of	 axial	 and	 peripheral	 joint	 manifestations	 are	 lacking.	 In	 this	 systematic	 review,	 we	
summarize	the	prevalence	and	incidence	of	the	various	axial	and	peripheral	joint	manifestations	of	
SpA	in	patients	with	IBD.	Secondly,	we	perform	a	meta-analysis	to	estimate	the	point	prevalence	of	
SI,	AS	and	peripheral	arthritis	in	patients	with	IBD.	
	
Methods	
This	systematic	review	was	reported	in	accordance	with	the	PRISMA	guidelines.11	
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In	collaboration	with	a	medical	librarian	a	search	strategy	was	developed.	Medline,	Embase,	Web	of	
Science	and	Pubmed	as	publisher	were	searched	to	identify	relevant	studies	from	database	inception	
to	 August	 2016.	 Keywords	 included	 terms	 and	 synonyms	 for	 all	 joint	 manifestations	 of	
spondylarthropathies,	inflammatory	bowel	disease	(including	Crohn’s	disease	and	ulcerative	colitis),	
incidence	and	prevalence.	The	full	search	strategy	is	available	in	supplemental	file	S1.	
	
Selection	of	studies	
Inclusion	of	studies	was	based	on	a	two-stage	process;	 first,	 titles	and	abstracts	were	screened	for	
eligibility	 followed	 by	 retrieval	 of	 full-text	 articles	 to	 further	 check	 the	 eligibility	 criteria.	 One	
investigator	(MK)	screened	all	articles	for	eligibility	on	title	and	abstract	and	subsequently	the	full	text	
of	all	articles	that	had	passed	the	first	eligibility	screening.	Studies	were	eligible	if	they	(i)	were	written	
in	Dutch	or	English	language,	(ii)	had	an	observational	design	and	(iii)	described	the	prevalence	of	axial	
manifestations	(SI,	AS)	or	peripheral	joint	manifestations	(arthritis,	enthesitis	or	dactylitis)	in	patients	
diagnosed	with	 IBD.	 Studies	were	 excluded	 if	 they	were	 only	 published	 as	 conference	 abstract	 or	
contained	no	original	data.	The	reference	section	in	review	articles	and	original	studies	were	searched	
for	additional	studies.		
	
Data	Extraction	
Data	was	extracted	by	one	 investigator	 (MK)	according	 to	a	pre-defined	data	 form.	 	The	 following	
information	 was	 extracted:	 setting	 (population	 based,	 secondary	 care,	 tertiary	 care	 (university	
hospital)),	 type	 of	 study,	 study	 population,	 number	 of	 IBD	 patients	 participating,	 mean	 age	 and	
percentage	women	of	 IBD	patients,	criteria	 for	establishment	of	 IBD,	disease	duration	of	 IBD,	case	
definition	 of	 axial	 and	 peripheral	 joint	 manifestations	 of	 SpA,	 outcome	 measurement,	 outcome	
assessor	and	number	of	cases	of	different	SpA	manifestations.	
	
Assessment	of	methodological	quality		
MK	assessed	all	and	AW	or	JL	each	assessed	half	of	the	papers	for	methods	of	data	collection	by	a	
quality	list,	comprising	six	yes-no	questions.	The	quality	list	was	based	on	a	recently	developed	quality	
assessment	tool	for	prevalence	studies,	slightly	adjusted	for	our	situation.12	We	included	the	questions	
about	 representativeness	 of	 the	 sample	 for	 the	 target	 population,	 appropriate	 recruitment	 of	 the	
study	 participants,	 adequate	 sample	 size	 calculation	 and	 if	 the	 data	 analysis	 was	 conducted	with	
sufficient	coverage	of	the	identified	sample.	With	regard	to	case	ascertainment,	we	included	questions	
about	 whether	 objective,	 standard	 criteria	 were	 used	 for	 the	 establishment	 of	 a	 case	 and	 if	 the	
condition	 was	 measured	 reliably	 (meaning	 by	 a	 qualified	 outcome	 assessor).	 The	 full	 quality	
assessment	tool	with	instructions	how	we	applied	the	tool	can	be	found	in	supplemental	file	S2.	All	
papers	were	discussed	between	MK	and	AW	or	JL	and	disagreements	were	resolved	by	consensus.		
	
Pooling	of	data	
A	meta-analysis	was	performed	for	the	prevalence	of	the	axial	manifestations	AS	and	SI	and	for	the	
peripheral	 manifestation	 arthritis	 in	 patients	 with	 CD	 and	 UC.	 For	 the	 peripheral	 manifestations	
enthesitis	 and	 dactylitis	 too	 few	 studies	 were	 available	 for	 pooling,	 so	 these	 were	 described	
narratively.	
Meta-analysis	was	 performed	using	 the	 ‘metaprop’	 command	 in	 Stata	 13,	 using	 a	 random	effects	
model.13	 I2	 was	 used	 to	 calculate	 the	 between-study	 heterogeneity.	 Meta-analysis	 according	 to	
different	subgroups	was	performed	to	explore	possible	sources	of	heterogeneity.	
	
Results	
Search	Results	
The	 search	 resulted	 in	 4533	 publications	 (Figure	 1).	 After	 removing	 duplicates	 2780	 publications	
remained	and	were	screened	on	title	and	abstract.	Eventually	658	publications	were	found	eligible	for	
full-text	 review,	after	which	71	publications	were	 included.	These	71	publications	 reported	on	 the	
prevalence	of	the	different	axial	and	peripheral	joint	manifestations	of	SpA	in	either	CD	or	UC.	Seven	
studies	did	not	specify	the	type	of	inflammatory	bowel	disease	and	are	described	as	unspecified	IBD.	
The	characteristics	of	the	included	studies	are	shown	in	table	1.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
assessment	tool	with	instructions	how	we	applied	the	tool	can	be	found	in	supplemental	file	S2.	All	
papers	were	discussed	between	MK	and	AW	or	JL	and	disagreements	were	resolved	by	consensus.		
	
Pooling	of	data	
A	meta-analysis	was	performed	for	the	prevalence	of	the	axial	manifestations	AS	and	SI	and	for	the	
peripheral	 manifestation	 arthritis	 in	 patients	 with	 CD	 and	 UC.	 For	 the	 peripheral	 manifestations	
enthesitis	 and	 dactylitis	 too	 few	 studies	 were	 available	 for	 pooling,	 so	 these	 were	 described	
narratively.	
Meta-analysis	was	 performed	using	 the	 ‘metaprop’	 command	 in	 Stata	 13,	 using	 a	 random	effects	
model.13	 I2	 was	 used	 to	 calculate	 the	 between-study	 heterogeneity.	 Meta-analysis	 according	 to	
different	subgroups	was	performed	to	explore	possible	sources	of	hetero eneity.	
	
Results	
Search	Results	
The	 search	 resulted	 in	 4533	 publications	 (Figure	 1).	 After	 removing	 duplicates	 2780	 publications	
remained	and	were	screened	on	title	and	abstract.	Eventually	658	publications	were	found	eligible	for	
full-text	 review,	after	which	71	publications	were	 included.	These	71	publications	 r p ted	on	 the	
prevalence	of	the	different	axial	and	peripheral	joint	manifestations	of	SpA	in	either	CD	or	UC.	Seven	
studies	did	not	specify	the	type	of	inflammatory	bowel	disease	and	are	described	as	unspecified	IBD.	
The	characteristics	of	the	included	studies	are	shown	in	table	1.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
assessment	tool	with	instructions	how	 e	applied	the	tool	can	be	found	in supplemental	fi e	S2.	All	
pa ers	were	discussed	between	MK	and	AW	or	JL and	disagreements	were	 solved	by	consensu .		
	
Pooling	of data	
A	met -an lysis	was	p rform d	for	the	prevalence	of	the	axi l	manifestations	AS	and	SI and	for	the	
peripheral	 manifestation	 arthritis	 n	 patients	 with	 CD	 and	 UC.	 For	 the	 peripheral	 manifestations	
enthesitis	 and	 actylitis	 too	 few	 studies	 were	 av il ble	 for	 pooling,	 so	 thes 	 were	 described	
narr tively.	
Meta-an lysis	was	 performed	using	 the	 ‘metaprop’	 com and	 in	 Stata	 13,	 using	 a	 random	eff cts	
model.13	 I2 was	 used	 to	 cal ulate	 the	 between-study	 heterogen ity.	 Meta-an lysis	 according	 to	
differen 	subgroups	was	performed	to xplore	p ssible	sources	of heterogen ity.	
	
Results	
Search	Results	
The	 search	 resulted	 in	 4533	 publications	 (Figure	 1).	 After	 removing	 duplicates	 2780	 publications	
remained	and	were	screen d	on	title	and	abstract.	Eventually	658	publications	were	found	eligible	for	
full-text	 revi w,	after whic 	71	publications	were	 i clude .	Thes 	71	publications	 reported	on	 the	
prevalence	of the	different	axi l	 nd	peripheral	joint	manifestations	of SpA	in either	CD	or	UC.	Sev n	
studies	did	not	specify	the	type	of inflam atory	bowel	disease	and	are	described	as	unspecified	IBD.	
The	characterist cs	of the	include 	studies	are	shown	i table	1.
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Introduction	
Inflammatory	Bowel	Disease	(IBD)	is	a	common	chronic	inflammatory	disease	of	the	gastro-intestinal	
tract,	 which	 encompasses	 both	 Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC).	 IBD	 can	 be	
accompanied	by	a	number	of	extra-intestinal	manifestations	(EIM)	in	multiple	organ	systems,	among	
which	 rheumatic	manifestations	 grouped	 together	 under	 the	 name	 spondyloarthritis	 (SpA),	which	
might	affect	2-46%	of	IBD	patients.1-4	SpA	can	lead	to	a	reduced	quality	of	life	as	well	as	work	disability,	
and	is	therefore	cause	of	significant	burden	on	patients	as	well	as	the	society	as	a	whole.5-8	Without	
treatment,	severe	joint	deformations	can	occur,	both	in	peripheral	joints	and	the	spine.	Detection	of	
patients	developing	SpA	is	therefore	important,	as	early	and	adequate	treatment	can	prevent	these	
complications.	
In	gastroenterology	a	distinction	is	made	between	type	1	and	type	2	arthritis.	Type	1	arthritis	parallels	
IBD	activity,	 usually	 affects	 five	 joints	or	 less	 and	 tends	 to	be	 self-limiting.	 Type	2	 arthritis	 usually	
affects	more	 than	 five	 joints	 and	does	not	 correlate	with	 IBD	activity.3	Although	 this	 distinction	 is	
widely	used	 in	gastroenterology	practice,	 it	 is	not	often	used	by	rheumatologists.	Rheumatologists	
tend	 to	 follow	 the	 recently	 developed	 ASAs	 criteria,	 which	make	 a	 distinction	 between	 axial	 and	
peripheral	manifestations.9,10	Both	axial	and	peripheral	manifestations	can	occur	in	patients	with	IBD.	
With	regard	to	the	axial	manifestations	of	SpA,	the	main	symptom	is	chronic	low	back	pain	induced	by	
inflammation	of	 the	sacroiliac	 joints,	 the	so-called	sacroiliitis	 (SI).	Ankylosing	spondylitis	 (AS)	 is	 the	
best	 known	 subtype,	 however	 it	 is	 the	 least	 frequent	 manifestation.	 In	 peripheral	 SpA,	 arthritis,	
enthesitis	and	dactylitis	are	the	main	symptoms.	Arthritis	can	be	observed	in	every	peripheral	joint,	
with	a	preference	for	the	large	joints.	Enthesitis	indicates	inflammation	of	the	tendon	insertion	to	the	
bone.	This	can	occur	in	every	location	of	tendon	insertions	to	bone,	but	best-known	locations	are	the	
Achilles	heel	and	the	fascia	plantaris.	Dactylitis	is	a	less	common	manifestation	of	SpA	and	indicates	
the	presence	of	inflammation	of	an	entire	digit,	the	so	called	sausage-fingers	or	–toes.	Patients	with	
IBD	are	at	increased	risk	for	developing	SpA	but	prevalence	estimates	based	on	the	recently	accepted	
definition	 of	 axial	 and	 peripheral	 joint	 manifestations	 are	 lacking.	 In	 this	 systematic	 review,	 we	
summarize	the	prevalence	and	incidence	of	the	various	axial	and	peripheral	joint	manifestations	of	
SpA	in	patients	with	IBD.	Secondly,	we	perform	a	meta-analysis	to	estimate	the	point	prevalence	of	
SI,	AS	and	peripheral	arthritis	in	patients	with	IBD.	
	
Methods	
This	systematic	review	was	reported	in	accordance	with	the	PRISMA	guidelines.11	
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In	collaboration	with	a	medical	librarian	a	search	strategy	was	developed.	Medline,	Embase,	Web	of	
Science	and	Pubmed	as	publisher	were	searched	to	identify	relevant	studies	from	database	inception	
to	 August	 2016.	 Keywords	 included	 terms	 and	 synonyms	 for	 all	 joint	 manifestations	 of	
spondylarthropathies,	inflammatory	bowel	disease	(including	Crohn’s	disease	and	ulcerative	colitis),	
incidence	and	prevalence.	The	full	search	strategy	is	available	in	supplemental	file	S1.	
	
Selection	of	studies	
Inclusion	of	studies	was	based	on	a	two-stage	process;	 first,	 titles	and	abstracts	were	screened	for	
eligibility	 followed	 by	 retrieval	 of	 full-text	 articles	 to	 further	 check	 the	 eligibility	 criteria.	 One	
investigator	(MK)	screened	all	articles	for	eligibility	on	title	and	abstract	and	subsequently	the	full	text	
of	all	articles	that	had	passed	the	first	eligibility	screening.	Studies	were	eligible	if	they	(i)	were	written	
in	Dutch	or	English	language,	(ii)	had	an	observational	design	and	(iii)	described	the	prevalence	of	axial	
manifestations	(SI,	AS)	or	peripheral	joint	manifestations	(arthritis,	enthesitis	or	dactylitis)	in	patients	
diagnosed	with	 IBD.	 Studies	were	 excluded	 if	 they	were	 only	 published	 as	 conference	 abstract	 or	
contained	no	original	data.	The	reference	section	in	review	articles	and	original	studies	were	searched	
for	additional	studies.		
	
Data	Extraction	
Data	was	extracted	by	one	 investigator	 (MK)	according	 to	a	pre-defined	data	 form.	 	The	 following	
information	 was	 extracted:	 setting	 (population	 based,	 secondary	 care,	 tertiary	 care	 (university	
hospital)),	 type	 of	 study,	 study	 population,	 number	 of	 IBD	 patients	 participating,	 mean	 age	 and	
percentage	women	of	 IBD	patients,	criteria	 for	establishment	of	 IBD,	disease	duration	of	 IBD,	case	
definition	 of	 axial	 and	 peripheral	 joint	 manifestations	 of	 SpA,	 outcome	 measurement,	 outcome	
assessor	and	number	of	cases	of	different	SpA	manifestations.	
	
Assessment	of	methodological	quality		
MK	assessed	all	and	AW	or	JL	each	assessed	half	of	the	papers	for	methods	of	data	collection	by	a	
quality	list,	comprising	six	yes-no	questions.	The	quality	list	was	based	on	a	recently	developed	quality	
assessment	tool	for	prevalence	studies,	slightly	adjusted	for	our	situation.12	We	included	the	questions	
about	 representativeness	 of	 the	 sample	 for	 the	 target	 population,	 appropriate	 recruitment	 of	 the	
study	 participants,	 adequate	 sample	 size	 calculation	 and	 if	 the	 data	 analysis	 was	 conducted	with	
sufficient	coverage	of	the	identified	sample.	With	regard	to	case	ascertainment,	we	included	questions	
about	 whether	 objective,	 standard	 criteria	 were	 used	 for	 the	 establishment	 of	 a	 case	 and	 if	 the	
condition	 was	 measured	 reliably	 (meaning	 by	 a	 qualified	 outcome	 assessor).	 The	 full	 quality	
assessment	tool	with	instructions	how	we	applied	the	tool	can	be	found	in	supplemental	file	S2.	All	
papers	were	discussed	between	MK	and	AW	or	JL	and	disagreements	were	resolved	by	consensus.		
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A	meta-analysis	was	performed	for	the	prevalence	of	the	axial	manifestations	AS	and	SI	and	for	the	
peripheral	 manifestation	 arthritis	 in	 patients	 with	 CD	 and	 UC.	 For	 the	 peripheral	 manifestations	
enthesitis	 and	 dactylitis	 too	 few	 studies	 were	 available	 for	 pooling,	 so	 these	 were	 described	
narratively.	
Meta-analysis	was	 performed	using	 the	 ‘metaprop’	 command	 in	 Stata	 13,	 using	 a	 random	effects	
model.13	 I2	 was	 used	 to	 calculate	 the	 between-study	 heterogeneity.	 Meta-analysis	 according	 to	
different	subgroups	was	performed	to	explore	possible	sources	of	heterogeneity.	
	
Results	
Search	Results	
The	 search	 resulted	 in	 4533	 publications	 (Figure	 1).	 After	 removing	 duplicates	 2780	 publications	
remained	and	were	screened	on	title	and	abstract.	Eventually	658	publications	were	found	eligible	for	
full-text	 review,	after	which	71	publications	were	 included.	These	71	publications	 reported	on	 the	
prevalence	of	the	different	axial	and	peripheral	joint	manifestations	of	SpA	in	either	CD	or	UC.	Seven	
studies	did	not	specify	the	type	of	inflammatory	bowel	disease	and	are	described	as	unspecified	IBD.	
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Risk	of	Bias	
A	complete	overview	of	the	assessment	of	methodological	quality	can	be	found	in	supplementary	file	
S2.	 In	 table	2	 the	different	 items	of	 the	quality	 list	are	 shown	with	 the	percentage	of	 studies	 that	
scored	 positive	 on	 this	 item.	 The	 majority	 of	 studies	 had	 a	 sample	 representative	 of	 the	 target	
population	(63.4%)	and	most	studies	recruited	their	patients	in	an	appropriate	way	(90.1%),	meaning	
consecutive,	at	random	or	all	patients	were	selected	for	the	study.	None	of	the	studies	reported	a	
sample	size	calculation	while	a	slight	majority	did	conduct	an	adequate	data-analysis	(59.2%).	With	
regard	 to	 case-ascertainment,	 in	 56.3%	objective	 standard	 criteria	were	used	 and	 in	 46.5%	of	 the	
studies	the	condition,	meaning	SpA,	was	measured	reliably.	
	
	
	
	
Prevalence	of	Axial	involvement	
Fifty-nine	studies	(125	estimates)	reported	the	prevalence	of	axial	SpA	in	patients	with	IBD.14-66		
	
Sacroiliitis	
The	prevalence	of	SI	in	patients	with	IBD	was	described	in	41	studies	(59	estimates)	(see	supplemental	
file	S3).16-18,21-26,28,30-32,34,35,37-40,42,43,45-49,51,52,55,57-62,65,67-71.	The	pooled	prevalence	of	SI	in	IBD	patients	is	
estimated	to	be	10%	(95%CI	8-12%),	with	an	I2	of	94.3%.	The	prevalence	of	SI	is	higher	in	patients	with	
CD	(13%,	95%CI	1-17%)	than	in	patients	with	UC	(7%,	95%CI	4-11%).		
As	there	was	considerable	heterogeneity	in	the	observed	prevalence	between	studies,	we	explored	
the	 variability	 by	 a	 meta-analysis	 of	 subgroups	 according	 to	 different	 demographical	 and	 study	
characteristics	(Figure	2).	Higher	prevalences	were	observed	in	European	and	studies	(11%;	95%CI	8-
15%	and11%;	95%CI	7-16%),	compared	to	North-America	(7%;	95%CI	2-14%)	and	South-America	(5%;	
95%CI	2-9%).	With	regard	to	mean	age,	the	prevalence	seemed	highest	in	the	three	studies	for	age	
category	20-30	years	of	age	with	16%	(95%CI	8-27%).	 In	the	age	group	30-40	years	the	prevalence	
dropped	towards	9%	(95%CI	5-14%),	to	rise	again	slightly	in	the	age	groups	of	40-50	years	and	50-60	
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category	20-30	years	of	age	with	16%	(95%CI	8-27%).	 In	the	age	group	30-40	years	the	prevalence	
dropped	towards	9%	(95%CI	5-14%),	to	rise	again	slightly	in	the	age	groups	of	40-50	years	and	50-60	
years.	Studies	were	performed	 in	different	settings,	resulting	 in	higher	prevalences	of	SI	 in	tertiary	
care	 (15%;	 95%CI	 1-22%)	 compared	 to	 secondary	 care	 (7%;	 95%CI	 5-11%)	 and	 population	 based	
studies	(3%;	95%	CI	1-7%).	The	use	of	clinical	evaluation	also	resulted	in	a	higher	prevalence	(15%,	
95%CI	10-21%)	than	studies	using	case	records	or	a	self-reported	diagnosis	as	outcome.	The	use	of	
different	imaging	techniques	to	establish	a	SI	did	not	seem	to	have	much	influence	on	the	prevalence	
estimates,	with	an	estimate	of	12%	(95%CI	8-16%)	when	using	X-ray,	15%	(95%CI	5-29%)	when	using	
CT	and	10%	(95%CI	6-14%)	when	using	MRI.		
When	 making	 the	 distinction	 between	 subclinical	 SI	 (i.e.	 no	 pain	 or	 stiffness)	 and	 clinical	 SI,	 the	
prevalence	differed	slightly.	The	prevalence	of	subclinical	SI	was	estimated	to	be	11%	(95%CI	7-17%)	
in	12	studies	(18	estimates).21,24,31,32,34,35,38,40,45,46,51,62	The	prevalence	of	clinical	SI	was	estimated	to	be	
8%	(95%CI	6-10%).16-18,22-26,28,30,32,34,37-40,42,43,47-49,52,55,57-62,65,67-71		
	
Ankylosing	Spondylitis	
The	prevalence	of	AS	in	IBD	patients	was	described	in	43	studies	(64	estimates)	(see	supplemental	file	
S3).	The	pooled	prevalence	of	AS	was	3%	(95%CI	2-4%)	with	considerable	heterogeneity	(I2=81.9%).	
Patients	 with	 CD	 had	 a	 slightly	 higher	 prevalence	 of	 AS	 than	 patients	 with	 UC;	 4%	 (95%CI	 3-5%)	
compared	to	2%	(95%CI	1-3%).	
To	look	into	potential	explanations	for	the	heterogeneity,	the	prevalence	estimates	for	AS	are	shown	
in	 figure	3	 according	 to	 several	 demographical	 and	 study	 characteristics.	 For	 geographic	 area,	 the	
prevalence	of	AS	in	IBD	patients	was	highest	in	Europe	with	3%	(95%	CI	3-4%)	and	North-America	(3%,	
95%CI	2-5%).	The	prevalence	was	slightly	lower	in	South-America	and	Asia	with	2%	(95%CI	0-5%/1-3%	
respectively).	For	the	mean	age	of	the	study	population,	patients	of	younger	age	(age	group	20-30)	
had	a	slightly	higher	prevalence	of	AS,	based	on	two	estimates	(4%,95%CI	3-6%),	compared	to	older	
age	 groups	 (3%,95%CI	 2/1%-5/%	 respectively).	 Study	 characteristics	 like	 setting,	 outcome	
measurement	and	case	ascertainment	seemed	to	influence	the	reported	prevalences.	The	differences	
are	 small,	 with	 slightly	 higher	 prevalences	 in	 tertiary	 care	 setting,	 diagnoses	 based	 on	 clinical	
evaluation	and	the	use	of	the	recommended	(modified)	New	York	criteria	to	diagnose	AS.	
	
Table 2 Risk of Bias Assessment
% Positive
Was the sample representative of the target population? 63.4
Were study participants recruited in an appropriate way? 90.1
Was the sample size adequate? 0
Was the data analysis conducted with sufficient coverage of the identified sample? 59.2
Were objective, standard criteria used for the measurement of the condition? 56.3
Was the condition measured reliably? 46.5
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Risk	of	Bias	
A	complete	overview	of	the	assessment	of	methodological	quality	can	be	found	in	supplementary	file	
S2.	 In	 table	2	 the	different	 items	of	 the	quality	 list	are	 shown	with	 the	percentage	of	 studies	 that	
scored	 positive	 on	 this	 item.	 The	 majority	 of	 studies	 had	 a	 sample	 representative	 of	 the	 target	
population	(63.4%)	and	most	studies	recruited	their	patients	in	an	appropriate	way	(90.1%),	meaning	
consecutive,	at	random	or	all	patients	were	selected	for	the	study.	None	of	the	studies	reported	a	
sample	size	calculation	while	a	slight	majority	did	conduct	an	adequate	data-analysis	(59.2%).	With	
regard	 to	 case-ascertainment,	 in	 56.3%	objective	 standard	 criteria	were	used	 and	 in	 46.5%	of	 the	
studies	the	condition,	meaning	SpA,	was	measured	reliably.	
	
	
	
	
Prevalence	of	Axial	involvement	
Fifty-nine	studies	(125	estimates)	reported	the	prevalence	of	axial	SpA	in	patients	with	IBD.14-66		
	
Sacroiliitis	
The	prevalence	of	SI	in	patients	with	IBD	was	described	in	41	studies	(59	estimates)	(see	supplemental	
file	S3).16-18,21-26,28,30-32,34,35,37-40,42,43,45-49,51,52,55,57-62,65,67-71.	The	pooled	prevalence	of	SI	in	IBD	patients	is	
estimated	to	be	10%	(95%CI	8-12%),	with	an	I2	of	94.3%.	The	prevalence	of	SI	is	higher	in	patients	with	
CD	(13%,	95%CI	1-17%)	than	in	patients	with	UC	(7%,	95%CI	4-11%).		
As	there	was	considerable	heterogeneity	in	the	observed	prevalence	between	studies,	we	explored	
the	 variability	 by	 a	 meta-analysis	 of	 subgroups	 according	 to	 different	 demographical	 and	 study	
characteristics	(Figure	2).	Higher	prevalences	were	observed	in	European	and	studies	(11%;	95%CI	8-
15%	and11%;	95%CI	7-16%),	compared	to	North-America	(7%;	95%CI	2-14%)	and	South-America	(5%;	
95%CI	2-9%).	With	regard	to	mean	age,	the	prevalence	seemed	highest	in	the	three	studies	for	age	
category	20-30	years	of	age	with	16%	(95%CI	8-27%).	 In	the	age	group	30-40	years	the	prevalence	
dropped	towards	9%	(95%CI	5-14%),	to	rise	again	slightly	in	the	age	groups	of	40-50	years	and	50-60	
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To	look	into	potential	explanations	for	the	heterogeneity,	the	prevalence	estimates	for	AS	are	shown	
in	 figure	3	 according	 to	 several	 demographical	 and	 study	 characteristics.	 For	 geographic	 area,	 the	
prevalence	of	AS	in	IBD	patients	was	highest	in	Europe	with	3%	(95%	CI	3-4%)	and	North-America	(3%,	
95%CI	2-5%).	The	prevalence	was	slightly	lower	in	South-America	and	Asia	with	2%	(95%CI	0-5%/1-3%	
respectively).	For	the	mean	age	of	the	study	population,	patients	of	younger	age	(age	group	20-30)	
had	a	slightly	higher	prevalence	of	AS,	based	on	two	estimates	(4%,95%CI	3-6%),	compared	to	older	
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are	 small,	 with	 slightly	 higher	 prevalences	 in	 tertiary	 care	 setting,	 diagnoses	 based	 on	 clinical	
evaluation	and	the	use	of	the	recommended	(modified)	New	York	criteria	to	diagnose	AS.	
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Figure	2.	Meta-analysis	of	the	Prevalence	of	Sacroiliitis	in	IBD	Patients	
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Unspecified	Axial	Involvement	
Six	studies	(9	estimates)	did	not	specify	the	type	of	axial	involvement,	in	these	studies	the	prevalence	
ranged	 from	 1	 to	 16%.14,15,33,36,53,72	 One	 recent	 study	 (2	 estimates)	 used	 the	 new	 ASAS	 criteria	 to	
diagnose	axial	spondyloarthritis.	Since	axial	spondyloarthritis	can	be	diagnosed	without	abnormalities	
on	imaging	(which	are	required	for	diagnosing	AS),	these	estimates	are	higher	at	18%	for	UC	and	19%	
for	CD.		
	
Prevalence	of	Peripheral	Involvement	
One	hundred	and	three	estimates	from	52	studies	were	available	for	the	prevalence	of	peripheral	joint	
manifestations	of	SpA	in	IBD	patients	(see	supplemental	file	S3).	
Arthritis	
The	pooled	prevalence	of	 peripheral	 arthritis	 (79	 estimates)	was	 13%	 (95%CI	 12-15%)	with	 a	 high	
heterogeneity	 (I2=92.3%).14-16,18,20,22-27,29,30,32-34,36-38,41,42,44,45,47-53,55,56,58,60-67,69-78	 Forty	 estimates	 were	
available	for	CD	and	37	for	UC,	while	two	studies	did	not	specify	the	type	of	IBD.	The	prevalence	was	
highest	in	this	unspecified	IBD	with	17%	(95%CI	14-20%),	followed	by	CD	(15%,95%CI	12-18%)	and	UC	
(12%,95%CI	9-15%).	
Figure	4	shows	the	estimates	according	to	several	subgroups	that	might	explain	the	heterogeneity.	
With	regard	to	geographic	area,	the	prevalence	seemed	comparable	among	the	different	continents.	
Most	studies	were	available	from	Europe	(14%,	95%	CI	11-16%)	and	Asia	(14%,	95%CI	9-20%),	followed	
by	North-	&	South-America	(13%,	95%CI	9-17%	and	12%,	95%	CI	6-20%	respectively).	The	prevalence	
of	arthritis	in	IBD	seemed	to	be	decreasing	with	increasing	age.	The	prevalence	in	the	youngest	age	
group	of	20-30	years	was	25%	(95%CI	19-32%),	while	the	prevalence	in	the	age	group	of	50-60	years	
was	2%	(95%CI	1-5%).		Estimates	from	tertiary	care	were	slightly	higher	compared	with	secondary	care	
and	 population	 based	 studies,	 but	 the	 difference	 is	 negligible.	 In	 the	 majority	 of	 studies	 clinical	
evaluation	was	used	as	an	outcome	measurement	and	this	led	to	the	highest	prevalence	estimate	with	
15%	(95%CI	13-19%).		
	
Enthesitis	
The	prevalence	of	enthesitis	was	reported	in	eight	studies	(14	estimates);	six	from	Europe20,24,44,45,55,62,	
one	from	South-America34	and	one	from	Asia15.	The	reported	prevalence	ranged	from	1%	(95%CI	0-
6%)	to	54%	(95%CI	42-65%).	Three	estimates	were	available	from	Turkey	and	these	were	considerably	
higher	than	the	other	estimates	with	20%	(95%CI	13-28%),	46%	(95%CI	35-58%)	and	54%	(95%CI	42-
65%).20,62	The	estimates	from	the	other	countries	ranged	from	1%	(95%CI	0-6%)	in	Kuwait	to	0.15%	
(95%CI	7-27%)	in	a	combined	study	from	Italy	and	the	Netherlands.15,55	With	regard	to	setting	or	type	
of	IBD,	the	differences	in	prevalence	were	negligible.		
	
Figure	4.	Meta-analysis	of	Peripheral	Arthritis	in	IBD	patients	
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Dactylitis	
For	the	prevalence	of	dactylitis	ten	estimates	from	six	studies	were	available.15,24,44,45,55,79	The	reported	
prevalence	were	all	quite	 low	with	a	 range	 from	0	 in	CD	patients	 in	Kuwait15	and	Belgium24	 to	5%	
(95%CI	2-10%)	in	CD	patients	in	Norway44.	The	range	in	UC	patients	was	reported	to	be	from	2%	(95%CI	
0-7%)	to	4%	(95%CI	1-15%).	Two	studies	did	not	specify	the	type	of	IBD	and	reported	prevalences	of	
4%	(95%	CI	3-7%)45	and	6%	(95%	CI	3-11%)79.	Geographic	area	or	setting	did	not	seem	to	influence	the	
prevalence	when	looking	at	the	available	estimates.	
	
Incidence	
Three	studies	that	report	incidence	figures	were	identified.80-82	All	were	performed	in	North-America	
and	using	database	records.		
In	CD	patients,	the	cumulative	 incidence	of	SpA	according	to	the	ASAS	criteria	 increased	from	0.67	
(95%CI	0.35-0.97)	at	10	years	towards	0.19	(95%CI	0.11-0.26%)	at	30	years.	The	5-year	cumulative	
incidence	of	AS	was	0.02	and	of	peripheral	arthritis	0.009.	
In	UC	patients,	the	cumulative	incidence	at	10	years	according	to	the	ASAS	criteria	was	0.48	(95%CI	
0.02-0.07)	increasing	towards	0.22	(95%CI	0.04-0.29)	at	30	years.	The	5-year	cumulative	incidence	for	
AS	was	0.03	and	of	peripheral	arthritis	0.05.	
	
Discussion	
In	this	systematic	review	we	calculated	the	pooled	prevalences	of	SpA	manifestations	in	IBD	patients.	
The	pooled	prevalence	of	SI	was	10%	(95%CI	8-12%)	and	for	its	subtype	AS	it	was	3%	(95%CI	3-4%).	
The	pooled	prevalence	of	peripheral	arthritis	was	13%	(95%CI	12-15%).	The	prevalence	of	AS,	SI	and	
peripheral	 arthritis	 was	 higher	 in	 patients	 with	 CD	 than	 in	 patients	 with	 UC.	 This	 difference	 in	
prevalence	estimates	has	been	described	before.2,4,83	For	the	prevalence	of	enthesitis	and	dactylitis	
fewer	estimates	were	available.	The	prevalence	of	enthesitis	had	a	wide	range	from	1%	(95%CI	0-6%)	
to	54%	 (95%CI	42-65%)	with	outliers	 in	 two	 studies	 from	Turkey.	 The	prevalence	of	dactylitis	was	
relatively	low	between	0	and	5%	(95%CI	2-10%).	Only	three	studies	reported	the	cumulative	incidence	
of	SpA	in	IBD	patients.	
As	the	heterogeneity	between	the	different	studies	was	high,	these	estimates	should	be	interpreted	
with	 caution.	Geographic	 area,	 setting	 and	 case	 ascertainment	 seemed	 to	 contribute	 to	 this	 large	
heterogeneity	in	prevalence	estimates.		
	Prevalence	estimates	of	AS	were	higher	if	case	ascertainment	was	done	by	using	validated	
criteria.	As	only	a	slight	majority	(60%)	of	studies	used	validated	criteria	for	diagnosing	AS,	a	 lot	of	
studies	will	underestimate	 the	prevalence	of	AS	 in	 IBD.	The	same	applies	 for	 studies	performed	 in	
secondary	care,	which	seem	to	estimate	a	lower	prevalence	of	the	different	SpA	manifestations	than	
studies	in	tertiary	care.	This	could	imply	that	tertiary	care	centers	are	more	focused	on	joined	care	
between	 gastroenterologists	 and	 rheumatologists	 to	 enhance	 recognition	 of	 SpA	 in	 IBD	 patients.	
Geographic	 area	 also	 contributes	 to	 the	 heterogeneity	 and	 prevalences	 for	 axial	 manifestations	
(SI&AS)	 are	 highest	 in	 Europe	 and	 North-America.	 This	 is	 in	 line	 with	 the	 estimates	 for	 SpA	 in	
general.84,85	 Clinical	 evaluation	 as	 an	 outcome	 measurement	 led	 to	 higher	 prevalence	 estimates	
compared	to	self-reported	diagnosis	or	case	records.	This	might	suggest	 that	our	estimates	are	an	
underestimation,	as	in	other	types	of	arthritis	it	has	been	shown	that	the	prevalence	of	self-reported	
diagnosis	is	higher	than	could	be	objectified	via	case	records	or	specialists.86,87	
As	shown,	there	was	large	variety	in	methodological	quality	of	studies.	Most	studies	included	
their	 participants	 adequately,	 but	 merely	 65%	 selected	 a	 sample	 representative	 of	 the	 target	
population.	The	results	of	these	studies	therefore	have	poor	external	validity.	Even	though	the	quality	
of	the	included	studies	differed	widely,	we	chose	not	to	pool	on	the	quality	in	the	meta-analysis	as	it	
has	 been	 shown	 before	 that	 the	 quality	 is	 highly	 dependent	 on	 the	 quality	 assessment	 tool	 you	
choose.88		
	 When	discussing	the	results	of	our	study,	several	strengths	and	limitations	should	be	taken	
into	account.	Although	some	narrative	reviews	about	the	prevalence	of	rheumatic	manifestations	in	
IBD	patients	have	been	published2-4,83,89,	the	strength	of	this	study	is	that	it	is	the	first	systematically	
performed	 review	 and	 it	 includes	 a	 meta-analysis.	 We	 set	 up	 an	 extensive	 search	 strategy	 in	
collaboration	with	an	experienced	librarian	in	order	to	identify	as	many	relevant	studies	as	possible.	
We	also	included	a	risk	of	bias	assessment	to	give	an	indication	of	the	methodological	quality	of	the	
included	studies.	Furthermore,	we	are	the	first	to	make	the	distinction	between	axial	and	peripheral	
manifestations	of	SpA,	as	recommended	by	the	widely	used	ASAS	criteria.9,10	Regarding	the	limitations,	
we	only	included	studies	that	were	available	in	the	English	language	so	we	cannot	rule	out	missing	
certain	 studies.	 	 Secondly,	 only	 one	 author	 performed	 the	 screening	 of	 the	 papers	 and	 the	 data	
extraction.	Ideally,	this	would	have	been	done	independently	by	two	authors.	However,	we	discussed	
beforehand	with	 all	 authors	which	 papers	 to	 include	 and	which	 not.	 In	 addition,	 the	 author	who	
performed	the	screening	was	very	liberal	and	in	case	of	any	doubt,	the	paper	was	discussed	with	one	
of	 the	 other	 authors	 until	 consensus	 was	 reached.	 Thirdly,	 we	 used	 a	 risk	 of	 bias	 tool	 especially	
developed	 for	 prevalence	 studies,	 but	 left	 some	 items	 out	 as	 these	 did	 not	 seem	 to	 apply	 to	 our	
selected	studies.	We	left	out	items	about	the	description	of	study	subjects	and	setting	as	we	gathered	
this	 information	 in	 the	 data-extraction.	 Items	 about	 the	 definition	 of	 subgroups	 and	 differences	
between	subgroups	were	also	left	out,	as	we	only	looked	at	prevalence	in	the	complete	groups.	As	we	
do	not	take	the	quality	into	account	when	pooling	the	results,	we	do	not	think	leaving	out	these	items	
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Dactylitis	
For	the	prevalence	of	dactylitis	ten	estimates	from	six	studies	were	available.15,24,44,45,55,79	The	reported	
prevalence	were	all	quite	 low	with	a	 range	 from	0	 in	CD	patients	 in	Kuwait15	and	Belgium24	 to	5%	
(95%CI	2-10%)	in	CD	patients	in	Norway44.	The	range	in	UC	patients	was	reported	to	be	from	2%	(95%CI	
0-7%)	to	4%	(95%CI	1-15%).	Two	studies	did	not	specify	the	type	of	IBD	and	reported	prevalences	of	
4%	(95%	CI	3-7%)45	and	6%	(95%	CI	3-11%)79.	Geographic	area	or	setting	did	not	seem	to	influence	the	
prevalence	when	looking	at	the	available	estimates.	
	
Incidence	
Three	studies	that	report	incidence	figures	were	identified.80-82	All	were	performed	in	North-America	
and	using	database	records.		
In	CD	patients,	the	cumulative	 incidence	of	SpA	according	to	the	ASAS	criteria	 increased	from	0.67	
(95%CI	0.35-0.97)	at	10	years	towards	0.19	(95%CI	0.11-0.26%)	at	30	years.	The	5-year	cumulative	
incidence	of	AS	was	0.02	and	of	peripheral	arthritis	0.009.	
In	UC	patients,	the	cumulative	incidence	at	10	years	according	to	the	ASAS	criteria	was	0.48	(95%CI	
0.02-0.07)	increasing	towards	0.22	(95%CI	0.04-0.29)	at	30	years.	The	5-year	cumulative	incidence	for	
AS	was	0.03	and	of	peripheral	arthritis	0.05.	
	
Discussion	
In	this	systematic	review	we	calculated	the	pooled	prevalences	of	SpA	manifestations	in	IBD	patients.	
The	pooled	prevalence	of	SI	was	10%	(95%CI	8-12%)	and	for	its	subtype	AS	it	was	3%	(95%CI	3-4%).	
The	pooled	prevalence	of	peripheral	arthritis	was	13%	(95%CI	12-15%).	The	prevalence	of	AS,	SI	and	
peripheral	 arthritis	 was	 higher	 in	 patients	 with	 CD	 than	 in	 patients	 with	 UC.	 This	 difference	 in	
prevalence	estimates	has	been	described	before.2,4,83	For	the	prevalence	of	enthesitis	and	dactylitis	
fewer	estimates	were	available.	The	prevalence	of	enthesitis	had	a	wide	range	from	1%	(95%CI	0-6%)	
to	54%	 (95%CI	42-65%)	with	outliers	 in	 two	 studies	 from	Turkey.	 The	prevalence	of	dactylitis	was	
relatively	low	between	0	and	5%	(95%CI	2-10%).	Only	three	studies	reported	the	cumulative	incidence	
of	SpA	in	IBD	patients.	
As	the	heterogeneity	between	the	different	studies	was	high,	these	estimates	should	be	interpreted	
with	 caution.	Geographic	 area,	 setting	 and	 case	 ascertainment	 seemed	 to	 contribute	 to	 this	 large	
heterogeneity	in	prevalence	estimates.		
	Prevalence	estimates	of	AS	were	higher	if	case	ascertainment	was	done	by	using	validated	
criteria.	As	only	a	slight	majority	(60%)	of	studies	used	validated	criteria	for	diagnosing	AS,	a	 lot	of	
studies	will	underestimate	 the	prevalence	of	AS	 in	 IBD.	The	same	applies	 for	 studies	performed	 in	
secondary	care,	which	seem	to	estimate	a	lower	prevalence	of	the	different	SpA	manifestations	than	
studies	in	tertiary	care.	This	could	imply	that	tertiary	care	centers	are	more	focused	on	joined	care	
between	 gastroenterologists	 and	 rheumatologists	 to	 enhance	 recognition	 of	 SpA	 in	 IBD	 patients.	
Geographic	 area	 also	 contributes	 to	 the	 heterogeneity	 and	 prevalences	 for	 axial	 manifestations	
(SI&AS)	 are	 highest	 in	 Europe	 and	 North-America.	 This	 is	 in	 line	 with	 the	 estimates	 for	 SpA	 in	
general.84,85	 Clinical	 evaluation	 as	 an	 outcome	 measurement	 led	 to	 higher	 prevalence	 estimates	
compared	to	self-reported	diagnosis	or	case	records.	This	might	suggest	 that	our	estimates	are	an	
underestimation,	as	in	other	types	of	arthritis	it	has	been	shown	that	the	prevalence	of	self-reported	
diagnosis	is	higher	than	could	be	objectified	via	case	records	or	specialists.86,87	
As	shown,	there	was	large	variety	in	methodological	quality	of	studies.	Most	studies	included	
their	 participants	 adequately,	 but	 merely	 65%	 selected	 a	 sample	 representative	 of	 the	 target	
population.	The	results	of	these	studies	therefore	have	poor	external	validity.	Even	though	the	quality	
of	the	included	studies	differed	widely,	we	chose	not	to	pool	on	the	quality	in	the	meta-analysis	as	it	
has	 been	 shown	 before	 that	 the	 quality	 is	 highly	 dependent	 on	 the	 quality	 assessment	 tool	 you	
choose.88		
	 When	discussing	the	results	of	our	study,	several	strengths	and	limitations	should	be	taken	
into	account.	Although	some	narrative	reviews	about	the	prevalence	of	rheumatic	manifestations	in	
IBD	patients	have	been	published2-4,83,89,	the	strength	of	this	study	is	that	it	is	the	first	systematically	
performed	 review	 and	 it	 includes	 a	 meta-analysis.	 We	 set	 up	 an	 extensive	 search	 strategy	 in	
collaboration	with	an	experienced	librarian	in	order	to	identify	as	many	relevant	studies	as	possible.	
We	also	included	a	risk	of	bias	assessment	to	give	an	indication	of	the	methodological	quality	of	the	
included	studies.	Furthermore,	we	are	the	first	to	make	the	distinction	between	axial	and	peripheral	
manifestations	of	SpA,	as	recommended	by	the	widely	used	ASAS	criteria.9,10	Regarding	the	limitations,	
we	only	included	studies	that	were	available	in	the	English	language	so	we	cannot	rule	out	missing	
certain	 studies.	 	 Secondly,	 only	 one	 author	 performed	 the	 screening	 of	 the	 papers	 and	 the	 data	
extraction.	Ideally,	this	would	have	been	done	independently	by	two	authors.	However,	we	discussed	
beforehand	with	 all	 authors	which	 papers	 to	 include	 and	which	 not.	 In	 addition,	 the	 author	who	
performed	the	screening	was	very	liberal	and	in	case	of	any	doubt,	the	paper	was	discussed	with	one	
of	 the	 other	 authors	 until	 consensus	 was	 reached.	 Thirdly,	 we	 used	 a	 risk	 of	 bias	 tool	 especially	
developed	 for	 prevalence	 studies,	 but	 left	 some	 items	 out	 as	 these	 did	 not	 seem	 to	 apply	 to	 our	
selected	studies.	We	left	out	items	about	the	description	of	study	subjects	and	setting	as	we	gathered	
this	 information	 in	 the	 data-extraction.	 Items	 about	 the	 definition	 of	 subgroups	 and	 differences	
between	subgroups	were	also	left	out,	as	we	only	looked	at	prevalence	in	the	complete	groups.	As	we	
do	not	take	the	quality	into	account	when	pooling	the	results,	we	do	not	think	leaving	out	these	items	
Chapter 4
70
will	 influence	our	results.	For	the	pooled	estimates	of	SI	and	AS,	we	cannot	rule	out	that	a	certain	
overlap	 between	 these	 two	 manifestations	 occurred.	 Some	 papers	 described	 very	 accurately	 if	
patients	only	suffered	from	SI	or	AS,	but	in	the	majority	of	studies	it	was	unclear	whether	the	patients	
with	AS	were	a	subset	of	the	patients	with	SI	or	if	they	were	completely	separated	in	establishing	the	
cases.	It	is	therefore	possible	that	the	prevalence	of	SI	is	slightly	overestimated.	
	Based	on	this	meta-analysis	the	prevalence	of	peripheral	arthritis	is	around	13%.	This	means	
that	one	in	every	eight	patients	will	develop	SpA.	The	prevalence	for	axial	involvement	in	slightly	lower	
with	10%	for	SI	(i.e.	one	in	every	ten	patients)	and	3%	for	AS	(i.e.	one	in	every	thirty-three	patients).	
Gastroenterologists,	 especially	 in	 secondary	 care,	 should	 pay	 attention	 to	 their	 IBD	 patients	 with	
musculoskeletal	complaints	since	they	are	common	and	might	cause	significant	impact	on	quality	of	
life,	 even	 in	 the	 absence	 of	 inflammation.8	 IBD	 patients	 are	 prone	 to	 develop	 SpA	 and	 should	 be	
recognized	early	as	the	benefits	of	early	treatment	are	well	established.90,91	
	 In	 conclusion,	 we	 calculated	 pooled	 prevalences	 for	 SI	 (10%),	 its	 subtype	 AS(3%)	 and	
peripheral	 arthritis(13%)	 in	 patients	 with	 IBD.	 It	 seems	 that	 there	 is	 room	 for	 improvement	 in	
gastroenterology,	especially	 in	secondary	care,	with	regard	to	recognition	of	SpA	manifestations	 in	
IBD	patients.	
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will	 influence	our	results.	For	the	pooled	estimates	of	SI	and	AS,	we	cannot	rule	out	that	a	certain	
overlap	 between	 these	 two	 manifestations	 occurred.	 Some	 papers	 described	 very	 accurately	 if	
patients	only	suffered	from	SI	or	AS,	but	in	the	majority	of	studies	it	was	unclear	whether	the	patients	
with	AS	were	a	subset	of	the	patients	with	SI	or	if	they	were	completely	separated	in	establishing	the	
cases.	It	is	therefore	possible	that	the	prevalence	of	SI	is	slightly	overestimated.	
	Based	on	this	meta-analysis	the	prevalence	of	peripheral	arthritis	is	around	13%.	This	means	
that	one	in	every	eight	patients	will	develop	SpA.	The	prevalence	for	axial	involvement	in	slightly	lower	
with	10%	for	SI	(i.e.	one	in	every	ten	patients)	and	3%	for	AS	(i.e.	one	in	every	thirty-three	patients).	
Gastroenterologists,	 especially	 in	 secondary	 care,	 should	 pay	 attention	 to	 their	 IBD	 patients	 with	
musculoskeletal	complaints	since	they	are	common	and	might	cause	significant	impact	on	quality	of	
life,	 even	 in	 the	 absence	 of	 inflammation.8	 IBD	 patients	 are	 prone	 to	 develop	 SpA	 and	 should	 be	
recognized	early	as	the	benefits	of	early	treatment	are	well	established.90,91	
	 In	 conclusion,	 we	 calculated	 pooled	 prevalences	 for	 SI	 (10%),	 its	 subtype	 AS(3%)	 and	
peripheral	 arthritis(13%)	 in	 patients	 with	 IBD.	 It	 seems	 that	 there	 is	 room	 for	 improvement	 in	
gastroenterology,	especially	 in	secondary	care,	with	regard	to	recognition	of	SpA	manifestations	 in	
IBD	patients.	
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defined	is	included	in	the	
manuscript.	
6.	 Was	the	condition	measured	
reliably?	
Outcome	assessor	was	qualified	to	use	
the	case	definition	criteria	(for	example;	
medical	specialist,	trained	research	
nurse)	
Outcome	assessor	was	not	
qualified	to	use	the	case	
definition	criteria	or	it	was	not	
mentioned	who	defined	a	case.	
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TS=(((spondyloarthr*	OR	spondylarthr*		OR	arthropath*	OR	((spondyl*	OR	enteropath*)	NEAR/1	
arthr*)	OR	((extra-intestinal	OR	extra-bowel	OR	extraintestin*	OR	rheumat*	OR	arthrit*	OR	articul*)	
NEAR/3	(manifestation*	OR	disorder*	OR	site*	OR	complicat*	OR	symptom*	OR	involv*))))	AND	
(((inflammat*	NEAR/3	bowel)	OR	crohn*	OR	(ulcerat*	NEAR/3	colit*)	OR	ibd	OR	ibds))	AND	
((prevalen*	OR	inciden*	OR	frequen*	OR	epidemiol*		OR	comorbid*	OR	occuren*	OR	coexist*)))	
Google	scholar	
Spondyloarthropathy|spondylarthritis|"extraintestinal|rheumatic|articular|arthritic	
manifestations|symptoms|involvement"	crohn|"ulcerative	colitis|ibd	
epidemiology|epidemiological|prevalence|incidence|comorbidity|frequency	
	 	
Supplemental	file	S2	 	 Risk	of	bias	assessment	
	
	
Risk	of	Bias	Assessment	Instructions	
		 	
	 	 YES	 NO	
1.	 Was	the	sample	
representative	of	the	target	
population?	
The	sample	was	representative	of	the	
target	population.		Selected	patients	
are	representative	of	an	IBD	population.	
No	pre-selection	took	place	in	selecting	
the	patients	based	on	for	example	
work.	
The	center	from	which	the	IBD	patients	
were	recruited	should	me	mentioned	
Sample	was	not	representative.	
2.	 Were	study	participants	
recruited	in	an	appropriate	
way?	
Patients	were	recruited	from	an	
appropriate	source	and	were	
“randomly”	invited	for	the	study	(all	
patients	OR	consecutive	patients	OR	
random	patients)	
Patients	were	not	recruited	
from	an	appropriate	source	and	
no	random	selection	was	used	
to	recruit	patients	
3.	 Was	the	sample	size	
adequate/	Was	sample	size	
calculation	performed?	
Sample	size	calculation	was	performed	
and	it	was	reported	if	this	target	was	
reached	
No	sample	size	calculation	
4.	 Was	the	data	analysis	
conducted	with	sufficient	
coverage	of	the	identified	
sample?	
Non-response	was	described	AND	a	
comparison	between	the	responders	
and	non-responders	was	performed.	
	
If	retrospective	design,	answer	is	yes	
No	information	about	response	
percentages	was	given	or	no	
comparison	between	
responders	and	non-responders	
was	made.	
5.	 Were	objective,	standard	
criteria	used	for	the	
measurement	of	the	
condition?	
Criteria	were	used	for	the	diagnosis	of	
SpA	(for	example	(modified)	New	York	
criteria,	ESSG	criteria)	
OR	
A	detailed	description	of	how	a	case	
(for	example	sacroillitis)	was	defined	is	
included	in	the	manuscript.	
OR	
In	case	of	use	of	ICD	codes,	a	
validation/check	was	performed	
No	criteria	were	used	and	no	
description	of	how	a	case	was	
defined	is	included	in	the	
manuscript.	
6.	 Was	the	condition	measured	
reliably?	
Outcome	assessor	was	qualified	to	use	
the	case	definition	criteria	(for	example;	
medical	specialist,	trained	research	
nurse)	
Outcome	assessor	was	not	
qualified	to	use	the	case	
definition	criteria	or	it	was	not	
mentioned	who	defined	a	case.	
Risk of Bias Assessment Instructions
YES NO
1. Was the sample 
representative of the 
target population?
The sample was representative of the 
target po ulation.  Selected p tients are 
representative of an IBD population. No pre-
selection took place in selecting the patients 
based on for example work.
The center from which the IBD patients 
were recruited should me mentioned
Sample was not 
representative.
2. Were study participants 
recruited in an appropriate 
way?
Patients were recruited from an appropriate 
source and were “randomly” invited for the 
study (all patients OR consecutive patients 
OR random patients)
Patients were not recruited 
from an appropriate source 
and no random selection was 
used to recruit patients
3. Was the sample size 
adequate/ Was sample size 
calculation performed?
Sample size calculation was performed and 
it was reported if this target was reached
No sample size calculation
4. Was the data analysis 
conducted with sufficient 
coverage of the identified 
sample?
Non-response was described AND a 
comparison between the responders and 
non-responders was performed.
If retrospective design, answer is yes
No information about 
response percentages was 
given or no comparison 
between responders and non-
responders was made.
5. Were objective, standard 
criteria used for the 
measurement of the 
condition?
Criteria were used for the diagnosis of SpA 
(for example (modified) New York criteria, 
ESSG criteria)
OR
A detailed description of how a case (for 
example sacroillitis) was defined is included 
in the manuscript.
OR
In case of use of ICD codes, a validation/
check was performed
No criteria were used and 
no description of how a case 
was defined is included in the 
manuscript.
6. Was the condition 
measured reliably?
Outcome assessor was qualified to use 
the case definition criteria (for example; 
medical specialist, trained research nurse)
Outcome assessor was not 
qualified to use the case 
definition criteria or it was 
not mentioned who defined 
a case.
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Overview of the Risk of Bias Assessment per study
Item on Risk of Bias Assessment
Author Journal 1 2 3 4 5 6 Total Score
Al-Jarallah Inflammatory Bowel Diseases; 2012, 
18(9): 1655-1662
0 1 0 0 1 0 2
Al-Jarallah Int J Rheum Dis; 2013, 16(2): 134-138 0 1 0 1 1 0 3
Al-Shamali Digestion; 2003, 67(4): 218-224 1 1 0 1 0 0 3
Ansell BM Annals of the Rheumatic Diseases; 1964: 1 1 0 0 0 0 2
Arora Dig Dis Sci; 2010, 55(6): 1689-1695 1 1 0 1 0 0 3
Bandyopadhyay Indian J Gastroenterol; 2015, 34(5): 387-
394
1 1 0 0 1 1 4
Bardazzi Ital J Gastroenterol Hepatol; 1997, 29(6): 
520-524
0 1 0 0 1 1 3
Barreiro-De 
Acosta
Eur J Gastroenterol Hepatol; 2007, 19(1): 
73-78
0 1 0 1 1 1 4
Bernstein Am J Gastroenterol; 2001, 96(4): 1116-
1122
1 1 0 1 1 0 4
Beslek Rheumatol Int; 2009, 29(8): 955-957 0 0 0 0 1 1 2
Bruining Inflammatory Bowel Dis; 2008, 14(12): 
1701-1706
1 1 0 1 0 1 4
Christodoulou Dig Liver Dis; 2002, 34(11): 781-786 0 1 0 1 0 1 3
Davis ARTHRITIS RHEUM; 1978, 21(2): 234-7 0 1 0 0 1 0 2
De Vlam J Rheumatol; 2000, 27(12): 2860-2865 0 1 0 0 1 1 3
Dekker Saeys Annals of the Rheumatic Diseases; 1978, 
37(1): 33-35
1 1 0 1 1 1 5
D'Inca Dig Liver Dis; 2009, 41(8): 565-569 1 1 0 0 1 1 4
Dorofeyev Dig Dis; 2009, 27(4): 502-510 0 0 0 0 0 0 0
Fatemi J Res Med Sci; 2016, 21(3): 0 1 0 1 0 1 3
Fielding AM J GASTROENTEROL; 1986, 81(7): 524-
528
1 1 0 1 0 0 3
Gotler J. Magn. Reson. Imaging; 2015, 42(1): 
121-127
0 1 0 1 1 1 4
Greenstein MEDICINE; 1976, 55(5): 401-412 1 1 0 1 1 0 4
Haslock MEDICINE; 1973, 52(3): 217-225 1 1 0 0 0 0 2
Hwangbo Gut Liver; 2010, 4(3): 338-344 0 1 0 1 1 1 4
Indiveri S Afr Gastroenterol Rev; 2010, 8(3): 6-18 0 1 0 1 0 0 2
Isene Scand J Gastroenterol; 2015, 50(3): 300-
305
1 1 0 0 0 1 3
Kamo Mod Rheumatol; 2015, 25(3): 435-437 1 1 0 0 0 0 2
Karmiris J Crohn's Colitis; 2016, 10(4): 429-436 0 1 0 1 0 0 2
Kochhar Indian J Gastroenterol; 1991, 10(3): 88-89 1 1 0 1 1 0 4
Lakatos World J Gastroenterol; 2003, 9(10): 2300-
2307
1 1 0 0 1 1 4
Lanna Clin Rheumatol; 2008, 27(4): 503-509 1 1 0 0 1 1 4
Leclerc-Jacob Aliment Pharmacol Ther; 2014, 39(9): 
957-962
1 1 0 1 1 1 5
Liu Medicine (Baltimore); 2016, 95(28): 
e4267
0 1 0 1 1 1 4
Table continues
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Maeda J GASTROENTEROL; 1994, 29(5): 577-582 1 0 0 1 0 0 2
Mocelin Digestion; 2015, 91(4): 303-306 0 1 0 0 1 1 3
Modena CLIN EXP RHEUMATOL; 1988, 6(3): 221-
225
1 1 0 0 1 1 4
Münch Hepato- …; 1986: 1 1 0 0 1 1 4
Nguyen Am J Gastroenterol; 2006, 101(5): 1012-
1023
0 1 0 0 1 0 2
Orchard GUT; 1998: 1 1 0 1 1 0 4
Orchard Aliment Pharmacol Ther; 2009, 29(2): 
193-197
1 1 0 1 1 1 5
Ott World J Gastroenterol; 2014, 20(34): 
12269-12276
1 1 0 0 0 0 2
Ozdil Hepatogastroenterology; 2003, 50 Suppl 2 0 0 0 1 0 0 1
Ozdil Hepato-Gastroenterology; 2004, 51(57): 
768-770
0 1 0 1 0 0 2
Palm Rheumatology; 2001, 40(11): 1256-1261 1 1 0 0 1 1 4
Palm J Rheumatol; 2002, 29(3): 511-515 1 1 0 0 1 1 4
Paparo Abdom Imaging; 2012, 37(3): 326-337 0 1 0 1 1 1 4
Peeters J Gastroenterol Hepatol; 2008, 23(1): 132-
137
0 0 0 0 1 1 2
Pezerovic Coll Antropol; 2013, 37(3): 919-927 0 1 0 1 0 0 2
Pokharna Indian J Gastroenterol; 2004, 23(3): 89-90 1 1 0 1 1 0 4
Pongprasobchai J Med Assoc Thailand; 2001, 84(9): 1281-
1288
1 1 0 1 0 0 3
Queiro Clin Rheumatol; 2000, 19(6): 445-449 1 1 0 1 1 1 5
Rajput S AFR MED J; 1992, 81(5): 245-248 1 1 0 0 0 0 2
Repiso Ortega Rev Esp Enferm Dig; 2006, 98(7): 510-517 1 1 0 1 0 0 3
Ricart Inflammatory Bowel Diseases; 2004, 
10(3): 207-214
1 1 0 0 0 0 2
Salvarani Scand J Gastroenterol; 2001, 36(12): 
1307-1313
1 1 0 0 1 1 4
Scarpa J RHEUMATOL; 1992, 19(3): 373-377 1 1 0 1 1 1 5
Shivashankar J Rheumatol; 2012, 39(11): 2148-2152 1 1 0 1 1 1 5
Shivashankar J Rheumatol; 2013, 40(7): 1153-1157 1 1 0 1 1 1 5
Singh Indian J Gastroenterol; 2015, 1 1 0 1 0 0 3
Steer Journal of Rheumatology; 2003, 30(3): 
518-522
1 1 0 1 1 1 5
Suh J Korean Med Sci; 1998, 13(1): 39-43 0 1 0 1 1 0 3
Teh Ann Acad Med Singap; 1987, 16(3): 480-
487 (CD)
0 1 0 1 0 0 2
Teh Ann Acad Med Singap; 1987, 16(3): 474-
479 (UC)
1 1 0 1 0 0 3
Torres Intern J Inflamm; 2012, 1 0 0 1 0 0 2
Tozun J Clin Gastroenterol; 2009, 43(1): 51-57 1 1 0 0 0 0 2
Turkcapar Rheumatol Int; 2006, 26(7): 663-668 0 1 0 0 1 1 3
Vavricka Am J Gastroenterol; 2011, 106(1): 110-
119
1 1 0 0 1 0 3
Veloso J CLIN GASTROENTEROL; 1996, 23(1): 
29-34
1 1 0 0 1 0 3
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Supplemental	file	S3		Individual	Forestplots	
	
Forestplot	of	the	prevalence	of	Sacroiliitis	of	all	included	studies	
Heterogeneity between groups: p = 0.002
Overall  (I^2 = 94.32%, p = 0.00);
Pokharna (2004)
Ozdil (2003)
Tozun (2009)
D'Inca (2009)
Study
Leclerc-Jacob (2014)
Ott (2014)
Wagtmans (2001)
Leclerc-Jacob (2014)
Gotler (2015)
Bandyopadhyay (2015)
Steer (2003)
Bardazzi (1997)
Queiro (2000)
Salvarani (2001)
Subtotal  (I^2 = 93.32%, p = 0.00)
Karmiris (2016)
Bandyopadhyay (2015)
Subtotal  (I^2 = 93.12%, p = 0.00)
Turkcapar (2006)
Dekker Saeys (1978)
Torres (2012)
Ozdil (2004)
Orchard (2009)
Modena (1988)
Fielding (1986)
Peeters (2008)
Haslock (1973)
Torres (2012)
Pezerovic (2013)
Ott (2014)
Palm (2002)
Dekker Saeys (1978)
Subtotal  (I^2 = 93.13%, p = 0.00)
Nguyen (2006)
Paparo (2012)
Salvarani (2001)
Hwangbo (2010)
CD
Suh (1998)
Queiro (2000)
Isene (2015)
De Vlam (2000)
Kochhar (1991)
Suh (1998)
Lanna (2008)
Davis (1978)
Rajput (1992)
Barreiro-De Acosta (2007)
Ansell BM (1964)
Isene (2015)
Hwangbo (2010)
Christodoulou (2002)
Teh (1987)
IBD
Turkcapar (2006)
UC
Christodoulou (2002)
Karmiris (2016)
Tozun (2009)
Pezerovic (2013)
De Vlam (2000)
D'Inca (2009)
Bruining (2008)
Lanna (2008)
Münch (1986)
0.10 (0.08, 0.12)
0.00 (0.00, 0.08)
0.08 (0.03, 0.14)
0.02 (0.01, 0.05)
0.02 (0.01, 0.04)
ES (95% CI)
0.18 (0.11, 0.25)
0.10 (0.06, 0.16)
0.04 (0.03, 0.06)
0.15 (0.06, 0.27)
0.09 (0.06, 0.13)
0.19 (0.10, 0.31)
0.23 (0.16, 0.31)
0.13 (0.06, 0.24)
0.23 (0.10, 0.40)
0.02 (0.00, 0.07)
0.07 (0.04, 0.11)
0.02 (0.01, 0.03)
0.21 (0.12, 0.33)
0.03 (0.01, 0.08)
0.62 (0.50, 0.72)
0.12 (0.05, 0.23)
0.03 (0.01, 0.05)
0.12 (0.07, 0.19)
0.39 (0.24, 0.55)
0.12 (0.04, 0.24)
0.01 (0.00, 0.07)
0.20 (0.15, 0.25)
0.16 (0.10, 0.24)
0.04 (0.02, 0.07)
0.10 (0.02, 0.26)
0.03 (0.01, 0.09)
0.01 (0.00, 0.03)
0.16 (0.07, 0.29)
0.13 (0.10, 0.17)
0.02 (0.01, 0.03)
0.24 (0.19, 0.30)
0.05 (0.01, 0.14)
0.12 (0.06, 0.21)
0.05 (0.01, 0.13)
0.26 (0.11, 0.46)
0.02 (0.01, 0.04)
0.35 (0.24, 0.46)
0.14 (0.09, 0.21)
0.08 (0.02, 0.19)
0.14 (0.07, 0.24)
0.12 (0.05, 0.23)
0.00 (0.00, 0.06)
0.07 (0.04, 0.12)
0.20 (0.12, 0.29)
0.02 (0.01, 0.03)
0.21 (0.13, 0.31)
0.16 (0.06, 0.32)
0.11 (0.00, 0.48)
0.57 (0.46, 0.68)
0.04 (0.02, 0.08)
0.07 (0.05, 0.09)
0.01 (0.00, 0.02)
0.03 (0.01, 0.07)
0.24 (0.09, 0.45)
0.06 (0.03, 0.09)
0.02 (0.01, 0.04)
0.03 (0.00, 0.12)
0.21 (0.15, 0.28)
100.00
1.54
1.73
1.83
1.87
Weight
1.77
1.80
1.89
1.59
1.85
1.60
1.77
1.64
1.45
1.72
38.91
1.90
1.62
5.63
1.68
1.60
1.85
1.75
1.52
1.57
1.66
1.84
1.75
1.86
1.40
1.72
1.87
1.57
55.46
1.91
1.83
1.61
1.69
1.67
1.35
1.87
1.68
1.79
1.57
1.65
1.61
1.63
1.80
1.71
1.90
1.68
1.47
0.86
1.69
1.83
1.90
1.89
1.75
1.32
1.85
1.87
1.61
1.80
%
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Forestplot	of	the	prevalence	of	Sacroiliitis	of	all	included	studies	
Heterogeneity betw en groups: p = 0.002
Overall  (I^2 = 94.32%, p = 0.00);
Pokharna (2004)
Ozdil (2003)
Tozun (2009)
D'Inca (2009)
Study
Leclerc-Jacob (2014)
Ott (2014)
Wagtmans (2001)
Leclerc-Jacob (2014)
Gotler (2015)
Bandyopadhyay (2015)
Steer (2003)
Bardazzi (1997)
Queiro (2000)
Salvarani (2001)
Subtotal  (I^2 = 93.32%, p = 0.00)
Karmiris (2016)
Bandyopadhyay (2015)
Subtotal  (I^2 = 93.12%, p = 0.00)
Turkcapar (2006)
Dekker Saeys (1978)
Torres (2012)
Ozdil (2004)
Orchard (2009)
Modena (1988)
Fielding (1986)
Peeters (2008)
Haslock (1973)
Torres (2012)
Pezerovic (2013)
Ott (2014)
Palm (2002)
Dekker Saeys (1978)
Subtotal  (I^2 = 93.13%, p = 0.00)
Nguyen (2006)
Paparo (2012)
Salvarani (2001)
Hwangbo (2010)
CD
Suh (1998)
Queiro (2000)
Isene (2015)
De Vlam (2000)
Kochhar (1991)
Suh (1998)
Lanna (2008)
Davis (1978)
Rajput (1992)
Barreiro-De Acosta (2007)
Ansell BM (1964)
Isene (2015)
Hwangbo (2010)
Christodoulou (2002)
Teh (1987)
IBD
Turkcapar (2006)
UC
Christodoulou (2002)
Karmiris (2016)
Tozun (2009)
Pezerovic (2013)
De Vlam (2000)
D'Inca (2009)
Bruining (2008)
Lanna (2008)
Münch (1986)
0.10 (0.08, . 2)
0.00 (0.00, . 8)
0.08 (0.03, .14)
0.02 (0.01, . 5)
0.02 (0.01, . 4)
ES (95% CI)
0.18 (0.11, .25)
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0.04 (0.03, . 6)
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0.07 (0.04, .11)
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0.03 (0.01, . 8)
0.62 (0.50, .7 )
0.12 (0.05, .23)
0.03 (0.01, . 5)
0.12 (0.07, . 9)
0.39 (0.24, .55)
0.12 (0.04, .24)
0.01 (0.00, . 7)
0.20 (0.15, . 5)
0.16 (0.10, .24)
0.04 (0.02, . 7)
0.10 (0.02, .26)
0.03 (0.01, . 9)
0.01 (0.00, . 3)
0.16 (0.07, .29)
0.13 (0.10, . 7)
0.02 (0.01, . 3)
0.24 (0.19, .30)
0.05 (0.01, .14)
0.12 (0.06, .21)
0.05 (0.01, .13)
0.26 (0.11, .4 )
0.02 (0.01, . 4)
0.35 (0.24, .46)
0.14 (0.09, .21)
0.08 (0.02, .19)
0.14 (0.07, .2 )
0.12 (0.05, .23)
0.00 (0.00, . 6)
0.07 (0.04, .12)
0.20 (0.12, . 9)
0.02 (0.01, . 3)
0.21 (0.13, .3 )
0.16 (0.06, .32)
0.11 (0.00, .48)
0.57 (0.46, .68)
0.04 (0.02, . 8)
0.07 (0.05, . 9)
0.01 (0.00, . 2)
0.03 (0.01, . 7)
0.24 (0.09, .45)
0.06 (0.03, . 9)
0.02 (0.01, . 4)
0.03 (0.00, .12)
0.21 (0.15, . 8)
100.00
1.54
1.73
1.83
1.87
Weight
.77
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Wagtmans Am J Gastroenterol; 2001, 96(5): 1541-
1546
0 0 0 1 0 0 1
Yi Eur J Gastroenterol Hepatol; 2012, 24(12): 
1424-1429
1 1 0 1 0 0 3
Yuksel Dig Dis Sci; 2011, 56(1): 183-187 1 1 0 1 0 1 4
Zippi World J Gastroenterol; 2014, 20(46): 
17463-17467
1 1 0 1 0 0 3
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Forestplot	of	the	prevalence	of	Sacroiliitis	of	all	included	studies	
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0.39 (0.24, 0.55)
0.12 (0.04, 0.24)
0.01 (0.00, 0.07)
0.20 (0.15, 0.25)
0.16 (0.10, 0.24)
0.04 (0.02, 0.07)
0.10 (0.02, 0.26)
0.03 (0.01, 0.09)
0.01 (0.00, 0.03)
0.16 (0.07, 0.29)
0.13 (0.10, 0.17)
0.02 (0.01, 0.03)
0.24 (0.19, 0.30)
0.05 (0.01, 0.14)
0.12 (0.06, 0.21)
0.05 (0.01, 0.13)
0.26 (0.11, 0.46)
0.02 (0.01, 0.04)
0.35 (0.24, 0.46)
0.14 (0.09, 0.21)
0.08 (0.02, 0.19)
0.14 (0.07, 0.24)
0.12 (0.05, 0.23)
0.00 (0.00, 0.06)
0.07 (0.04, 0.12)
0.20 (0.12, 0.29)
0.02 (0.01, 0.03)
0.21 (0.13, 0.31)
0.16 (0.06, 0.32)
0.11 (0.00, 0.48)
0.57 (0.46, 0.68)
0.04 (0.02, 0.08)
0.07 (0.05, 0.09)
0.01 (0.00, 0.02)
0.03 (0.01, 0.07)
0.24 (0.09, 0.45)
0.06 (0.03, 0.09)
0.02 (0.01, 0.04)
0.03 (0.00, 0.12)
0.21 (0.15, 0.28)
100.00
1.54
1.73
1.83
1.87
Weight
1.77
1.80
1.89
1.59
1.85
1.60
1.77
1.64
1.45
1.72
38.91
1.90
1.62
5.63
1.68
1.60
1.85
1.75
1.52
1.57
1.66
1.84
1.75
1.86
1.40
1.72
1.87
1.57
55.46
1.91
1.83
1.61
1.69
1.67
1.35
1.87
1.68
1.79
1.57
1.65
1.61
1.63
1.80
1.71
1.90
1.68
1.47
0.86
1.69
1.83
1.90
1.89
1.75
1.32
1.85
1.87
1.61
1.80
%
  
0 .723
Supplemental	fil 	S3		Individual	Forestplots	
	
Forestplot	of	the	prevalence	of	Sacroiliitis	of	all	included	studies	
Heterogeneity betw en groups: p = 0.002
Overall  (I^2 = 94.32%, p = 0.00);
Pokharna (2004)
Ozdil (2003)
Tozun (2009)
D'Inca (2009)
Study
Leclerc-Jacob (2014)
Ott (2014)
Wagtmans (2001)
Leclerc-Jacob (2014)
Gotler (2015)
Bandyopadhyay (2015)
Steer (2003)
Bardazzi (1997)
Queiro (2000)
Salvarani (2001)
Subtotal  (I^2 = 93.32%, p = 0.00)
Karmiris (2016)
Bandyopadhyay (2015)
Subtotal  (I^2 = 93.12%, p = 0.00)
Turkcapar (2006)
Dekker Saeys (1978)
Torres (2012)
Ozdil (2004)
Orchard (2009)
Modena (1988)
Fielding (1986)
Peeters (2008)
Haslock (1973)
Torres (2012)
Pezerovic (2013)
Ott (2014)
Palm (2002)
Dekker Saeys (1978)
Subtotal  (I^2 = 93.13%, p = 0.00)
Nguyen (2006)
Paparo (2012)
Salvarani (2001)
Hwangbo (2010)
CD
Suh (1998)
Queiro (2000)
Isene (2015)
De Vlam (2000)
Kochhar (1991)
Suh (1998)
Lanna (2008)
Davis (1978)
Rajput (1992)
Barreiro-De Acosta (2007)
Ansell BM (1964)
Isene (2015)
Hwangbo (2010)
Christodoulou (2002)
Teh (1987)
IBD
Turkcapar (2006)
UC
Christodoulou (2002)
Karmiris (2016)
Tozun (2009)
Pezerovic (2013)
De Vlam (2000)
D'Inca (2009)
Bruining (2008)
Lanna (2008)
Münch (1986)
0.10 (0.08, . 2)
0.00 (0.00, . 8)
0.08 (0.03, .14)
0.02 (0.01, . 5)
0.02 (0.01, . 4)
ES (95% CI)
0.18 (0.11, .25)
0.10 (0.06, . 6)
0.04 (0.03, . 6)
0.15 (0.06, .27)
0.09 (0.06, .13)
0.19 (0.10, .31)
0.23 (0.16, .31)
0.13 (0.06, .24)
0.23 (0.10, .40)
0.02 (0.00, . 7)
0.07 (0.04, .11)
0.02 (0.01, . 3)
0.21 (0.12, .33)
0.03 (0.01, . 8)
0.62 (0.50, .7 )
0.12 (0.05, .23)
0.03 (0.01, . 5)
0.12 (0.07, . 9)
0.39 (0.24, .55)
0.12 (0.04, .24)
0.01 (0.00, . 7)
0.20 (0.15, . 5)
0.16 (0.10, .24)
0.04 (0.02, . 7)
0.10 (0.02, .26)
0.03 (0.01, . 9)
0.01 (0.00, . 3)
0.16 (0.07, .29)
0.13 (0.10, . 7)
0.02 (0.01, . 3)
0.24 (0.19, .30)
0.05 (0.01, .14)
0.12 (0.06, .21)
0.05 (0.01, .13)
0.26 (0.11, .4 )
0.02 (0.01, . 4)
0.35 (0.24, .46)
0.14 (0.09, .21)
0.08 (0.02, .19)
0.14 (0.07, .2 )
0.12 (0.05, .23)
0.00 (0.00, . 6)
0.07 (0.04, .12)
0.20 (0.12, . 9)
0.02 (0.01, . 3)
0.21 (0.13, .3 )
0.16 (0.06, .32)
0.11 (0.00, .48)
0.57 (0.46, .68)
0.04 (0.02, . 8)
0.07 (0.05, . 9)
0.01 (0.00, . 2)
0.03 (0.01, . 7)
0.24 (0.09, .45)
0.06 (0.03, . 9)
0.02 (0.01, . 4)
0.03 (0.00, .12)
0.21 (0.15, . 8)
100.00
1.54
1.73
1.83
1.87
Weight
.77
1.80
1.89
1.59
1.85
.60
.77
1.64
.45
1.72
38.91
1.90
.62
5.63
1.68
1.60
1.85
1.75
1.52
1.57
1.66
.84
.75
1.86
1.40
1.72
1.87
1.57
55.46
1.91
.83
1.61
1.69
1.67
.35
1.87
1.68
1.79
1.57
1.65
1.61
1.63
1.80
.71
1.90
.68
1.47
.86
1.69
1.83
1.90
1.89
1.75
1.32
1.85
1.87
1.61
.80
%
  
0 .723
Chapter 4
88
Forestplot	of	the	prevalence	of	Ankylosking	Spondylitis	of	all	included	studies	
Heterogeneity between groups: p = 0.006
Overall  (I^2 = 81.93%, p = 0.00);
Isene (2015)
Vavricka (2011)
Wagtmans (2001)
Dekker Saeys (1978)
Dorofeyev (2009)
Ozdil (2003)
IBD
Suh (1998)
Yi (2012)
Münch (1986)
Greenstein (1976)
Veloso (1996)
Palm (2002)
Palm (2002)
Pezerovic (2013)
Haslock (1973)
Subtotal  (I^2 = 79.66%, p = 0.00)
Bernstein (2001)
Singh (2015)
Modena (1988)
Zippi (2014)
Dekker Saeys (1978)
Salvarani (2001)
Fatemi (2016)
Queiro (2000)
De Vlam (2000)
Steer (2003)
Queiro (2000)
Subtotal  (I^2 = 93.01%, p = 0.00)
Scarpa (1992)
Subtotal  (I^2 = 69.93%, p = 0.00)
Ricart (2004)
Pezerovic (2013)
Mocelin (2015)
Orchard (1998)
Barreiro-De Acosta (2007)
Liu (2016)
Ansell BM (1964)
Lanna (2008)
Fatemi (2016)
Veloso (1996)
Torres (2012)
Palm (2001)
Beslek (2009)
Tozun (2009)
Karmiris (2016)
Tozun (2009)
Zippi (2014)
Nguyen (2006)
Pongprasobchai (2001)
Lanna (2008)
Isene (2015)
Suh (1998)
D'Inca (2009)
Salvarani (2001)
Turkcapar (2006)
Singh (2015)
Karmiris (2016)
Study
Davis (1978)
UC
Orchard (1998)
De Vlam (2000)
D'Inca (2009)
Orchard (2009)
Vavricka (2011)
Torres (2012)
Greenstein (1976)
Turkcapar (2006)
Peeters (2008)
CD
0.03 (0.02, 0.04)
0.01 (0.00, 0.02)
0.06 (0.04, 0.08)
0.04 (0.02, 0.06)
0.03 (0.00, 0.12)
0.03 (0.01, 0.05)
0.05 (0.02, 0.11)
0.02 (0.00, 0.10)
0.01 (0.00, 0.04)
0.09 (0.05, 0.14)
0.04 (0.02, 0.08)
0.03 (0.02, 0.05)
0.06 (0.03, 0.12)
0.03 (0.01, 0.05)
0.03 (0.01, 0.08)
0.07 (0.03, 0.13)
0.02 (0.01, 0.03)
0.04 (0.04, 0.05)
0.02 (0.01, 0.03)
0.10 (0.03, 0.21)
0.02 (0.01, 0.05)
0.04 (0.00, 0.13)
0.05 (0.01, 0.14)
0.02 (0.00, 0.07)
0.03 (0.00, 0.15)
0.12 (0.03, 0.31)
0.07 (0.03, 0.12)
0.04 (0.00, 0.19)
0.03 (0.01, 0.05)
0.25 (0.16, 0.36)
0.04 (0.03, 0.05)
0.04 (0.02, 0.07)
0.13 (0.04, 0.30)
0.03 (0.01, 0.09)
0.01 (0.00, 0.02)
0.02 (0.01, 0.06)
0.04 (0.02, 0.08)
0.05 (0.02, 0.12)
0.00 (0.00, 0.06)
0.00 (0.00, 0.02)
0.03 (0.01, 0.05)
0.00 (0.00, 0.02)
0.01 (0.01, 0.03)
0.08 (0.04, 0.15)
0.01 (0.00, 0.02)
0.01 (0.00, 0.01)
0.01 (0.00, 0.04)
0.01 (0.01, 0.03)
0.01 (0.01, 0.02)
0.03 (0.00, 0.13)
0.11 (0.05, 0.21)
0.02 (0.01, 0.04)
0.00 (0.00, 0.05)
0.01 (0.00, 0.03)
0.02 (0.00, 0.07)
0.12 (0.05, 0.21)
0.03 (0.02, 0.06)
0.03 (0.02, 0.05)
ES (95% CI)
0.05 (0.01, 0.14)
0.01 (0.00, 0.03)
0.09 (0.04, 0.18)
0.02 (0.01, 0.04)
0.11 (0.04, 0.25)
0.02 (0.01, 0.03)
0.01 (0.00, 0.02)
0.04 (0.02, 0.06)
0.08 (0.03, 0.16)
0.06 (0.04, 0.10)
100.00
2.12
2.06
2.04
1.03
1.89
1.37
0.97
1.57
1.62
1.70
1.99
1.50
1.83
1.44
1.43
38.04
2.28
2.18
0.96
1.73
0.96
1.04
1.32
0.76
0.60
1.50
0.64
7.94
1.21
54.02
1.78
0.70
1.34
2.16
1.63
1.69
1.29
1.04
1.64
1.91
1.91
2.03
1.45
2.09
2.14
1.73
2.06
2.17
0.83
1.15
1.93
1.20
1.95
1.33
1.20
1.87
2.16
Weight
1.05
2.01
1.20
1.82
0.88
1.94
1.86
2.02
1.25
1.80
%
  
0 .364
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Background.	Musculoskeletal	complaints	(MSC)	are	the	most	frequent	extra-intestinal	manifestation	
of	 inflammatory	bowel	disease	 (IBD).	The	aim	of	 this	 study	was	 to	assess	 the	 influence	of	MSC	on	
quality	of	life,	disability	and	work	participation	in	patients	with	IBD.	
	
Methods.	A	cross-sectional	survey	was	set	up	among	IBD	patients	18-55	years	of	age	selected	from	
primary	 care	databases	and	via	 the	patient	organization.	Participating	patients	 completed	a	 set	of	
questionnaires	including	questions	about	their	IBD,	the	presence	of	MSC	(joint,	tendon	or	lower	back),	
disability	(HAQ,	RMDQ),	quality	of	life	(IBDQ,	SF-36)	and	work	participation	and	productivity.	
	
Results.	338	IBD	patients	completed	the	questionnaires	(45.6%	Crohn’s	disease	(CD),	45.0%	ulcerative	
colitis	 (UC)).	Mean	age	was	42.3±9.3	years	and	25.4%	were	male.	MSC	were	very	 common	with	a	
prevalence	of	81.1%,	with	higher	percentages	for	CD	patients	compared	to	UC	patients.	IBD	patients	
with	MSC	had	significantly	lower	quality	of	life	on	both	the	IBDQ	and	the	SF-36.	With	regard	to	work	
status	and	productivity,	IBD	patients	with	MSC	were	more	often	unemployed	and	work-disabled	and	
reported	lower	work	productivity	compared	to	IBD	patients	without	MSC.	Activity	impairment	in	daily	
life	was	also	higher	for	patients	with	MSC.	
	
Conclusion.	 MSC	 are	 a	 very	 common	 extra-intestinal	 manifestation	 of	 IBD	 and	 cause	 significant	
burden,	both	in	quality	of	life	as	on	work	status	and	productivity.	Reduced	quality	of	life	in	IBD	patients	
seems	to	be	influenced	explicitly	by	MSC.	
	
	 	
Introduction	
Inflammatory	Bowel	Disease	(IBD)	is	a	chronic	inflammatory	disease	of	the	intestines,	comprising	both	
Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC).	 IBD	 often	 manifests	 at	 young	 age	 and	 it	 can	 be	
accompanied	by	a	number	of	extra-intestinal	manifestations	which	have	a	significant	impact	on	health	
related	 quality	 of	 life	 (HRQoL).1-4	Musculoskeletal	 complaints	 (MSC)	 are	 the	most	 common	 extra-
intestinal	manifestation	and	could	be	caused	by	the	underlying	inflammatory		rheumatic	disease	called	
spondyloarthritis	(SpA).5,6	SpA	is	an	umbrella	term	for	a	group	of	rheumatic	manifestations	with	the	
same	pathophysiological		mechanisms	like	IBD	but	also	psoriasis,	ankylosing	spondylitis	and	uveitis.7	
SpA	is	divided	into	axial	or	peripheral	manifestations	according	to	the	recent	and	widely	used	criteria	
from	the	ASAS	group.8,9	Back	pain	is	the	predominant	symptom	in	axial	disease	whereas	peripheral	
disease	is	characterized	by	arthritis,	enthesitis	or	dactylitis.	The	prevalence	of	axial	manifestations	in	
IBD	 is	estimated	 to	be	around	11%,	while	peripheral	manifestations	 like	arthritis	are	 slightly	more	
common	with	an	estimated	prevalence	of	14%.10	Detection	of	patients	developing	SpA	is	important	as	
early	and	adequate	treatment	can	reduce		pain,	stiffness	and	functional	impairment	but	also	prevent	
late	complications	like	severe	joint	deformations.11,12	IBD	and	SpA	both	have	a	significant	impact	on	
health	 related	quality	 of	 life	 (HRQoL).1-3,13	 Less	 is	 known	however	 about	 the	 impact	 of	 these	MSC	
complaints	on	patients	with	IBD.	Because	we	wanted	to	assess	this	 impact	 in	a	real	 life	unselected	
population	of	 IBD	patients,	we	selected	patients	 from	a	primary	care	setting.	The	objective	of	 this	
study	 therefore	was	 to	assess	 the	burden	of	MSC	 (from	health	 related	quality	of	 life	 to	 functional	
ability	and	work	participation)	in	IBD	patients	from	primary	care.	
	
Materials	&	Methods	
Patients	
Between	December	 2014	 and	 August	 2015,	 81	GPs	 from	 the	 Southwest	 of	 the	Netherlands	were	
recruited	to	participate	in	our	study.	These	GPs	selected	all	their	IBD	patients	aged	18	to	55	years	from	
their	 databases	 using	 ICPC	 code	 D94	 (international	 Classification	 of	 Primary	 Care	 code	 for	 IBD,	
including	CD,	UC	and	undifferentiated	IBD).	ICPC	is	the	standard	for	coding	and	classification	of	signs	
and	symptoms	in	general	practice	in	the	Netherlands.	All	identified	IBD	patients	received	an	invitation,	
including	a	reply	slip,	from	their	GP	asking	them	to	participate	in	this	study.	The	invitation	explained	
that	this	was	a	study	to	assess	the	prevalence	and	burden	of	musculoskeletal	complaints	in	patients	
with	IBD	and	consisted	solely	of	a	set	of	questionnaires.	In	addition,	we	reached	out	to	the	patient	
organization	for	IBD	in	the	Netherlands	(CCUVN,	approximately	5400	members)	asking	for	their	help	
in	 recruiting	 patients.	 They	 placed	 information	 about	 this	 study	 on	 their	 website	 as	 well	 as	 an	
announcement	in	their	newsletter,	which	was	distributed	via	e-mail.	
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Background.	Musculoskeletal	complaints	(MSC)	are	the	most	frequent	extra-intestinal	manifestation	
of	 inflammatory	bowel	disease	 (IBD).	The	aim	of	 this	 study	was	 to	assess	 the	 influence	of	MSC	on	
quality	of	life,	disability	and	work	participation	in	patients	with	IBD.	
	
Methods.	A	cross-sectional	survey	was	set	up	among	IBD	patients	18-55	years	of	age	selected	from	
primary	 care	databases	and	via	 the	patient	organization.	Participating	patients	 completed	a	 set	of	
questionnaires	including	questions	about	their	IBD,	the	presence	of	MSC	(joint,	tendon	or	lower	back),	
disability	(HAQ,	RMDQ),	quality	of	life	(IBDQ,	SF-36)	and	work	participation	and	productivity.	
	
Results.	338	IBD	patients	completed	the	questionnaires	(45.6%	Crohn’s	disease	(CD),	45.0%	ulcerative	
colitis	 (UC)).	Mean	age	was	42.3±9.3	years	and	25.4%	were	male.	MSC	were	very	 common	with	a	
prevalence	of	81.1%,	with	higher	percentages	for	CD	patients	compared	to	UC	patients.	IBD	patients	
with	MSC	had	significantly	lower	quality	of	life	on	both	the	IBDQ	and	the	SF-36.	With	regard	to	work	
status	and	productivity,	IBD	patients	with	MSC	were	more	often	unemployed	and	work-disabled	and	
reported	lower	work	productivity	compared	to	IBD	patients	without	MSC.	Activity	impairment	in	daily	
life	was	also	higher	for	patients	with	MSC.	
	
Conclusion.	 MSC	 are	 a	 very	 common	 extra-intestinal	 manifestation	 of	 IBD	 and	 cause	 significant	
burden,	both	in	quality	of	life	as	on	work	status	and	productivity.	Reduced	quality	of	life	in	IBD	patients	
seems	to	be	influenced	explicitly	by	MSC.	
	
	 	
Introduction	
Inflammatory	Bowel	Disease	(IBD)	is	a	chronic	inflammatory	disease	of	the	intestines,	comprising	both	
Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC).	 IBD	 often	 manifests	 at	 young	 age	 and	 it	 can	 be	
accompanied	by	a	number	of	extra-intestinal	manifestations	which	have	a	significant	impact	on	health	
related	 quality	 of	 life	 (HRQoL).1-4	Musculoskeletal	 complaints	 (MSC)	 are	 the	most	 common	 extra-
intestinal	manifestation	and	could	be	caused	by	the	underlying	inflammatory		rheumatic	disease	called	
spondyloarthritis	(SpA).5,6	SpA	is	an	umbrella	term	for	a	group	of	rheumatic	manifestations	with	the	
same	pathophysiological		mechanisms	like	IBD	but	also	psoriasis,	ankylosing	spondylitis	and	uveitis.7	
SpA	is	divided	into	axial	or	peripheral	manifestations	according	to	the	recent	and	widely	used	criteria	
from	the	ASAS	group.8,9	Back	pain	is	the	predominant	symptom	in	axial	disease	whereas	peripheral	
disease	is	characterized	by	arthritis,	enthesitis	or	dactylitis.	The	prevalence	of	axial	manifestations	in	
IBD	 is	estimated	 to	be	around	11%,	while	peripheral	manifestations	 like	arthritis	are	 slightly	more	
common	with	an	estimated	prevalence	of	14%.10	Detection	of	patients	developing	SpA	is	important	as	
early	and	adequate	treatment	can	reduce		pain,	stiffness	and	functional	impairment	but	also	prevent	
late	complications	like	severe	joint	deformations.11,12	IBD	and	SpA	both	have	a	significant	impact	on	
health	 related	quality	 of	 life	 (HRQoL).1-3,13	 Less	 is	 known	however	 about	 the	 impact	 of	 these	MSC	
complaints	on	patients	with	IBD.	Because	we	wanted	to	assess	this	 impact	 in	a	real	 life	unselected	
population	of	 IBD	patients,	we	selected	patients	 from	a	primary	care	setting.	The	objective	of	 this	
study	 therefore	was	 to	assess	 the	burden	of	MSC	 (from	health	 related	quality	of	 life	 to	 functional	
ability	and	work	participation)	in	IBD	patients	from	primary	care.	
	
Materials	&	Methods	
Patients	
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recruited	to	participate	in	our	study.	These	GPs	selected	all	their	IBD	patients	aged	18	to	55	years	from	
their	 databases	 using	 ICPC	 code	 D94	 (international	 Classification	 of	 Primary	 Care	 code	 for	 IBD,	
including	CD,	UC	and	undifferentiated	IBD).	ICPC	is	the	standard	for	coding	and	classification	of	signs	
and	symptoms	in	general	practice	in	the	Netherlands.	All	identified	IBD	patients	received	an	invitation,	
including	a	reply	slip,	from	their	GP	asking	them	to	participate	in	this	study.	The	invitation	explained	
that	this	was	a	study	to	assess	the	prevalence	and	burden	of	musculoskeletal	complaints	in	patients	
with	IBD	and	consisted	solely	of	a	set	of	questionnaires.	In	addition,	we	reached	out	to	the	patient	
organization	for	IBD	in	the	Netherlands	(CCUVN,	approximately	5400	members)	asking	for	their	help	
in	 recruiting	 patients.	 They	 placed	 information	 about	 this	 study	 on	 their	 website	 as	 well	 as	 an	
announcement	in	their	newsletter,	which	was	distributed	via	e-mail.	
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If	patients	agreed	to	participate,	they	received	an	e-mail	with	a	link	to	a	set	of	questionnaires,	which	
could	be	completed	online.	If	patients	did	not	have	access	to	internet	or	preferred	to	complete	the	
questionnaires	 on	 paper,	 they	 received	 the	 questionnaires	 on	 paper.	 The	 questionnaires	 included	
questions	 about	 IBD	 (such	 as	 type	 of	 IBD,	 characteristics	 and	 current	 treatment),	 about	
musculoskeletal	complaints,	quality	of	life	and	work	participation.	
This	 study	was	 exempted	 from	medical	 ethical	 approval	 by	 the	medical	 ethical	 committee	 of	 the	
Erasmus	University	Medical	Centre	as	patients	only	had	to	complete	a	set	of	questionnaires	(MEC-
2014-269).	All	patients	signed	the	reply	slip	when	they	agreed	to	participate.	
	
Musculoskeletal	Complaints	
With	regard	to	musculoskeletal	complaints,	patients	were	asked	if	they	suffered	regularly	from	joint,	
tendon	and/or	 lower	back	complaints.	 For	each	of	 the	 three	domains	of	MSC,	 the	duration	of	 the	
complaints	was	asked,	as	well	as	medication	use	and	pain	in	the	preceding	7	days	(VAS	scale	0-100,	
where	0	indicates	no	pain	and	100	indicates	worst	pain	imaginable).	If	patients	suffered	from	lower	
back	 complaints,	 they	 also	 completed	 the	 Assessment	 of	 SpondyloArthritis	 International	 Society	
questionnaire	 on	 Inflammatory	 Back	 Pain	 (ASAS-IBP).14	 This	 questionnaire	 consists	 of	 5	 yes/no	
questions	and	is	positive	when	4	or	more	questions	are	answered	positively.	All	patients	were	asked	
if	they	ever	visited	a	rheumatologist	and	if	so	which	diagnosis	was	made.	
	
Functional	Ability	
Patients	with	joint	and/or	tendon	complaints	completed	the	HAQ	(Health	Assessment	Questionnaire)	
to	 assess	 functional	 ability.15	 It	 contains	 questions	 on	 different	 domains	 like	 dressing,	 getting	 up,	
eating,	walking,	personal	hygiene,	reaching,	grip	and	activity.	The	score	for	the	HAG	ranges	from	0	to	
3,	where	higher	scores	indicate	more	disability.	
Patients	who	indicated	to	have	complaints	of	the	lower	back,	completed	the	RMDQ	(Roland	Morris	
Disability	Questionnaire).16	This	questionnaire	measures	limitations	in	physical	functioning	in	patients	
with	low	back	pain.	It	has	a	score	from	0-24,	where	a	higher	score	represents	more	severe	disability.	
	
Health	Related	Quality	of	Life	(HRQoL)	
Patients	completed	the	IBDQ	and	SF-36	to	assess	HRQoL.		
IBDQ	 (Inflammatory	Bowel	Disease	Questionnaire)	 is	 the	most	widely	 used	 and	 validated	disease-
specific	 quality	 of	 life	 questionnaire	 for	 patient	 with	 IBD.17-19	 It	 consists	 of	 32	 questions	 and	 the	
responses	are	graded	on	a	7	point	Likert	scale,	giving	a	possible	score	range	from	32	to	224,	where	a	
higher	score	represents	better	HRQoL.	The	questionnaire	can	be	subdivided	in	four	different	domains:	
bowel	 symptoms	 (10	 questions,	 score	 0-70),	 systemic	 symptoms	 (5	 questions,	 score	 0-35),	 social	
function	(5	questions,	score	0-35)	and	emotional	function	(12	questions,	score	0-84).	The	individual	
scores	for	the	different	domains	are	calculated	as	average	scores	per	domain.	
SF-36	 (Short	 Form	 36)	 is	 a	 widely	 used	 questionnaire	 on	 general	 HRQoL	 with	 high	 validity	 and	
reliability.20	It	consists	of	36	questions	and	the	score	is	presented	in	the	following	8	domains:	physical	
functioning,	 role	 physical	 (limitations	 due	 to	 physical	 problems),	 bodily	 pain,	 vitality,	 social	
functioning,	 role	 emotional	 (limitations	 due	 to	 emotional	 problems),	 mental	 health	 and	 general	
health.	The	score	on	all	eight	separate	domains	 is	compared	with	the	scores	 from	the	background	
population	in	the	Netherlands.21	Scores	may	range	from	0-100,	where	a	higher	score	indicates	a	better	
HRQoL.	
	
Education	and	Work	Status			
All	patients	answered	questions	about	 their	highest	 completed	educational	 level;	 low	 (elementary	
school),	medium	(high	school)	or	high	(university).	Current	work	status	(employed	or	not	employed)	
and	work-disability	were	also	asked	for	and	compared	with	the	general	Dutch	population.22	To	assess	
the	 impact	 of	 MSC	 on	 work	 participation,	 we	 used	 the	 WPAI	 (Work	 Productivity	 and	 Activity	
Impairment)	questionnaires.23	The	WPAI	measures	4	different	domains	related	to	work	and	activity	
over	the	past	seven	days,	namely	absenteeism	(%	work	time	lost),	presenteism	(%	productivity	loss	at	
work),	work	impairment	(combination	of	absenteeism	and	presenteism)	and	activity	impairment	(%	
activity	loss	in	general,	not	necessarily	work	related).	Patients	were	asked	to	complete	these	questions	
separately	 for	 impairment	 caused	by	 their	 IBD,	 joint	 complaints,	 tendon	complaints	or	 lower	back	
complaints.	
	
Statistical	Analysis	
Descriptive	 statistics	 were	 used	 to	 describe	 patient	 characteristics	 and	 outcomes	 in	 STATA	 14.	
Statistically	significant	differences	for	HAQ,	IBDQ	and	SF-36	between	patients	with	and	without	MSC	
were	tested	with	the	Wilcoxon	rank	sum	test.	A	p-value	below	0.05	was	considered	as	statistically	
significant.	
	
Results	
Participants	
In	 total,	 535	 patients	 with	 IBD	 aged	 18-55	 years	 of	 age	 (37.9%	 male)	 were	 selected	 out	 of	 the	
databases	of	the	81	participating	GPs.	In	the	process	of	inviting	the	patients	to	participate,	23	(4.3%)	
reported	 not	 to	 have	 IBD,	 so	 eventually	 512	 IBD	 patients	 selected	 by	 the	 GP	 were	 eligible	 to	
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participate.	Of	these	patients,	292	(57.0%)	responded	to	the	invitation,	of	whom	273	were	willing	to	
participate	(Figure	1).	Via	the	patient	organization	another	120	IBD	patients	(17.5%	male)	responded	
on	the	advertisement	and	wanted	to	participate.	In	total,	393	IBD	patients	were	willing	to	participate,	
of	whom	338	completed	the	set	of	questionnaires.	
	
Figure	1.	Flowchart	of	Patients’	Inclusion	
	
Table	1	provides	an	overview	of	 the	clinical	 characteristics	 for	 the	 total	 group	of	 IBD	patients	and	
separately	for	CD	and	UC	patients.	Of	the	participants,	45.6%	suffered	from	CD	while	45.0%	suffered	
from	UC.	The	remaining	9.4%	suffered	from	unspecified	IBD.	Mean	age	of	the	participants	was	42.3	
years	(SD	9.3),	with	25.1%	being	male	(Table	1).	Median	duration	of	IBD	was	10	years	(IQR	5-18).	With	
regard	 to	medication,	 the	majority	 (around	70%)	used	 some	kind	of	medication	 for	 their	 IBD	with	
mesalazine	 and	 immunosuppressants	 being	 used	 most	 often.	 Approximately	 25%	 of	 patients	
underwent	surgery	for	their	bowel	disease,	patients	with	CD	considerably	more	often	than	patients	
with	UC.		
	
	
	
Presence	of	Musculoskeletal	Complaints	
Out	of	the	total	of	338	IBD	patients,	274	(81.1%)	indicated	to	suffer	from	any	kind	of	MSC;	either	joint,	
tendon	or	 lower	back	(Figure	2).	This	percentage	was	higher	for	patients	with	CD	than	for	patients	
with	UC.	About	one	third	(33.9%)	of	the	patients	visited	a	rheumatologist	 for	these	complaints,	36	
(10.7%)	were	diagnosed	with	an	inflammatory	rheumatological	disease,	again	slightly	more	patients	
with	CD	compared	with	UC	(Table	2).	
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Table 1 Baseline Characteristics
Total Crohn’s Disease Ulcerative Colitis
No of Patients, n (%)# 338 154 (45.6) 152 (45.0)
Age, mean (SD) 42.3 (9.3) 41.7 (9.7) 42.5 (9.0)
Male sex, n (%) 85 (25.1) 32 (20.8) 44 (28.9)
Dutch nationality, n (%) 333 (98.5) 153 (99.4) 148 (97.4)
Median duration IBD, years (IQR) 10 (5-18) 12 (7-21) 9 (4-15)
Level of Education 
Low, n (%) 32 (9.5) 10 (6.5) 17 (11.3)
Intermediate, n (%) 175 (52.1) 81 (52.9) 75 (49.7)
High, n (%) 129 (38.4) 62 (40.5) 59 (39.1)
Medication IBD, n (%)
None 94 (27.8) 41 (26.6) 41 (27.0)
Mesalazine 119 (35.2) 27 (17.5) 83 (54.6)
Corticosteroids 41 (12.1) 22 (14.3) 14 (9.2)
Immunosuppressants$ 99 (29.3) 59 (38.3) 35 (23.0) 
Anti-TNF* 69 (20.4) 44 (28.6) 17 (11.2)
Other 16 (4.7) 8 (5.2) 5 (3.3)
Bowel surgery, n (%)
None 245 (72.5) 84 (54.5) 135 (88.8)
Partial resection 61 (18.0) 57 (37.0) 3 (2.0)
Stoma 17 (5.0) 7 (4.5) 8 (5.3)
Pouch 9 (2.7) 0 3 (2.0)
Other 6 (1.8)  6 (3.9) 3 (2.0)
# The remaining 32 patients suffered from unclassified IBD and were disregarded for the scope of this study. $ 
azathioprine, thioguanine & methotrexate. *Adalumimab & Infliximab
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If	patients	reported	joint	complaints,	the	median	symptom	duration	was	about	7	years	with	a	mean	
VAS	pain	score	of	43.4	over	 the	prior	week.	About	50%	 indicated	to	use	medication	 for	 their	 joint	
complaints.	Patients	suffering	from	tendon	complaints	reported	a	lower	median	symptom	duration	
with	4	years.	The	mean	VAS	pain	score	over	the	prior	week	is	similar	at	42.8	even	as	medication	use	
(50.9%).	Tendon	complaints	are	more	often	reported	by	patients	with	UC	(30.9%)	compared	with	CD	
(27.9%).	The	HAQ	was	completed	by	228	patients	suffering	from	either	joint	or	tendon	complaints.	
Disability	was	higher	if	patients	indicated	to	suffer	from	both	joint	and	tendon	complaints	(n=80)	with	
a	median	score	of	0.63	(IQR	0.25-1.25),	compared	with	suffering	only	from	joint	complaints	(n=127;	
median	score	0.38)	or	tendon	complaints	(n=21;	median	score	0.13).	If	looking	into	the	type	of	IBD,	
patients	with	CD	had	a	higher	median	score	(0.5;	IQR	0.13-1)	than	patients	with	UC	(0.25;	IQR	0.13-
0.63)	(Table	2).	
Of	the	203	patients	who	indicated	to	have	complaints	of	the	lower	back,	75	patients	had	a	positive	
ASAS-IBP	 questionnaire	 (36.9%),	 meaning	 their	 lower	 back	 complaints	 had	 an	 inflammatory	
component.	The	RMDQ	median	score	was	4	(IQR	1-10),	with	higher	scores	for	CD	patients	(5;	IQR	2-
10)	compared	to	UC	patients	(3;	IQR	1-9).	Median	duration	of	complaints	was	10	years	with	mean	VAS	
pain	score	of	39.0.	Medication	was	used	by	58.8%	of	the	patients	(Table	2).	
	
Influence	of	Musculoskeletal	Complaints	on	Health	Related	Quality	of	Life	
The	total	score	for	the	IBDQ	was	significantly	lower	in	for	patients	with	MSC	(165.4±27.8)	compared	
to	patients	without	MSC	(182.8±26.3),	where	lower	scores	represent	worse	HRQoL	(Table	3).	When	
looking	 into	 the	 four	different	 subscores,	 these	were	all	 	 significantly	 lower	 for	patients	with	MSC	
compared	with	patients	without	MSC,	except	bowel	symptoms	in	UC	patients	which	were	lower	but	
not	significantly	(p=0.06).	Overall,	the	scores	for	UC	were	slightly	higher	than	the	scores	for	CD.	
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compared	with	patients	without	MSC,	except	bowel	symptoms	in	UC	patients	which	were	lower	but	
not	significantly	(p=0.06).	Overall,	the	scores	for	UC	were	slightly	higher	than	the	scores	for	CD.	
SF-36	was	completed	by	all	338	patients.	Compared	with	the	Dutch	reference	population,	patients	
with	IBD	had	lower	scores	on	all	dimensions,	with	lower	scores	for	CD	compared	to	UC	(Figure	3).	If	
the	distinction	is	made	between	IBD	patients	with	and	without	MSC,	it	can	be	demonstrated	that	IBD	
patients	without	MSC	showed	similar	scores	on	almost	all	domains	as	the	Dutch	reference	population,	
while	patients	with	MSC	scored	significantly	lower	on	all	domains	(Figure	4).	When	dividing	the	MSC	
into	 joint,	 tendon	 or	 back	 complaints,	 all	 three	 domains	 of	MSC	 showed	 comparable	 decrease	 in	
subscores	compared	with	 the	Dutch	 reference	population.	As	 in	 the	 IBDQ,	 the	scores	 for	UC	were	
slightly	 higher	 than	 the	 scores	 for	 CD.	 Looking	 into	 non-inflammatory	 and	 inflammatory	 (positive	
ASAS-IBP	 or	 rheumatological	 diagnosis)	MSC,	 the	 scores	 on	 both	 IBDQ	 and	 SF-36	 were	 lower	 for	
patients	with	inflammatory	MSC	than	for	patients	with	non-inflammatory	MSC.	
	 	
Table 2 Characteristics of Musculoskeletal Complaints in patients with IBD
IBD (n=338) CD (n=154) UC (n=152)
Musculoskeletal Complaints, n (%) 274 (81.1) 133 (86.4) 114 (75.0)
Rheumatological Diagnosis, n (%) 36 (10.7) 20 (13.0) 11 (7.2)
Joint complaints
No of Patients, n (%) 214 (63.3) 109 (70.8) 81 (53.3)
Duration of complaints, median (IQR) years 7 (3-15) 7 (3-13) 6 (2-15)
Pain in preceding week, mean (SD) 43.4 (24.7) 44.6 (24.7) 41.3 (25.2)
HAQ score, median (IQR) 0.38 (0.13-0.63) 0.5 (0.13-0.75) 0.13 (0-0.5)
(n=127) (n=72) (n=45)
Medication use, n (%) 110 (51.4) 54 (40.6) 42 (51.9)
Paracetamol, n (%) 79 (71.8) 40 (74.1) 30 (71.4)
NSAIDs, n (%) 29 (26.4) 11 (20.4) 12 (28.6)
Morphinomimetics, n (%) 28 (25.5) 19 (35.2) 5 (11.9)
Tendon Complaints
No of Patients, n (%) 104 (30.8) 43 (27.9) 47 (30.9)
Duration of complaints, median (IQR) years 4 (2-10) 5 (1-15) 3 (2-8)
Pain in preceding week, mean (SD) 42.8 (25.9) 48.1 (24.7) 39.7 (25.7)
HAQ score, median (IQR) 0.13 (0-0.25)
(n=21)
0 (0-0.44)
(n=8)
0.13 (0-0.13)
(n=13)
Medication use, n (%) 52 (50%) 22 (51.2) 23 (48.9)
Paracetamol, n (%) 43 (82.7) 19 (86.4) 20 (87.0)
NSAIDs, n (%) 14 (26.9) 6 (27.3) 4 (17.4)
Morphinomimetics, n (%) 11 (21.2) 7 (31.8) 2 (8.7)
Lower Back Complaints
No of Patients, n (%) 203 (60.1) 99 (64.3) 85 (55.9)
Duration of complaints, median (IQR) years 10 (4-20) 8 (3-15) 10 (4-20)
Positive ASAS-IBP, n (%) 75 (36.9) 30 (30.3) 37 (43.5)
Pain in preceding week, mean (SD) 39.0 (27.1) 39.9 (25.9) 36.4 (28.6)
RMDQ score, median (IQR) 4 (1-10) 5 (2-10) 3 (1-9)
Medication use, n (%) 86 (42.4) 41 (41.4) 36 (42.4)
Paracetamol, n (%) 66 (76.7) 36 (87.8) 24 (66.7)
NSAIDs, n (%) 21 (24.4) 8 (19.5) 9 (25.0)
Morphinomimetics, n (%) 25 (29.1) 15 (36.6) 9 (25.0)
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If	patients	reported	joint	complaints,	the	median	symptom	duration	was	about	7	years	with	a	mean	
VAS	pain	score	of	43.4	over	 the	prior	week.	About	50%	 indicated	to	use	medication	 for	 their	 joint	
complaints.	Patients	suffering	from	tendon	complaints	reported	a	lower	median	symptom	duration	
with	4	years.	The	mean	VAS	pain	score	over	the	prior	week	is	similar	at	42.8	even	as	medication	use	
(50.9%).	Tendon	complaints	are	more	often	reported	by	patients	with	UC	(30.9%)	compared	with	CD	
(27.9%).	The	HAQ	was	completed	by	228	patients	suffering	from	either	joint	or	tendon	complaints.	
Disability	was	higher	if	patients	indicated	to	suffer	from	both	joint	and	tendon	complaints	(n=80)	with	
a	median	score	of	0.63	(IQR	0.25-1.25),	compared	with	suffering	only	from	joint	complaints	(n=127;	
median	score	0.38)	or	tendon	complaints	(n=21;	median	score	0.13).	If	looking	into	the	type	of	IBD,	
patients	with	CD	had	a	higher	median	score	(0.5;	IQR	0.13-1)	than	patients	with	UC	(0.25;	IQR	0.13-
0.63)	(Table	2).	
Of	the	203	patients	who	indicated	to	have	complaints	of	the	lower	back,	75	patients	had	a	positive	
ASAS-IBP	 questionnaire	 (36.9%),	 meaning	 their	 lower	 back	 complaints	 had	 an	 inflammatory	
component.	The	RMDQ	median	score	was	4	(IQR	1-10),	with	higher	scores	for	CD	patients	(5;	IQR	2-
10)	compared	to	UC	patients	(3;	IQR	1-9).	Median	duration	of	complaints	was	10	years	with	mean	VAS	
pain	score	of	39.0.	Medication	was	used	by	58.8%	of	the	patients	(Table	2).	
	
Influence	of	Musculoskeletal	Complaints	on	Health	Related	Quality	of	Life	
The	total	score	for	the	IBDQ	was	significantly	lower	in	for	patients	with	MSC	(165.4±27.8)	compared	
to	patients	without	MSC	(182.8±26.3),	where	lower	scores	represent	worse	HRQoL	(Table	3).	When	
looking	 into	 the	 four	different	 subscores,	 these	were	all	 	 significantly	 lower	 for	patients	with	MSC	
compared	with	patients	without	MSC,	except	bowel	symptoms	in	UC	patients	which	were	lower	but	
not	significantly	(p=0.06).	Overall,	the	scores	for	UC	were	slightly	higher	than	the	scores	for	CD.	
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SF-36	was	completed	by	all	338	patients.	Compared	with	the	Dutch	reference	population,	patients	
with	IBD	had	lower	scores	on	all	dimensions,	with	lower	scores	for	CD	compared	to	UC	(Figure	3).	If	
the	distinction	is	made	between	IBD	patients	with	and	without	MSC,	it	can	be	demonstrated	that	IBD	
patients	without	MSC	showed	similar	scores	on	almost	all	domains	as	the	Dutch	reference	population,	
while	patients	with	MSC	scored	significantly	lower	on	all	domains	(Figure	4).	When	dividing	the	MSC	
into	 joint,	 tendon	 or	 back	 complaints,	 all	 three	 domains	 of	MSC	 showed	 comparable	 decrease	 in	
subscores	compared	with	 the	Dutch	 reference	population.	As	 in	 the	 IBDQ,	 the	scores	 for	UC	were	
slightly	 higher	 than	 the	 scores	 for	 CD.	 Looking	 into	 non-inflammatory	 and	 inflammatory	 (positive	
ASAS-IBP	 or	 rheumatological	 diagnosis)	MSC,	 the	 scores	 on	 both	 IBDQ	 and	 SF-36	 were	 lower	 for	
patients	with	inflammatory	MSC	than	for	patients	with	non-inflammatory	MSC.	
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Figure	3.	Mean	scores	for	the	SF-36	in	CD	and	UC	patients,	compared	with	the	Dutch	reference	
population	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.	Mean	scores	for	the	SF-36	in	IBD	patients	with	and	without	MSC,	compared	with	the	
Dutch	reference	population	
	
	
Influence	of	Musculoskeletal	Complaints	on	Work	Status	&	Productivity	
Of	the	participating	IBD	patients,	73.8%	was	currently	employed,	which	is	lower	than	the	employment	
status	 in	 the	 general	 Dutch	 population	 (93.2%).	 Of	 the	 patients	who	were	 currently	 unemployed,	
45.6%	 (n=41)	 reported	 to	 be	 work-disabled,	 of	 whom	 82.9%	 were	 80-100%	 work-disabled.	 If	
comparing	 IBD	 patients	 with	 and	 without	 MSC	 differences	 can	 be	 shown.	 Table	 4	 shows	 the	
percentages	 of	 absenteeism	 and	 presenteism	 and	 the	 mean	 work	 productivity	 loss	 and	 activity	
impairment	 subdivided	 by	 the	 cause	 (IBD,	 joint	 complaints,	 tendon	 complaints	 or	 lower	 back	
complaints).	The	level	of	unemployment	was	higher	in	IBD	patients	suffering	from	any	kind	of	MSC	
compared	with	IBD	patients	not	suffering	from	IBD.	If	patients	were	unemployed;	work-disability	was	
an	important	cause	in	patients	with	MSC.	The	percentage	of	absenteeism	(=absence)	caused	by	MSC	
was	comparable	 to	 the	percentage	of	absenteeism	caused	by	 IBD.	The	percentage	of	presenteism	
(=reduced	effectiveness	while	at	work)	caused	by	IBD	was	36.4%	compared	to	53.1%	caused	by	lower	
back	complaints,	61.2%	for	joint	complaints	and	63.4%	for	tendon	complaints.	Both	work	productivity	
loss	 (=overall	work	 impairment)	and	activity	 impairment	were	higher	 if	caused	by	any	kind	of	MSC	
compared	to	if	caused	by	IBD.	
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Table 3 Mean scores of the IBDQ questionnaire in IBD patients with and without MSC
IBD CD UC
No MSC MSC No MSC MSC No MSC MSC
Number of Patients, n 64 274 21 133 38 114
Total score
(range 0-224)
183.6 (26.7) 165.4 (27.8) 180.1 (30.5) 158.2 (26.9) 187.0 (24.7) 174 (26.2)
Bowel Symptoms
(range 0-70)
58.0 (8.6) 52.9 (8.9) 58.6 (9.2) 51.1 (8.7) 58.3 (8.5)# 55.4 (8.6)#
Systemic Symptoms
(range 0-35)
25.5 (6.2) 21.2 (5.9) 25.4 (6.0) 19.8 (5.7) 26.1 (6.4) 22.7 (5.5)
Social Function
(range 0-35)
31.9 (4.9) 29.3 (5.9) 30.2 (5.8) 27.4 (6.4) 32.9 (4.1) 31.3 (4.5)
Emotional Function
(range 0-84)
68.2 (10.1) 62.1 (11.6) 66.0 (11.6) 59.9 (11.4) 69.7 (9.4) 64.6 (11.5)
For all differences between No MSC and MSC p-value is lower than 0.05, except for #
	
PF RF BP V SF RE MH GH
Dutch	Reference	Population 82,5 77,7 80,2 65,9 84,2 87,2 77,3 69,4
UC 82,5 70,8 67,2 55,8 78,9 80,0 73,5 52,3
CD 70,7 51,7 56,9 44,1 70,0 69,2 67,7 42,9
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Figure	3.	Mean	scores	for	the	SF-36	in	CD	and	UC	patients,	compared	with	the	Dutch	reference	
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45.6%	 (n=41)	 reported	 to	 be	 work-disabled,	 of	 whom	 82.9%	 were	 80-100%	 work-disabled.	 If	
comparing	 IBD	 patients	 with	 and	 without	 MSC	 differences	 can	 be	 shown.	 Table	 4	 shows	 the	
percentages	 of	 absenteeism	 and	 presenteism	 and	 the	 mean	 work	 productivity	 loss	 and	 activity	
impairment	 subdivided	 by	 the	 cause	 (IBD,	 joint	 complaints,	 tendon	 complaints	 or	 lower	 back	
complaints).	The	level	of	unemployment	was	higher	in	IBD	patients	suffering	from	any	kind	of	MSC	
compared	with	IBD	patients	not	suffering	from	IBD.	If	patients	were	unemployed;	work-disability	was	
an	important	cause	in	patients	with	MSC.	The	percentage	of	absenteeism	(=absence)	caused	by	MSC	
was	comparable	 to	 the	percentage	of	absenteeism	caused	by	 IBD.	The	percentage	of	presenteism	
(=reduced	effectiveness	while	at	work)	caused	by	IBD	was	36.4%	compared	to	53.1%	caused	by	lower	
back	complaints,	61.2%	for	joint	complaints	and	63.4%	for	tendon	complaints.	Both	work	productivity	
loss	 (=overall	work	 impairment)	and	activity	 impairment	were	higher	 if	caused	by	any	kind	of	MSC	
compared	to	if	caused	by	IBD.	
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Discussion	
This	study	demonstrates	that	MSC	are	frequent	 in	patients	with	 IBD	and	have	great	 impact	on	the	
burden	of	disease.	The	impact	of	these	MSC	is	demonstrated	by	significantly	lower	scores	in	quality	of	
life,	 in	both	physical	and	mental	health	domains.	With	regard	to	work	status	and	productivity,	 IBD	
patients	 with	 MSC	 are	 less	 often	 employed	 and	 if	 they	 are	 employed,	 they	 experience	 more	
presenteism	and	work	productivity	loss.	
The	prevalence	of	MSC	was	fairly	high	(80%)	in	our	study,	compared	to	the	general	population	in	the	
Netherlands	(53.9%).24	A	lot	of	studies	have	been	performed	concerning	the	prevalence	of	rheumatic	
manifestations	in	IBD	patients,	but	most	focus	on	inflammatory	rheumatic	manifestations	as	SpA	with	
arthritis	and	sacroiliitis.	One	population	based	study	from	Norway	reported	on	the	prevalence	of	non-
inflammatory	joint	pain	and	this	was	estimated	at	16%.25	However,	they	only	studied	joint	complaints	
and	our	sample	consists	of	all	forms	of	MSC	pain.	A	recent	study	from	the	Netherlands	looked	into	the	
prevalence	of	arthropathy	in	IBD	patients,	defined	as	chronic	back	pain	for	at	least	3	months	and/or	
peripheral	joint	swelling	at	presentation	or	in	the	past	year	and	they	report	a	prevalence	of	60.1%.26	
The	percentage	of	patients	in	our	study	with	joint	or	back	pain	(excluding	tendon	complaints)	is	slightly	
higher	at	72.5%.	This	difference	could	be	explained	by	the	fact	that	we	used	self-reported	joint	or	back	
complaints	without	specific	criteria	like	they	used.	
The	impact	of	MSC	in	IBD	patients	on	quality	of	life	is	considerable.	This	was	also	demonstrated	in	the	
non-inflammatory	joint	pain	study	from	Norway	and	the	study	from	the	Netherlands	with	more	or	less	
comparable	 scores	on	 the	 SF-36	and	 IBDQ.25,26	 Several	other	 studies	have	been	performed	on	 the	
quality	of	life	in	patients	with	IBD.	Most	show	decreased	quality	of	life1,3,27,28,	while	some	studies	show	
no	difference	between	IBD	patients	and	the	reference	population2,29.	However,	most	studies	do	not	
make	the	distinction	between	IBD	with	and	without	MSC.	A	recent	study	from	the	Netherlands	did	
show	 decreased	 quality	 of	 life	 as	measured	with	 the	 SF-36	 and	 short-IBDQ	 in	 patients	 with	 joint	
complaints	compared	to	 IBD	patients	without	 joint	complaints.26	 In	our	study,	 the	quality	of	 life	of	
patients	with	IBD	was	lower	than	the	quality	of	 life	of	the	reference	Dutch	population.	However,	 if	
making	the	distinction	between	IBD	patients	with	and	without	MSC,	the	SF-36	scores	for	IBD	patients	
without	MSC	are	comparable	with	the	Dutch	reference	population.	Since	the	quality	of	 life	for	 IBD	
patients	with	MSC	was	significantly	lower	on	all	domains,	 it	could	certainly	be	possible	that	a	large	
part	of	the	quality	of	life	in	IBD	patients	is	determined	by	EIMs	like	MSC.	
With	 regard	 to	work	productivity	 and	activity	 impairment,	 the	 study	 from	van	der	Have	et	 al	 also	
showed	higher	work	and	activity	impairment	for	IBD	patients	with	joint/back	pain	compared	to	IBD	
patients	without	joint/back	pain.26	More	data	is	available	on	the	influence	of	IBD	in	general	on	work	
productivity,	but	not	specifically	for	the	additional	burden	of	MSC	in	these	patients.	A	large	systematic	
review	showed	that	IBD	patients	experience	a	high	burden	in	work-related	outcomes,	but	the	factors	
causing	this	are	not	investigated.30		
This	study	has	several	limitations.	First,	only	25%	of	participating	patients	was	male,	so	there	seems	
to	be	an	overrepresentation	of	women	in	our	sample.	However,	in	the	initial	unselected	selection	out	
of	the	GP	databases,	the	percentage	of	women	was	already	slightly	higher	(62.1%).	Second,	we	did	
not	do	a	clinical	evaluation	of	the	patients,	so	certain	information	like	IBD	classification	or	IBD	activity	
was	not	available.	Third,	it	is	possible	that	a	selection	bias	towards	patients	with	MSC	occurred	and	
that	the	prevalence	of	MSC	in	this	study	is	overestimated.	Although	we	asked	patients	to	participate	
irrespective	 of	 their	 complaints,	 we	 cannot	 rule	 out	 that	 patients	with	MSC	were	more	 prone	 to	
participate.	If	these	limitations	are	taken	into	account,	we	think	that	this	study	provides	valuable	data	
on	the	impact	of	MSC	in	patients	with	IBD.	We	have	a	fairly	large	sample	of	IBD	patients	with	complete	
data.	In	addition,	this	study	is	one	of	the	first	to	describe	the	various	components	of	the	burden	of	
unselected	MSC	in	IBD	patients	from	HRQoL	to	impact	on	work	status	and	productivity.	In	this	study	
we	selected	the	IBD	patients	from	primary	care.	Although	the	vast	majority	of	patients	will	be	treated	
by	a	gastroenterologist	for	their	IBD,	patients	could	also	visit	their	GP	if	experiencing	MSC.	Most	likely,	
if	patients	are	not	aware	of	the	fact	that	MSC	could	be	an	extra-intestinal	manifestation	of	IBD,	they	
will	visit	the	GP	with	MSC.	This	primary	care	setting	is	therefore	also	important	in	detecting	these	MSC	
in	IBD	patients.	Another	advantage	of	selecting	IBD	patients	from	various	GP	databases,	is	that	it	gives	
a	good	unselected	representation	of	the	general	IBD	population	in	the	Netherlands.	We	recruited	GPs	
from	various	regions	of	the	Netherlands,	thereby	also	representing	a	large	variety	in	hospitals	where	
the	IBD	patients	will	be	treated.	
	
Table 4 Work status and productivity in IBD patients with or without joint, tendon or lower back 
complaints
Without MSC With MSC
IBD(n=69) Joint
(n=214)
Tendon
(n=104)
Back
(n=203)
Activity Impairment, mean (SD) 0.17 (0.24) 0.36 (0.27) 0.33 (0.27) 0.29 (0.28)
Not Working 14 (20.3) 67 (31.3) 33 (31.7) 56 (27.6)
Work-disabled, n (%) 1 (1.4) 38 (17.8) 19 (18.3) 33 (16.3)
80-100%, n (%) Unknown 27 (71.1) 17 (89.5) 28 (84.8)
Working 55 (79.7) 147 (68.7) 71 (68.3) 147 (72.4)
Absenteism, n/N (%) 5/51 (9.8) 14/131 (10.7) 6/61 (9.8) 8/129 (6.2)
Presenteism, n (%) 20 (36.4) 90 (61.2) 45 (63.4) 78 (53.1)
Work productivity loss, mean (SD) N 0.14 (0.25)
N=51
0.23 (0.28)
N=131
0.27 (0.32)
N=61
0.20 (0.27)
N=129
Musculoskeletal complaints in IBD
103
5
	
	
	
Discussion	
This	study	demonstrates	that	MSC	are	frequent	 in	patients	with	 IBD	and	have	great	 impact	on	the	
burden	of	disease.	The	impact	of	these	MSC	is	demonstrated	by	significantly	lower	scores	in	quality	of	
life,	 in	both	physical	and	mental	health	domains.	With	regard	to	work	status	and	productivity,	 IBD	
patients	 with	 MSC	 are	 less	 often	 employed	 and	 if	 they	 are	 employed,	 they	 experience	 more	
presenteism	and	work	productivity	loss.	
The	prevalence	of	MSC	was	fairly	high	(80%)	in	our	study,	compared	to	the	general	population	in	the	
Netherlands	(53.9%).24	A	lot	of	studies	have	been	performed	concerning	the	prevalence	of	rheumatic	
manifestations	in	IBD	patients,	but	most	focus	on	inflammatory	rheumatic	manifestations	as	SpA	with	
arthritis	and	sacroiliitis.	One	population	based	study	from	Norway	reported	on	the	prevalence	of	non-
inflammatory	joint	pain	and	this	was	estimated	at	16%.25	However,	they	only	studied	joint	complaints	
and	our	sample	consists	of	all	forms	of	MSC	pain.	A	recent	study	from	the	Netherlands	looked	into	the	
prevalence	of	arthropathy	in	IBD	patients,	defined	as	chronic	back	pain	for	at	least	3	months	and/or	
peripheral	joint	swelling	at	presentation	or	in	the	past	year	and	they	report	a	prevalence	of	60.1%.26	
The	percentage	of	patients	in	our	study	with	joint	or	back	pain	(excluding	tendon	complaints)	is	slightly	
higher	at	72.5%.	This	difference	could	be	explained	by	the	fact	that	we	used	self-reported	joint	or	back	
complaints	without	specific	criteria	like	they	used.	
The	impact	of	MSC	in	IBD	patients	on	quality	of	life	is	considerable.	This	was	also	demonstrated	in	the	
non-inflammatory	joint	pain	study	from	Norway	and	the	study	from	the	Netherlands	with	more	or	less	
comparable	 scores	on	 the	 SF-36	and	 IBDQ.25,26	 Several	other	 studies	have	been	performed	on	 the	
quality	of	life	in	patients	with	IBD.	Most	show	decreased	quality	of	life1,3,27,28,	while	some	studies	show	
no	difference	between	IBD	patients	and	the	reference	population2,29.	However,	most	studies	do	not	
make	the	distinction	between	IBD	with	and	without	MSC.	A	recent	study	from	the	Netherlands	did	
show	 decreased	 quality	 of	 life	 as	measured	with	 the	 SF-36	 and	 short-IBDQ	 in	 patients	 with	 joint	
complaints	compared	to	 IBD	patients	without	 joint	complaints.26	 In	our	study,	 the	quality	of	 life	of	
patients	with	IBD	was	lower	than	the	quality	of	 life	of	the	reference	Dutch	population.	However,	 if	
making	the	distinction	between	IBD	patients	with	and	without	MSC,	the	SF-36	scores	for	IBD	patients	
without	MSC	are	comparable	with	the	Dutch	reference	population.	Since	the	quality	of	 life	for	 IBD	
patients	with	MSC	was	significantly	lower	on	all	domains,	 it	could	certainly	be	possible	that	a	large	
part	of	the	quality	of	life	in	IBD	patients	is	determined	by	EIMs	like	MSC.	
With	 regard	 to	work	productivity	 and	activity	 impairment,	 the	 study	 from	van	der	Have	et	 al	 also	
showed	higher	work	and	activity	impairment	for	IBD	patients	with	joint/back	pain	compared	to	IBD	
patients	without	joint/back	pain.26	More	data	is	available	on	the	influence	of	IBD	in	general	on	work	
productivity,	but	not	specifically	for	the	additional	burden	of	MSC	in	these	patients.	A	large	systematic	
review	showed	that	IBD	patients	experience	a	high	burden	in	work-related	outcomes,	but	the	factors	
causing	this	are	not	investigated.30		
This	study	has	several	limitations.	First,	only	25%	of	participating	patients	was	male,	so	there	seems	
to	be	an	overrepresentation	of	women	in	our	sample.	However,	in	the	initial	unselected	selection	out	
of	the	GP	databases,	the	percentage	of	women	was	already	slightly	higher	(62.1%).	Second,	we	did	
not	do	a	clinical	evaluation	of	the	patients,	so	certain	information	like	IBD	classification	or	IBD	activity	
was	not	available.	Third,	it	is	possible	that	a	selection	bias	towards	patients	with	MSC	occurred	and	
that	the	prevalence	of	MSC	in	this	study	is	overestimated.	Although	we	asked	patients	to	participate	
irrespective	 of	 their	 complaints,	 we	 cannot	 rule	 out	 that	 patients	with	MSC	were	more	 prone	 to	
participate.	If	these	limitations	are	taken	into	account,	we	think	that	this	study	provides	valuable	data	
on	the	impact	of	MSC	in	patients	with	IBD.	We	have	a	fairly	large	sample	of	IBD	patients	with	complete	
data.	In	addition,	this	study	is	one	of	the	first	to	describe	the	various	components	of	the	burden	of	
unselected	MSC	in	IBD	patients	from	HRQoL	to	impact	on	work	status	and	productivity.	In	this	study	
we	selected	the	IBD	patients	from	primary	care.	Although	the	vast	majority	of	patients	will	be	treated	
by	a	gastroenterologist	for	their	IBD,	patients	could	also	visit	their	GP	if	experiencing	MSC.	Most	likely,	
if	patients	are	not	aware	of	the	fact	that	MSC	could	be	an	extra-intestinal	manifestation	of	IBD,	they	
will	visit	the	GP	with	MSC.	This	primary	care	setting	is	therefore	also	important	in	detecting	these	MSC	
in	IBD	patients.	Another	advantage	of	selecting	IBD	patients	from	various	GP	databases,	is	that	it	gives	
a	good	unselected	representation	of	the	general	IBD	population	in	the	Netherlands.	We	recruited	GPs	
from	various	regions	of	the	Netherlands,	thereby	also	representing	a	large	variety	in	hospitals	where	
the	IBD	patients	will	be	treated.	
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In	conclusion,	EIMS	like	MSC	have	significant	 impact	on	the	quality	of	 life	and	work	productivity	 in	
patients	with	IBD.	The	reduced	quality	of	life	found	in	IBD	seems	to	be	explicitly	influenced	by	MSC.	
Gastroenterologists	 and	 general	 practitioners	 should	 be	 aware	 of	 this	 frequent	 extra-intestinal	
manifestation	of	IBD	to	aid	early	recognition	as	it	could	possibly	be	a	symptom	of	SpA,	which	is	well	
treatable	in	early	stages.	
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In	conclusion,	EIMS	like	MSC	have	significant	 impact	on	the	quality	of	 life	and	work	productivity	 in	
patients	with	IBD.	The	reduced	quality	of	life	found	in	IBD	seems	to	be	explicitly	influenced	by	MSC.	
Gastroenterologists	 and	 general	 practitioners	 should	 be	 aware	 of	 this	 frequent	 extra-intestinal	
manifestation	of	IBD	to	aid	early	recognition	as	it	could	possibly	be	a	symptom	of	SpA,	which	is	well	
treatable	in	early	stages.	
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Abstract	
	
Objective.	To	assess	(1)	the	current	skills	of	general	practitioners	(GPs)	with	regard	to	their	ability	to	
identify	symptoms	of	spondyloarthritis	(SpA)	and	(2)	the	level	of	awareness	of	SpA	symptoms	among	
patients	at	risk.	
	
Methods.	A	cross-sectional	study	was	set	up	in	(1)	Dutch	GPs	and	(2)	in	patients	having	psoriasis	(PSO)	
or	 inflammatory	bowel	disease	 (IBD).	A	survey	was	developed	and	sent	out	 to	GPs	and	patients	 in	
various	 regions	 of	 the	 Netherlands	 and	 included	 questions	 about	 recognition	 of	 inflammatory	
symptoms	and	SpA	specific	features.	The	patient	survey	focused	on	the	presence	of	musculoskeletal	
complaints	and	the	awareness	of	developing	SpA.	
	
Results.	312	of	the	949	GPs	returned	the	survey	(response	rate	32.9%),	with	185	GPs	having	completed	
the	survey.	With	regard	to	the	recognition	of	signs	of	inflammatory	pain,	especially	classic	symptoms	
like	morning	stiffness	and	pain	relieve	by	NSAIDs	were	recognized,	whereas	other	symptoms	like	pain	
improvement	with	exercise	were	poorly	recognized.	Of	all	patient	at	risk	42.6%	were	aware	of	the	
possibility	of	developing	SpA,	this	was	43.1%	in	PSO	and	41.9%	in	IBD	patients.	
	
Conclusions.	 Overall,	 recognition	 of	 inflammatory	 disease	 by	 GPs	 is	 suboptimal,	 with	 about	 50%	
recognizing	less	than	half	of	the	features	known	to	be	indicative	of	inflammatory	joint	or	back	pain.	In	
addition,	less	than	half	of	the	patients	with	PSO	or	IBD	are	aware	of	the	possibility	of	developing	SpA.	
The	 recognition	 of	 SpA	 in	 primary	 care	 both	 by	 patients	 and	GPs	 needs	 improvement	 in	 order	 to	
facilitate	the	necessary	referrals	to	rheumatologists.	
	
	
	 	
Introduction	
Musculoskeletal	complaints	(MSC)	are	very	common	in	the	general	population	and	account	for	about	
20%	 of	 consultations	 in	 primary	 care.1,2	 A	 part	 of	 these	 MSC	 could	 be	 caused	 by	 inflammatory	
rheumatic	diseases	(IRD)	like	rheumatoid	arthritis	(RA)	and	spondyloarthritis	(SpA),	which	are	the	most	
common	IRD	with	prevalences	of	0.4-1.3%	and	0.2-1.6%	respectively.3,4	As	in	RA,	effective	treatment	
for	SpA	is	available	as	is	the	evidence	that	treatment	should	be	initiated	as	early	as	possible.5,6	Short	
disease	duration	before	starting	treatment	leads	to	better	treatment	response	with	its	consequences	
for	daily	life.7,8		
Initiating	treatment	early	requires	early	diagnosing	of	SpA.	To	aid	early	diagnosing,	both	physicians	
and	patients	at	risk	(psoriasis	(PSO)	or	inflammatory	bowel	disease	(IBD))	play	an	important	role.	For	
rheumatologists,	 a	 lot	 of	 effort	 has	 been	 put	 into	 reducing	 the	 diagnostic	 delay	 by	 developing	
internationally	accepted	diagnostic	algorithms	for	SpA	that	will	help	the	rheumatologist	to	diagnose	
these	diseases	in	an	early	phase	of	the	disease.9-11	Moreover	in	several	countries	early	arthritis	clinics	
were	set	up,	providing	early	access	to	specialized	rheumatology	care	for	patients	with	arthritis.12,13	
However,	to	optimize	early	referral	to	these	clinics,	recognition	of	IRD	by	the	physicians	who	refer	is	
a	must.	 In	countries	with	a	primary	care	healthcare	system,	 like	 the	Netherlands,	GPs	will	 refer	 to	
secondary	care.		Since	a	single	test	for	screening	on	rheumatic	diseases	does	not	exist,	GPs	have	to	
distinguish	inflammatory	from	non-inflammatory	musculoskeletal	disease	based	on	their	own	skills.	
In	addition,	another	factor	to	decrease	diagnostic	delay	are	the	patients	themselves.	Several	studies	
have	been	performed	concerning	patient	delay	in	RA,	which	show	that	symptom	interpretation	was	a	
key	 factor	 in	 seeking	 help	 at	 the	 onset	 of	 RA.14-16	 By	 educating	 patients	 at	 risk,	 patients	 could	 be	
informed	 to	 consult	 a	 GP	 when	 they	 experience	 MSC.	 Where	 internationally	 campaigns	 for	
rheumatoid	 arthritis	 increased	 the	 awareness	 in	 both	 GPs	 and	 patients,	 the	 focus	 of	 SpA	 lags	
behind.17,18				
The	aim	of	 this	 survey	was	 (1)	 to	assess	 the	current	practice	of	GPs	with	 regard	 to	 their	ability	 to	
identify	inflammatory	signs	and	symptoms	suggestive	of	SpA	and	(2)	to	assess	whether	patients	at	risk	
for	SpA	(i.e.	patients	with	PSO	or	IBD)	are	aware	of	the	risk	of	developing	SpA.		
	
Materials	&	Methods	
General	Practitioners	
A	survey	was	sent	out	to	GPs	from	various	regions	in	the	Netherlands		(city	and	surroundings	of	The	
Hague,	Gouda,	Dordrecht,	Breda,	Tilburg	and	Den	Bosch)	in	the	Netherlands,	selected	out	of	a	central	
database	containing	approximately	10	000	GPS.		
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secondary	care.		Since	a	single	test	for	screening	on	rheumatic	diseases	does	not	exist,	GPs	have	to	
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have	been	performed	concerning	patient	delay	in	RA,	which	show	that	symptom	interpretation	was	a	
key	 factor	 in	 seeking	 help	 at	 the	 onset	 of	 RA.14-16	 By	 educating	 patients	 at	 risk,	 patients	 could	 be	
informed	 to	 consult	 a	 GP	 when	 they	 experience	 MSC.	 Where	 internationally	 campaigns	 for	
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The	aim	of	 this	 survey	was	 (1)	 to	assess	 the	current	practice	of	GPs	with	 regard	 to	 their	ability	 to	
identify	inflammatory	signs	and	symptoms	suggestive	of	SpA	and	(2)	to	assess	whether	patients	at	risk	
for	SpA	(i.e.	patients	with	PSO	or	IBD)	are	aware	of	the	risk	of	developing	SpA.		
	
Materials	&	Methods	
General	Practitioners	
A	survey	was	sent	out	to	GPs	from	various	regions	in	the	Netherlands		(city	and	surroundings	of	The	
Hague,	Gouda,	Dordrecht,	Breda,	Tilburg	and	Den	Bosch)	in	the	Netherlands,	selected	out	of	a	central	
database	containing	approximately	10	000	GPS.		
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GPs	received	the	survey	by	mail,	including	an	accompanying	letter	asking	the	GPs	for	ten	minutes	of	
their	 time	 to	 complete	 the	 survey.	 In	 addition,	 the	 survey	was	handed	out	 during	 several	 plenary	
training	sessions	for	GPs	organized	by	different	hospitals.	Approximately	two	weeks	after	receiving	
the	survey	either	during	a	training	or	by	mail,	GP	practices	were	called	by	medical	students	to	remind	
them	 of	 the	 survey.	 Besides	 these	 reminders,	 the	 survey	 was	 sent	 again	 to	 all	 GPs	 who	 had	 not	
responded	to	the	survey	within	a	month.	
	
Patients	
GPs	were	recruited	(either	via	the	GP-survey	of	directly	by	personal	letter)	to	invite	their	patients	with	
PSO	or	IBD	to	participate	in	this	study.	Subsequently	these	patients	were	selected	out	of	GP	databases	
based	on	ICPC	coding	(S91	for	PSO	and	D94	for	IBD).	In	the	Netherlands,	the	ICPC	is	the	standard	for	
coding	and	classification	of	 signs	and	symptoms	 in	general	practice.19	Patients	between	18	and	55	
years	of	age	were	invited	to	participate	by	an	invitation	letter	including	a	reply	slip.	The	maximum	age	
was	set	at	55	years	in	an	attempt	to	prevent	including	a	lot	of	osteoarthritis	patients.		
Patients	 willing	 to	 participate	 returned	 their	 reply	 slip	 and	 received	 the	 set	 of	 questionnaires	 to	
complete	either	via	a	specially	developed	electronic	system	or	on	paper	if	preferred.	
Besides	the	recruitment	via	GPs,	we	also	contact	patient	organizations.	The	“Crohn	en	Colitis	Ulcerosa	
Vereniging	Nederland	(CCUVN)”	included	information	about	our	study	with	an	invitation	to	participate	
in	their	newsletter	which	was	sent	out	to	5400	patients	with	IBD	via	e-mail.	The	“Psoriasis	Vereniging	
Nederland	(PVN)”,	placed	an	advertisement	on	their	website	and	sent	out	our	invitation	letter	as	an	
attachment	to	their	two-monthly	magazine	(target	population	4500	psoriasis	patients).		
This	 study	was	 exempted	 from	medical	 ethical	 approval	 by	 the	medical	 ethical	 committee	 of	 the	
Erasmus	University	Medical	Centre	as	patients	only	had	to	complete	a	set	of	questionnaires	(MEC-
2014-269).	All	patients	signed	the	reply	slip	when	they	agreed	to	participate.	
	
GP	Survey	
We	developed	a	survey	partly	based	on	a	study	by	Jois	et	al	that	assessed	the	current	practice	of	GPs.20	
This	 study	 focused	 on	 the	 recognition	 of	 inflammatory	 back	 pain	 as	 a	 symptom	 of	 ankylosing	
spondylitis.	Since	we	were	interested	in	the	ability	of	GPs	to	recognize	signs	and	symptoms	of	the	total	
group	of	axial	and	peripheral	SpA,	we	added	some	extra	questions.	After	setting	up	the	survey,	it	was	
discussed	in	a	group	of	rheumatologists	and	researchers	from	the	rheumatology	department	to	make	
sure	that	the	included	questions	were	clearly	stated.		
The	 final	 survey	 included	 questions	 about	 the	 recognition	 of	 signs	 and	 symptoms	 that	 indicate	
inflammatory	 peripheral	 as	 well	 as	 axial	 manifestations.	 We	 also	 included	 questions	 about	 the	
importance	and	assessment	of	certain	diagnostic	tests	like		HLA-B27,	rheumatoid	factor	(RF)	and	anti-
citrullinated	protein	antibody(ACPA).	The	importance	was	measured	on	a	scale	from	0	to	10	where	0	
meant	“not	important	at	all”	and	10	meant	“very	important”.		For	the	assessment,	GPs	were	asked	
when	they	would	decide	to	use	these	diagnostic	tests.	We	asked	about	knowledge	of	associated	SpA	
features	(like	PSO,	IBD,	uveitis,	enthesitis	and	dactylitis),	familiarity	with	the	term	SpA	if	GPs	educate	
their	patients	at	risk	for	SpA	(e.g.	patients	with	PSO,	IBD	and	uveitis).		
	
Patient	Questionnaires		
The	set	of	questionnaires	included	questions	about	demographics,	characteristics	of	their	disease	(PSO	
or	IBD)	and	the	presence	of	MSC	(joint,	tendon	or	back).	Patients	were	asked	if	they	were	aware	of	
the	possibility	of	developing	a	rheumatic	condition	and	if	so,	how	they	became	aware.	
	
Statistical	Analysis	
Descriptive	statistics	were	used	to	describe	participant	characteristics	and	survey	outcomes	in	STATA	
14.	Statistically	significant	differences	for	baseline	characteristics	and	patients’	awareness	between	
patients	recruited	via	the	GP	or	via	the	patient	organization	were	tested	with	the	t-test	or	Chi	square	
test,	where	appropriate.	A	p-value	below	0.05	was	considered	as	statistically	signicant.	
	
Results	
General	Practitioners	
After	sending	out	the	survey	to	1019	GPs,	 it	turned	out	that	70	GPs	were	no	longer	working	in	the	
practice,	either	because	they	were	GPs	in	training	and	had	moved	on	or	because	the	GP	retired.	In	
total,	312	of	the	949	GPs	responded	(32.9%).	Of	these,	127	GPs	indicated	that	they	did	not	want	to	
participate	in	the	survey,	mostly	because	they	found	it	too	time	consuming.	The	remaining	185	GPs	
(19.5%)	completed	the	survey.		
The	responding	GPs	had	a	mean	age	of	47.2	years	(SD	10.3	years)	and	48.1%	were	male.	Mean	time	
working	as	a	GP	was	16.0	years	 (SD	10.6	years).	 Forty	percent	of	 the	GPs	 indicated	 to	be	working	
fulltime	and	40%	indicated	to	supervise	GPs	in	training	in	their	practice.	
	
Knowledge	of	Spondyloarthritis	
Almost	all	GPs	(97.2%)	indicated	to	be	familiar	with	the	term	spondyloarthritis.	However,	the	majority	
associated	SpA	with	ankylosing	spondylitis	(90.9%)	and	sacroiliitis	(53.1%).	More	than	half	of	the	GPs	
(55.4%)	associated	SpA	solely	with	these	axial	manifestations.	Up	to	one	third	of	the	GPs	associated	
the	term	SpA	with	psoriatic	arthritis	(24.0%)	and	Inflammatory	Bowel	Disease	(34.3%).	GPs	associated	
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GPs	received	the	survey	by	mail,	including	an	accompanying	letter	asking	the	GPs	for	ten	minutes	of	
their	 time	 to	 complete	 the	 survey.	 In	 addition,	 the	 survey	was	handed	out	 during	 several	 plenary	
training	sessions	for	GPs	organized	by	different	hospitals.	Approximately	two	weeks	after	receiving	
the	survey	either	during	a	training	or	by	mail,	GP	practices	were	called	by	medical	students	to	remind	
them	 of	 the	 survey.	 Besides	 these	 reminders,	 the	 survey	 was	 sent	 again	 to	 all	 GPs	 who	 had	 not	
responded	to	the	survey	within	a	month.	
	
Patients	
GPs	were	recruited	(either	via	the	GP-survey	of	directly	by	personal	letter)	to	invite	their	patients	with	
PSO	or	IBD	to	participate	in	this	study.	Subsequently	these	patients	were	selected	out	of	GP	databases	
based	on	ICPC	coding	(S91	for	PSO	and	D94	for	IBD).	In	the	Netherlands,	the	ICPC	is	the	standard	for	
coding	and	classification	of	 signs	and	symptoms	 in	general	practice.19	Patients	between	18	and	55	
years	of	age	were	invited	to	participate	by	an	invitation	letter	including	a	reply	slip.	The	maximum	age	
was	set	at	55	years	in	an	attempt	to	prevent	including	a	lot	of	osteoarthritis	patients.		
Patients	 willing	 to	 participate	 returned	 their	 reply	 slip	 and	 received	 the	 set	 of	 questionnaires	 to	
complete	either	via	a	specially	developed	electronic	system	or	on	paper	if	preferred.	
Besides	the	recruitment	via	GPs,	we	also	contact	patient	organizations.	The	“Crohn	en	Colitis	Ulcerosa	
Vereniging	Nederland	(CCUVN)”	included	information	about	our	study	with	an	invitation	to	participate	
in	their	newsletter	which	was	sent	out	to	5400	patients	with	IBD	via	e-mail.	The	“Psoriasis	Vereniging	
Nederland	(PVN)”,	placed	an	advertisement	on	their	website	and	sent	out	our	invitation	letter	as	an	
attachment	to	their	two-monthly	magazine	(target	population	4500	psoriasis	patients).		
This	 study	was	 exempted	 from	medical	 ethical	 approval	 by	 the	medical	 ethical	 committee	 of	 the	
Erasmus	University	Medical	Centre	as	patients	only	had	to	complete	a	set	of	questionnaires	(MEC-
2014-269).	All	patients	signed	the	reply	slip	when	they	agreed	to	participate.	
	
GP	Survey	
We	developed	a	survey	partly	based	on	a	study	by	Jois	et	al	that	assessed	the	current	practice	of	GPs.20	
This	 study	 focused	 on	 the	 recognition	 of	 inflammatory	 back	 pain	 as	 a	 symptom	 of	 ankylosing	
spondylitis.	Since	we	were	interested	in	the	ability	of	GPs	to	recognize	signs	and	symptoms	of	the	total	
group	of	axial	and	peripheral	SpA,	we	added	some	extra	questions.	After	setting	up	the	survey,	it	was	
discussed	in	a	group	of	rheumatologists	and	researchers	from	the	rheumatology	department	to	make	
sure	that	the	included	questions	were	clearly	stated.		
The	 final	 survey	 included	 questions	 about	 the	 recognition	 of	 signs	 and	 symptoms	 that	 indicate	
inflammatory	 peripheral	 as	 well	 as	 axial	 manifestations.	 We	 also	 included	 questions	 about	 the	
importance	and	assessment	of	certain	diagnostic	tests	like		HLA-B27,	rheumatoid	factor	(RF)	and	anti-
citrullinated	protein	antibody(ACPA).	The	importance	was	measured	on	a	scale	from	0	to	10	where	0	
meant	“not	important	at	all”	and	10	meant	“very	important”.		For	the	assessment,	GPs	were	asked	
when	they	would	decide	to	use	these	diagnostic	tests.	We	asked	about	knowledge	of	associated	SpA	
features	(like	PSO,	IBD,	uveitis,	enthesitis	and	dactylitis),	familiarity	with	the	term	SpA	if	GPs	educate	
their	patients	at	risk	for	SpA	(e.g.	patients	with	PSO,	IBD	and	uveitis).		
	
Patient	Questionnaires		
The	set	of	questionnaires	included	questions	about	demographics,	characteristics	of	their	disease	(PSO	
or	IBD)	and	the	presence	of	MSC	(joint,	tendon	or	back).	Patients	were	asked	if	they	were	aware	of	
the	possibility	of	developing	a	rheumatic	condition	and	if	so,	how	they	became	aware.	
	
Statistical	Analysis	
Descriptive	statistics	were	used	to	describe	participant	characteristics	and	survey	outcomes	in	STATA	
14.	Statistically	significant	differences	for	baseline	characteristics	and	patients’	awareness	between	
patients	recruited	via	the	GP	or	via	the	patient	organization	were	tested	with	the	t-test	or	Chi	square	
test,	where	appropriate.	A	p-value	below	0.05	was	considered	as	statistically	signicant.	
	
Results	
General	Practitioners	
After	sending	out	the	survey	to	1019	GPs,	 it	turned	out	that	70	GPs	were	no	longer	working	in	the	
practice,	either	because	they	were	GPs	in	training	and	had	moved	on	or	because	the	GP	retired.	In	
total,	312	of	the	949	GPs	responded	(32.9%).	Of	these,	127	GPs	indicated	that	they	did	not	want	to	
participate	in	the	survey,	mostly	because	they	found	it	too	time	consuming.	The	remaining	185	GPs	
(19.5%)	completed	the	survey.		
The	responding	GPs	had	a	mean	age	of	47.2	years	(SD	10.3	years)	and	48.1%	were	male.	Mean	time	
working	as	a	GP	was	16.0	years	 (SD	10.6	years).	 Forty	percent	of	 the	GPs	 indicated	 to	be	working	
fulltime	and	40%	indicated	to	supervise	GPs	in	training	in	their	practice.	
	
Knowledge	of	Spondyloarthritis	
Almost	all	GPs	(97.2%)	indicated	to	be	familiar	with	the	term	spondyloarthritis.	However,	the	majority	
associated	SpA	with	ankylosing	spondylitis	(90.9%)	and	sacroiliitis	(53.1%).	More	than	half	of	the	GPs	
(55.4%)	associated	SpA	solely	with	these	axial	manifestations.	Up	to	one	third	of	the	GPs	associated	
the	term	SpA	with	psoriatic	arthritis	(24.0%)	and	Inflammatory	Bowel	Disease	(34.3%).	GPs	associated	
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SpA	less	with	SpA	features	such	as	uveitis	(13.1%),	dactylitis	(4.0%)	and	enthesitis	(5.1%).	Interestingly,	
14.9%	of	GPs	thought	SpA	is	associated	with	rheumatoid	arthritis.	
	
Signs,	symptoms	and	blood	tests	
With	regard	to	the	signs	and	symptoms	GPs	associate	with	inflammatory	joint	pain,	morning	stiffness	
lasting	for	longer	than	30	minutes	and	pain	relieve	by	NSAIDs	were	recognized	by	the	majority	of	GPs	
(Table	1).	This	was	similar	for	inflammatory	back	pain.	
If	we	look	at	the	knowledge	of	specific	criteria	of	inflammatory	joint	pain,	57.3%	of	GPs	knew	less	than	
half	of	all	6	criteria.	For	inflammatory	back	pain	this	was	39.4%.	For	both	inflammatory	joint	and	back	
pain,	only	4	GPs	(2.2%)	were	able	to	indicate	all	six	respectively	eight	features.		
	
	
	
	
With	regard	to	importance	of	determining	rheumatoid	factor,	GPs	valued	this	with	a	mean	score	of	
5.2	(SD2.2),	for	ACPA	the	mean	score	was	5.7	(SD	2.0)	and	for	HLA-B27	it	was	6.5	(SD	2.2).	Reasons	to	
check	rheumatoid	factor	status,	ACPA	status	or	HLA-B27	status	are	summarized	in	table	2.	Rheumatoid	
factor	is	most	often	checked	in	patients	who	often	return	with	complaints,	while	ACPA	is	most	often	
checked	in	patients	with	inflammatory	complaints.	About	one	third	of	GPs	indicated	to	check	HLA-B27	
in	patients	with	 inflammatory	complaints,	while	44.3%	 indicated	 to	never	check	HLA-B27	status	 in	
their	patients	(Table	2).	
	
	
	
	
	
	
Table 1  Proportion of GPs who identified correct signs of inflammatory joint and back pain (n=185)
Signs of inflammatory pain Joint Back
Insidious onset of complaints, n (%)            53 (28.7) 90 (48.7)
Symptom duration>3 months, n (%)           57 (30.8) 93 (50.3)
Pain improved with exercise, n (%)             25 (13.5) 39 (21.1)
Pain not relieved by rest, n (%) 30 (16.2) 40 (21.6)
Pain relieved by NSAIDs, n (%)                     162 (87.6) 152 (82.2)
Morning Stiffness>30min, n (%)   142 (76.8) 139 (75.1)
Nocturnal Pain, n (%)                                     Not Applicable 145 (78.4)
Alternating Buttock Pain, n (%)                   Not Applicable 38 (20.5)
SpA	less	with	SpA	features	such	as	uveitis	(13.1%),	dactylitis	(4.0%)	and	enthesitis	(5.1%).	Interestingly,	
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half	of	all	6	criteria.	For	inflammatory	back	pain	this	was	39.4%.	For	both	inflammatory	joint	and	back	
pain,	only	4	GPs	(2.2%)	were	able	to	indicate	all	six	respectively	eight	features.		
	
	
	
	
With	regard	to	importance	of	determining	rheumatoid	factor,	GPs	valued	this	with	a	mean	score	of	
5.2	(SD2.2),	for	ACPA	the	mean	score	was	5.7	(SD	2.0)	and	for	HLA-B27	it	was	6.5	(SD	2.2).	Reasons	to	
check	rheumatoid	factor	status,	ACPA	status	or	HLA-B27	status	are	summarized	in	table	2.	Rheumatoid	
factor	is	most	often	checked	in	patients	who	often	return	with	complaints,	while	ACPA	is	most	often	
checked	in	patients	with	inflammatory	complaints.	About	one	third	of	GPs	indicated	to	check	HLA-B27	
in	patients	with	 inflammatory	complaints,	while	44.3%	 indicated	 to	never	check	HLA-B27	status	 in	
their	patients	(Table	2).	
	
	
	
	
	
	
	
	
Associated	SpA	Features	
When	a	patient	presents	with	inflammatory	joint	or	back	pain,	most	GPs	indicated	to	ask	for	the	SpA	
features	psoriasis,	inflammatory	bowel	disease	and	uveitis,	whereas	enthesitis	and	dactylitis	are	not	
often	asked	for	(Table	3).	
	
	
	
Education	of	patients	at	risk	for	SpA	
With	regard	to	educating	patients	with	psoriasis	or	inflammatory	bowel	disease	about	their	increased	
risk	of	developing	SpA,	only	3.3%	of	GPs	indicated	to	always	educate	these	patients.	Twenty-nine	GPs	
(15.9%)	 indicated	to	never	educate	their	patients	about	this	 increased	risk	and	37.4%	educate	 less	
than	half	of	their	patients	at	risk.	
	
Patient	Survey	
Psoriasis	
In	total,	1220	PSO	patients	between	18-55	years	of	age	were	selected	out	of	81	GP	databases,	of	which	
606	patients	responded.	Of	the	responders,	461	were	willing	to	participate.	Reasons	not	to	participate	
were	mainly	not	having	PSO	(n=79)	or	lack	of	interest	(n=51).	Via	the	patient	organization,	203	patients	
responded,	of	which	177	agreed	to	participate.		
Of	the	in	total	638	patients	who	agreed	to	participate,	552	(86.5%)	completed	the	questionnaires.	The	
mean	age	of	the	participating	PSO	patients	was	45.2	(SD	8.5)	years	with	46.7%	being	male.	Mean	time	
suffering	from	PSO	was	19.0	(SD	12.0)	years	with	71.4%	currently	treated	by	their	GP.	Patients	from	
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SpA	less	with	SpA	features	such	as	uveitis	(13.1%),	dactylitis	(4.0%)	and	enthesitis	(5.1%).	Interestingly,	
14.9%	of	GPs	thought	SpA	is	associated	with	rheumatoid	arthritis.	
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With	regard	to	the	signs	and	symptoms	GPs	associate	with	inflammatory	joint	pain,	morning	stiffness	
lasting	for	longer	than	30	minutes	and	pain	relieve	by	NSAIDs	were	recognized	by	the	majority	of	GPs	
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If	we	look	at	the	knowledge	of	specific	criteria	of	inflammatory	joint	pain,	57.3%	of	GPs	knew	less	than	
half	of	all	6	criteria.	For	inflammatory	back	pain	this	was	39.4%.	For	both	inflammatory	joint	and	back	
pain,	only	4	GPs	(2.2%)	were	able	to	indicate	all	six	respectively	eight	features.		
	
	
	
	
With	regard	to	importance	of	determining	rheumatoid	factor,	GPs	valued	this	with	a	mean	score	of	
5.2	(SD2.2),	for	ACPA	the	mean	score	was	5.7	(SD	2.0)	and	for	HLA-B27	it	was	6.5	(SD	2.2).	Reasons	to	
check	rheumatoid	factor	status,	ACPA	status	or	HLA-B27	status	are	summarized	in	table	2.	Rheumatoid	
factor	is	most	often	checked	in	patients	who	often	return	with	complaints,	while	ACPA	is	most	often	
checked	in	patients	with	inflammatory	complaints.	About	one	third	of	GPs	indicated	to	check	HLA-B27	
in	patients	with	 inflammatory	complaints,	while	44.3%	 indicated	 to	never	check	HLA-B27	status	 in	
their	patients	(Table	2).	
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If	we	look	at	the	knowledge	of	specific	criteria	of	inflammatory	joint	pain,	57.3%	of	GPs	knew	less	than	
half	of	all	6	criteria.	For	inflammatory	back	pain	this	was	39.4%.	For	both	inflammatory	joint	and	back	
pain,	only	4	GPs	(2.2%)	were	able	to	indicate	all	six	respectively	eight	features.		
	
	
	
	
With	regard	to	importance	of	determining	rheumatoid	factor,	GPs	valued	this	with	a	mean	score	of	
5.2	(SD2.2),	for	ACPA	the	mean	score	was	5.7	(SD	2.0)	and	for	HLA-B27	it	was	6.5	(SD	2.2).	Reasons	to	
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factor	is	most	often	checked	in	patients	who	often	return	with	complaints,	while	ACPA	is	most	often	
checked	in	patients	with	inflammatory	complaints.	About	one	third	of	GPs	indicated	to	check	HLA-B27	
in	patients	with	 inflammatory	complaints,	while	44.3%	 indicated	 to	never	check	HLA-B27	status	 in	
their	patients	(Table	2).	
	
	
	
	
	
	
	
	
Associated	SpA	Features	
When	a	patient	presents	with	inflammatory	joint	or	back	pain,	most	GPs	indicated	to	ask	for	the	SpA	
features	psoriasis,	inflammatory	bowel	disease	and	uveitis,	whereas	enthesitis	and	dactylitis	are	not	
often	asked	for	(Table	3).	
	
	
	
Education	of	patients	at	risk	for	SpA	
With	regard	to	educating	patients	with	psoriasis	or	inflammatory	bowel	disease	about	their	increased	
risk	of	developing	SpA,	only	3.3%	of	GPs	indicated	to	always	educate	these	patients.	Twenty-nine	GPs	
(15.9%)	 indicated	to	never	educate	their	patients	about	this	 increased	risk	and	37.4%	educate	 less	
than	half	of	their	patients	at	risk.	
	
Patient	Survey	
Psoriasis	
In	total,	1220	PSO	patients	between	18-55	years	of	age	were	selected	out	of	81	GP	databases,	of	which	
606	patients	responded.	Of	the	responders,	461	were	willing	to	participate.	Reasons	not	to	participate	
were	mainly	not	having	PSO	(n=79)	or	lack	of	interest	(n=51).	Via	the	patient	organization,	203	patients	
responded,	of	which	177	agreed	to	participate.		
Of	the	in	total	638	patients	who	agreed	to	participate,	552	(86.5%)	completed	the	questionnaires.	The	
mean	age	of	the	participating	PSO	patients	was	45.2	(SD	8.5)	years	with	46.7%	being	male.	Mean	time	
suffering	from	PSO	was	19.0	(SD	12.0)	years	with	71.4%	currently	treated	by	their	GP.	Patients	from	
Table 2 Reasons to check rheumatoid factor, ACPA and HLA-B27 status
Rheumatoid Factor ACPA HLA-B27
Every patient with complaints, n (%) 1 (0.54) 0 1 (0.54)
Patients who often return with complaints, n (%) 103 (55.7) 94 (50.8) 20 (10.8)
Patients with inflammatory complaints, n (%) 90 (48.7) 104 (56.2) 64 (34.6)
Patients with a positive family history, n (%) 51 (27.6) 48 (26.0) 20 (10.8)
Never, n (%) 28 (15.1) 22 (11.9) 82 (44.3)
I don’t know what it is, n (%) 0 4 (2.2) 5 (2.7)
Table 3 Proportion of GPs who ask about associated SpA features when a patient presents with 
inflammatory joint or back pain (n=185)
Associated SpA Features
Psoriasis, n (%) 155 (83.8)
Inflammatory Bowel Disease, n (%) 134 (72.4)
Enthesitis, n (%) 35 (18.9)
Dactylitis, n (%) 35 (18.9)
Uveitis, n (%) 116 (62.7)
Urinary tract or gut infection in preceding month, n (%) 72 (38.9)
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the	patient	organization	were	significantly	older	(46.5	vs	44.7	years),	suffering	significantly	longer	from	
PSO	(16.5	vs	24.4	years)	and	significantly	more	often	treated	by	a	dermatologist.	
With	regard	to	awareness,	238	patients	(43.1%)	indicated	to	be	aware	of	the	possibility	of	developing	
a	rheumatic	condition	already	before	the	study-invitation,	with	more	than	one	third	having	gained	this	
knowledge	themselves	(Table	4).	Patients	participating	via	the	patient	organisation	were	significantly	
more	aware	than	patients	selected	via	the	GP	(p<0.01).	
	
Inflammatory	Bowel	Disease	
For	IBD,	535	patients	aged	18-55	years	were	selected	out	of	81	GP	databases,	of	which	316	responded.	
Of	the	responders	273	were	willing	to	participate.	Reasons	not	to	participate	were	mainly	not	having	
IBD	(n=22)	and	not	interested	(n=15).	Via	the	patient	organization	116	patients	agreed	to	participate,	
leading	to	a	total	of	432	patients	willing	to	participle.	Of	these	patients,	344	(79.6%)	completed	the	
questionnaires.	The	mean	age	of	these	344	patients	was	42.2	(SD	9.4)	years	with	25.4%	being	male.	
Forty-five	per	cent	suffered	from	ulcerative	colitis	(UC),	45.6%	from	Crohn’s	disease	(CD)	and	in	9.4%	
the	type	of	IBD	was	unspecified.	Mean	time	suffering	from	IBD	was	12.3	(SD	9.3)	years.	The	distribution	
between	CD	and	UC	was	statistically	significantly	different	for	patients	recruited	via	the	GP	versus	the	
patient	organization,	with	CD	patients	being	more	often	recruited	via	the	patient	organization.	
With	regard	to	awareness,	41.9%	was	aware	of	the	possibility	of	developing	a	rheumatic	condition	
before	the	invitation	for	the	study,	with	the	majority	being	informed	by	their	medical	specialist	(Table	
4).	As	with	the	PSO	patients,	IBD	patients	selected	via	the	patient	organization	were	significantly	more	
aware	than	patients	selected	via	the	GPs	(p<0.01).	
	
	
	
	
Discussion	
This	 survey	 among	 GPs	 and	 patients	 at	 risk	 for	 SpA	 in	 the	 Netherlands	 demonstrates	 that	 the	
knowledge	and	awareness	of	patients	for	axial	and	peripheral	SpA	could	be	improved.	Almost	60%	of	
GPs	 did	 not	 recognize	 half	 of	 the	 features	 indicative	 of	 inflammatory	 peripheral	 joint	 disease,	 for	
the	patient	organization	were	significantly	older	(46.5	vs	44.7	years),	suffering	significantly	longer	from	
PSO	(16.5	vs	24.4	years)	and	significantly	more	often	treated	by	a	dermatologist.	
With	regard	to	awareness,	238	patients	(43.1%)	indicated	to	be	aware	of	the	possibility	of	developing	
a	rheumatic	condition	already	before	the	study-invitation,	with	more	than	one	third	having	gained	this	
knowledge	themselves	(Table	4).	Patients	participating	via	the	patient	organisation	were	significantly	
more	aware	than	patients	selected	via	the	GP	(p<0.01).	
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Discussion	
This	 survey	 among	 GPs	 and	 patients	 at	 risk	 for	 SpA	 in	 the	 Netherlands	 demonstrates	 that	 the	
knowledge	and	awareness	of	patients	for	axial	and	peripheral	SpA	could	be	improved.	Almost	60%	of	
GPs	 did	 not	 recognize	 half	 of	 the	 features	 indicative	 of	 inflammatory	 peripheral	 joint	 disease,	 for	
Table 4 Level of Awareness in Patients with Psoriasis or IBD
Psoriasis (n=552) IBD (n=344)
% Awareness 43.1 41.9
       % Informed by GP 13.5 1.4
       % Informed by medical specialist 24.4 40.3
       % Via family and friends 18.5 9.7
       % By information gathering 34.0 39.6
       % Patient organization 8.4 2.8
       % Other 1.3 6.3
inflammatory	axial	disease	this	percentage	is	slightly	lower	but	still	40%.	More	than	half	of	the	GPs	
associated	SpA	this	solely	with	the	axial	manifestations	and	especially	dactylitis	and	enthesitis	were	
poorly	 recognized.	 These	 SpA	 features	 were	 also	 not	 often	 asked	 for	 in	 patients	 presenting	 with	
inflammatory	musculoskeletal	symptoms.	Besides,	the	majority	of	GPs	indicated	to	never	or	seldom	
educate	their	patients	at	risk	for	SpA	(e.g.	patients	with	psoriasis	or	IBD).	From	the	patient	perspective,	
less	than	half	of	the	patients	with	PSO	or	IBD	are	aware	of	the	possibility	of	developing	a	rheumatic	
condition.	If	patients	are	aware,	the	majority	of	them	gained	this	knowledge	by	themselves	and	were	
not	informed	by	a	medical	professional.	
IRD	is	difficult	to	diagnose	for	GPs.	Although	the	estimated	prevalence	of	RA	and	SPA	is	around	
2%,	for	the	individual	GP	this	prevalence	is	fairly	low	and	therefore	most	GPs	have	little	experience	in	
clinically	evaluating	IRD.	A	recent	study	from	Newsum	et	al	used	electronical	medical	records	from	
GPs	 to	 assess	 how	 they	 identify	 peripheral	 arthritis.21	 They	 showed	 that	 GPs	 often	 evaluate	 the	
classical	 symptoms	 of	 arthritis;	 pain,	 swelling,	 warmth,	 redness	 and	 loss	 of	 function,	 while	
rheumatologists	 work	 with	 the	 inflammatory	 features	 as	 mentioned	 in	 this	 paper.	 In	 about	 20%	
morning	stiffness	and	family	history	were	reported,	while	about	75%	of	GPs	from	this	survey	said	they	
ask	for	morning	stiffness	
Regarding	 the	 inflammatory	 back	 pain,	 we	 show	 low	 knowledge	 of	 the	 criteria	 for	
inflammatory	axial	disease.	This	 is	 in	 line	with	Van	Onna	et	al	who	showed	 insufficient	knowledge	
about	axial	SpA	in	a	qualitative	study	in	primary	care	in	the	Netherlands	by	interviewing	GPs.22	The	
results	of	our	study	are	slightly	different	from	the	results	of	the	survey	in	the	United	Kingdom,	where	
17%	 of	 GPs	 was	 unable	 to	 recognize	 more	 than	 half	 of	 the	 features.20	 This	 difference	 could	 be	
explained	by	the	fact	that	the	study	from	the	UK	is	eight	years	old	and	awareness	might	have	improved	
over	 the	 last	 couple	 of	 years.	With	 regard	 to	 symptoms	 indicative	 of	 inflammatory	 axial	 disease,	
morning	stiffness	 lasting	longer	than	30	minutes	and	pain	relieve	by	NSAIDs	were	among	the	most	
frequent	recognized	features	 in	their	survey	as	well.	Recently,	a	similar	survey	about	 inflammatory	
back	pain	and	axial	SpA	was	performed	among	secondary	care	specialists	in	the	UK.	The	recognition	
of	IBP	seems	slightly	better	with	28%	recognizing	all	8	features	and	only	7%	recognizing	less	than	4	
features.23	
When	interpreting	the	results	of	this	study,	certain	strengths	and	limitations	should	be	taken	
into	account.	We	received	a	completed	survey	from	a	fairly	large	number	of	GPs	representing	different	
regions	in	het	Netherlands.	We	also	aimed	to	make	the	survey	as	complete	as	possible	by	including	
questions	about	both	peripheral	and	axial	joint	manifestations.	We	think	a	survey	is	an	adequate	way	
to	assess	the	current	practice	of	GPs	as	it	is	possible	to	reach	a	large	amount	of	GPs.	Unfortunately	
our	response	rate	was	quite	low	at	32.9%.	Ideally	we	would	have	liked	to	achieve	a	higher	response	
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the	patient	organization	were	significantly	older	(46.5	vs	44.7	years),	suffering	significantly	longer	from	
PSO	(16.5	vs	24.4	years)	and	significantly	more	often	treated	by	a	dermatologist.	
With	regard	to	awareness,	238	patients	(43.1%)	indicated	to	be	aware	of	the	possibility	of	developing	
a	rheumatic	condition	already	before	the	study-invitation,	with	more	than	one	third	having	gained	this	
knowledge	themselves	(Table	4).	Patients	participating	via	the	patient	organisation	were	significantly	
more	aware	than	patients	selected	via	the	GP	(p<0.01).	
	
Inflammatory	Bowel	Disease	
For	IBD,	535	patients	aged	18-55	years	were	selected	out	of	81	GP	databases,	of	which	316	responded.	
Of	the	responders	273	were	willing	to	participate.	Reasons	not	to	participate	were	mainly	not	having	
IBD	(n=22)	and	not	interested	(n=15).	Via	the	patient	organization	116	patients	agreed	to	participate,	
leading	to	a	total	of	432	patients	willing	to	participle.	Of	these	patients,	344	(79.6%)	completed	the	
questionnaires.	The	mean	age	of	these	344	patients	was	42.2	(SD	9.4)	years	with	25.4%	being	male.	
Forty-five	per	cent	suffered	from	ulcerative	colitis	(UC),	45.6%	from	Crohn’s	disease	(CD)	and	in	9.4%	
the	type	of	IBD	was	unspecified.	Mean	time	suffering	from	IBD	was	12.3	(SD	9.3)	years.	The	distribution	
between	CD	and	UC	was	statistically	significantly	different	for	patients	recruited	via	the	GP	versus	the	
patient	organization,	with	CD	patients	being	more	often	recruited	via	the	patient	organization.	
With	regard	to	awareness,	41.9%	was	aware	of	the	possibility	of	developing	a	rheumatic	condition	
before	the	invitation	for	the	study,	with	the	majority	being	informed	by	their	medical	specialist	(Table	
4).	As	with	the	PSO	patients,	IBD	patients	selected	via	the	patient	organization	were	significantly	more	
aware	than	patients	selected	via	the	GPs	(p<0.01).	
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not	informed	by	a	medical	professional.	
IRD	is	difficult	to	diagnose	for	GPs.	Although	the	estimated	prevalence	of	RA	and	SPA	is	around	
2%,	for	the	individual	GP	this	prevalence	is	fairly	low	and	therefore	most	GPs	have	little	experience	in	
clinically	evaluating	IRD.	A	recent	study	from	Newsum	et	al	used	electronical	medical	records	from	
GPs	 to	 assess	 how	 they	 identify	 peripheral	 arthritis.21	 They	 showed	 that	 GPs	 often	 evaluate	 the	
classical	 symptoms	 of	 arthritis;	 pain,	 swelling,	 warmth,	 redness	 and	 loss	 of	 function,	 while	
rheumatologists	 work	 with	 the	 inflammatory	 features	 as	 mentioned	 in	 this	 paper.	 In	 about	 20%	
morning	stiffness	and	family	history	were	reported,	while	about	75%	of	GPs	from	this	survey	said	they	
ask	for	morning	stiffness	
Regarding	 the	 inflammatory	 back	 pain,	 we	 show	 low	 knowledge	 of	 the	 criteria	 for	
inflammatory	axial	disease.	This	 is	 in	 line	with	Van	Onna	et	al	who	showed	 insufficient	knowledge	
about	axial	SpA	in	a	qualitative	study	in	primary	care	in	the	Netherlands	by	interviewing	GPs.22	The	
results	of	our	study	are	slightly	different	from	the	results	of	the	survey	in	the	United	Kingdom,	where	
17%	 of	 GPs	 was	 unable	 to	 recognize	 more	 than	 half	 of	 the	 features.20	 This	 difference	 could	 be	
explained	by	the	fact	that	the	study	from	the	UK	is	eight	years	old	and	awareness	might	have	improved	
over	 the	 last	 couple	 of	 years.	With	 regard	 to	 symptoms	 indicative	 of	 inflammatory	 axial	 disease,	
morning	stiffness	 lasting	longer	than	30	minutes	and	pain	relieve	by	NSAIDs	were	among	the	most	
frequent	recognized	features	 in	their	survey	as	well.	Recently,	a	similar	survey	about	 inflammatory	
back	pain	and	axial	SpA	was	performed	among	secondary	care	specialists	in	the	UK.	The	recognition	
of	IBP	seems	slightly	better	with	28%	recognizing	all	8	features	and	only	7%	recognizing	less	than	4	
features.23	
When	interpreting	the	results	of	this	study,	certain	strengths	and	limitations	should	be	taken	
into	account.	We	received	a	completed	survey	from	a	fairly	large	number	of	GPs	representing	different	
regions	in	het	Netherlands.	We	also	aimed	to	make	the	survey	as	complete	as	possible	by	including	
questions	about	both	peripheral	and	axial	joint	manifestations.	We	think	a	survey	is	an	adequate	way	
to	assess	the	current	practice	of	GPs	as	it	is	possible	to	reach	a	large	amount	of	GPs.	Unfortunately	
our	response	rate	was	quite	low	at	32.9%.	Ideally	we	would	have	liked	to	achieve	a	higher	response	
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rate,	 but	we	were	 not	 able	 to	 achieve	 this	 despite	 the	 fact	 that	we	 used	 several	 evidence-based	
recommendations	to	increase	response,	like	personal	letters,	postal	reminders	and	called	all	GPs	to	
remind	them	of	the	survey.24,25	However,	despite	the	fact	that	the	response	rate	was	quite	low,	the	
participating	GPs	are	an	accurate	reflection	of	the	total	GP	population	in	the	Netherlands.26		For	the	
patient	 part,	 we	 achieved	 a	 large	 sample	 of	 patients	 with	 PSO	 and	 IBD	 and	 to	 the	 best	 of	 our	
knowledge	not	much	is	known	about	awareness	in	patients	at	risk	for	SpA.	A	possible	limitation	is	that	
a	lot	of	patients	who	participated	were	suffering	from	MSC.	One	could	say	that	these	patients	would	
be	more	aware	since	they	have	complaints	and	might	already	have	been	looking	for	possible	causes.	
Over	 the	 last	 years	 it	 has	 been	 tried	 to	 increase	 awareness	 for	 diseases	 in	 general	 but	
especially	for	rheumatic	diseases	via	guidelines	and	education	of	GPs.	The	Dutch	College	of	General	
Practitioners	(NHG)	has	set	up	a	guideline	for	arthritis,	supporting	GPs	in	the	workup	of	patients	with	
inflammatory	joint	complaints.27	With	regard	to	education,	despite	the	fact	that	only	a	small	selected	
group	of	GPs	can	be	reached	this	way,	education	does	seem	to	improve	referral	of	patients	suspected	
of	 having	 SpA.28-30	 However,	 guidelines	 and	 education	 alone	 does	 not	 seem	 to	 be	 sufficient.	 Two	
reviews,	 of	which	 one	was	 specifically	 aimed	 at	 inflammatory	 arthritis,	 showed	 that	 referral	 from	
primary	to	secondary	care	could	also	be	 improved	via	the	use	of	self-administered	questionnaires,	
referral	sheets	or	triage	by	a	specialist	in	a	primary	care	setting.29,30		
With	regard	to	patient	awareness,	we	show	that	this	should	also	be	improved	since	less	than	
half	of	the	patients	at	risk	are	aware	and	the	majority	of	GPs	indicated	to	never	or	seldom	educate	
their	 patients.	 To	 increase	 this	 awareness	 in	 patients	 at	 risk	 and	 thereby	 reducing	 patient	 delay,	
several	options	have	been	studied,	for	example	community	case	finding	strategies,	public	awareness	
programs	and	internet	and	website	information.30,31	As	the	Netherlands	has	a	very	extensive	primary	
health	care	system,	GPs	themselves	should	also	be	involved	in	patient	education.	
In	conclusion,	the	knowledge	and	awareness	of	GPs	with	regard	to	distinguishing	non-inflammatory	
symptoms	 from	 inflammatory	 rheumatic	 disease	 should	 be	 improved	 in	 order	 to	 facilitate	 early	
diagnosis	 and	 treatment.	 More	 research	 is	 necessary	 to	 analyse	 the	 impact	 of	 adequate	 referral	
strategies	 like	 referral	 sheets	 or	 triage	 by	 a	 rheumatologist	 in	 a	 primary	 care	 setting.	 Educating	
patients	at	risk	could	also	be	an	important	factor	in	enhancing	early	recognition,	as	at	the	moment	
less	than	half	of	the	patients	at	risk	is	aware	of	the	possibility	of	developing	SpA.	Furthermore,	the	
result	of	this	survey	can	be	used	by	rheumatologists	for	optimizing	their	education	programs	in	for	
both	colleagues	and	patients	at	risk	on	SpA.   
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rate,	 but	we	were	 not	 able	 to	 achieve	 this	 despite	 the	 fact	 that	we	 used	 several	 evidence-based	
recommendations	to	increase	response,	like	personal	letters,	postal	reminders	and	called	all	GPs	to	
remind	them	of	the	survey.24,25	However,	despite	the	fact	that	the	response	rate	was	quite	low,	the	
participating	GPs	are	an	accurate	reflection	of	the	total	GP	population	in	the	Netherlands.26		For	the	
patient	 part,	 we	 achieved	 a	 large	 sample	 of	 patients	 with	 PSO	 and	 IBD	 and	 to	 the	 best	 of	 our	
knowledge	not	much	is	known	about	awareness	in	patients	at	risk	for	SpA.	A	possible	limitation	is	that	
a	lot	of	patients	who	participated	were	suffering	from	MSC.	One	could	say	that	these	patients	would	
be	more	aware	since	they	have	complaints	and	might	already	have	been	looking	for	possible	causes.	
Over	 the	 last	 years	 it	 has	 been	 tried	 to	 increase	 awareness	 for	 diseases	 in	 general	 but	
especially	for	rheumatic	diseases	via	guidelines	and	education	of	GPs.	The	Dutch	College	of	General	
Practitioners	(NHG)	has	set	up	a	guideline	for	arthritis,	supporting	GPs	in	the	workup	of	patients	with	
inflammatory	joint	complaints.27	With	regard	to	education,	despite	the	fact	that	only	a	small	selected	
group	of	GPs	can	be	reached	this	way,	education	does	seem	to	improve	referral	of	patients	suspected	
of	 having	 SpA.28-30	 However,	 guidelines	 and	 education	 alone	 does	 not	 seem	 to	 be	 sufficient.	 Two	
reviews,	 of	which	 one	was	 specifically	 aimed	 at	 inflammatory	 arthritis,	 showed	 that	 referral	 from	
primary	to	secondary	care	could	also	be	 improved	via	the	use	of	self-administered	questionnaires,	
referral	sheets	or	triage	by	a	specialist	in	a	primary	care	setting.29,30		
With	regard	to	patient	awareness,	we	show	that	this	should	also	be	improved	since	less	than	
half	of	the	patients	at	risk	are	aware	and	the	majority	of	GPs	indicated	to	never	or	seldom	educate	
their	 patients.	 To	 increase	 this	 awareness	 in	 patients	 at	 risk	 and	 thereby	 reducing	 patient	 delay,	
several	options	have	been	studied,	for	example	community	case	finding	strategies,	public	awareness	
programs	and	internet	and	website	information.30,31	As	the	Netherlands	has	a	very	extensive	primary	
health	care	system,	GPs	themselves	should	also	be	involved	in	patient	education.	
In	conclusion,	the	knowledge	and	awareness	of	GPs	with	regard	to	distinguishing	non-inflammatory	
symptoms	 from	 inflammatory	 rheumatic	 disease	 should	 be	 improved	 in	 order	 to	 facilitate	 early	
diagnosis	 and	 treatment.	 More	 research	 is	 necessary	 to	 analyse	 the	 impact	 of	 adequate	 referral	
strategies	 like	 referral	 sheets	 or	 triage	 by	 a	 rheumatologist	 in	 a	 primary	 care	 setting.	 Educating	
patients	at	risk	could	also	be	an	important	factor	in	enhancing	early	recognition,	as	at	the	moment	
less	than	half	of	the	patients	at	risk	is	aware	of	the	possibility	of	developing	SpA.	Furthermore,	the	
result	of	this	survey	can	be	used	by	rheumatologists	for	optimizing	their	education	programs	in	for	
both	colleagues	and	patients	at	risk	on	SpA.   
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Abstract	
	
Objective.	 To	 compare	 the	 screening	 performance	 of	 the	 PEST,	 PASE	 &	 EARP	 questionnaires	 for	
detecting	psoriatic	arthritis	(PsA)	among	psoriasis	patients	in	a	primary	care	setting.	
	
Methods.	In	a	cross-sectional	study,	473	primary	care	psoriasis	patients	at	risk	for	PsA	completed	the	
PEST,	PASE	&	EARP	questionnaires	and	were	clinically	evaluated	by	a	trained	research	nurse.	A	PsA	
case	was	defined	by	a	rheumatologist	according	to	the	CASPAR	criteria.	Sensitivity	and	specificity	were	
determined	for	the	PEST	and	EARP	cut-offs	(≥3)	and	the	PASE	cut-offs	(≥44	and	≥47).	
	
Results.	PsA	was	diagnosed	in	53	patients.	The	PEST	had	a	sensitivity	of	0.68	and	a	specificity	of	0.71.	
The	PASE	was	validated	for	two	different	cut-offs.	The	cut-off	of	47	led	to	a	sensitivity	of	0.59	and	a	
specificity	of	0.66,	whereas	the	lower	cut-off	of	44	led	to	a	sensitivity	of	0.66	and	a	specificity	of	0.57.	
For	the	EARP	and	we	found	a	sensitivity	of	0.87	with	a	specificity	of	0.34.	
	
Conclusions.	 The	 PEST	 questionnaire	 has	 the	 most	 favourable	 trade-off	 between	 sensitivity	 and	
specificity	to	screen	for	PsA.	However,	as	the	prevalence	of	psoriasis	and	PsA	is	fairly	low	in	primary	
care,	screening	only	psoriasis	patients	with	musculoskeletal	complaints	may	be	a	better	allocation	of	
resources.	
	 	
Introduction	
Psoriatic	 arthritis	 (PsA)	 is	 an	 inflammatory	 joint	 disease,	 associated	 with	 psoriasis.1	 Increasing	
evidence	 suggests	 that	 diagnosing	 PsA	 early	 and	 subsequently	 provide	 early	 treatment,	 improves	
patients’	outcomes	substantially.2-5	Since	in	the	majority	of	cases	the	symptoms	of	the	skin	precede	
the	musculoskeletal	 symptoms,	an	opportunity	 for	screening	arises.6	Physicians	who	treat	patients	
with	 psoriasis,	 like	 general	 practitioners	 (GPs)	 and	 dermatologists,	 should	 pay	 attention	 to	 these	
musculoskeletal	 symptoms,	 as	 timely	 referral	 to	 a	 rheumatologist	 can	 assure	 early	 diagnosis	 and	
adequate	treatment.	
To	 enhance	 early	 recognition	 by	 dermatologists	 and	 GPs	 several	 screening	 questionnaires	 were	
developed,	like	the	PEST,	PASE	and	EARP.7-9	These	were	mostly	developed	in	secondary	care	and	until	
now	 four	 different	 validation	 studies	 have	 been	 published,	 also	 mostly	 in	 secondary	 care.10-13	
However,	in	many	western	countries	including	the	Netherlands	the	majority	of	patients	remain	under	
care	of	their	GP.	Screening	in	a	primary	care	setting	may	therefore	be	very	useful.		
The	primary	objective	of	this	study	was	to	compare	the	screening	performance	of	the	validated	PEST,	
PASE	&	EARP	questionnaires	in	detecting	PsA	among	primary	care	psoriasis	patients.		
	
Methods	
Patients	
Between	 June	2013	and	March	2014	a	 large	cross-sectional	 study	 in	primary	 care	was	performed.	
Ninety-seven	GPs	from	the	greater	Rotterdam	area	were	willing	to	participate,	with	an	average	patient	
population	of	1600	patients	aged	18	years	and	over	per	GP.	Participating	GPs	selected	their	psoriasis	
patients	aged	18	years	and	over	using	ICPC	code	S91	(International	Classification	of	Primary	Care	code	
for	 psoriasis).14	 The	 ICPC	 is	 widely	 used	 for	 coding	 signs	 and	 symptoms	 in	 primary	 care	 in	 the	
Netherlands.	 All	 identified	 psoriasis	 patients	 received	 an	 invitation	 from	 their	 GP	 asking	 them	 to	
participate	in	our	study.	If	patients	were	willing	to	participate	they	were	called	by	a	trained	interviewer	
to	verify	the	ever	presence	of	musculoskeletal	complaints	(either	joints,	tendons	or	lower	back).	The	
interviewer	also	verified	whether	they	had	a	diagnosis	of	psoriasis	and	sufficient	knowledge	of	the	
Dutch	 language	 to	 complete	 the	 questionnaires.	 For	 the	 purpose	 of	 screening	 we	 only	 included	
patients	who	were	at	risk	for	the	target	disorder	(PsA),	so	patients	with	an	established	diagnosis	of	
PsA	were	excluded.	All	patients	fulfilling	the	 inclusion	criteria	during	the	telephone	 interview	were	
invited	for	clinical	evaluation.	Ethics	approval	from	the	Dutch	Medical	Ethical	Committee	(M12-1275)	
was	obtained	as	well	as	written	informed	consent	from	all	participating	patients.	Detailed	information	
on	methodology	and	inclusion	is	written	in	our	recently	published	paper.15	
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for	 psoriasis).14	 The	 ICPC	 is	 widely	 used	 for	 coding	 signs	 and	 symptoms	 in	 primary	 care	 in	 the	
Netherlands.	 All	 identified	 psoriasis	 patients	 received	 an	 invitation	 from	 their	 GP	 asking	 them	 to	
participate	in	our	study.	If	patients	were	willing	to	participate	they	were	called	by	a	trained	interviewer	
to	verify	the	ever	presence	of	musculoskeletal	complaints	(either	joints,	tendons	or	lower	back).	The	
interviewer	also	verified	whether	they	had	a	diagnosis	of	psoriasis	and	sufficient	knowledge	of	the	
Dutch	 language	 to	 complete	 the	 questionnaires.	 For	 the	 purpose	 of	 screening	 we	 only	 included	
patients	who	were	at	risk	for	the	target	disorder	(PsA),	so	patients	with	an	established	diagnosis	of	
PsA	were	excluded.	All	patients	fulfilling	the	 inclusion	criteria	during	the	telephone	 interview	were	
invited	for	clinical	evaluation.	Ethics	approval	from	the	Dutch	Medical	Ethical	Committee	(M12-1275)	
was	obtained	as	well	as	written	informed	consent	from	all	participating	patients.	Detailed	information	
on	methodology	and	inclusion	is	written	in	our	recently	published	paper.15	
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Data	collection	
Screeningtools	
Patients	 were	 asked	 to	 complete	 a	 set	 of	 questionnaires	 just	 before	 clinical	 evaluation.	 Three	
screening	 questionnaires	 were	 completed;	 PEST	 (Psoriasis	 Epidemiology	 Screening	 Tool),	 PASE	
(Psoriatic	 Arthritis	 Screening	 &	 Evaluation)	 &	 EARP	 (Early	 Arthritis	 for	 Psoriatic	 Patients	
Questionnaire).7-9	 In	brief,	PEST	consists	of	five	yes/no	questions	and	was	developed	in	the	UK	in	a	
primary	care	setting.	It	is	considered	positive	if	three	or	more	questions	are	answered	positively.	In	
addition,	a	manikin	is	included	on	which	patients	can	tick	off	stiff,	swollen	or	painful	joints.8	It	has	been	
validated	 multiple	 times	 in	 secondary	 care	 and	 its	 sensitivity	 ranges	 from	 0.28	 to	 0.77	 while	 its	
specificity	ranges	from	0.37	to	0.98.10-13	
PASE	was	developed	in	the	USA	and	consists	of	15	questions	with	a	5-point	answer	scale	(from	
strongly	disagree	 to	strongly	agree).	The	cut-off	was	set	at	47	 in	 the	development,	but	 in	 the	 first	
validation	by	the	same	group	a	cut-off	value	of	44	provided	better	sensitivity	and	specificity.7,16	This	
questionnaire	 has	 been	 validated	 in	 different	 studies	 and	 for	 its	 developmental	 cut-off	 of	 47	 the	
sensitivity	ranges	from	0.24	to	0.75	and	the	specificity	from	0.39	to	0.94.3,10,13	Looking	at	the	cut-off	
of	44,	the	sensitivity	increases	towards	0.76-0.91,	whereas	the	specificity	remains	in	the	same	range	
with	0.41-0.67.9,13	
EARP	 is	one	of	 the	more	 recently	developed	screening	 tools	and	was	developed	 in	 Italy	 in	
2012.	It	consists	of	10	yes/no	questions	with	a	cut-off	value	of	3	or	higher	to	be	considered	positive.9	
This	questionnaire	has	not	been	validated	yet.	
The	PEST	and	PASE	questionnaire	were	available	in	Dutch	translation,	while	the	EARP	was	translated	
by	the	research	team	before	the	start	of	the	study.		
	
Clinical	Evaluation	
All	patients	who	reported	MSC	during	the	telephone	interview	were	clinically	evaluated	by	a	trained	
research	assistant,	blinded	for	the	outcomes	of	the	questionnaires.	A	detailed	history	was	completed,	
focusing	 on	 psoriasis,	 musculoskeletal	 complaints	 and	 other	 factors	 like	 family	 history	 and	
comorbidities.	Physical	examination	focused	on	the	skin,	nails,	joints	and	entheses.	Psoriasis	severity	
was	 assessed	 by	 the	 PASI	 score.	 The	 nails	 were	 visually	 inspected	 and	 in	 case	 of	 abnormalities	 a	
photograph	 was	 taken	 which	 later	 on	 was	 evaluated	 for	 the	 presence	 of	 nail	 psoriasis	 by	 a	
dermatologist.	The	joints	were	evaluated	for	tenderness	and	swelling	using	the	66/68	joint	count.	For	
the	 evaluation	 of	 the	 entheses,	 the	 LEI	 and	MASES	 scores	were	 used.	 These	 scores	 are	 based	 on	
tenderness	 upon	manual	 palpation.	 If	 clinical	 evaluation	 resulted	 in	 at	 least	 one	 tender	 enthesis,	
patients	were	referred	for	an	ultrasonographic	examination	by	an	independent	trained	examiner	using	
Esaote	Mylab60	 (probe	LA	435).	US	enthesitis	was	defined	as	 the	presence	of	power	Doppler	 (PD)	
signal	(<2mm	of	the	bony	cortex)	or	in	case	of	the	plantar	fascia	an	increased	thickness	of	the	enthesis	
(>4.4mm)	as	PD	signal	could	not	be	obtained	at	the	plantar	fascia	
	
Case	definition	
The	diagnosis	of	PsA	was	based	on	 the	CASPAR	criteria17,	where	patients	must	have	 inflammatory	
articular	disease		in	the	joints,	spine	or	entheses.	On	top	of	this,	at	least	3	out	of	the	following	6	points	
are	 required:	 the	 presence	 of	 psoriasis	 (current	 (2	 points)	 or	 history),	 presence	 of	 psoriatic	 nail	
dystrophy,	absence	of	rheumatoid	factor,	dactylitis	(diagnosed	by	rheumatologist)	and	radiographic	
evidence	of	juxtaarticular	new	bone	formation.	The	presence	of	peripheral	arthritis	and	axial	disease	
were	 confirmed	 by	 a	 rheumatologist.	 Since	 there	 is	 no	 commonly	 accepted	 clinical	 definition	 for	
enthesitis,	we	decided	 to	use	a	 combination	of	 clinical	 characteristics	 and	positive	Power	Doppler	
signal	at	the	enthesis	(<2mm	of	the	bony	cortex).	
	
Statistical	Analysis	
Descriptive	statistics	were	used	to	describe	the	patient	characteristics.	Sensitivity	and	specificity	were	
calculated	using	the	diagti	command	in	STATA	14.	
	
Results	
Study	participants	
For	this	analysis	we	had	473	psoriasis	patients	with	MSC	at	risk	for	PsA	available.	The	mean	age	of	the	
473	 evaluated	 patients	 was	 55.7	 years	 (SD	 13.9)	 and	 51.0%	were	male	 (Table	 1).	Mean	 psoriasis	
duration	was	20.7±16.2	years,	with	73.2%	of	the	psoriasis	diagnoses	confirmed	by	a	dermatologist.	
The	remaining	26.9%	of	psoriasis	cases	were	confirmed	by	the	GP.	At	clinical	evaluation	71	patients	
(15.0%)	had	nail	abnormalities	consistent	with	psoriatic	nail	dystrophy.	Median	PASI	score	in	the	study	
population	was	2.3	(IQR	1-4).		
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Performance	of	screeningtools	
53	out	of	473	patients	fulfilled	our	case	definition	of	inflammatory	joint	disease	for	which	we	evaluated	
the	three	screeningtools.	The	PEST	questionnaire	was	completed	by	all	473	patients.	The	sensitivity	
was	0.68	(95%	CI	0.54-0.80)	and	the	specificity	was	0.71	(95%	CI	0.67-0.76).	The	PASE	questionnaire	
was	completed	by	461	patients,	12	patients	did	not	complete	this	questionnaire.	For	the	original	cut-
off	value	of	47	the	sensitivity	was	0.59	(95%	CI	0.44-0.72)	and	the	specificity	0.66	(95%	CI	0.61-0.71).	
When	using	the	cut-off	value	of	44	the	sensitivity	increased	towards	0.66	(95%	CI	0.52-0.79)	whereas	
the	 specificity	 dropped	 to	 0.57	 (95%	 CI	 0.52-0.62).	 The	 EARP	 questionnaire	was	 complete	 by	 465	
patients,	8	patients	did	not	complete	this	questionnaire.	The	sensitivity	was	0.87	(95%	CI	0.75-0.95)	
and	the	specificity	0.34	(95%	CI	0.30-0.39)	(Table	2).		
	 	
Table 1 Characteristics of 473 psoriasis patients with musculoskeletal complaints screened for PsA
Psoriasis without 
PsA
(n=420)
Axial manifestations or 
Peripheral Arthritis*
(n=17)
Enthesitis**
(n=36)
Mean Age, years (±SD) 55.9 (14.0) 47.4 (10.7) 58 (12.3)
Male sex, n (%) 216 (51.4) 8 (47.1) 17 (47.2)
Body Mass Index, mean (±SD) 27.8 (4.8) 27.9 (6.2) 30.0 (4.1)
Median Psoriasis Symptom Duration, years (IQR) 15 (8-30) 15 (4-30) 20 (11-37)
Psoriasis Diagnosis by Dermatologist, n (%) 302 (71.9) 13 (76.5) 31 (86.1)
Nail psoriasis, n (%) 64 (15.2) 5 (29.4) 2 (5.6)
PASI, median (IQR) 2.2 (1-4) 3 (1.3-4) 3.1 (1.7-4.4)
Median MSC Symptom Duration, years (IQR)                          
Joints 8 (4-14) 12.5 (2-23) 10 (5-25)
Lower Back 12 (5-25) 18 (9-25) 33 (14-41)
LEI, median (IQR) 0 (0-0) 0 (0-1) 1 (1-2)
MASES, median (IQR) 0 (0-0) 0 (0-3) 2 (0-3)
PsA=Psoriatic Arthritis, PASI=Psoriasis Area&Severity Index, MSC=musculoskeletal complaints, LEI=Leeds 
Enthesitis Index, MASES= Maastricht Ankylosing Spondylitis Enthesitis Score
*Axial manifestations & arthritis are the patients who were diagnosed as having PsA by the rheumatologist. 
**Enthesitis, confirmed by ultrasound, are the patients who would have a diagnosis of PsA based on the 
CASPAR criteria
	
	
	
The	 sensitivity	 and	 specificity	 were	 calculated	 separately	 for	 enthesitis	 and	 axial	 or	 peripheral	
manifestations	of	PsA.	These	results	were	very	similar	and	can	be	found	in	supplemental	file	S1.	When	
only	selecting	patients	without	systemic	therapy	for	their	psoriasis	(5	methotrexate,	4	ciclosporin,	4	
etanercept	 &	 5	 adalumimab),	 the	 sensitivity	 increased	 slightly	 with	 approximately	 0.02	 while	 the	
specificity	remained	more	or	less	the	same	(see	supplemental	file	S1).		
With	 regard	 to	 false	 negatives,	 i.e.	 the	 patients	 with	 PsA	 who	 are	 missed	 when	 using	 these	
screeningtools,	60%	of	axial	manifestations	were	missed	by	the	PEST	(Table	3).	For	peripheral	arthritis	
only	16.7%	was	missed	by	the	PEST,	while	for	enthesitis	33.3%	of	the	cases	were	missed.	For	the	PASE	
one	third	of	the	peripheral	arthritis	was	missed,	independent	of	the	cut-off	value,	while	36.1%	and	
44.4%	 of	 enthesitis	 was	 missed	 when	 using	 the	 cut-off	 values	 of	 respectively	 44	 and	 47.	 Axial	
manifestations	were	missed	in	20%	when	using	the	cut-off	value	of	44	and	in	40%	then	using	the	cut-
off	value	of	47.	EARP	missed	16.7%	of	the	peripheral	arthritis,	11.1%	of	the	enthesitis	and	20%	of	axial	
manifestations.		
	
	
	
	
Influence	of	prevalence	
Improving	early	 recognition	of	PsA	 in	primary	and	secondary	care	 is	challenging.	Given	the	
different	performance	of	the	screeningtools,	the	question	what	would	be	best	to	do	in	clinical	practice	
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Performance	of	screeningtools	
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was	0.68	(95%	CI	0.54-0.80)	and	the	specificity	was	0.71	(95%	CI	0.67-0.76).	The	PASE	questionnaire	
was	completed	by	461	patients,	12	patients	did	not	complete	this	questionnaire.	For	the	original	cut-
off	value	of	47	the	sensitivity	was	0.59	(95%	CI	0.44-0.72)	and	the	specificity	0.66	(95%	CI	0.61-0.71).	
When	using	the	cut-off	value	of	44	the	sensitivity	increased	towards	0.66	(95%	CI	0.52-0.79)	whereas	
the	 specificity	 dropped	 to	 0.57	 (95%	 CI	 0.52-0.62).	 The	 EARP	 questionnaire	was	 complete	 by	 465	
patients,	8	patients	did	not	complete	this	questionnaire.	The	sensitivity	was	0.87	(95%	CI	0.75-0.95)	
and	the	specificity	0.34	(95%	CI	0.30-0.39)	(Table	2).		
	 	
	
	
	
The	 sensitivity	 and	 specificity	 were	 calculated	 separately	 for	 enthesitis	 and	 axial	 or	 peripheral	
manifestations	of	PsA.	These	results	were	very	similar	and	can	be	found	in	supplemental	file	S1.	When	
only	selecting	patients	without	systemic	therapy	for	their	psoriasis	(5	methotrexate,	4	ciclosporin,	4	
etanercept	 &	 5	 adalumimab),	 the	 sensitivity	 increased	 slightly	 with	 approximately	 0.02	 while	 the	
specificity	remained	more	or	less	the	same	(see	supplemental	file	S1).		
With	 regard	 to	 false	 negatives,	 i.e.	 the	 patients	 with	 PsA	 who	 are	 missed	 when	 using	 these	
screeningtools,	60%	of	axial	manifestations	were	missed	by	the	PEST	(Table	3).	For	peripheral	arthritis	
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different	performance	of	the	screeningtools,	the	question	what	would	be	best	to	do	in	clinical	practice	
Table 2 Sensitivity and specificity of PEST, PASE & EARP
AUC Cut-off True 
Positive
False 
positive
True 
negative
False 
negative
Sensitivity Specificity
PEST 0.71 ≥ 3 36 120 300 17 0.68
0.54-0.80
0.71
0.67-0.76
PASE 0.64 ≥47 31 139 269 22 0.59
0.44-0.72
0.66
0.61-0.71
≥44 35 176 232 18 0.66
0.52-0.79
0.57
0.52-0.62
EARP 0.68 ≥ 3 46 273 139 7 0.87
0.75-0.95
0.34
0.30-0.39
Table 3 Number of Missed Cases per Questionnaire per Manifestation of PsA
PEST
n (%)
PASE44
n (%)
PASE47
n (%)
EARP
n (%)
Peripheral Arthritis (n=12) 2 (16.7) 4 (33.3) 4 (33.3) 2 (16.7)
Enthesitis (n=36) 12 (33.3) 13 (36.1) 16 (44.4) 4 (11.1)
Axial Manifestations (n=5) 3 (60) 1 (20) 2 (40) 1 (20)
Chapter 7
132
is	often	asked.	To	answer	this	question	one	has	to	consider	the	performance	of	the	tools	but	also	the	
harm	 and	 benefit	 of	 the	 decision	 after	 screening	 and	 the	 prior	 probability	 of	 having	 the	 disease.	
Interpreting	 these	 factors	 together	 creates	 relevant	 information	 to	 make	 an	 informed	 decision	
whether	or	not	to	implement	a	certain	screeningtool	in	primary	care	or	dermatological	care.	The	ideal	
scenario	for	the	performance	would	be	to	have	perfect	sensitivity	and	specificity	so	both	patients	and	
non-patients	receive	optimal	care.	Unfortunately,	perfect	tests	are	often	not	available	in	practice,	so	
one	has	to	trade	off	sensitivity	against	specificity	or	vice	versa.	The	choice	 in	this	trade-off	directly	
relates	to	the	subsequent	clinical	decision,	in	our	case	referral	to	the	rheumatologist.	One	could	argue	
that	the	EARP	would	be	the	best	screeningtool	to	use,	because	of	its	high	sensitivity	(0.87),	where	only	
a	few	patients	would	be	missed.	However,	when	choosing	for	the	EARP,	this	would	also	result	in	about	
70%	false	positive	patients	because	of	the	low	specificity.	This	becomes	especially	relevant	if	the	prior	
probability,	here	 the	prevalence	of	psoriasis	and	 the	prevalence	of	psoriatic	arthritis,	 is	 low.	 If	 the	
prevalence		of	PsA	is	low,	say	3	per	100	patients	as	found	in	our	primary	care	sample15,	70%	of	the	97	
non-PsA	patients	will	be	identified	as	potential	PsA	and	referred	to	the	rheumatologist.	This	means	
that	the	rheumatologist	will	have	to	see	26	psoriasis	patients	in	order	to	find	one	patient	with	PsA,	
maybe	not	the	best	way	to	use	scarce	outpatient	clinic	time.	We	believe	the	PEST	fits	the	trade-off	
between	sensitivity	and	specificity	best,	although	this	still	means	that	a	rheumatologist	has	to	see	15	
patients	 to	 find	 one	 true	 PsA	 as	 the	 prevalence	 we	 found	 was	 3.2%	 (increasing	 towards	 7.0%,	
depending	on	how	we	dealt	with	the	non-responders).15	If	the	prevalence	of	PsA	is	moderate,	say	30	
per	100	patients	in	dermatological	care,	the	same	test	will	lead	to	20	detected	PsA	cases	and	20	false	
positive	cases.	In	this	case	one	in	every	two	referred	patients	actually	has	PsA.	A	graph	of	the	influence	
of	various	prevalences	on	the	posterior	probability	of	having	PsA,	when	using	different	tests	can	be	
found	in	supplemental	file	S2.		
	
Discussion	
In	 this	 large	primary	 care	based	 study	among	psoriasis	patients	we	validated	 three	of	 the	existing	
screening	questionnaires	for	PsA.	The	PEST	had	the	best	performance	with	a	sensitivity	of	0.68	(i.e.	
68%	of	the	PsA	cases	were	identified)	and	a	specificity	of	0.71	(i.e.	29%	was	falsely	identified	as	PsA).	
The	PASE	performed	slightly	worse	with	a	sensitivity	of	0.59	for	the	cut-off	of	47	and	0.66	for	the	cut-
off	of	44.	The	specificity	for	the	PASE	cut-off	of	47	was	0.66	and	0.57	for	the	cut-off	of	44.	The	EARP	
has	not	been	validated	before	and	while	the	sensitivity	we	found	(0.87)	is	comparable	to	the	sensitivity	
in	 the	 development	 study	 (0.85),	 the	 specificity	 was	 considerably	 lower	 with	 0.34	 (vs	 0.92	 in	
development	study).9		
As	we	did	one	of	the	first	validations	in	primary	care,	it	is	interesting	to	put	this	in	perspective	
with	 studies	 that	 have	 validated	 the	 tools	 in	 secondary	 care.	 Three	 out	 of	 four	 studies	 showed	
sensitivity	 of	 0.63-0.9110,12,13,	 while	 one	 study	 among	 psoriasis	 patients	 with	 and	 without	
musculoskeletal	pain	resulted	in	sensitivity	of	0.24-0.2811.	Specificity	varied	from	0.37-0.80	in	the	same	
three	studies	while	0.94-0.98	was	found	in	the	other	study.	Why	these	strong	differences	occurred	is	
unclear,	but	it	may	have	to	do	with	patient	selection	and/or	case	definition.	Recently,	the	CONTEST	
group	 developed	 a	 new	 screeningtool	 based	 on	 the	 best	 performing	 items	 of	 several	 individual	
screeningtools	for	PsA	using	data	from	secondary	care.18	Recently	it	was	validated	and	compared	with	
the	PEST	in	a	primary	care	setting.	Compared	to	our	study,	they	found	slightly	lower	sensitivity	and	
specificity	for	the	PEST	in	their	cohort.		
With	a	prevalence	of	PsA	in	the	range	of	3-7%	implementing	a	screeningtool	for	all	psoriasis	
patients	 seems	 a	 big	 effort	 to	 identify	 approximately	 one	PsA	patient	 per	GP	 at	 a	 given	moment.	
Another	option	could	be	to	screen	patients	only	if	they	suffer	from	musculoskeletal	complaints.	The	
prevalence	of	PsA	increased	in	our	study	than	towards	9.8%,	which	would	lead	to	approximately	three	
PsA	patients	per	practice.	Adding	the	PEST	in	this	situation,	would	increase	the	probability	of	having	
PsA	after	a	positive	PEST	screening	tool	towards	20%	(see	supplemental	file	S2).		
Besides	implementing	a	screening	tool,	raising	awareness	among	both	patients	with	psoriasis	
and	GPs	could	also	aid	early	recognition.	On	the	one	hand,	one	could	think	about	making	patients	
themselves	more	aware	of	their	risk	at	developing	PsA,	this	could	be	achieved	by	setting	up	campaigns	
involving	for	example	psoriasis	patients	organisations.	One	could	also	think	about	educating	GPs	by	
local	rheumatologists,	this	seems	to	be	an	effective	way	to	enhance	adequate	referral	from	primary	
to	secondary	care	for	early	referral	of	any	inflammatory	arthritis	including	PsA.19	
Certain	strengths	and	limitations	should	be	taken	into	account	when	interpreting	the	results	
of	this	study.	One	of	the	strengths	of	our	study	is	that	it	is	one	of	the	first	validations	of	the	screening	
tools	 in	 primary	 care.	Most	 developments	 (except	 PEST)	 and	 validations	 have	 been	 performed	 in	
secondary	care.	Secondly,	our	study	is	the	first	validation	of	the	EARP	questionnaire	and	we	have	a	
fairly	large	and	complete	database	of	psoriasis	patients	at	risk	for	PsA.	With	regard	to	limitations,	we	
only	 included	 patients	 with	 musculoskeletal	 complaints	 in	 this	 study.	 This	 implicates	 that	 the	
specificity	figures	we	found	are	probably	an	underestimation	if	interpreted	for	a	cross	section	of	the	
psoriasis	patient	spectrum.		
In	conclusion,	in	our	primary	care	based	study	the	PEST	questionnaire	has	the	most	favourable	
trade-off	between	sensitivity	and	specificity	to	screen	for	PsA.	However,	as	the	prevalence	of	both	
psoriasis	 and	 PsA	 is	 fairly	 low	 in	 our	 primary	 care	 setting,	 screening	 only	 patients	 suffering	 from	
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is	often	asked.	To	answer	this	question	one	has	to	consider	the	performance	of	the	tools	but	also	the	
harm	 and	 benefit	 of	 the	 decision	 after	 screening	 and	 the	 prior	 probability	 of	 having	 the	 disease.	
Interpreting	 these	 factors	 together	 creates	 relevant	 information	 to	 make	 an	 informed	 decision	
whether	or	not	to	implement	a	certain	screeningtool	in	primary	care	or	dermatological	care.	The	ideal	
scenario	for	the	performance	would	be	to	have	perfect	sensitivity	and	specificity	so	both	patients	and	
non-patients	receive	optimal	care.	Unfortunately,	perfect	tests	are	often	not	available	in	practice,	so	
one	has	to	trade	off	sensitivity	against	specificity	or	vice	versa.	The	choice	 in	this	trade-off	directly	
relates	to	the	subsequent	clinical	decision,	in	our	case	referral	to	the	rheumatologist.	One	could	argue	
that	the	EARP	would	be	the	best	screeningtool	to	use,	because	of	its	high	sensitivity	(0.87),	where	only	
a	few	patients	would	be	missed.	However,	when	choosing	for	the	EARP,	this	would	also	result	in	about	
70%	false	positive	patients	because	of	the	low	specificity.	This	becomes	especially	relevant	if	the	prior	
probability,	here	 the	prevalence	of	psoriasis	and	 the	prevalence	of	psoriatic	arthritis,	 is	 low.	 If	 the	
prevalence		of	PsA	is	low,	say	3	per	100	patients	as	found	in	our	primary	care	sample15,	70%	of	the	97	
non-PsA	patients	will	be	identified	as	potential	PsA	and	referred	to	the	rheumatologist.	This	means	
that	the	rheumatologist	will	have	to	see	26	psoriasis	patients	in	order	to	find	one	patient	with	PsA,	
maybe	not	the	best	way	to	use	scarce	outpatient	clinic	time.	We	believe	the	PEST	fits	the	trade-off	
between	sensitivity	and	specificity	best,	although	this	still	means	that	a	rheumatologist	has	to	see	15	
patients	 to	 find	 one	 true	 PsA	 as	 the	 prevalence	 we	 found	 was	 3.2%	 (increasing	 towards	 7.0%,	
depending	on	how	we	dealt	with	the	non-responders).15	If	the	prevalence	of	PsA	is	moderate,	say	30	
per	100	patients	in	dermatological	care,	the	same	test	will	lead	to	20	detected	PsA	cases	and	20	false	
positive	cases.	In	this	case	one	in	every	two	referred	patients	actually	has	PsA.	A	graph	of	the	influence	
of	various	prevalences	on	the	posterior	probability	of	having	PsA,	when	using	different	tests	can	be	
found	in	supplemental	file	S2.		
	
Discussion	
In	 this	 large	primary	 care	based	 study	among	psoriasis	patients	we	validated	 three	of	 the	existing	
screening	questionnaires	for	PsA.	The	PEST	had	the	best	performance	with	a	sensitivity	of	0.68	(i.e.	
68%	of	the	PsA	cases	were	identified)	and	a	specificity	of	0.71	(i.e.	29%	was	falsely	identified	as	PsA).	
The	PASE	performed	slightly	worse	with	a	sensitivity	of	0.59	for	the	cut-off	of	47	and	0.66	for	the	cut-
off	of	44.	The	specificity	for	the	PASE	cut-off	of	47	was	0.66	and	0.57	for	the	cut-off	of	44.	The	EARP	
has	not	been	validated	before	and	while	the	sensitivity	we	found	(0.87)	is	comparable	to	the	sensitivity	
in	 the	 development	 study	 (0.85),	 the	 specificity	 was	 considerably	 lower	 with	 0.34	 (vs	 0.92	 in	
development	study).9		
As	we	did	one	of	the	first	validations	in	primary	care,	it	is	interesting	to	put	this	in	perspective	
with	 studies	 that	 have	 validated	 the	 tools	 in	 secondary	 care.	 Three	 out	 of	 four	 studies	 showed	
sensitivity	 of	 0.63-0.9110,12,13,	 while	 one	 study	 among	 psoriasis	 patients	 with	 and	 without	
musculoskeletal	pain	resulted	in	sensitivity	of	0.24-0.2811.	Specificity	varied	from	0.37-0.80	in	the	same	
three	studies	while	0.94-0.98	was	found	in	the	other	study.	Why	these	strong	differences	occurred	is	
unclear,	but	it	may	have	to	do	with	patient	selection	and/or	case	definition.	Recently,	the	CONTEST	
group	 developed	 a	 new	 screeningtool	 based	 on	 the	 best	 performing	 items	 of	 several	 individual	
screeningtools	for	PsA	using	data	from	secondary	care.18	Recently	it	was	validated	and	compared	with	
the	PEST	in	a	primary	care	setting.	Compared	to	our	study,	they	found	slightly	lower	sensitivity	and	
specificity	for	the	PEST	in	their	cohort.		
With	a	prevalence	of	PsA	in	the	range	of	3-7%	implementing	a	screeningtool	for	all	psoriasis	
patients	 seems	 a	 big	 effort	 to	 identify	 approximately	 one	PsA	patient	 per	GP	 at	 a	 given	moment.	
Another	option	could	be	to	screen	patients	only	if	they	suffer	from	musculoskeletal	complaints.	The	
prevalence	of	PsA	increased	in	our	study	than	towards	9.8%,	which	would	lead	to	approximately	three	
PsA	patients	per	practice.	Adding	the	PEST	in	this	situation,	would	increase	the	probability	of	having	
PsA	after	a	positive	PEST	screening	tool	towards	20%	(see	supplemental	file	S2).		
Besides	implementing	a	screening	tool,	raising	awareness	among	both	patients	with	psoriasis	
and	GPs	could	also	aid	early	recognition.	On	the	one	hand,	one	could	think	about	making	patients	
themselves	more	aware	of	their	risk	at	developing	PsA,	this	could	be	achieved	by	setting	up	campaigns	
involving	for	example	psoriasis	patients	organisations.	One	could	also	think	about	educating	GPs	by	
local	rheumatologists,	this	seems	to	be	an	effective	way	to	enhance	adequate	referral	from	primary	
to	secondary	care	for	early	referral	of	any	inflammatory	arthritis	including	PsA.19	
Certain	strengths	and	limitations	should	be	taken	into	account	when	interpreting	the	results	
of	this	study.	One	of	the	strengths	of	our	study	is	that	it	is	one	of	the	first	validations	of	the	screening	
tools	 in	 primary	 care.	Most	 developments	 (except	 PEST)	 and	 validations	 have	 been	 performed	 in	
secondary	care.	Secondly,	our	study	is	the	first	validation	of	the	EARP	questionnaire	and	we	have	a	
fairly	large	and	complete	database	of	psoriasis	patients	at	risk	for	PsA.	With	regard	to	limitations,	we	
only	 included	 patients	 with	 musculoskeletal	 complaints	 in	 this	 study.	 This	 implicates	 that	 the	
specificity	figures	we	found	are	probably	an	underestimation	if	interpreted	for	a	cross	section	of	the	
psoriasis	patient	spectrum.		
In	conclusion,	in	our	primary	care	based	study	the	PEST	questionnaire	has	the	most	favourable	
trade-off	between	sensitivity	and	specificity	to	screen	for	PsA.	However,	as	the	prevalence	of	both	
psoriasis	 and	 PsA	 is	 fairly	 low	 in	 our	 primary	 care	 setting,	 screening	 only	 patients	 suffering	 from	
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musculoskeletal	complaints	instead	of	all	patients	with	psoriasis	is	likely	to	be	a	better	allocation	of	
resources.	
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Supplemental	File	S1	Sensitivity	and	specificity	of	PEST,	PASE	&	EARP	according	to	type	of	
psoriatic	arthritis	(Axial,	Peripheral	Arthritis	or	Enthesitis)	
	
Table	S1.1	Performance	of	Screeningtools	in	non-DMARD-users	
	 Cut	
off	
True	
Positive	
False	
positive	
True	
negative	
False	
negative	
Sensitivity	 Specificity	
PEST	 ≥	3	 35	 116	 288	 15	 0.70	
0.554-0.821	
0.713	
0.666-0.757	
PASE	 ≥47	 30	 135	 255	 20	 0.600	
0.452-0.736	
0.654	
0.604-0.701	
	 ≥44	 34	 168	 222	 16	 0.680	
0.533-0.805	
0.569	
0.518-0.619	
EARP	 	3	 44	 258	 134	 5	 0.898	
0.778-0.966	
0.342	
0.295-0.391	
	
	
	
Table	S1.2	Performance	of	Screeningtools	in	patients	with	articular	or	axial	disease	
	 Cut	
off	
True	
Positive	
False	
positive	
True	
negative	
False	
negative	
Sensitivity	 Specificity	
PEST	 ≥	3	 12	 144	 312	 5	 0.71	
0.44-0.90	
0.68	
0.64-0.73	
PASE	 ≥47	 11	 159	 285	 6	 0.65	
0.38-0.86	
0.64	
0.60-0.69	
	 ≥44	 12	 199	 245	 12	 0.71	
0.44-0.90	
0.55	
0.50-0.60	
EARP	 	3	 14	 305	 143	 3	 0.82	
0.57-0.96	
0.32	
0.28-0.37	
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positive
True 
negative
False 
negative
Sensitivity Specificity
P T ≥ 3 35 116 288 15 0.70
0.554-0.821
0.713
0.666-0.757
PASE ≥47 30 135 255 20 0.600
0.452-0.736
0.654
0.604-0.701
≥44 34 168 222 16 0.680
0.533-0.805
0.569
0.518-0.619
EARP  3 44 258 134 5 0.898
0.778-0.966
0.342
0.295-0.391
Table S2.2 Performance of Screeningtools in patients with articular or axial disease
Cut off True Positive False 
positive
True negative False 
negative
Sensitivity Specificity
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0.44-0.90
0.68
0.64-0.73
PASE ≥47 11 159 285 6 0.65
0.38-0.86
0.64
0.60-0.69
≥44 12 199 245 12 0.71
0.44-0.90
0.55
0.50-0.60
EARP  3 14 305 143 3 0.82
0.57-0.96
0.32
0.28-0.37
Table S2. Performance of Screeningtools in patients with Entheseal Disease
Cut off True Positive False 
positive
True negative False 
negative
Sensitivity Specificity
PEST ≥ 3 24 132 305 12 0.67
0.49-0.81
0.70
0.65-0.74
PASE ≥47 20 150 275 16 0.56
0.38-0.72
0.65
0.60-0.69
≥44 35 174 231 18 0.64
0.46-0.79
0.56
0.51-0.61
EARP  3 32 287 142 4 0.89
0.74-0.97
0.33
0.29-0.38
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	 Cut	
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True	
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False	
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True	
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False	
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Table S3  Parameter estimates used in the sensitivity analysis for the non-responders (n=891)
Scenario 1 Scenario 2 Scenario 3
First 
step:
MSC prevalence among 
responders (n=1673; 49.2%)
MSC prevalence among those 
returning the reply slip but did 
not want to participate (n=704; 
23.3%)
MSC prevalence among those 
returning the reply slip but did 
not want to participate (n=704; 
23.3%)
Second 
step:
PsA prevalence among MSC 
(n=823; 9.8%)
PsA prevalence among MSC ( 
n=823; 9.8%)
PsA among those with MSC 
and clinically evaluated 
(n=524;13.0%)
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Supplemental	File	S2		Which	tool	to	use,	influence	of	prevalence	
	
Figure	1	illustrates	the	influence	of	the	PsA	prevalence	of	the	population	screened	on	the	added	
value	of	screening	for	PsA	with	the	PEST	questionnaire.		
	
Fig	1.	Influence	of	Prevalence	on	the	additional	value	of	the	PEST	
	
On	the	X-axis	the	prevalence	of	PsA	is	varied	between	0.5	per	100	and	95	per	100	psoriasis	patients.	
On	the	Y-axis	the	post-test-probability	(i.e.	positive	predictive	value),	calculated	as	odds,	is	
presented	combining	the	prevalence	with	the	sensitivity	and	specificity	(i.e.	the	positive	Likelihood	
ratio)	of	a	screeningtool.	This	is	in	other	words	the	prevalence	of	PsA	after	you	have	a	PEST	
questionnaire	with	a	score	of	3	or	higher	(positive	PEST).	The	blue	line	indicates	the	situation	in	
which	we	would	not	use	any	screeningtool.	The	orange	line	indicates	the	situation	with	the	
performance	of	the	PEST	questionnaire	as	found	in	this	study.	The	difference	between	the	blue	line	
and	the	orange	line	shows	the	information	gain	you	have	by	using	the	PEST	questionnaire.	As	is	
shown,	the	information	gain	is	lower	in	the	low	and	high	prevalent	disease	than	in	the	prevalence	
range	in	between.	This	suggests	that	adding	a	screeningtool	in	these	middle	part	of	the	prevalence	
distribution	does	not	help	very	much,	unless	there	are	serious	consequences	from	missing	a	case	
(i.e.	death).	The	grey	line	indicates	the	situation	of	an	almost	‘perfect	test’	with	a	sensitivity	and	
specificity	of	0.9.	Compared	to	the	difference	between	blue	and	orange	line,	the	information	gain	is	
substantially	higher,	as	one	would	expect.		
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Abstract	
	
Background.	Early	treatment	of	PsA	can	prevent	joint	damage,	but	requires	early	recognition.	To	aid	
this,	 several	 screening	 tools	 have	 been	 developed	with	 suboptimal	 performance.	 Recently,	 a	 new	
screening	 tool	was	developed	based	on	 the	best	performing	 items	of	previous	screeningtools.	The	
objective	of	this	study	was	to	assess	the	additional	value	of	this	CONTEST	questionnaire	in	psoriasis	
patient	in	a	primary	care	setting	compared	to	existing	tools.	
	
Methods.	 Data	 from	 the	 SENSOR	 study	 was	 used,	 a	 cross-sectional	 study	 in	 adult	 primary	 care	
psoriasis	 patients.	 Sensitivity,	 specificity	 and	 area	 under	 the	 curve	 (AUC)	 were	 calculated	 for	 the	
CONTEST	with	a	cutoff	of	4,	as	well	as	the	CONTEST-w	(weighted	version,	cutoff	of	8)	and	the	CONTEST-
jt	(including	the	PEST	manikin,	cutoff	of	5).	Its	performance	was	compared	to	the	PEST,	PASE	and	EARP.	
	
Results.	For	this	analysis	473	psoriasis	patients	at	risk	for	PsA	were	available.	The	AUC	of	the	CONTEST	
questionnaires	 ranged	 between	 0.67-0.69	 and	 sensitivities	 between	 0.30-0.51	 in	 our	 primary	 care	
population,	 whereas	 the	 specificities	 were	 between	 0.74-0.86.	 On	 sensitivity	 the	 PEST	 (0.68),	
PASE(0.66)	 and	 EARP(0.87)	 performed	 better	 than	 the	 CONTEST	 questionnaires,	 whereas	 the	
specificities	of	the	CONTEST	were	slightly	higher		than	those	of	the	PEST	(0.71),	PASE	(0.57)	and	EARP	
(0.34).		
	
Conclusion.The	performance	of	the	CONTEST	questionnaires	in	PsA	screening	did	not	seem	to	exceed	
the	performance	of	 the	PEST,	PASE	or	EARP	 in	a	primary	 care	 setting	unless	you	are	 interested	 in	
patients	not	having	the	disease		
	
	
	 	
Background	
Psoriatic	Arthritis	(PsA)	 is	a	chronic	inflammatory	rheumatic	disease,	usually	preceded	by	psoriasis.	
Adequate	treatment	is	available	for	PsA	and	since	increasing	evidence	suggests	patients	benefit	from	
timely	 treatment,	 it	 is	 important	 to	 recognize	 these	patients	early.1,2	Over	 the	 last	couple	of	years	
several	screeningtools	were	developed	in	order	to	enhance	this	early	recognition	of	patients	with	PsA.	
Most	 of	 these	 screeningtools	 have	 been	 validated	 in	 several	 settings.3-6	 Unfortunately,	 the	
discriminative	properties	of	these	tools	are	slightly	disappointing.		
One	of	the	validation	studies	was	the	CONTEST	study,	which	was	set	up	in	order	to	perform	a	head-
to-head	comparison	of	three	popular	screening	questionnaires	(PEST,	PASE	&	TOPAS)	in	a	secondary	
care	 setting.3	 They	 found	 lower	 sensitivities	 and	 specificities	 than	 previously	 reported	 and	 AUCs	
around	0.6.	However,	the	prevalence	of	PsA	increased	according	to	the	number	of	positively	answered	
questionnaires.	This	 led	 them	to	develop	a	new	screening	questionnaire	 (CONTEST	questionnaire),	
based	 on	 the	 best	 performing	 items	 of	 the	 individual	 questionnaires.7	 	 Since	 this	 is	 yet	 another	
screening	tool,	the	question	raises	which	tool	could	best	be	used	to	screen	psoriasis	patients	for	the	
presence	of	PsA.	Various	 validations	have	been	performed,	but	mostly	 in	 secondary	 care	 settings.	
However,	primary	care	could	also	play	an	important	role	in	screening.	The	objective	of	this	study	was	
therefore	 to	 compare	 the	 performance	of	 the	 newly	 developed	CONTEST	questionnaires	with	 the	
existing	ones	in	a	primary	care	setting.		
	
Methods	
Patients	
Between	 June	 2013	 and	March	 2014	 a	 cross-sectional	 study	 in	 primary	 care	 was	 performed,	 the	
SENSOR	 study.	Ninety-seven	GPs	 from	 the	greater	Rotterdam	area	participated	and	 selected	 their	
adult	 psoriasis	 patients	 using	 ICPC	 code	 S91	 (International	 Classification	 of	 Primary	 Care	 code	 for	
psoriasis).8	 All	 identified	 psoriasis	 patients	 received	 an	 invitation	 from	 their	 GP	 asking	 them	 to	
participate	in	the	study.	If	patients	were	willing	to	participate	they	were	contacted	by	telephone	by	a	
trained	 interviewer	 to	verify	 the	presence	of	musculoskeletal	 complaints	 (either	 joints,	 tendons	or	
lower	back).	The	interviewer	also	verified	whether	they	were	diagnosed	with	psoriasis	and	sufficient	
knowledge	of	 the	Dutch	 language	 to	complete	 the	questionnaires.	Ethics	approval	 from	the	Dutch	
Medical	Ethical	Committee	 (M12-1275)	was	obtained	as	well	as	written	 informed	consent	 from	all	
participating	 patients.	 Extensive	 information	 about	 the	 patient	 selection	 in	 the	 SENSOR	 study	 is	
available	in	our	previously	published	paper.9	
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Abstract	
	
Background.	Early	treatment	of	PsA	can	prevent	joint	damage,	but	requires	early	recognition.	To	aid	
this,	 several	 screening	 tools	 have	 been	 developed	with	 suboptimal	 performance.	 Recently,	 a	 new	
screening	 tool	was	developed	based	on	 the	best	performing	 items	of	previous	screeningtools.	The	
objective	of	this	study	was	to	assess	the	additional	value	of	this	CONTEST	questionnaire	in	psoriasis	
patient	in	a	primary	care	setting	compared	to	existing	tools.	
	
Methods.	 Data	 from	 the	 SENSOR	 study	 was	 used,	 a	 cross-sectional	 study	 in	 adult	 primary	 care	
psoriasis	 patients.	 Sensitivity,	 specificity	 and	 area	 under	 the	 curve	 (AUC)	 were	 calculated	 for	 the	
CONTEST	with	a	cutoff	of	4,	as	well	as	the	CONTEST-w	(weighted	version,	cutoff	of	8)	and	the	CONTEST-
jt	(including	the	PEST	manikin,	cutoff	of	5).	Its	performance	was	compared	to	the	PEST,	PASE	and	EARP.	
	
Results.	For	this	analysis	473	psoriasis	patients	at	risk	for	PsA	were	available.	The	AUC	of	the	CONTEST	
questionnaires	 ranged	 between	 0.67-0.69	 and	 sensitivities	 between	 0.30-0.51	 in	 our	 primary	 care	
population,	 whereas	 the	 specificities	 were	 between	 0.74-0.86.	 On	 sensitivity	 the	 PEST	 (0.68),	
PASE(0.66)	 and	 EARP(0.87)	 performed	 better	 than	 the	 CONTEST	 questionnaires,	 whereas	 the	
specificities	of	the	CONTEST	were	slightly	higher		than	those	of	the	PEST	(0.71),	PASE	(0.57)	and	EARP	
(0.34).		
	
Conclusion.The	performance	of	the	CONTEST	questionnaires	in	PsA	screening	did	not	seem	to	exceed	
the	performance	of	 the	PEST,	PASE	or	EARP	 in	a	primary	 care	 setting	unless	you	are	 interested	 in	
patients	not	having	the	disease		
	
	
	 	
Background	
Psoriatic	Arthritis	(PsA)	 is	a	chronic	inflammatory	rheumatic	disease,	usually	preceded	by	psoriasis.	
Adequate	treatment	is	available	for	PsA	and	since	increasing	evidence	suggests	patients	benefit	from	
timely	 treatment,	 it	 is	 important	 to	 recognize	 these	patients	early.1,2	Over	 the	 last	couple	of	years	
several	screeningtools	were	developed	in	order	to	enhance	this	early	recognition	of	patients	with	PsA.	
Most	 of	 these	 screeningtools	 have	 been	 validated	 in	 several	 settings.3-6	 Unfortunately,	 the	
discriminative	properties	of	these	tools	are	slightly	disappointing.		
One	of	the	validation	studies	was	the	CONTEST	study,	which	was	set	up	in	order	to	perform	a	head-
to-head	comparison	of	three	popular	screening	questionnaires	(PEST,	PASE	&	TOPAS)	in	a	secondary	
care	 setting.3	 They	 found	 lower	 sensitivities	 and	 specificities	 than	 previously	 reported	 and	 AUCs	
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therefore	 to	 compare	 the	 performance	of	 the	 newly	 developed	CONTEST	questionnaires	with	 the	
existing	ones	in	a	primary	care	setting.		
	
Methods	
Patients	
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participate	in	the	study.	If	patients	were	willing	to	participate	they	were	contacted	by	telephone	by	a	
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Medical	Ethical	Committee	 (M12-1275)	was	obtained	as	well	as	written	 informed	consent	 from	all	
participating	 patients.	 Extensive	 information	 about	 the	 patient	 selection	 in	 the	 SENSOR	 study	 is	
available	in	our	previously	published	paper.9	
	
Clinical	Evaluation	
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All	patients	with	any	type	of	musculoskeletal	complaints	(MSC)	were	invited	for	clinical	evaluation	by	
a	 trained	 research	nurse.	Beforehand,	all	patients	 completed	a	 set	of	questionnaires	 including	 the	
screening	questionnaires	PEST,	PASE	&	EARP.	During	clinical	evaluation	a	detailed	history	was	taken	
as	well	 as	 a	physical	 examination	of	 skin,	 nails,	 joints,	 entheses	 and	 spine.	 The	nails	were	 visually	
inspected	and	in	cases	of	abnormalities	a	photograph	was	taken	for	further	evaluation	of	nail	psoriasis	
by	a	trained	dermatologist.	Entheses	were	assessed	with	the	LEI	and	MASES	scores,	which	are	based	
on	tenderness	upon	manual	palpation.	If	one	or	more	entheses	were	tender	during	clinical	evaluation,	
the	patient	was	referred	for	ultrasonographic	evaluation	by	an	independent	trained	examiner	using	
Esaote	Mylab60	(probe	LA	435).		
	
Case	Definition	
The	diagnosis	of	PsA	was	made	based	on	the	CASPAR	criteria.10	To	fulfill	these	criteria	a	patient	must	
have	inflammatory	articular	disease	in	the	joints,	spine	or	entheses.	In	addition,	at	least	3	out	of	the	
following	6	points	are	required:	the	presence	of	psoriasis	(current	(2	points)	or	history),	presence	of	
psoriatic	nail	dystrophy,	absence	of	 rheumatoid	 factor,	dactylitis	 (diagnosed	by	 rheumatologist)	or	
radiographic	evidence	of	juxtaarticular	new	bone	formation.	The	presence	of	peripheral	arthritis	and	
axial	disease	were	confirmed	by	a	rheumatologist.	Since	no	commonly	accepted	clinical	definition	for	
enthesitis	is	available,	we	decided	to	use	a	combination	of	clinical	characteristics	and	positive	Power	
Doppler	signal	(<2mm	of	the	bony	cortex)	at	the	same	enthesis	to	diagnose	enthesitis.11		
	
CONTEST	questionnaires	
In	 the	 initial	 study,	 a	 new	 questionnaire	 was	 developed	 via	 three	 different	methods,	 namely	 the	
CONTEST	(addition	of	questions),	the	CONTEST-w	(weighted	version	using	logistic	regression)	and	the	
CONTEST-jt	 (adding	a	manikin).7	 The	questionnaires	 consisted	of	 the	best	performing	 items	of	 the	
individual	screeningtools	PEST,	PASE	and	ToPAS.	 	The	CONTEST	consists	of	eight	questions	and	the	
total	 score	 is	 the	 sum	of	 all	 individual	positively	 answered	questions	 (range	0-8),	 the	 cut	off	 for	 a	
positive	questionnaire	was	 set	at	 four	 in	 the	development	 cohort.	 The	CONTEST-w	consists	of	 the	
same	 eight	 items,	 but	 item	 PEST4	 (‘have	 you	 had	 pain	 in	 your	 heel?’)	 weighted	 as	 two	 and	 item	
TOPAS2A	(in	our	dataset	PEST3;	‘do	your	fingernails	or	toenails	have	holes	or	pits?’)	as	five.	The	total	
score	of	this	weighted	version	sums	up	to	13	and	the	cutoff	was	set	at	eight.	The	third	variation	was	
the	CONTEST-jt,	this	version	includes	the	PEST	manikin.	If	a	patients	has	ticked	of	6	or	more	locations	
on	the	PEST	manikin,	one	point	is	added	to	the	total	sum.	This	questionnaire	thus	has	a	score	range	
from	0	to	9	and	the	cutoff	was	set	at	five.	Table	1	provides	an	overview	of	the	different	versions	of	the	
CONTEST	questionnaires.	
	
In	our	dataset	the	answers	to	the	individual	questions	of	the	PEST	(Psoriasis	Epidemiology	Screening	
Tool)12	 and	 PASE	 (Psoriatic	 Arthritis	 Screening	 and	 Evaluation)13	 were	 available,	 but	 the	 ToPAS	
(Toronto	Psoriatic	Arthritis	Screen)14	was	not	 included	in	our	study.	Since	three	questions	from	the	
CONTEST	questionnaire	originated	from	the	TOPAS,	we	replaced	these	items	with	data	we	did	have	
available	(Table	1).	The	two	items	regarding	the	nail	abnormalities	were	replaced	with	the	question	
about	nails	from	the	PEST	and	an	assessment	of	nail	photographs,	the	question	about	neck	pain	was	
replaced	by	data	from	the	PEST	manikin.	Performance	of	the	individual	PEST	and	PASE	screeningtools	
can	be	found	in	our	previously	published	paper.15	
	
	
Statistical	Analysis	
Sensitivity,	 specificity	and	area	under	 the	curve	 (AUC)	were	calculated	 for	all	 three	versions	of	 the	
CONTEST	and	the	PEST,	PASE	&	EARP	using	STATA	14.	Additionally,	we	did	a	subgroup	analysis	in	which	
we	approximated	the	patient	selection	of	the	CONTEST	study,	meaning	only	patients	with	at	least	one	
positive	 screeningtool	 were	 invited	 for	 clinical	 evaluation.	 As	 we	 did	 not	 include	 the	 TOPAS,	 we	
selected	only	patients	with	a	positive	PEST	or	PASE	questionnaire	in	this	subgroup	analysis.		
	
Results	
Patients	
For	 this	analysis	473	psoriasis	patients	with	MSC	were	available	 (Figure	1).	The	mean	age	of	 these	
patients	was	55.7	years	(SD	13.9)	and	51.0%	were	male.	Mean	psoriasis	duration	was	20.7±16.2	years,	
with	73.2%	of	the	psoriasis	diagnoses	made	by	a	dermatologist.	The	remaining	26.9%	of	psoriasis	cases	
were	made	by	the	GP.	Median	PASI	score	in	the	study	population	was	2.3	(IQR	1-4).	During	clinical	
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For	 this	analysis	473	psoriasis	patients	with	MSC	were	available	 (Figure	1).	The	mean	age	of	 these	
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Table 1 Overview of the different versions of the CONTEST questionnaire, including  substitutes used in the 
SENSOR study
CONTEST (0-8) CONTEST-w 
(0-13)
CONTEST-jt 
(0-9)
Substitutes in the 
SENSOR
PEST 4 Have you had pain in your heel? Weight 2
PEST 5 Have you had a finger or toe that 
was completely swollen and painful 
for no apparent reason?
PASE 3 My back hurts
PASE 4 My joints become swollen
PASE 5 My joints feel “hot”
TOPAS 2A Have you ever noticed any of these 
changes in your fingernails: pits in 
the nails as shown in Figure 1
Weight 5 PEST 3. Do your 
fingernails or toenails 
have holes or pits?
TOPAS 2B Have you ever noticed any of these 
changes in your fingernails: lifting of 
the nail from the nailbed as shown 
in Figure 2
Assessment of the 
nail photographs by a 
dermatologist
TOPAS 7 Have you ever had neck pain lasting 
at least 3 months that was not 
injury related?
PEST mannikin: Positive 
when the neck is 
checked.
PEST Mannikin 
≥6 joint ticked
1 point
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evaluation	71	patients	(15.0%)	had	nail	abnormalities	consistent	with	psoriatic	nail	dystrophy.	Table	2	
provides	the	clinical	details	for	psoriasis	patients	with	and	without	PsA.	PsA	was	newly	diagnosed	by	
a	 rheumatologist	 in	 17	 cases.	 Within	 the	 PsA	 cases	 11	 patients	 (64.7%)	 presented	 solely	 with	
peripheral	arthritis.	Five	cases	(29.4%)	of	axial	PsA	were	diagnosed	and	one	patient	(5.9%)	presented	
with	 a	 combination	of	 axial	 PsA	and	peripheral	 arthritis.	Moreover,	we	also	 identified	36	 cases	of	
enthesitis,	in	which	the	inflammatory	component	was	confirmed	by	US,	resulting	in	a	total	of	53	PsA	
cases.	More	information	about	the	prevalence	of	PsA	in	our	population	can	be	found	in	our	previously	
published	paper.9	
	
Figure	1.	Flowchart	of	recruitment	of	psoriasis	patients	
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Performance	of	the	CONTEST	
The	AUCs	 for	 the	three	different	versions	of	 the	CONTEST	were	all	around	0.7	 in	our	primary	care	
population	(Table	3).	Sensitivities	ranged	from	0.30	for	the	CONTEST-w	to	0.51	for	the	CONTEST-jt	and	
0.53	for	the	CONTEST.	Specificity	was	highest	for	the	CONTEST-w	at	0.86,	while	de	specificities	for	the	
CONTEST-jt	and	CONTEST	were	lower	at	0.77	and	0.74	respectively.		
When	 comparing	 the	 performance	 of	 the	 CONTEST	 with	 the	 already	 existing	 screeningtools,	
differences	can	be	shown.	First	of	all,	where	the	AUC	of	the	CONTEST	questionnaires	are	lower	than	
the	AUC	of	the	other	three	screeningtools	in	the	development	studies,	this	difference	is	not	as	obvious	
in	 our	 SENSOR	 population.	 The	 sensitivities	 of	 the	 CONTEST	 questionnaires	 are	 lower	 than	 the	
sensitivities	of	the	other	questionnaires	in	our	population,	whereas	the	specificities	for	the	CONTEST	
are	slightly	higher.	
	
Subgroup	Analysis	
For	 the	subgroup	analysis,	where	patients	were	selected	 in	approximately	 the	same	way	as	 in	 the	
initial	development	study,	227	patients	were	available	as	they	had	a	positive	PEST	(value	≥3)	and/or	
PASE	 (value≥47).	 	 AUC	was	 the	 same	 for	 all	 three	 versions	 of	 the	 contest	 at	 0.60.	 Sensitivity	was	
comparable	 between	 the	 CONTEST	 and	 the	 CONTEST-jt	 versions,	with	 0.64	 and	 0.62	 respectively,	
whereas	 the	 CONTEST-w	 had	 a	 lower	 sensitivity	 at	 0.36.	 Specificities	 of	 the	 CONTEST	 and	 the	
CONTEST-jt	were	also	in	the	same	range	with	0.49	and	0.54	respectively,	while	de	specificity	of	the	
CONTEST-w	was	0.71	(Table	3).		
	
Discussion	
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enthesitis,	in	which	the	inflammatory	component	was	confirmed	by	US,	resulting	in	a	total	of	53	PsA	
cases.	More	information	about	the	prevalence	of	PsA	in	our	population	can	be	found	in	our	previously	
published	paper.9	
	
Figure	1.	Flowchart	of	recruitment	of	psoriasis	patients	
	 	
	
In	our	dataset	the	answers	to	the	individual	questions	of	the	PEST	(Psoriasis	Epidemiology	Screening	
Tool)12	 and	 PASE	 (Psoriatic	 Arthritis	 Screening	 and	 Evaluation)13	 were	 available,	 but	 the	 ToPAS	
(Toronto	Psoriatic	Arthritis	Screen)14	was	not	 included	in	our	study.	Since	three	questions	from	the	
CONTEST	questionnaire	originated	from	the	TOPAS,	we	replaced	these	items	with	data	we	did	have	
available	(Table	1).	The	two	items	regarding	the	nail	abnormalities	were	replaced	with	the	question	
about	nails	from	the	PEST	and	an	assessment	of	nail	photographs,	the	question	about	neck	pain	was	
replaced	by	data	from	the	PEST	manikin.	Performance	of	the	individual	PEST	and	PASE	screeningtools	
can	be	found	in	our	previously	published	paper.15	
	
	
Statistical	Analysis	
Sensitivity,	 specificity	and	area	under	 the	curve	 (AUC)	were	calculated	 for	all	 three	versions	of	 the	
CONTEST	and	the	PEST,	PASE	&	EARP	using	STATA	14.	Additionally,	we	did	a	subgroup	analysis	in	which	
we	approximated	the	patient	selection	of	the	CONTEST	study,	meaning	only	patients	with	at	least	one	
positive	 screeningtool	 were	 invited	 for	 clinical	 evaluation.	 As	 we	 did	 not	 include	 the	 TOPAS,	 we	
selected	only	patients	with	a	positive	PEST	or	PASE	questionnaire	in	this	subgroup	analysis.		
	
Results	
Patients	
For	 this	analysis	473	psoriasis	patients	with	MSC	were	available	 (Figure	1).	The	mean	age	of	 these	
patients	was	55.7	years	(SD	13.9)	and	51.0%	were	male.	Mean	psoriasis	duration	was	20.7±16.2	years,	
with	73.2%	of	the	psoriasis	diagnoses	made	by	a	dermatologist.	The	remaining	26.9%	of	psoriasis	cases	
were	made	by	the	GP.	Median	PASI	score	in	the	study	population	was	2.3	(IQR	1-4).	During	clinical	
	
	
	
Performance	of	the	CONTEST	
The	AUCs	 for	 the	three	different	versions	of	 the	CONTEST	were	all	around	0.7	 in	our	primary	care	
population	(Table	3).	Sensitivities	ranged	from	0.30	for	the	CONTEST-w	to	0.51	for	the	CONTEST-jt	and	
0.53	for	the	CONTEST.	Specificity	was	highest	for	the	CONTEST-w	at	0.86,	while	de	specificities	for	the	
CONTEST-jt	and	CONTEST	were	lower	at	0.77	and	0.74	respectively.		
When	 comparing	 the	 performance	 of	 the	 CONTEST	 with	 the	 already	 existing	 screeningtools,	
differences	can	be	shown.	First	of	all,	where	the	AUC	of	the	CONTEST	questionnaires	are	lower	than	
the	AUC	of	the	other	three	screeningtools	in	the	development	studies,	this	difference	is	not	as	obvious	
in	 our	 SENSOR	 population.	 The	 sensitivities	 of	 the	 CONTEST	 questionnaires	 are	 lower	 than	 the	
sensitivities	of	the	other	questionnaires	in	our	population,	whereas	the	specificities	for	the	CONTEST	
are	slightly	higher.	
	
Subgroup	Analysis	
For	 the	subgroup	analysis,	where	patients	were	selected	 in	approximately	 the	same	way	as	 in	 the	
initial	development	study,	227	patients	were	available	as	they	had	a	positive	PEST	(value	≥3)	and/or	
PASE	 (value≥47).	 	 AUC	was	 the	 same	 for	 all	 three	 versions	 of	 the	 contest	 at	 0.60.	 Sensitivity	was	
comparable	 between	 the	 CONTEST	 and	 the	 CONTEST-jt	 versions,	with	 0.64	 and	 0.62	 respectively,	
whereas	 the	 CONTEST-w	 had	 a	 lower	 sensitivity	 at	 0.36.	 Specificities	 of	 the	 CONTEST	 and	 the	
CONTEST-jt	were	also	in	the	same	range	with	0.49	and	0.54	respectively,	while	de	specificity	of	the	
CONTEST-w	was	0.71	(Table	3).		
	
Discussion	
Table 2 Characteristics of the 473 participating psoriasis patients
Psoriasis patients*
(n=420)
Axial 
manifestations 
& Peripheral 
Arthritis*
(n=17)
Enthesitis*
(n=36)
Mean Age, years (±SD) 55.9 (14.0) 47.4 (10.7) 58.0 (12.3)
Male sex, n (%) 216 (51.4) 8 (47.1) 17 (47.2)
Body Mass Index, mean (±SD) 27.8 (4.8) 27.9 (6.2) 30.0 (4.1)
Median Psoriasis Symptom Duration, years (IQR) 15 (8-30) 15 (4-30) 20 (11-37)
Psoriasis Diagnosis by Dermatologist, n (%) 302 (71.9) 13 (76.5) 31 (86.1)
Nail psoriasis, n (%) 64 (15.2) 5 (29.4) 2 (5.6)
PASI, median (IQR) 2.2 (1-4) 3 (1.3-4) 3.1 (1.7-4.4)
Median MSC Symptom Duration, years (IQR)  
                                                                              Joints 8 (4-14) 12.5 (2-23) 10 (5-25)
Lower Back 12 (5-25) 18 (9-25) 33 (14-41)
LEI, median (IQR) 0 (0-0) 0 (0-1) 1 (1-2)
MASES, median (IQR) 0 (0-0) 0 (0-3) 2 (0-3)
*Axial manifestations & arthritis are the patients who were diagnosed as having PsA by the rheumatologist. 
Enthesitis are the patients who would have a diagnosis of PsA based on the CASPAR criteria. Established 
PsA are the patients already diagnosed with PsA at the beginning of the study and psoriasis patients are the 
patients with MSC but without PsA.
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In	this	study	we	compared	the	recently	developed	CONTEST	questionnaires	with	three	other	existing	
screeningtools	in	a	primary	care	setting.	Although	the	AUCs	for	the	CONTEST	are	comparable	between	
the	 development	 and	 this	 validation,	 the	 discriminative	 properties	 differed.	 In	 our	 primary	 care	
setting,	sensitivity	was	considerably	lower	whereas	specificity	was	higher	for	all	three	versions.	When	
we	approximated	the	patient	selection	of	 the	development	 (i.e.	 those	with	a	positive	PEST	and/or	
PASE),	 these	differences	became	smaller,	but	were	still	present.	Comparing	 the	CONTEST	with	 the	
already	existing	screeningtools	PEST,	PASE	and	EARP	in	our	primary	care	setting,	showed	no	additional	
value	of	the	CONTEST.	Lowering	the	cutoffs	of	the	CONTEST	questionnaires	(CONTEST	to	2,	CONTEST-
w	&-jt	to	3)	could	increase	its	value	by	increasing	the	sensitivity	(0.89,	0.81,	0.81	respectively),	but	as	
this	 is	 at	 the	 expense	 of	 the	 specificity	 (0.33,	 0.37,	 0.43	 respectively)	 it	 would	 result	 in	 a	 lot	 of	
unnecessary	referrals.	
The	developers	of	the	CONTEST	aimed	to	develop	a	questionnaire	with	considerably	improved	
performance	 than	 the	 previously	 developed	 individual	 screening	 questionnaires.	 Although	 the	
performance	 in	 the	 initial	 development	 study	 seemed	 to	 be	 better	 than	 the	 performance	 of	 the	
individual	 questionnaires	 (PEST,	 PASE,	 ToPAS),	 this	 could	not	be	 fully	 replicated	 in	 their	 validation	
cohorts	from	Utah	and	Dublin.6,7,12	The	Dublin	study	4	included	consecutive	patients	from	dermatology	
clinics	and	showed	low	sensitivity	and	high	specificity	for	all	three	CONTEST	questionnaires.	The	Utah	
study6	included	patients	from	a	psoriasis	registry	as	well	as	dermatology	clinics	and	the	performance	
of	the	CONTEST	questionnaires	was	slightly	worse	than	in	its	development	cohort.		
The	results	of	this	study	should	be	interpreted	in	the	light	of	the	setup	of	the	study.	The	TOPAS	
was	not	included	in	our	study	and	we	therefore	had	to	substitute	the	questions	from	the	TOPAS	that	
were	included	in	the	CONTEST	with	data	we	did	have	available.	We	replaced	the	items	with	very	similar	
questions	and	were	 therefore	able	 to	give	a	good	estimation	of	 its	performance	 in	a	primary	care	
setting.	 The	 considerably	 different	 results	 for	 CONTEST-w	might,	 however,	 be	 explained	 by	 these	
replacements,	as	an	item	from	the	TOPAS	is	weighted	as	five	in	this	version	and	we	had	to	substitute	
this	item	with	an	item	from	the	PEST.		As	the	mean	age	of	our	included	population	is	55	years	of	age,	
it	is	to	be	expected	that	some	other	diagnoses	like	osteoarthritis	may	be	causing	the	musculoskeletal	
complaints	in	our	population.	We	chose	to	only	include	patients	with	musculoskeletal	complaints	and	
although	 this	 may	 have	 resulted	 in	 a	 slight	 underestimation	 of	 the	 specificity,	 we	 think	 it	 is	 a	
representative	population	to	test	such	a	screeningtool.	Since	the	prevalence	of	both	psoriasis	and	PsA	
is	fairly	low	in	primary	care,	it	may	be	a	better	use	of	resources	to	screen	only	those	patients	suffering	
from	musculoskeletal	complaints	instead	of	all	patients	with	psoriasis.		
In	conclusion,	in	this	study	we	assessed	the	additional	value	of	the	CONTEST	questionnaires	over	the	
already	 existing	 screeningtools	 in	 a	 primary	 care	 setting.	 We	 showed	 that	 the	 newly	 developed	
	
	
	
Performance	of	the	CONTEST	
The	AUCs	 for	 the	three	different	versions	of	 the	CONTEST	were	all	around	0.7	 in	our	primary	care	
population	(Table	3).	Sensitivities	ranged	from	0.30	for	the	CONTEST-w	to	0.51	for	the	CONTEST-jt	and	
0.53	for	the	CONTEST.	Specificity	was	highest	for	the	CONTEST-w	at	0.86,	while	de	specificities	for	the	
CONTEST-jt	and	CONTEST	were	lower	at	0.77	and	0.74	respectively.		
When	 comparing	 the	 performance	 of	 the	 CONTEST	 with	 the	 already	 existing	 screeningtools,	
differences	can	be	shown.	First	of	all,	where	the	AUC	of	the	CONTEST	questionnaires	are	lower	than	
the	AUC	of	the	other	three	screeningtools	in	the	development	studies,	this	difference	is	not	as	obvious	
in	 our	 SENSOR	 population.	 The	 sensitivities	 of	 the	 CONTEST	 questionnaires	 are	 lower	 than	 the	
sensitivities	of	the	other	questionnaires	in	our	population,	whereas	the	specificities	for	the	CONTEST	
are	slightly	higher.	
	
Subgroup	Analysis	
For	 the	subgroup	analysis,	where	patients	were	selected	 in	approximately	 the	same	way	as	 in	 the	
initial	development	study,	227	patients	were	available	as	they	had	a	positive	PEST	(value	≥3)	and/or	
PASE	 (value≥47).	 	 AUC	was	 the	 same	 for	 all	 three	 versions	 of	 the	 contest	 at	 0.60.	 Sensitivity	was	
comparable	 between	 the	 CONTEST	 and	 the	 CONTEST-jt	 versions,	with	 0.64	 and	 0.62	 respectively,	
whereas	 the	 CONTEST-w	 had	 a	 lower	 sensitivity	 at	 0.36.	 Specificities	 of	 the	 CONTEST	 and	 the	
CONTEST-jt	were	also	in	the	same	range	with	0.49	and	0.54	respectively,	while	de	specificity	of	the	
CONTEST-w	was	0.71	(Table	3).		
	
Discussion	
In	this	study	we	compared	the	recently	developed	CONTEST	questionnaires	with	three	other	existing	
screeningtools	in	a	primary	care	setting.	Although	the	AUCs	for	the	CONTEST	are	comparable	between	
the	 development	 and	 this	 validation,	 the	 discriminative	 properties	 differed.	 In	 our	 primary	 care	
setting,	sensitivity	was	considerably	lower	whereas	specificity	was	higher	for	all	three	versions.	When	
we	approximated	the	patient	selection	of	 the	development	 (i.e.	 those	with	a	positive	PEST	and/or	
PASE),	 these	differences	became	smaller,	but	were	still	present.	Comparing	 the	CONTEST	with	 the	
already	existing	screeningtools	PEST,	PASE	and	EARP	in	our	primary	care	setting,	showed	no	additional	
value	of	the	CONTEST.	Lowering	the	cutoffs	of	the	CONTEST	questionnaires	(CONTEST	to	2,	CONTEST-
w	&-jt	to	3)	could	increase	its	value	by	increasing	the	sensitivity	(0.89,	0.81,	0.81	respectively),	but	as	
this	 is	 at	 the	 expense	 of	 the	 specificity	 (0.33,	 0.37,	 0.43	 respectively)	 it	 would	 result	 in	 a	 lot	 of	
unnecessary	referrals.	
The	developers	of	the	CONTEST	aimed	to	develop	a	questionnaire	with	considerably	improved	
performance	 than	 the	 previously	 developed	 individual	 screening	 questionnaires.	 Although	 the	
performance	 in	 the	 initial	 development	 study	 seemed	 to	 be	 better	 than	 the	 performance	 of	 the	
individual	 questionnaires	 (PEST,	 PASE,	 ToPAS),	 this	 could	not	be	 fully	 replicated	 in	 their	 validation	
cohorts	from	Utah	and	Dublin.6,7,12	The	Dublin	study	4	included	consecutive	patients	from	dermatology	
clinics	and	showed	low	sensitivity	and	high	specificity	for	all	three	CONTEST	questionnaires.	The	Utah	
study6	included	patients	from	a	psoriasis	registry	as	well	as	dermatology	clinics	and	the	performance	
of	the	CONTEST	questionnaires	was	slightly	worse	than	in	its	development	cohort.		
The	results	of	this	study	should	be	interpreted	in	the	light	of	the	setup	of	the	study.	The	TOPAS	
was	not	included	in	our	study	and	we	therefore	had	to	substitute	the	questions	from	the	TOPAS	that	
were	included	in	the	CONTEST	with	data	we	did	have	available.	We	replaced	the	items	with	very	similar	
questions	and	were	 therefore	able	 to	give	a	good	estimation	of	 its	performance	 in	a	primary	care	
setting.	 The	 considerably	 different	 results	 for	 CONTEST-w	might,	 however,	 be	 explained	 by	 these	
replacements,	as	an	item	from	the	TOPAS	is	weighted	as	five	in	this	version	and	we	had	to	substitute	
this	item	with	an	item	from	the	PEST.		As	the	mean	age	of	our	included	population	is	55	years	of	age,	
it	is	to	be	expected	that	some	other	diagnoses	like	osteoarthritis	may	be	causing	the	musculoskeletal	
complaints	in	our	population.	We	chose	to	only	include	patients	with	musculoskeletal	complaints	and	
although	 this	 may	 have	 resulted	 in	 a	 slight	 underestimation	 of	 the	 specificity,	 we	 think	 it	 is	 a	
representative	population	to	test	such	a	screeningtool.	Since	the	prevalence	of	both	psoriasis	and	PsA	
is	fairly	low	in	primary	care,	it	may	be	a	better	use	of	resources	to	screen	only	those	patients	suffering	
from	musculoskeletal	complaints	instead	of	all	patients	with	psoriasis.		
In	conclusion,	in	this	study	we	assessed	the	additional	value	of	the	CONTEST	questionnaires	over	the	
already	 existing	 screeningtools	 in	 a	 primary	 care	 setting.	 We	 showed	 that	 the	 newly	 developed	
CONTEST	questionnaires	did	not	exceed	the	performance	of	the	already	existing	screeningtools	PEST,	
PASE	and	EARP.		
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In	this	study	we	compared	the	recently	developed	CONTEST	questionnaires	with	three	other	existing	
screeningtools	in	a	primary	care	setting.	Although	the	AUCs	for	the	CONTEST	are	comparable	between	
the	 development	 and	 this	 validation,	 the	 discriminative	 properties	 differed.	 In	 our	 primary	 care	
setting,	sensitivity	was	considerably	lower	whereas	specificity	was	higher	for	all	three	versions.	When	
we	approximated	the	patient	selection	of	 the	development	 (i.e.	 those	with	a	positive	PEST	and/or	
PASE),	 these	differences	became	smaller,	but	were	still	present.	Comparing	 the	CONTEST	with	 the	
already	existing	screeningtools	PEST,	PASE	and	EARP	in	our	primary	care	setting,	showed	no	additional	
value	of	the	CONTEST.	Lowering	the	cutoffs	of	the	CONTEST	questionnaires	(CONTEST	to	2,	CONTEST-
w	&-jt	to	3)	could	increase	its	value	by	increasing	the	sensitivity	(0.89,	0.81,	0.81	respectively),	but	as	
this	 is	 at	 the	 expense	 of	 the	 specificity	 (0.33,	 0.37,	 0.43	 respectively)	 it	 would	 result	 in	 a	 lot	 of	
unnecessary	referrals.	
The	developers	of	the	CONTEST	aimed	to	develop	a	questionnaire	with	considerably	improved	
performance	 than	 the	 previously	 developed	 individual	 screening	 questionnaires.	 Although	 the	
performance	 in	 the	 initial	 development	 study	 seemed	 to	 be	 better	 than	 the	 performance	 of	 the	
individual	 questionnaires	 (PEST,	 PASE,	 ToPAS),	 this	 could	not	be	 fully	 replicated	 in	 their	 validation	
cohorts	from	Utah	and	Dublin.6,7,12	The	Dublin	study	4	included	consecutive	patients	from	dermatology	
clinics	and	showed	low	sensitivity	and	high	specificity	for	all	three	CONTEST	questionnaires.	The	Utah	
study6	included	patients	from	a	psoriasis	registry	as	well	as	dermatology	clinics	and	the	performance	
of	the	CONTEST	questionnaires	was	slightly	worse	than	in	its	development	cohort.		
The	results	of	this	study	should	be	interpreted	in	the	light	of	the	setup	of	the	study.	The	TOPAS	
was	not	included	in	our	study	and	we	therefore	had	to	substitute	the	questions	from	the	TOPAS	that	
were	included	in	the	CONTEST	with	data	we	did	have	available.	We	replaced	the	items	with	very	similar	
questions	and	were	 therefore	able	 to	give	a	good	estimation	of	 its	performance	 in	a	primary	care	
setting.	 The	 considerably	 different	 results	 for	 CONTEST-w	might,	 however,	 be	 explained	 by	 these	
replacements,	as	an	item	from	the	TOPAS	is	weighted	as	five	in	this	version	and	we	had	to	substitute	
this	item	with	an	item	from	the	PEST.		As	the	mean	age	of	our	included	population	is	55	years	of	age,	
it	is	to	be	expected	that	some	other	diagnoses	like	osteoarthritis	may	be	causing	the	musculoskeletal	
complaints	in	our	population.	We	chose	to	only	include	patients	with	musculoskeletal	complaints	and	
although	 this	 may	 have	 resulted	 in	 a	 slight	 underestimation	 of	 the	 specificity,	 we	 think	 it	 is	 a	
representative	population	to	test	such	a	screeningtool.	Since	the	prevalence	of	both	psoriasis	and	PsA	
is	fairly	low	in	primary	care,	it	may	be	a	better	use	of	resources	to	screen	only	those	patients	suffering	
from	musculoskeletal	complaints	instead	of	all	patients	with	psoriasis.		
In	conclusion,	in	this	study	we	assessed	the	additional	value	of	the	CONTEST	questionnaires	over	the	
already	 existing	 screeningtools	 in	 a	 primary	 care	 setting.	 We	 showed	 that	 the	 newly	 developed	
	
	
	
Performance	of	the	CONTEST	
The	AUCs	 for	 the	three	different	versions	of	 the	CONTEST	were	all	around	0.7	 in	our	primary	care	
population	(Table	3).	Sensitivities	ranged	from	0.30	for	the	CONTEST-w	to	0.51	for	the	CONTEST-jt	and	
0.53	for	the	CONTEST.	Specificity	was	highest	for	the	CONTEST-w	at	0.86,	while	de	specificities	for	the	
CONTEST-jt	and	CONTEST	were	lower	at	0.77	and	0.74	respectively.		
When	 comparing	 the	 performance	 of	 the	 CONTEST	 with	 the	 already	 existing	 screeningtools,	
differences	can	be	shown.	First	of	all,	where	the	AUC	of	the	CONTEST	questionnaires	are	lower	than	
the	AUC	of	the	other	three	screeningtools	in	the	development	studies,	this	difference	is	not	as	obvious	
in	 our	 SENSOR	 population.	 The	 sensitivities	 of	 the	 CONTEST	 questionnaires	 are	 lower	 than	 the	
sensitivities	of	the	other	questionnaires	in	our	population,	whereas	the	specificities	for	the	CONTEST	
are	slightly	higher.	
	
Subgroup	Analysis	
For	 the	subgroup	analysis,	where	patients	were	selected	 in	approximately	 the	same	way	as	 in	 the	
initial	development	study,	227	patients	were	available	as	they	had	a	positive	PEST	(value	≥3)	and/or	
PASE	 (value≥47).	 	 AUC	was	 the	 same	 for	 all	 three	 versions	 of	 the	 contest	 at	 0.60.	 Sensitivity	was	
comparable	 between	 the	 CONTEST	 and	 the	 CONTEST-jt	 versions,	with	 0.64	 and	 0.62	 respectively,	
whereas	 the	 CONTEST-w	 had	 a	 lower	 sensitivity	 at	 0.36.	 Specificities	 of	 the	 CONTEST	 and	 the	
CONTEST-jt	were	also	in	the	same	range	with	0.49	and	0.54	respectively,	while	de	specificity	of	the	
CONTEST-w	was	0.71	(Table	3).		
	
Discussion	
In	this	study	we	compared	the	recently	developed	CONTEST	questionnaires	with	three	other	existing	
screeningtools	in	a	primary	care	setting.	Although	the	AUCs	for	the	CONTEST	are	comparable	between	
the	 development	 and	 this	 validation,	 the	 discriminative	 properties	 differed.	 In	 our	 primary	 care	
setting,	sensitivity	was	considerably	lower	whereas	specificity	was	higher	for	all	three	versions.	When	
we	approximated	the	patient	selection	of	 the	development	 (i.e.	 those	with	a	positive	PEST	and/or	
PASE),	 these	differences	became	smaller,	but	were	still	present.	Comparing	 the	CONTEST	with	 the	
already	existing	screeningtools	PEST,	PASE	and	EARP	in	our	primary	care	setting,	showed	no	additional	
value	of	the	CONTEST.	Lowering	the	cutoffs	of	the	CONTEST	questionnaires	(CONTEST	to	2,	CONTEST-
w	&-jt	to	3)	could	increase	its	value	by	increasing	the	sensitivity	(0.89,	0.81,	0.81	respectively),	but	as	
this	 is	 at	 the	 expense	 of	 the	 specificity	 (0.33,	 0.37,	 0.43	 respectively)	 it	 would	 result	 in	 a	 lot	 of	
unnecessary	referrals.	
The	developers	of	the	CONTEST	aimed	to	develop	a	questionnaire	with	considerably	improved	
performance	 than	 the	 previously	 developed	 individual	 screening	 questionnaires.	 Although	 the	
performance	 in	 the	 initial	 development	 study	 seemed	 to	 be	 better	 than	 the	 performance	 of	 the	
individual	 questionnaires	 (PEST,	 PASE,	 ToPAS),	 this	 could	not	be	 fully	 replicated	 in	 their	 validation	
cohorts	from	Utah	and	Dublin.6,7,12	The	Dublin	study	4	included	consecutive	patients	from	dermatology	
clinics	and	showed	low	sensitivity	and	high	specificity	for	all	three	CONTEST	questionnaires.	The	Utah	
study6	included	patients	from	a	psoriasis	registry	as	well	as	dermatology	clinics	and	the	performance	
of	the	CONTEST	questionnaires	was	slightly	worse	than	in	its	development	cohort.		
The	results	of	this	study	should	be	interpreted	in	the	light	of	the	setup	of	the	study.	The	TOPAS	
was	not	included	in	our	study	and	we	therefore	had	to	substitute	the	questions	from	the	TOPAS	that	
were	included	in	the	CONTEST	with	data	we	did	have	available.	We	replaced	the	items	with	very	similar	
questions	and	were	 therefore	able	 to	give	a	good	estimation	of	 its	performance	 in	a	primary	care	
setting.	 The	 considerably	 different	 results	 for	 CONTEST-w	might,	 however,	 be	 explained	 by	 these	
replacements,	as	an	item	from	the	TOPAS	is	weighted	as	five	in	this	version	and	we	had	to	substitute	
this	item	with	an	item	from	the	PEST.		As	the	mean	age	of	our	included	population	is	55	years	of	age,	
it	is	to	be	expected	that	some	other	diagnoses	like	osteoarthritis	may	be	causing	the	musculoskeletal	
complaints	in	our	population.	We	chose	to	only	include	patients	with	musculoskeletal	complaints	and	
although	 this	 may	 have	 resulted	 in	 a	 slight	 underestimation	 of	 the	 specificity,	 we	 think	 it	 is	 a	
representative	population	to	test	such	a	screeningtool.	Since	the	prevalence	of	both	psoriasis	and	PsA	
is	fairly	low	in	primary	care,	it	may	be	a	better	use	of	resources	to	screen	only	those	patients	suffering	
from	musculoskeletal	complaints	instead	of	all	patients	with	psoriasis.		
In	conclusion,	in	this	study	we	assessed	the	additional	value	of	the	CONTEST	questionnaires	over	the	
already	 existing	 screeningtools	 in	 a	 primary	 care	 setting.	 We	 showed	 that	 the	 newly	 developed	
CONTEST	questionnaires	did	not	exceed	the	performance	of	the	already	existing	screeningtools	PEST,	
PASE	and	EARP.		
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Part III. 
General Discussion, Summary & Addendum

Chapter 9.
General Discussion
Over	the	years	 it	has	become	more	and	more	apparent	that	early	recognition	of	SpA	 is	 important.	
However,	early	signs	of	 inflammatory	SpA	resembles	those	of	aspecific	 low	back	pain	or	 joint	pain.	
Therefore	 it	 is	not	easy	to	disentangle	those	with	benign	symptoms	from	those	with	 inflammatory	
symptoms.	To	prevent	screening	all	patients	with	aspecific	joint	or	back	pain	it	is	necessary	to	increase	
the	prior	probability	by	selecting	subpopulations.	Patients	with	psoriasis	or	IBD	have	an	increased	risk	
of	developing	SpA	and	are	thus	good	examples	of	groups	to	focus	on	in	the	early	recognition	of	SpA.	
In	the	Netherlands,	we	have	an	extensive	primary	healthcare	system.	It	is	therefore	most	likely	that	
patients	with	 psoriasis	 or	 IBD	who	 suffer	 from	musculoskeletal	 complaints,	will	 visit	 their	 general	
practitioner	for	these	complaints.	To	get	more	insight	in	the	early	recognition	of	SpA	in	primary	care,	
this	thesis	focused	on	the	following	aims:	
	
- To	 get	 insight	 in	 the	 prevalence	 of	 PsA	 and	 ultrasound	 findings	 in	 enthesitis	 in	 psoriasis	
patients	in	a	primary	care	setting		
- To	give	an	overview	of	the	prevalence	of	axial	and	peripheral	SpA	in	IBD	patients		
- To	describe	the	burden	of	musculoskeletal	complaints	in	patients	with	IBD	
- To	evaluate	the	awareness	of	SpA	in	both	GPs	and	patients	with	IBD	or	PSO		
- To	assess	the	optimal	screening-strategy	for	PsA	in	a	primary	care	setting	
		
To	answer	these	questions,	the	cross	sectional	SENSOR	and	AppSpA	study	were	set	up.	The	SENSOR	
study	 was	 a	 study	 in	 primary	 care	 in	 which	 we	 included	 patients	 with	 psoriasis	 who	 had	
musculoskeletal	complaints.	The	AppSpA	study	consisted	of	two	parts;	first	the	GP-part	in	which	we	
invited	GPs	to	complete	a	survey	on	knowledge	of	inflammatory	symptoms	and	SpA-specific	features.	
The	patients-part	included	patients	at	risk	for	SpA,	i.e.	patients	with	psoriasis	or	IBD	between	18	and	
55	years	of	age.	These	patients	were	selected	out	of	GP	databases	and	completed	questionnaires	on	
awareness,	presence	of	musculoskeletal	complaints,	quality	of	life	and	work	participation.	
	
Prevalence	
The	 first	 part	 of	 this	 thesis	 focused	 on	 the	 prevalence	 and	 burden	 of	 SpA	 in	 patients	 at	 risk.	 The	
prevalence	of	PsA	in	patients	with	psoriasis	was	investigated	within	the	SENSOR	study.	In	this	study,	
524	patients	with	psoriasis	were	clinically	evaluated	and	we	found	a	prevalence	of	PsA	 in	psoriasis	
patients	of	3.2%.	This	number	increased	towards	4.6%	if	patients	with	solely	enthesitis	were	also	taken	
into	 account.	 Enthesitis	 was	 defined	 as	 active	 inflammation	 on	 ultrasound	 in	 combination	with	 a	
tender	enthesis	at	the	same	site.	According	to	this	definition,	40	patients	(36%)	had	clinically	relevant	
enthesitis.		
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The	 prevalence	 of	 SpA	 in	 patients	 with	 IBD	 was	 established	 with	 a	 systematic	 review	 and	meta-
analysis.	We	 found	 a	 pooled	 prevalence	 of	 11%	 for	 sacroiliitis	 and	 3%	 for	 its	 subtype	 ankylosing	
spondylitis.	The	pooled	prevalence	for	peripheral	arthritis	was	found	to	be	14%.		
Once	 the	 prevalence	was	 established,	we	 looked	 at	 the	 impact	 of	musculoskeletal	 complaints	 for	
patients	with	IBD	and	showed	that	the	musculoskeletal	complaints	had	significant	impact	on	quality	
of	life.	
	 	
Awareness	
To	aid	early	recognition,	physicians	and	patients	should	be	aware	of	the	concept	of	SpA.	In	the	first	
part	 of	 the	 AppSpA	 study	we	 therefore	 invited	 general	 practitioners	 to	 complete	 a	 questionnaire	
regarding	inflammatory	symptoms	and	features	of	SpA.	We	showed	that	almost	60%	of	GPs	did	not	
recognize	half	of	the	symptoms	indicative	for	inflammatory	peripheral	joint	disease,	for	inflammatory	
axial	 disease	 this	was	 40%.	 The	 second	 part	 of	 the	 AppSpA	 study	 focused	 on	 patients	 at	 risk,	 i.e.	
patients	with	psoriasis	or	IBD.	We	found	that	only	42.6%	of	patients	with	psoriasis	or	IBD	was	aware	
of	the	fact	that	they	could	develop	SpA.	
Besides	increasing	awareness,	the	use	of	screeningtools	could	also	aid	early	recognition.		We	therefore	
evaluated	the	performance	of	the	PEST,	PASE	and	EARP	screeningtools	for	PsA	in	our	study	population.	
The	PEST	screeningtool	was	found	to	have	the	best	trade-off	between	sensitivity	(0.68)	and	specificity	
(0.71).	We	 also	 investigated	 the	 added	 value	 of	 a	 newly	 developed	 screeningtool	 (CONTEST).	 The	
difference	between	the	CONTEST	and	the	PEST,	PASE,	EARP	was	so	small	that	we	concluded	that	the	
CONTEST	does	not	exceed	the	performance	of	these	older	tools.	
	
Generalizability	
As	the	most	important	findings	of	this	thesis	are	summarized	above,	it	is	important	to	look	into	the	
generalizability	of	our	 results.	The	 following	part	of	 the	discussion	will	 focus	on	 several	aspects	of	
generalizability,	 namely	 population	 definition	 (including	 recruitment	 of	 subjects	 and	 eligibility	
criteria),	patient	characteristics	and	definition	of	outcome.	
	
The	first	thing	to	look	at	is	the	study	population,	including	recruitment	and	in-	&	exclusion	criteria	of	
participants.	In	the	estimation	of	disease	prevalence	the	recruitment	of	all	patients	at	risk	is	of	utmost	
importance.	 In	case	of	PsA	among	psoriasis	patient	 in	primary	care	 that	meant	 that	we	needed	to	
reach	out	to	every	possible	patient	that	was	diagnosed	with	psoriasis.	In	the	set-up	of	the	study	this	
was	extensively	accounted	for	by	selecting	patients	based	on	ICPC	code.	To	ensure	whether	this	code	
was	applied	correctly	to	the	participating	patients,	we	also	verified	the	diagnosis	of	psoriasis	or	IBD	
with	the	patients	themselves.	
The	results	of	the	SENSOR	study	apply	to	those	adult	patients	that	reported	regular	spells	of	MSC.	
Patient	that	initially	consult	the	GP	with	a	single	spell	still	may	be	at	risk,	but	due	to	our	requirement	
of	 regular	 spells,	 current	 results	 do	 not	 apply	 to	 those	with	 a	 single	 spell	 of	MSC.	Given	 the	 high	
frequency	of	GP	consultations	for	MSC	the	prevalence	of	PsA	is	likely	to	be	lower	than	in	those	with	
regular	spells,	but	it	is	unclear	how	much	lower.		
In	the	AppSpA	study	we	included	patients	aged	18	to	55	years	of	age.	The	upper	limit	of	55	years	was	
chosen	as	we	saw	in	the	SENSOR	study,	where	no	age	 limit	was	applied,	that	the	mean	age	of	the	
participating	patients	was	fairly	high.	The	incidence	of	SpA	above	the	age	of	55	years	is	very	low,	while	
in	this	age	group	other	problems	like	osteoarthritis	play	a	more	important	role.		
In	both	studies	self-selection	of	patients	may	be	an	issue.	Patients	who	have	a	lot	of	musculoskeletal	
complaints	could	have	been	more	interested	in	participating	in	a	study	than	patients	who	do	not	suffer	
that	much	from	their	musculoskeletal	complaints.	In	the	AppSpA	study	the	invitation	stated	that	the	
study	was	 about	musculoskeletal	 complaints.	 Although	we	 explicitly	 asked	 patients	 to	 participate	
irrespective	 of	 the	 presence	 of	 musculoskeletal	 complaints,	 it	 is	 possible	 that	 the	 prevalence	 of	
musculoskeletal	complaints	in	this	study	is	an	overestimation.	
	
The	second	subject	to	look	at	in	the	context	of	generalizability	are	the	patient	characteristics.	In	the	
SENSOR	study	about	half	of	the	patients	was	male,	comparable	with	a	general	psoriasis	population.1	
The	mean	age	of	our	population	was	55.8	years,	which	is	older	than	the	peak	incidence	of	psoriasis	
which	is	between	30	and	50	years	of	age.	It	is	therefore	possible	that	we	missed	some	cases	of	PsA	
among	the	younger	population.	Our	study	population	consisted	for	98%	of	Caucasian	people,	although	
the	prevalence	of	psoriasis	is	highest	in	Caucasian	people,	it	also	occurs	in	people	from	other	parts	of	
the	world.	In	the	AppSpA	study	there	seemed	to	be	an	overrepresentation	of	females	as	only	25%	of	
the	 participants	 was	male.	Most	 studies	 show	 an	 equal	 distribution	 between	males	 and	 females,	
although	 some	 studies	 tend	 to	 show	a	 trend	 towards	 female	predominance	 in	 Europe	and	North-
America.2	Nonetheless,	it	should	be	taken	into	account	that	the	results	described	in	chapter	5	of	these	
thesis	may	not	be	a	completely	adequate	representation	with	regard	to	gender.	
	
The	definition	of	the	outcome	is	also	an	important	factor	for	the	generalizability	of	the	results.	The	
outcome	 in	 the	 SENSOR	 study	was	 a	 diagnosis	 of	 PsA,	which	was	made	 by	 a	 rheumatologist.	 	 As	
enthesitis	 is	 still	 very	difficult	 to	diagnose,	we	used	 the	CASPAR	criteria	 to	diagnose	PsA	based	on	
enthesitis.	 In	 the	 CASPAR	 critera	 enthesitis	 is	 stated	 as	 an	 entry	 criteria,	 so	 patients	 with	 solely	
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The	 prevalence	 of	 SpA	 in	 patients	 with	 IBD	 was	 established	 with	 a	 systematic	 review	 and	meta-
analysis.	We	 found	 a	 pooled	 prevalence	 of	 11%	 for	 sacroiliitis	 and	 3%	 for	 its	 subtype	 ankylosing	
spondylitis.	The	pooled	prevalence	for	peripheral	arthritis	was	found	to	be	14%.		
Once	 the	 prevalence	was	 established,	we	 looked	 at	 the	 impact	 of	musculoskeletal	 complaints	 for	
patients	with	IBD	and	showed	that	the	musculoskeletal	complaints	had	significant	impact	on	quality	
of	life.	
	 	
Awareness	
To	aid	early	recognition,	physicians	and	patients	should	be	aware	of	the	concept	of	SpA.	In	the	first	
part	 of	 the	 AppSpA	 study	we	 therefore	 invited	 general	 practitioners	 to	 complete	 a	 questionnaire	
regarding	inflammatory	symptoms	and	features	of	SpA.	We	showed	that	almost	60%	of	GPs	did	not	
recognize	half	of	the	symptoms	indicative	for	inflammatory	peripheral	joint	disease,	for	inflammatory	
axial	 disease	 this	was	 40%.	 The	 second	 part	 of	 the	 AppSpA	 study	 focused	 on	 patients	 at	 risk,	 i.e.	
patients	with	psoriasis	or	IBD.	We	found	that	only	42.6%	of	patients	with	psoriasis	or	IBD	was	aware	
of	the	fact	that	they	could	develop	SpA.	
Besides	increasing	awareness,	the	use	of	screeningtools	could	also	aid	early	recognition.		We	therefore	
evaluated	the	performance	of	the	PEST,	PASE	and	EARP	screeningtools	for	PsA	in	our	study	population.	
The	PEST	screeningtool	was	found	to	have	the	best	trade-off	between	sensitivity	(0.68)	and	specificity	
(0.71).	We	 also	 investigated	 the	 added	 value	 of	 a	 newly	 developed	 screeningtool	 (CONTEST).	 The	
difference	between	the	CONTEST	and	the	PEST,	PASE,	EARP	was	so	small	that	we	concluded	that	the	
CONTEST	does	not	exceed	the	performance	of	these	older	tools.	
	
Generalizability	
As	the	most	important	findings	of	this	thesis	are	summarized	above,	it	is	important	to	look	into	the	
generalizability	of	our	 results.	The	 following	part	of	 the	discussion	will	 focus	on	 several	aspects	of	
generalizability,	 namely	 population	 definition	 (including	 recruitment	 of	 subjects	 and	 eligibility	
criteria),	patient	characteristics	and	definition	of	outcome.	
	
The	first	thing	to	look	at	is	the	study	population,	including	recruitment	and	in-	&	exclusion	criteria	of	
participants.	In	the	estimation	of	disease	prevalence	the	recruitment	of	all	patients	at	risk	is	of	utmost	
importance.	 In	case	of	PsA	among	psoriasis	patient	 in	primary	care	 that	meant	 that	we	needed	to	
reach	out	to	every	possible	patient	that	was	diagnosed	with	psoriasis.	In	the	set-up	of	the	study	this	
was	extensively	accounted	for	by	selecting	patients	based	on	ICPC	code.	To	ensure	whether	this	code	
was	applied	correctly	to	the	participating	patients,	we	also	verified	the	diagnosis	of	psoriasis	or	IBD	
with	the	patients	themselves.	
The	results	of	the	SENSOR	study	apply	to	those	adult	patients	that	reported	regular	spells	of	MSC.	
Patient	that	initially	consult	the	GP	with	a	single	spell	still	may	be	at	risk,	but	due	to	our	requirement	
of	 regular	 spells,	 current	 results	 do	 not	 apply	 to	 those	with	 a	 single	 spell	 of	MSC.	Given	 the	 high	
frequency	of	GP	consultations	for	MSC	the	prevalence	of	PsA	is	likely	to	be	lower	than	in	those	with	
regular	spells,	but	it	is	unclear	how	much	lower.		
In	the	AppSpA	study	we	included	patients	aged	18	to	55	years	of	age.	The	upper	limit	of	55	years	was	
chosen	as	we	saw	in	the	SENSOR	study,	where	no	age	 limit	was	applied,	that	the	mean	age	of	the	
participating	patients	was	fairly	high.	The	incidence	of	SpA	above	the	age	of	55	years	is	very	low,	while	
in	this	age	group	other	problems	like	osteoarthritis	play	a	more	important	role.		
In	both	studies	self-selection	of	patients	may	be	an	issue.	Patients	who	have	a	lot	of	musculoskeletal	
complaints	could	have	been	more	interested	in	participating	in	a	study	than	patients	who	do	not	suffer	
that	much	from	their	musculoskeletal	complaints.	In	the	AppSpA	study	the	invitation	stated	that	the	
study	was	 about	musculoskeletal	 complaints.	 Although	we	 explicitly	 asked	 patients	 to	 participate	
irrespective	 of	 the	 presence	 of	 musculoskeletal	 complaints,	 it	 is	 possible	 that	 the	 prevalence	 of	
musculoskeletal	complaints	in	this	study	is	an	overestimation.	
	
The	second	subject	to	look	at	in	the	context	of	generalizability	are	the	patient	characteristics.	In	the	
SENSOR	study	about	half	of	the	patients	was	male,	comparable	with	a	general	psoriasis	population.1	
The	mean	age	of	our	population	was	55.8	years,	which	is	older	than	the	peak	incidence	of	psoriasis	
which	is	between	30	and	50	years	of	age.	It	is	therefore	possible	that	we	missed	some	cases	of	PsA	
among	the	younger	population.	Our	study	population	consisted	for	98%	of	Caucasian	people,	although	
the	prevalence	of	psoriasis	is	highest	in	Caucasian	people,	it	also	occurs	in	people	from	other	parts	of	
the	world.	In	the	AppSpA	study	there	seemed	to	be	an	overrepresentation	of	females	as	only	25%	of	
the	 participants	 was	male.	Most	 studies	 show	 an	 equal	 distribution	 between	males	 and	 females,	
although	 some	 studies	 tend	 to	 show	a	 trend	 towards	 female	predominance	 in	 Europe	and	North-
America.2	Nonetheless,	it	should	be	taken	into	account	that	the	results	described	in	chapter	5	of	these	
thesis	may	not	be	a	completely	adequate	representation	with	regard	to	gender.	
	
The	definition	of	the	outcome	is	also	an	important	factor	for	the	generalizability	of	the	results.	The	
outcome	 in	 the	 SENSOR	 study	was	 a	 diagnosis	 of	 PsA,	which	was	made	 by	 a	 rheumatologist.	 	 As	
enthesitis	 is	 still	 very	difficult	 to	diagnose,	we	used	 the	CASPAR	criteria	 to	diagnose	PsA	based	on	
enthesitis.	 In	 the	 CASPAR	 critera	 enthesitis	 is	 stated	 as	 an	 entry	 criteria,	 so	 patients	 with	 solely	
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enthesitis	 (without	 arthritis	 or	 axial	 involvement)	 could	 classify	 as	 PsA.	However,	when	 a	 patients	
would	classify	as	having	enthesitis	is	not	defined.	This	is	why	we	chose	to	combine	clinical	evaluation	
(LEI/MASES)	 with	 ultrasound	 findings.	 In	 this	 way	 we	 tried	 to	 diagnose	 enthesitis	 as	 objective	 as	
possible.	In	addition,	the	CASPAR	criteria	are	classification	criteria	and	not	diagnostic	criteria,	so	one	
could	say	they	are	not	to	be	used	to	diagnose	a	disease.	This	is	why	we	mentioned	the	prevalence	of	
enthesitis	 separately	 in	 our	 prevalence	 study.	 During	 our	 study	we	 found	 that	many	 participating	
rheumatologists	 found	 it	 difficult	 to	 diagnose	 PsA	 solely	 based	 on	 enthesitis,	 as	 it	 seems	 quite	
unspecific	and	there	is	still	so	much	unknown.		
In	 the	 AppSpA	 study,	 the	main	 outcome	 in	 the	 patient-part	was	 the	 presence	 of	musculoskeletal	
complaints.	As	the	AppSpA	study	consisted	only	of	questionnaires,	the	prevalence	of	musculoskeletal	
complaints	is	self-reported.	However,	this	seems	to	be	an	adequate	way	to	describe	the	prevalence	of	
musculoskeletal	complaints,	as	there	is	no	objective	measure	available	and	it	is	always	self-reported	
by	the	patients.	The	questionnaires	we	used	to	describe	quality	of	life	and	work	participation	were	all	
validated	 self-reported	 questionnaires.	 The	 same	 goes	 for	 the	GP-part,	were	we	 also	 used	 a	 self-
developed	survey	to	get	insight	in	their	knowledge	of	SpA.	We	think	the	results	of	this	study	give	good	
insight	in	the	gaps	in	the	knowledge	of	SpA	and	would	not	have	differed	much	if	we	would	have	used	
interviews	for	example.	
	
Overall,	 we	 think	 the	 results	 of	 our	 studies	 are	 representative	 of	 the	 Dutch	 situation.	 In	 the	
Netherlands	we	have	an	extensive	primary	care	system,	which	we	used	in	our	studies.	We	used	ICPC	
codes	to	include	every	patient	with	psoriasis	to	get	a	fair	estimate	of	the	prevalence	of	PsA	in	the	end.	
By	combining	ultrasound	and	clinical	examination	we	were	also	able	to	give	an	adequate	estimate	of	
the	prevalence	of	enthesitis,	as	a	clear	definition	is	still	lacking.	In	the	AppSpA	studies	the	prevalence	
of	musculoskeletal	complaints	may	be	overestimated	and	there	is	an	overrepresentation	of	females,	
which	should	be	taken	into	account.	However,	the	use	of	questionnaires	is	an	adequate	way	to	get	an	
overview	of	the	knowledge	gaps	of	GPs	and	complaints	of	the	patients.		
	
Implications	for	clinical	practice	
In	this	thesis	we	showed	that	musculoskeletal	complaints	and	SpA	occur	frequently	in	patients	at	risk,	
i.e.	patients	with	psoriasis	or	IBD.	However,	these	complaints	are	often	not	recognized	as	being	SpA,	
as	medical	professionals	and	patients	themselves	often	are	not	aware	of	the	link	between	psoriasis	or	
IBD	and	SpA.	Increasing	this	awareness	is	important	as	it	could	aid	early	recognition.	In	the	following	
part	of	the	discussion	ways	to	increase	this	awareness	are	described.	
	
Increasing	Awareness	
Multiple	 target	 groups	 can	 be	 distinguished	 to	 increase	 awareness;	 general	 practitioners,	medical	
specialists	and	patients	themselves.	
	
General	Practitioners		
Over	the	last	years	it	has	been	tried	to	increase	awareness	for	rheumatic	disease	via	guidelines	and	
education	 of	 GPs.	 However,	 guidelines	 and	 education	 alone	 does	 not	 seem	 to	 be	 sufficient.	 Two	
reviews,	 of	which	 one	was	 specifically	 aimed	 at	 inflammatory	 arthritis,	 showed	 that	 referral	 from	
primary	to	secondary	care	could	also	be	 improved	via	the	use	of	self-administered	questionnaires,	
referral	sheets	or	triage	by	a	specialist	in	a	primary	care	setting.3,4	
Looking	 into	 self-administered	 questionnaires	 or	 referral	 sheets,	 the	 screeningtools	 for	 PsA	 as	
described	 in	 this	 thesis	 might	 be	 useful	 in	 this	 matter.	 They	 could	 play	 an	 important	 role	 to	 aid	
necessary	referrals	and	avoid	the	unnecessary	ones.	Unfortunately	the	sensitivity	and	specificity	of	
these	tools	remains	moderate,	also	in	primary	care	as	described	in	chapter	7.5-8	The	PEST	screeningtool	
seems	to	perform	relatively	well	and	is	very	short	and	easy	to	complete.	However,	axial	manifestations	
are	not	represented	in	the	PEST.	It	might	therefore	be	useful	to	use	another	tool	if	patients	present	
themselves	 with	 axial	 manifestations.	 Multiple	 referral	 tools	 have	 been	 developed	 for	 axial	 SpA,	
among	which	 the	Berlin,	MASTER,	RADAR,	ASAS	and	CaFaSpA.9-13	 	 For	 the	Dutch	 situation	with	an	
extensive	primary	care	system,	the	CaFaSpA	seems	to	be	most	feasible,	as	you	don’t	need	any	invasive	
or	costly	investigations	like	laboratory	tests	or	imaging.		
To	increase	awareness	another	quite	simple	thing	that	might	aid	recognition	is	linking	of	ICPC	codes.	
If	a	patient	has	psoriasis	or	IBD	this	will	be	registered	by	ICPC	code	in	the	electronic	patients	file	of	the	
GP.	If	a	patient	presents	later	on	with	musculoskeletal	complaints,	the	GP	will	add	a	new	ICPC	code	
for	this	complaint.	It	might	be	rather	useful	if	some	sort	of	pop-up	will	occur	to	draw	attention	to	the	
fact	that	the	patient	also	has	a	diagnosis	of	psoriasis	or	IBD.		
Triage	by	a	specialist	in	a	primary	care	setting	could	also	be	useful.	The	GP	could	select	patients	with	
possible	inflammatory	symptoms,	who	could	be	evaluated	by	a	specialist	in	an	easily	accessible,	low-
cost	 setting.	 If	 the	 rheumatologist	 confirms	 the	 presence	 of	 inflammatory	 symptoms,	 the	 patient	
would	be	referred	to	secondary	care	for	specialized	care.	
	
Medical	Specialists	
Besides	 the	 GPs,	 medical	 specialists	 should	 also	 be	 involved	 when	 improving	 awareness.	 All	 IBD	
patients	will	be	treated	by	a	gastroenterologist,	while	a	certain	part	of	the	psoriasis	patients	(e.g.	the	
more	 severe	psoriasis	or	psoriasis	with	a	 lot	of	 comorbidity)	will	 be	 treated	by	a	dermatologist.	A	
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enthesitis	 (without	 arthritis	 or	 axial	 involvement)	 could	 classify	 as	 PsA.	However,	when	 a	 patients	
would	classify	as	having	enthesitis	is	not	defined.	This	is	why	we	chose	to	combine	clinical	evaluation	
(LEI/MASES)	 with	 ultrasound	 findings.	 In	 this	 way	 we	 tried	 to	 diagnose	 enthesitis	 as	 objective	 as	
possible.	In	addition,	the	CASPAR	criteria	are	classification	criteria	and	not	diagnostic	criteria,	so	one	
could	say	they	are	not	to	be	used	to	diagnose	a	disease.	This	is	why	we	mentioned	the	prevalence	of	
enthesitis	 separately	 in	 our	 prevalence	 study.	 During	 our	 study	we	 found	 that	many	 participating	
rheumatologists	 found	 it	 difficult	 to	 diagnose	 PsA	 solely	 based	 on	 enthesitis,	 as	 it	 seems	 quite	
unspecific	and	there	is	still	so	much	unknown.		
In	 the	 AppSpA	 study,	 the	main	 outcome	 in	 the	 patient-part	was	 the	 presence	 of	musculoskeletal	
complaints.	As	the	AppSpA	study	consisted	only	of	questionnaires,	the	prevalence	of	musculoskeletal	
complaints	is	self-reported.	However,	this	seems	to	be	an	adequate	way	to	describe	the	prevalence	of	
musculoskeletal	complaints,	as	there	is	no	objective	measure	available	and	it	is	always	self-reported	
by	the	patients.	The	questionnaires	we	used	to	describe	quality	of	life	and	work	participation	were	all	
validated	 self-reported	 questionnaires.	 The	 same	 goes	 for	 the	GP-part,	were	we	 also	 used	 a	 self-
developed	survey	to	get	insight	in	their	knowledge	of	SpA.	We	think	the	results	of	this	study	give	good	
insight	in	the	gaps	in	the	knowledge	of	SpA	and	would	not	have	differed	much	if	we	would	have	used	
interviews	for	example.	
	
Overall,	 we	 think	 the	 results	 of	 our	 studies	 are	 representative	 of	 the	 Dutch	 situation.	 In	 the	
Netherlands	we	have	an	extensive	primary	care	system,	which	we	used	in	our	studies.	We	used	ICPC	
codes	to	include	every	patient	with	psoriasis	to	get	a	fair	estimate	of	the	prevalence	of	PsA	in	the	end.	
By	combining	ultrasound	and	clinical	examination	we	were	also	able	to	give	an	adequate	estimate	of	
the	prevalence	of	enthesitis,	as	a	clear	definition	is	still	lacking.	In	the	AppSpA	studies	the	prevalence	
of	musculoskeletal	complaints	may	be	overestimated	and	there	is	an	overrepresentation	of	females,	
which	should	be	taken	into	account.	However,	the	use	of	questionnaires	is	an	adequate	way	to	get	an	
overview	of	the	knowledge	gaps	of	GPs	and	complaints	of	the	patients.		
	
Implications	for	clinical	practice	
In	this	thesis	we	showed	that	musculoskeletal	complaints	and	SpA	occur	frequently	in	patients	at	risk,	
i.e.	patients	with	psoriasis	or	IBD.	However,	these	complaints	are	often	not	recognized	as	being	SpA,	
as	medical	professionals	and	patients	themselves	often	are	not	aware	of	the	link	between	psoriasis	or	
IBD	and	SpA.	Increasing	this	awareness	is	important	as	it	could	aid	early	recognition.	In	the	following	
part	of	the	discussion	ways	to	increase	this	awareness	are	described.	
	
Increasing	Awareness	
Multiple	 target	 groups	 can	 be	 distinguished	 to	 increase	 awareness;	 general	 practitioners,	medical	
specialists	and	patients	themselves.	
	
General	Practitioners		
Over	the	last	years	it	has	been	tried	to	increase	awareness	for	rheumatic	disease	via	guidelines	and	
education	 of	 GPs.	 However,	 guidelines	 and	 education	 alone	 does	 not	 seem	 to	 be	 sufficient.	 Two	
reviews,	 of	which	 one	was	 specifically	 aimed	 at	 inflammatory	 arthritis,	 showed	 that	 referral	 from	
primary	to	secondary	care	could	also	be	 improved	via	the	use	of	self-administered	questionnaires,	
referral	sheets	or	triage	by	a	specialist	in	a	primary	care	setting.3,4	
Looking	 into	 self-administered	 questionnaires	 or	 referral	 sheets,	 the	 screeningtools	 for	 PsA	 as	
described	 in	 this	 thesis	 might	 be	 useful	 in	 this	 matter.	 They	 could	 play	 an	 important	 role	 to	 aid	
necessary	referrals	and	avoid	the	unnecessary	ones.	Unfortunately	the	sensitivity	and	specificity	of	
these	tools	remains	moderate,	also	in	primary	care	as	described	in	chapter	7.5-8	The	PEST	screeningtool	
seems	to	perform	relatively	well	and	is	very	short	and	easy	to	complete.	However,	axial	manifestations	
are	not	represented	in	the	PEST.	It	might	therefore	be	useful	to	use	another	tool	if	patients	present	
themselves	 with	 axial	 manifestations.	 Multiple	 referral	 tools	 have	 been	 developed	 for	 axial	 SpA,	
among	which	 the	Berlin,	MASTER,	RADAR,	ASAS	and	CaFaSpA.9-13	 	 For	 the	Dutch	 situation	with	an	
extensive	primary	care	system,	the	CaFaSpA	seems	to	be	most	feasible,	as	you	don’t	need	any	invasive	
or	costly	investigations	like	laboratory	tests	or	imaging.		
To	increase	awareness	another	quite	simple	thing	that	might	aid	recognition	is	linking	of	ICPC	codes.	
If	a	patient	has	psoriasis	or	IBD	this	will	be	registered	by	ICPC	code	in	the	electronic	patients	file	of	the	
GP.	If	a	patient	presents	later	on	with	musculoskeletal	complaints,	the	GP	will	add	a	new	ICPC	code	
for	this	complaint.	It	might	be	rather	useful	if	some	sort	of	pop-up	will	occur	to	draw	attention	to	the	
fact	that	the	patient	also	has	a	diagnosis	of	psoriasis	or	IBD.		
Triage	by	a	specialist	in	a	primary	care	setting	could	also	be	useful.	The	GP	could	select	patients	with	
possible	inflammatory	symptoms,	who	could	be	evaluated	by	a	specialist	in	an	easily	accessible,	low-
cost	 setting.	 If	 the	 rheumatologist	 confirms	 the	 presence	 of	 inflammatory	 symptoms,	 the	 patient	
would	be	referred	to	secondary	care	for	specialized	care.	
	
Medical	Specialists	
Besides	 the	 GPs,	 medical	 specialists	 should	 also	 be	 involved	 when	 improving	 awareness.	 All	 IBD	
patients	will	be	treated	by	a	gastroenterologist,	while	a	certain	part	of	the	psoriasis	patients	(e.g.	the	
more	 severe	psoriasis	or	psoriasis	with	a	 lot	of	 comorbidity)	will	 be	 treated	by	a	dermatologist.	A	
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recent	 study	 showed	 that	 the	 knowledge	 about	 in	 this	 case	 axial	 SpA	was	 insufficient	 in	medical	
specialists,	 leading	to	diagnostic	delay.14	To	 increase	awareness	 in	this	group,	certain	strategies	for	
GPs	could	also	be	used,	like	education	and	the	use	of	screeningtools.	As	in	a	primary	care	setting,	the	
PEST	could	also	be	used	in	dermatology	practice.	Another	way	to	improve	care	for	psoriasis	and	IBD	
patients	 in	 secondary	 care	 is	 setting	 up	 standardised	 referral	 pathways,	 or	 as	 called	 in	 Dutch	
‘zorgpaden’.	The	purpose	of	such	a	standardised	referral	pathway	is	to	standardize	care	with	regard	
to,	in	this	case,	screening	for	MSC	in	patients	with	psoriasis	or	IBD.	The	other	way	around	could	also	
be	useful;	patients	from	the	rheumatologist	with	abdominal	or	skin	problems	can	be	easily	referred	
to	the	right	specialist.	Another	advantage	in	the	secondary	care	setting	is	the	presence	of	specialized	
nurses	or	physician	assistants	who	could	be	very	helpful	in	these	matters.	
	
Patients	
It	is	to	be	expected	that	the	highest	increase	in	awareness	could	be	achieved	in	the	patient	group.	GPs	
and	medical	specialists	have	very	little	time	during	their	consultations	and	see	many	patients	per	day.	
If	patients	themselves	are	aware	of	the	link	between	MSC	and	their	IBD/psoriasis,	they	can	actively	
ask	their	GP	or	medical	specialist	about	their	complaints.	To	increase	this	awareness	in	patients	at	risk	
and	thereby	reducing	patient	delay,	several	options	have	been	studied,	for	example	community	case	
finding	strategies,	public	awareness	programs	and	internet	and	website	information.4,15	
For	patients	with	psoriasis	or	IBD,	public	awareness	campaigns	or	posters	in	the	waiting	room	of	the	
GP	may	not	be	the	right	way	to	go.	SpA	in	these	patients	is	relatively	rare	compared	to	the	general	
prevalence	 of	 musculoskeletal	 complaints.	 It	 may	 be	 more	 efficient	 to	 add	 information	 about	
musculoskeletal	complaints	and	SpA	to	the	information	folders	of	psoriasis	and	IBD.	In	that	way,	when	
patients	are	diagnosed	with	psoriasis	or	IBD,	they	will	receive	an	information	folder	about	their	disease	
and	 directly	 have	 information	 about	 their	 risk	 of	 developing	 SpA.	 For	 psoriasis	 this	 could	 be	
implemented	in	general	practice	as	well	as	in	outpatient	clinics	dermatology.	For	IBD	patients,	as	they	
will	all	visit	a	gastroenterologist	to	be	diagnosed	with	IBD,	it	is	more	efficient	to	implement	this	at	the	
gastroenterology	outpatient	clinic.	Some	of	the	larger	hospital	have	physician	assistants	especially	for	
IBD	patients,	which	would	be	an	excellent	opportunity	to	inform	these	patients	about	SpA.	In	addition	
to	medical	professionals,	the	patient	organizations	for	psoriasis	and	IBD	could	also	play	an	important	
role.	The	patient	organizations	have	a	broad	reach	among	patients	and	could	inform	their	patients	via	
their	website,	newsletters,	social	media	etcetera.		
	
	
	
Recommendations	for	further	research	
Over	 the	 years	 a	 lot	 of	 different	 classification	 criteria	 for	 SpA	have	been	developed.16-20	 The	most	
recent	set	of	criteria	are	the	ASAS	criteria	developed	around	2010.19,20	When	using	these	criteria	a	
distinction	is	made	between	axial	and	peripheral	SpA,	based	on	the	most	predominant	symptoms.	A	
lot	 of	 studies	 can	 be	 found	 on	 spondyloarthritis,	 but	 these	 studies	 mostly	 only	 cover	 axial	
spondyloarthritis.	Data	about	prevalence,	quality	of	life,	and	work	participation	of	peripheral	SpA	are	
scarce.	Our	recommendation	would	therefore	be	to	conduct	more	research	on	peripheral	SpA.	
	
Our	second	recommendation	for	further	research	would	be	to	develop	screeningtools	and	screening	
strategies	voor	SpA	 in	patients	with	 IBD.	For	PsA	multiple	screeningtools	and	strategies	have	been	
developed	 and	 although	 SpA	 in	 IBD	 occurs	 as	 frequently,	 no	 screeningtools	 are	 available.	 As	 all	
patients	 with	 IBD	 will	 be	 attending	 an	 outpatient	 gastroenterology	 clinic,	 this	 can	 be	 a	 good	
opportunity	for	screening.	Some	of	the	larger	hospitals	even	work	with	IBD	specialized	nurses,	who	
could	be	trained	in	screening	these	patients.	If	you	look	for	example	at	the	existing	screeningtools	for	
PsA,	most	of	these	questions	are	fairly	general	and	could	be	applied	to	SpA	in	IBD	patients	as	well.	It	
would	 be	 interesting	 to	 set	 up	 a	 study	 in	 a	 gastroenterology	 outpatient	 clinic,	 using	 parts	 of	 the	
screeningtools	developed	for	PsA	to	see	which	items	are	most	indicative	of	a	diagnosis	of	SpA.		
	
Awareness	for	SpA	should	be	improved,	however	the	best	way	to	achieve	this	is	still	unclear.	It	would	
be	 very	 interesting	 to	 set	 up	 a	 trial	 to	 compare	 standard	 care	 as	 used	 nowadays	with	 the	 use	 of	
screeningtools	and	with	triage	of	a	rheumatologist/rheumatology	nurse.	The	screeningtools	could	be	
implemented	fairly	easily	as	most	GP	practices	work	with	practice	assistants.	They	have	proven	to	be	
very	useful	in	chronic	care	for	for	example	patients	with	diabetes	or	chronic	obstructive	pulmonary	
disease.	Patients	with	psoriasis	or	IBD	could	be	selected	by	ICPC	code	and	complete	the	screeningtool,	
the	practice	assistant	could	aid	in	checking	the	completed	tools	and	arrange	a	referral	to	secondary	
care	 if	 necessary.	 In	 a	 head-to-head	 comparison,	 practices	 should	 be	 randomized	 to	 either	 use	
standard	care,	screeningtools	or	triage	by	a	rheumatologist.		
In	the	secondary	care	setting,	the	added	value	of	using	screeningtools	should	be	investigated.	These	
tools	are	not	used	in	daily	practice	nowadays	but	could	lead	to	more	adequate	and	early	referrals	to	
the	rheumatologist.	
	
For	 both	 the	 screeningtools	 for	 PsA	 as	 the	 referral	 tools	 for	 axial	 SpA,	 multiple	 tools	 have	 been	
developed	over	the	years.	Most	of	these	tools	have	also	been	validated	in	different	cohorts.	However,	
studies	 looking	 at	 the	 impact	 of	 implementing	 such	 tools	 is	 lacking.	 Literature	 shows	 that	 early	
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recent	 study	 showed	 that	 the	 knowledge	 about	 in	 this	 case	 axial	 SpA	was	 insufficient	 in	medical	
specialists,	 leading	to	diagnostic	delay.14	To	 increase	awareness	 in	this	group,	certain	strategies	for	
GPs	could	also	be	used,	like	education	and	the	use	of	screeningtools.	As	in	a	primary	care	setting,	the	
PEST	could	also	be	used	in	dermatology	practice.	Another	way	to	improve	care	for	psoriasis	and	IBD	
patients	 in	 secondary	 care	 is	 setting	 up	 standardised	 referral	 pathways,	 or	 as	 called	 in	 Dutch	
‘zorgpaden’.	The	purpose	of	such	a	standardised	referral	pathway	is	to	standardize	care	with	regard	
to,	in	this	case,	screening	for	MSC	in	patients	with	psoriasis	or	IBD.	The	other	way	around	could	also	
be	useful;	patients	from	the	rheumatologist	with	abdominal	or	skin	problems	can	be	easily	referred	
to	the	right	specialist.	Another	advantage	in	the	secondary	care	setting	is	the	presence	of	specialized	
nurses	or	physician	assistants	who	could	be	very	helpful	in	these	matters.	
	
Patients	
It	is	to	be	expected	that	the	highest	increase	in	awareness	could	be	achieved	in	the	patient	group.	GPs	
and	medical	specialists	have	very	little	time	during	their	consultations	and	see	many	patients	per	day.	
If	patients	themselves	are	aware	of	the	link	between	MSC	and	their	IBD/psoriasis,	they	can	actively	
ask	their	GP	or	medical	specialist	about	their	complaints.	To	increase	this	awareness	in	patients	at	risk	
and	thereby	reducing	patient	delay,	several	options	have	been	studied,	for	example	community	case	
finding	strategies,	public	awareness	programs	and	internet	and	website	information.4,15	
For	patients	with	psoriasis	or	IBD,	public	awareness	campaigns	or	posters	in	the	waiting	room	of	the	
GP	may	not	be	the	right	way	to	go.	SpA	in	these	patients	is	relatively	rare	compared	to	the	general	
prevalence	 of	 musculoskeletal	 complaints.	 It	 may	 be	 more	 efficient	 to	 add	 information	 about	
musculoskeletal	complaints	and	SpA	to	the	information	folders	of	psoriasis	and	IBD.	In	that	way,	when	
patients	are	diagnosed	with	psoriasis	or	IBD,	they	will	receive	an	information	folder	about	their	disease	
and	 directly	 have	 information	 about	 their	 risk	 of	 developing	 SpA.	 For	 psoriasis	 this	 could	 be	
implemented	in	general	practice	as	well	as	in	outpatient	clinics	dermatology.	For	IBD	patients,	as	they	
will	all	visit	a	gastroenterologist	to	be	diagnosed	with	IBD,	it	is	more	efficient	to	implement	this	at	the	
gastroenterology	outpatient	clinic.	Some	of	the	larger	hospital	have	physician	assistants	especially	for	
IBD	patients,	which	would	be	an	excellent	opportunity	to	inform	these	patients	about	SpA.	In	addition	
to	medical	professionals,	the	patient	organizations	for	psoriasis	and	IBD	could	also	play	an	important	
role.	The	patient	organizations	have	a	broad	reach	among	patients	and	could	inform	their	patients	via	
their	website,	newsletters,	social	media	etcetera.		
	
	
	
Recommendations	for	further	research	
Over	 the	 years	 a	 lot	 of	 different	 classification	 criteria	 for	 SpA	have	been	developed.16-20	 The	most	
recent	set	of	criteria	are	the	ASAS	criteria	developed	around	2010.19,20	When	using	these	criteria	a	
distinction	is	made	between	axial	and	peripheral	SpA,	based	on	the	most	predominant	symptoms.	A	
lot	 of	 studies	 can	 be	 found	 on	 spondyloarthritis,	 but	 these	 studies	 mostly	 only	 cover	 axial	
spondyloarthritis.	Data	about	prevalence,	quality	of	life,	and	work	participation	of	peripheral	SpA	are	
scarce.	Our	recommendation	would	therefore	be	to	conduct	more	research	on	peripheral	SpA.	
	
Our	second	recommendation	for	further	research	would	be	to	develop	screeningtools	and	screening	
strategies	voor	SpA	 in	patients	with	 IBD.	For	PsA	multiple	screeningtools	and	strategies	have	been	
developed	 and	 although	 SpA	 in	 IBD	 occurs	 as	 frequently,	 no	 screeningtools	 are	 available.	 As	 all	
patients	 with	 IBD	 will	 be	 attending	 an	 outpatient	 gastroenterology	 clinic,	 this	 can	 be	 a	 good	
opportunity	for	screening.	Some	of	the	larger	hospitals	even	work	with	IBD	specialized	nurses,	who	
could	be	trained	in	screening	these	patients.	If	you	look	for	example	at	the	existing	screeningtools	for	
PsA,	most	of	these	questions	are	fairly	general	and	could	be	applied	to	SpA	in	IBD	patients	as	well.	It	
would	 be	 interesting	 to	 set	 up	 a	 study	 in	 a	 gastroenterology	 outpatient	 clinic,	 using	 parts	 of	 the	
screeningtools	developed	for	PsA	to	see	which	items	are	most	indicative	of	a	diagnosis	of	SpA.		
	
Awareness	for	SpA	should	be	improved,	however	the	best	way	to	achieve	this	is	still	unclear.	It	would	
be	 very	 interesting	 to	 set	 up	 a	 trial	 to	 compare	 standard	 care	 as	 used	 nowadays	with	 the	 use	 of	
screeningtools	and	with	triage	of	a	rheumatologist/rheumatology	nurse.	The	screeningtools	could	be	
implemented	fairly	easily	as	most	GP	practices	work	with	practice	assistants.	They	have	proven	to	be	
very	useful	in	chronic	care	for	for	example	patients	with	diabetes	or	chronic	obstructive	pulmonary	
disease.	Patients	with	psoriasis	or	IBD	could	be	selected	by	ICPC	code	and	complete	the	screeningtool,	
the	practice	assistant	could	aid	in	checking	the	completed	tools	and	arrange	a	referral	to	secondary	
care	 if	 necessary.	 In	 a	 head-to-head	 comparison,	 practices	 should	 be	 randomized	 to	 either	 use	
standard	care,	screeningtools	or	triage	by	a	rheumatologist.		
In	the	secondary	care	setting,	the	added	value	of	using	screeningtools	should	be	investigated.	These	
tools	are	not	used	in	daily	practice	nowadays	but	could	lead	to	more	adequate	and	early	referrals	to	
the	rheumatologist.	
	
For	 both	 the	 screeningtools	 for	 PsA	 as	 the	 referral	 tools	 for	 axial	 SpA,	 multiple	 tools	 have	 been	
developed	over	the	years.	Most	of	these	tools	have	also	been	validated	in	different	cohorts.	However,	
studies	 looking	 at	 the	 impact	 of	 implementing	 such	 tools	 is	 lacking.	 Literature	 shows	 that	 early	
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diagnosis	of	rheumatic	disease	leads	to	better	outcomes	in	the	longterm.	However,	focusing	on	early	
recognition,	also	leads	to	more	patients	referred	to	secondary	care	which	is	rather	costly.	On	top	of	
that,	care	nowadays	becomes	much	more	patient-centered	with	shared-decision	making	becoming	
more	and	more	important.	So	the	question	raises,	what	is	the	actual	benefit	for	the	patient?	With	the	
severe	destructing	 forms	of	SpA,	 it	 seems	rather	clear	 that	preventing	 this	as	much	as	possible	by	
starting	treatment	early	on	is	beneficial.	But	patients	who	present	with	mild	forms	of	SpA,	what	is	the	
additional	value	of	diagnosing	and	treating	as	early	as	possible	for	them?	Does	it	increase	their	quality	
of	life?	I	think	patients	who	might	suffer	from	inflammatory	joint	disease	should	always	be	seen	by	a	
rheumatologist,	for	example	in	a	less	costly	construction	like	consultation	in	a	primary	care	setting.	
However,	 it	should	be	 investigated	what	the	value	 is	of	diagnosing	and	treating	patients	with	mild	
forms	early	on,	for	both	the	patients	and	the	costs	associated	with	this.		
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diagnosis	of	rheumatic	disease	leads	to	better	outcomes	in	the	longterm.	However,	focusing	on	early	
recognition,	also	leads	to	more	patients	referred	to	secondary	care	which	is	rather	costly.	On	top	of	
that,	care	nowadays	becomes	much	more	patient-centered	with	shared-decision	making	becoming	
more	and	more	important.	So	the	question	raises,	what	is	the	actual	benefit	for	the	patient?	With	the	
severe	destructing	 forms	of	SpA,	 it	 seems	rather	clear	 that	preventing	 this	as	much	as	possible	by	
starting	treatment	early	on	is	beneficial.	But	patients	who	present	with	mild	forms	of	SpA,	what	is	the	
additional	value	of	diagnosing	and	treating	as	early	as	possible	for	them?	Does	it	increase	their	quality	
of	life?	I	think	patients	who	might	suffer	from	inflammatory	joint	disease	should	always	be	seen	by	a	
rheumatologist,	for	example	in	a	less	costly	construction	like	consultation	in	a	primary	care	setting.	
However,	 it	should	be	 investigated	what	the	value	 is	of	diagnosing	and	treating	patients	with	mild	
forms	early	on,	for	both	the	patients	and	the	costs	associated	with	this.		
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Chapter 10.
Summary
Samenvatting
Summary	
	
Chapter	1	provides	a	general	introduction	to	this	thesis.	Spondyloarthritis	(SpA)	is	an	umbrella	term	
for	a	group	of	inflammatory	rheumatic	diseases.	It	can	manifest	with	axial	symptoms	(low	back	pain,	
sacroiliitis)	 or	 peripheral	 symptoms	 (arthritis,	 enthesitis,	 dactylitis).	 Patients	 with	 psoriasis	 or	
inflammatory	 bowel	 disease	 (IBD)	 have	 an	 increased	 risk	 of	 developing	 SpA,	 as	 there	 are	 many	
overlapping	mechanisms	in	the	pathogenesis	of	these	diseases	leading	to	subtypes	of	SpA	as	psoriatic	
arthritis	(PsA)	and	SpA	in	IBD	patients	(IBD-SpA).	Early	recognition	of	SpA	is	important,	as	early	and	
adequate	treatment	lead	to	better	outcomes	in	the	longterm.	This	thesis	is	divided	in	two	parts.	The	
first	part	described	the	prevalence	and	impact	of	SpA	in	patients	at	risk,	while	the	second	part	focused	
on	early	recognition	by	means	of	increasing	awareness	and	using	screeningtools.	
	
Part	I.	Prevalence	and	Burden	of	Spondyloarthritis	in	Patients	at	Risk	
In	chapter	2	we	evaluated	 the	prevalence	of	PsA	and	musculoskeletal	 complaints	among	psoriasis	
patients	in	a	primary	care	setting.	GPs	who	were	willing	to	participate,	selected	psoriasis	patients	out	
of	their	databases	and	invited	them	to	participate.	Patients	were	eligible	to	participate	if	they	were	18	
years	and	over,	had	a	diagnosis	of	psoriasis	and	experienced	any	kind	of	musculoskeletal	complaints.	
Out	of	the	total	of	97	GPs	who	participated,	2564	psoriasis	patients	were	selected	of	whom	841	were	
eligible	 and	willing	 to	 participate.	 Participating	 patients	 completed	 a	 set	 of	 questionnaires	 before	
clinical	evaluation	by	a	 trained	research	nurse.	Clinical	evaluation	 included	assessment	of	 the	skin,	
joints,	tendon	and	back.	If	there	were	indications	for	underlying	inflammatory	disease,	patients	were	
advised	to	consult	a	rheumatologist.		
PsA	was	diagnosed	by	a	rheumatologist	in	17	cases	and	64	were	diagnosed	with	psoriasis	before	the	
study,	leading	to	a	prevalence	of	3.2%.	Besides	these	cases,	36	patients	were	found	to	have	enthesitis,	
confirmed	by	ultrasound,	and	could	classify	als	PsA	according	to	the	CASPAR	criteria.	Classifying	these	
patients	as	PsA,	would	increase	the	prevalence	to	4.6%.	The	prevalence	of	musculoskeletal	complaints	
was	with	32.1%	comparable	with	the	prevalence	in	the	Dutch	population.	
	
Chapter	 3	 describes	 the	 ultrasound	 findings	 in	 the	 patients	 who	 were	 found	 to	 clinically	 have	
enthesitis.	 In	 the	 CASPAR	 criteria	 enthesitis	 is	 stated	 as	 an	 entry	 criteria,	 leading	 to	 the	 fact	 that	
patients	with	enthesitis	could	classify	as	PsA.	The	problem	is	that	the	definition	of	enthesitis	 is	not	
entirely	 clear.	 We	 therefore	 performed	 ultrasound	 of	 the	 entheses	 on	 patients	 with	 clinically	
suspected	enthesitis	as	defined	by	the	LEI	or	MASES	scores.	In	total,	we	found	111	patients	with	tender	
entheses	who	underwent	ultrasound	examination	of	seven	entheses	according	to	the	MASEI	score.	
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Chapter 10
172
We	defined	 clinically	 relevant	 inflammation	 as	 active	 inflammation	 on	 ultrasound	 (positive	 power	
Doppler	 signal	 or	 in	 case	 of	 the	 plantar	 fascia	 increased	 thickness)	 in	 combination	 with	 a	 tender	
enthesis	at	the	same	site	during	clinical	examination.	Forty	patients	(36%)	of	the	patients	had	clinically	
relevant	inflammation.	The	most	common	sites	were	the	knee	and	the	plantar	aponeurosis.	Structural	
changes	 were	 found	 in	 95%	 of	 the	 screened	 psoriasis	 patients	 independent	 of	 their	 clinical	
manifestation.	
	
Besides	patients	with	psoriasis,	patients	with	IBD	are	also	at	risk	for	developing	SpA.	To	assess	the	size	
of	this	problem,	we	performed	a	systematic	review	and	meta-analysis	on	the	prevalence	and	incidence	
of	 axial	 and	 peripheral	 manifestations	 of	 SpA	 in	 patients	 with	 IBD	 as	 described	 in	 chapter	 4.	 An	
extensive	 search	 strategy	 was	 set	 up	 in	 collaboration	 with	 the	 medical	 library,	 leading	 to	 4845	
potentially	relevant	articles.	After	screening	the	titles	and	abstracts	and	subsequently	the	full	text	of	
these	papers,	60	were	relevant	and	were	included.	Quality	assessment	of	the	included	articles	showed	
moderate	 overall	 quality.	 With	 regard	 to	 axial	 manifestations	 (i.e.	 sacroiliitis	 and	 ankylosing	
spondylitis),	53	papers	reported	on	the	prevalence	in	IBD	patients.	The	pooled	prevalence	was	11%	
for	 sacroiliitis	 and	 3%	 for	 its	 subtype	 ankylosing	 spondylitis.	 Forty-four	 studies	 reported	 on	 the	
prevalence	of	peripheral	arthritis,	leading	to	a	pooled	estimate	of	14%.For	the	prevalence	of	the	other	
peripheral	manifestations	few	estimates	were	available,	leading	to	a	prevalence	range	from	1-54%	for	
enthesitis	and	0-5%	for	dactylitis.	Only	three	studies	reported	on	the	incidence	of	SpA	in	IBD,	reporting	
cumulative	incidences	from	0.48	at	10	years	to	0.22	at	30	years.	
	
We	now	know	that	SpA	occurs	frequently	in	patients	with	IBD.	Most	of	these	patients	will	suffer	from	
musculoskeletal	 complaints	 before	 they	 are	 diagnosed	with	 SpA.	 In	 chapter	 5	we	 looked	 into	 the	
burden	of	these	musculoskeletal	complaints	in	patients	with	IBD.	We	set	up	a	cross-sectional	survey	
among	 patients	 diagnosed	 with	 IBD	 between	 18	 and	 55	 years	 of	 age.	 They	 completed	 different	
questionnaires	regarding	their	MSC,	but	also	on	quality	of	life,	disability	and	work	participation	and	
productivity.	 In	 total,	 338	 patients	 completed	 the	 questionnaires,	 of	 whom	 45.6%	 suffered	 from	
Crohn’s	 disease	 and	 45.0%	 suffered	 from	ulcerative	 colitis.	 The	mean	 age	 of	 the	 participants	was	
42.3±9.3	years	and	25.4%	were	male.	MSC	were	very	common	with	a	prevalence	of	81.1%,	with	more	
frequent	occurrence	in	patients	with	CD	compared	to	UC.	Overall,	patients	with	IBD	and	MSC	reported	
significantly	lower	quality	of	life	on	both	the	IBDQ	and	the	SF-36.	Differences	could	also	be	shown	in	
work	participation	and	productivity,	where	patients	with	MSC	were	more	often	unemployed,	work-
disabled	 and	 reported	 lower	 work	 productivity.	With	 this	 study	 we	 showed	 that	MSC	 are	 a	 very	
common	extra-intestinal	manifestation	with	significant	impact	on	quality	of	life	and	work	participation	
and	productivity.	Interestingly,	reduced	quality	of	life	seemed	to	be	influenced	explicitly	by	MSC.	
	
Part	II.	Awareness	and	Early	Recognition	of	Spondyloarthritis	in	Patients	at	Risk	
In	the	first	part	of	this	thesis	we	established	the	prevalence	of	spondyloarthritis	in	patients	at	risk	and	
its	 impact.	We	know	that	early	recognition	of	SpA	 in	these	patients	 leads	to	earlier	 treatment	and	
thereby	 better	 outcomes	 in	 the	 longterm.	 To	 enhance	 this	 early	 recognition,	 there	 should	 be	
awareness	for	SpA.	 In	chapter	6	we	describe	the	results	of	the	AppSpA	study,	which	was	set	up	to	
assess	 the	 current	 awareness	 for	 SpA	 in	 both	 general	 practitioners	 and	 patients	 themselves.	We	
developed	a	survey	for	GPs	to	complete,	focussing	on	recognition	of	inflammatory	symptoms	and	SpA-
specific	 features.	 Patients’	 awareness	 was	 also	 assessed	 with	 a	 survey.	 We	 invited	 949	 GPs	 to	
participate,	of	whom	312	returned	the	survey	(response	rate	32.9%)	of	whom	185	GPs	completed	the	
survey.	With	regard	to	the	recognition	of	signs	of	inflammatory	pain,	especially	classic	symptoms	like	
morning	 stiffness	 and	pain	 relieve	by	NSAIDs	were	 recognized,	whereas	other	 symptoms	 like	pain	
improvement	with	exercise	were	poorly	recognized.	Almost	60%	of	GPs	did	not	recognize	half	of	the	
features	indicative	of	inflammatory	peripheral	joint	disease,	for	inflammatory	axial	disease	this	was	
40%.	The	majority	of	GPs	also	associated	SpA	solely	with	axial	disease.	In	the	patient-part	of	this	study,	
we	 saw	 that	 less	 than	 half	 of	 the	 patients	 with	 psoriasis	 or	 IBD	 was	 aware	 of	 the	 possibility	 of	
developing	 SpA,	 namely	 42.6%.	 If	 they	 were	 aware	 of	 this	 possibility,	 most	 of	 them	 gained	 this	
knowledge	 themselves	and	were	not	 informed	by	a	medical	professional.	The	 results	of	 this	 study	
indicate	that	there	is	room	for	improvement	of	the	awareness	for	SpA	in	both	GPs	and	patients	at	risk.	
	
One	thing	that	could	aid	early	recognition	and	awareness	is	the	use	of	screeningtools.	For	PsA	several	
screeningtools	have	been	developed.	Most	of	these	tools	were	developed	and	tested	 in	secondary	
care	settings.	However,	in	the	Netherlands,	where	we	have	an	extensive	primary	care	system	these	
tools	could	best	be	used	in	primary	care.	In	chapter	7	we	investigated	the	performance	of	the	existing	
screeningtools	in	primary	care.	For	this	part	we	used	data	from	the	SENSOR	study.	We	included	473	
psoriasis	patients	without	a	diagnosis	of	PsA.	They	completed	the	PEST,	PASE	and	EARP	screeningtools	
before	they	were	clinically	evaluated	by	a	trained	research	nurse.	In	53	patients	a	diagnosis	of	PsA	was	
made	by	a	rheumatologist	according	to	the	CASPAR	criteria.	The	PEST	had	a	sensitivity	of	0.68	and	a	
specificity	 of	 0.71.	 The	 PASE	 was	 validated	 for	 two	 different	 cut-offs.	 The	 cut-off	 of	 47	 led	 to	 a	
sensitivity	of	0.59	and	a	specificity	of	0.66,	whereas	the	lower	cut-off	of	44	led	to	a	sensitivity	of	0.66	
and	a	specificity	of	0.57.	For	the	EARP	and	we	found	a	sensitivity	of	0.87	with	a	specificity	of	0.34.	In	
this	study	the	PEST	seems	to	have	the	most	favourable	trade-off	between	sensitivity	and	specificity	to	
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prevalence	of	peripheral	arthritis,	leading	to	a	pooled	estimate	of	14%.For	the	prevalence	of	the	other	
peripheral	manifestations	few	estimates	were	available,	leading	to	a	prevalence	range	from	1-54%	for	
enthesitis	and	0-5%	for	dactylitis.	Only	three	studies	reported	on	the	incidence	of	SpA	in	IBD,	reporting	
cumulative	incidences	from	0.48	at	10	years	to	0.22	at	30	years.	
	
We	now	know	that	SpA	occurs	frequently	in	patients	with	IBD.	Most	of	these	patients	will	suffer	from	
musculoskeletal	 complaints	 before	 they	 are	 diagnosed	with	 SpA.	 In	 chapter	 5	we	 looked	 into	 the	
burden	of	these	musculoskeletal	complaints	in	patients	with	IBD.	We	set	up	a	cross-sectional	survey	
among	 patients	 diagnosed	 with	 IBD	 between	 18	 and	 55	 years	 of	 age.	 They	 completed	 different	
questionnaires	regarding	their	MSC,	but	also	on	quality	of	life,	disability	and	work	participation	and	
productivity.	 In	 total,	 338	 patients	 completed	 the	 questionnaires,	 of	 whom	 45.6%	 suffered	 from	
Crohn’s	 disease	 and	 45.0%	 suffered	 from	ulcerative	 colitis.	 The	mean	 age	 of	 the	 participants	was	
42.3±9.3	years	and	25.4%	were	male.	MSC	were	very	common	with	a	prevalence	of	81.1%,	with	more	
frequent	occurrence	in	patients	with	CD	compared	to	UC.	Overall,	patients	with	IBD	and	MSC	reported	
significantly	lower	quality	of	life	on	both	the	IBDQ	and	the	SF-36.	Differences	could	also	be	shown	in	
work	participation	and	productivity,	where	patients	with	MSC	were	more	often	unemployed,	work-
disabled	 and	 reported	 lower	 work	 productivity.	With	 this	 study	 we	 showed	 that	MSC	 are	 a	 very	
common	extra-intestinal	manifestation	with	significant	impact	on	quality	of	life	and	work	participation	
and	productivity.	Interestingly,	reduced	quality	of	life	seemed	to	be	influenced	explicitly	by	MSC.	
	
Part	II.	Awareness	and	Early	Recognition	of	Spondyloarthritis	in	Patients	at	Risk	
In	the	first	part	of	this	thesis	we	established	the	prevalence	of	spondyloarthritis	in	patients	at	risk	and	
its	 impact.	We	know	that	early	recognition	of	SpA	 in	these	patients	 leads	to	earlier	 treatment	and	
thereby	 better	 outcomes	 in	 the	 longterm.	 To	 enhance	 this	 early	 recognition,	 there	 should	 be	
awareness	for	SpA.	 In	chapter	6	we	describe	the	results	of	the	AppSpA	study,	which	was	set	up	to	
assess	 the	 current	 awareness	 for	 SpA	 in	 both	 general	 practitioners	 and	 patients	 themselves.	We	
developed	a	survey	for	GPs	to	complete,	focussing	on	recognition	of	inflammatory	symptoms	and	SpA-
specific	 features.	 Patients’	 awareness	 was	 also	 assessed	 with	 a	 survey.	 We	 invited	 949	 GPs	 to	
participate,	of	whom	312	returned	the	survey	(response	rate	32.9%)	of	whom	185	GPs	completed	the	
survey.	With	regard	to	the	recognition	of	signs	of	inflammatory	pain,	especially	classic	symptoms	like	
morning	 stiffness	 and	pain	 relieve	by	NSAIDs	were	 recognized,	whereas	other	 symptoms	 like	pain	
improvement	with	exercise	were	poorly	recognized.	Almost	60%	of	GPs	did	not	recognize	half	of	the	
features	indicative	of	inflammatory	peripheral	joint	disease,	for	inflammatory	axial	disease	this	was	
40%.	The	majority	of	GPs	also	associated	SpA	solely	with	axial	disease.	In	the	patient-part	of	this	study,	
we	 saw	 that	 less	 than	 half	 of	 the	 patients	 with	 psoriasis	 or	 IBD	 was	 aware	 of	 the	 possibility	 of	
developing	 SpA,	 namely	 42.6%.	 If	 they	 were	 aware	 of	 this	 possibility,	 most	 of	 them	 gained	 this	
knowledge	 themselves	and	were	not	 informed	by	a	medical	professional.	The	 results	of	 this	 study	
indicate	that	there	is	room	for	improvement	of	the	awareness	for	SpA	in	both	GPs	and	patients	at	risk.	
	
One	thing	that	could	aid	early	recognition	and	awareness	is	the	use	of	screeningtools.	For	PsA	several	
screeningtools	have	been	developed.	Most	of	these	tools	were	developed	and	tested	 in	secondary	
care	settings.	However,	in	the	Netherlands,	where	we	have	an	extensive	primary	care	system	these	
tools	could	best	be	used	in	primary	care.	In	chapter	7	we	investigated	the	performance	of	the	existing	
screeningtools	in	primary	care.	For	this	part	we	used	data	from	the	SENSOR	study.	We	included	473	
psoriasis	patients	without	a	diagnosis	of	PsA.	They	completed	the	PEST,	PASE	and	EARP	screeningtools	
before	they	were	clinically	evaluated	by	a	trained	research	nurse.	In	53	patients	a	diagnosis	of	PsA	was	
made	by	a	rheumatologist	according	to	the	CASPAR	criteria.	The	PEST	had	a	sensitivity	of	0.68	and	a	
specificity	 of	 0.71.	 The	 PASE	 was	 validated	 for	 two	 different	 cut-offs.	 The	 cut-off	 of	 47	 led	 to	 a	
sensitivity	of	0.59	and	a	specificity	of	0.66,	whereas	the	lower	cut-off	of	44	led	to	a	sensitivity	of	0.66	
and	a	specificity	of	0.57.	For	the	EARP	and	we	found	a	sensitivity	of	0.87	with	a	specificity	of	0.34.	In	
this	study	the	PEST	seems	to	have	the	most	favourable	trade-off	between	sensitivity	and	specificity	to	
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screen	 for	 PsA.	 It	 might	 however	 be	 more	 useful	 to	 only	 screen	 patients	 with	 musculoskeletal	
complaints,	due	to	the	fairly	low	prevalence	of	PsA	in	primary	care.	
	
As	 shown	 in	 chapter	 7	 and	 various	 other	 validation	 studies,	 the	 existing	 screeningtools	 perform	
moderately.	 This	 is	 why	 the	 CONTEST	 group	 developed	 a	 new	 screeningtool	 based	 on	 the	 best	
performing	items	of	the	previous	screeningtools.	In	chapter	8	we	assessed	the	additional	value	of	this	
CONTEST	 questionnaire	 in	 a	 primary	 care	 setting.	 Data	 from	 the	 SENSOR	 study	was	 used	 and	we	
calculated	sensitivity,	specificity	and	area	under	the	curve	for	the	various	versions	of	the	CONTEST.	
For	 this	 analysis,	 473	 psoriasis	 patients	 without	 PsA	 were	 available.	 The	 AUC	 of	 the	 CONTEST	
questionnaires	 ranged	 between	 0.67-0.69	 and	 sensitivities	 between	 0.30-0.51	 in	 our	 primary	 care	
population,	 whereas	 the	 specificities	 were	 between	 0.74-0.86.	 On	 sensitivity	 the	 PEST	 (0.68),	
PASE(0.66)	and	EARP(0.87)	performed	better	than	the	CONTEST	questionnaires,	whereas	with	regard	
to	specificity	the	CONTEST	performed	slightly	better	than	the	PEST	(0.71),	PASE	(0.57)	and	EARP	(0.34).	
In	our	primary	care	setting	we	therefore	conclude	that	 the	performance	of	 the	CONTEST	does	not	
exceed	the	performance	of	the	PEST,	PASE	or	EARP.	
	
Chapter	9	provides	a	general	discussion	about	our	results.	The	discussion	focuses	on	generalizability	
of	our	results	and	recommendations	for	future	research.	In	this	chapter	we	also	describe	possibilities	
to	 improve	 awareness	 for	 SpA	 and	 ideas	 for	 research	 to	 investigate	 the	best	way	 to	 improve	 this	
awareness.	
	 	
Samenvatting	
	
Hoofdstuk	 1	 vormt	 de	 algemene	 introductie	 van	 dit	 proefschrift.	 Spondylarthopathie	 (SpA)	 is	 een	
overkoepelende	 term	 voor	 een	 groep	 van	 inflamamtoire	 reumatische	 aandoeningen.	Het	 kan	 zich	
presenteren	 met	 axiale	 symptomen	 (lage	 rugpijn,	 sacroiliitis)	 of	 perifere	 symptomen	 (artritis,	
enthesitis,	 dactylitis).	 Patienten	 met	 psoriasis	 of	 inflammatoire	 darmziekten	 (IBD)	 hebben	 een	
verhoogd	risico	op	het	ontwikkelen	van	SpA,	vanwege	de	grote	overlap	in	de	pathogenese	van	deze	
ziekten,	 wat	 kan	 leiden	 tot	 de	 subtypes	 artritis	 psoriatica	 (PsA)	 of	 IBD	 gerelateerde	 SpA.	
Vroegherkenning	van	SpA	is	belangrijk,	aangezien	vroege	en	adequate	behandeling	leidt	tot	betere	
uitkomsten	op	de	lange	termijn.	
	
Dit	proefschrift	bestaat	uit	twee	delen.	Het	eerste	deel	richt	zich	op	de	prevalentie	en	impact	van	SpA	
in	patienten	met	een	verhoogd	risico.	Het	tweede	gedeelte	richt	zich	op	vroegherkenning	en	hoe	dit	
verbeterd	kan	worden	met	het	vergroten	van	de	awareness	en	het	inzetten	van	screeningtools.	
	
In	hoofdstuk	2	wordt	de	prevalentie	van	PsA	en	musculoskeletale	klachten	bij	patienten	met	psoriasis	
in	de	eerste	lijn	beschreven.	Huisartsen	die	bereid	waren	deel	te	nemen,	selecteerden	de	psoriasis	
patienten	uit	hun	praktijk	op	basis	van	 ICPC	code	en	nodigden	hen	uit	om	mee	te	doen.	Patienten	
konden	deelenemen	als	ze	18	jaar	of	ouder	waren,	een	diagnose	psoriasis	hadden	en	musculoskeletale	
klachten	hadden.	Er	deden	97	huisartsen	mee,	die	samen	2564	patienten	met	psoriasis	in	hun	praktijk	
hadden,	van	wie	841	geschikt	waren	en	mee	wilden	doen.	Deelnemende	patienten	vulden	een	set	
vragenlijsten	 in	 voordat	 ze	 klinisch	 geevalueerd	 warden.	 De	 klinische	 evaluatie	 bestond	 uit	 een	
uitgebreide	 anamnese	 en	 lichamelijk	 onderzoek	 van	 de	 huid,	 gewrichten,	 pezen	 en	 rug.	 Als	 er	
aanwijzingen	waren	voor	een	onderliggende	reumatische	ziekte	werden	patienten	geadviseerd	zich	
naar	een	reumatoloog	te	 laten	verwijzen.	PsA	werd	gediagnosticeerd	door	een	reumatoloog	bij	17	
patienten	en	64	patienten	hadden	al	een	diagnose	PsA	voordat	de	studie	begon.	Tezamen	leidt	dit	tot	
een	prevalentie	van	3,2%.	Naast	deze	gediagnosticeerde	patienten,	bleken	er	36	patienten	te	zijn	die	
enthesitis	 hadden,	 bevestigd	 met	 echo,	 die	 op	 basis	 van	 de	 CASPAR	 criteria	 zouden	 kunnen	
classificeren	als	PsA.	Als	je	deze	patienten	mee	zou	nemen	in	je	prevalentie,	zou	je	op	een	prevalentie	
van	4.6%	uitkomen.	De	prevalentie	van	musculoskeletale	klachten	was	met	32.6%	vergelijkbaar	met	
de	prevalentie	van	de	algemene	Nederlandse	bevolking.	
	
Zoals	hierboven	beschreven	waren	er	patienten	met	enkel	enthesitis	klachten.	In	hoofdstuk	3	worden	
de	echo	bevindingen	bij	deze	patienten	besproken.	In	de	CASPAR	criteria	is	enthesitis	opgenomen	als	
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For	 this	 analysis,	 473	 psoriasis	 patients	 without	 PsA	 were	 available.	 The	 AUC	 of	 the	 CONTEST	
questionnaires	 ranged	 between	 0.67-0.69	 and	 sensitivities	 between	 0.30-0.51	 in	 our	 primary	 care	
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PASE(0.66)	and	EARP(0.87)	performed	better	than	the	CONTEST	questionnaires,	whereas	with	regard	
to	specificity	the	CONTEST	performed	slightly	better	than	the	PEST	(0.71),	PASE	(0.57)	and	EARP	(0.34).	
In	our	primary	care	setting	we	therefore	conclude	that	 the	performance	of	 the	CONTEST	does	not	
exceed	the	performance	of	the	PEST,	PASE	or	EARP.	
	
Chapter	9	provides	a	general	discussion	about	our	results.	The	discussion	focuses	on	generalizability	
of	our	results	and	recommendations	for	future	research.	In	this	chapter	we	also	describe	possibilities	
to	 improve	 awareness	 for	 SpA	 and	 ideas	 for	 research	 to	 investigate	 the	best	way	 to	 improve	 this	
awareness.	
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Vroegherkenning	van	SpA	is	belangrijk,	aangezien	vroege	en	adequate	behandeling	leidt	tot	betere	
uitkomsten	op	de	lange	termijn.	
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patienten	uit	hun	praktijk	op	basis	van	 ICPC	code	en	nodigden	hen	uit	om	mee	te	doen.	Patienten	
konden	deelenemen	als	ze	18	jaar	of	ouder	waren,	een	diagnose	psoriasis	hadden	en	musculoskeletale	
klachten	hadden.	Er	deden	97	huisartsen	mee,	die	samen	2564	patienten	met	psoriasis	in	hun	praktijk	
hadden,	van	wie	841	geschikt	waren	en	mee	wilden	doen.	Deelnemende	patienten	vulden	een	set	
vragenlijsten	 in	 voordat	 ze	 klinisch	 geevalueerd	 warden.	 De	 klinische	 evaluatie	 bestond	 uit	 een	
uitgebreide	 anamnese	 en	 lichamelijk	 onderzoek	 van	 de	 huid,	 gewrichten,	 pezen	 en	 rug.	 Als	 er	
aanwijzingen	waren	voor	een	onderliggende	reumatische	ziekte	werden	patienten	geadviseerd	zich	
naar	een	reumatoloog	te	 laten	verwijzen.	PsA	werd	gediagnosticeerd	door	een	reumatoloog	bij	17	
patienten	en	64	patienten	hadden	al	een	diagnose	PsA	voordat	de	studie	begon.	Tezamen	leidt	dit	tot	
een	prevalentie	van	3,2%.	Naast	deze	gediagnosticeerde	patienten,	bleken	er	36	patienten	te	zijn	die	
enthesitis	 hadden,	 bevestigd	 met	 echo,	 die	 op	 basis	 van	 de	 CASPAR	 criteria	 zouden	 kunnen	
classificeren	als	PsA.	Als	je	deze	patienten	mee	zou	nemen	in	je	prevalentie,	zou	je	op	een	prevalentie	
van	4.6%	uitkomen.	De	prevalentie	van	musculoskeletale	klachten	was	met	32.6%	vergelijkbaar	met	
de	prevalentie	van	de	algemene	Nederlandse	bevolking.	
	
Zoals	hierboven	beschreven	waren	er	patienten	met	enkel	enthesitis	klachten.	In	hoofdstuk	3	worden	
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een	 ingangscriteria,	 wat	 er	 toe	 leidt	 dat	 patienten	 met	 enthesitis	 geclassificeerd	 zouden	 kunnen	
worden	als	PsA.	Het	problem	is	echter	dat	er	geen	duidelijke	definitie	is	van	enthesitis.	In	deze	studie	
hebben	we	daarom	een	echo	gemaakt	van	de	entheses	van	patienten	die	klinisch	verdacht	werden	
van	enthesitis,	zoals	gedefineerd	met	de	LEI	en	MASES	scores.	In	total	waren	er	111	patienten	met	
een	pijnlijke	enthesis	die	een	echo	kregen	van	7	entheses	zoals	omschreven	in	de	MASEI	score.	Onze	
definitie	 van	klinisch	 relevante	enthesitis	was	een	combinatie	 van	actieve	 inflammatie	op	de	echo	
(positief	power	Doppler	signaal	of	in	het	geval	van	de	fascia	plantaris	verdikking)	in	combinatie	met	
een	pijnlijke	enthesis	op	dezelfde	plek.	Volgens	deze	definitie	hadden	40	patienten	(36%)	een	klinisch	
relevante	 ontsteking	 van	 de	 enthesis.	 De	 meest	 voorkomende	 plekken	 waren	 de	 knie	 en	 de	
aponeurosis	plantaris.	Structurele	afwijkingen	werden	gevonden	bij	95%	van	de	psoriasis	patienten,	
onafhankelijk	van	hun	klinische	presentatie.	
	
Naast	patienten	met	psoriasis	hebben	patienten	met	IBD	ook	een	verhoogd	risico	op	het	ontwikkelen	
van	SpA.	Om	de	grootte	van	dit	problem	in	kaart	te	brengen,	hebben	we	een	systematic	review	en	
meta-analyse	opgezet	naar	de	prevalentie	en	incidentie	van	axiale	en	perifere	manifestaties	van	SpA	
in	patienten	met	IBD,	zoals	beschreven	in	hoofdstuk	4.	In	samenwerking	met	de	medische	bibliotheek	
werd	 een	 uitgebreide	 zoekstrategie	 opgezet,	 die	 leidde	 tot	 een	 total	 aantal	 van	 4845	 potentieel	
relevante	 artikelen.	 Na	 het	 screenen	 van	 de	 titels	 en	 abstracts	 en	 daaropvolgende	 de	 complete	
artikelen,	bleven	er	60	relevante	artikelen	over	die	werden	geincludeerd.	Beoordeling	van	de	kwaliteit	
van	de	geincludeerde	artikelen	middels	een	standaard	score	system	liet	matige	algehele	kwaliteit	zien.	
De	prevalentie	van	axiale	manifestaties	van	SpA	bij	patienten	met	IBD	werd	genoemd	in	53	artikelen.	
De	gepoolde	prevalentie	was	11%	voor	sacroiliitis	en	3%	voor	het	subtype	ankylosing	spondylitis.	De	
prevalentie	 van	 perifere	 artritis	 werd	 beschreven	 in	 44	 studies,	 wat	 leidde	 tot	 een	 gepoolde	
prevalentie	van	14%.	De	prevalentie	van	de	andere	perifere	manifestaties	enthesitis	en	dactylitis	werd	
in	maar	weinig	artikelen	beschreven,	met	een	prevalentie	varierend	van	1-54%	voor	enthesitis	en	0-
5%	voor	dactylitis.	Er	waren	slechts	drie	studies	die	de	incidentie	van	SpA	bij	IBD	patienten	beschreven,	
met	cumulatieve	incidenties	van	0.48	in	10	jaar	tot	0.22	in	30	jaar.	
	
We	 weten	 nu	 dat	 SpA	 relatief	 vaak	 voorkomt	 bij	 patienten	 met	 IBD.	 Het	 meerendeel	 van	 deze	
patienten	zal	eerst	last	krijgen	van	musculoskeletale	klachten	voor	ze	gediagnosticeerd	worden	met	
SpA.	In	hoofdstuk	5	kijken	we	naar	de	last	van	deze	musculoskeletale	klachten	bij	patienten	met	IBD.	
We	hebben	 een	 cross-sectionele	 studie	 opgezet	 gebaseerd	 op	 vragenlijsten	 bij	 patienten	met	 IBD	
tussen	 de	 18	 en	 55	 jaar.	 De	 vragenlijsten	 gingen	 over	 het	 al	 dan	 niet	 aanwezig	 zijn	 van	
musculoskeletale	klachten,	maar	ook	over	kwaliteit	van	leven	en	het	werkend	leven.	In	total	hebben	
338	de	vragenlijsten	 ingevuld,	van	wie	45.6%	de	ziekte	van	Crohn	(CD)	had	en	45%	colitis	ulcerosa	
(UC).	 De	 gemiddelde	 leeftijd	 van	 de	 deelnemers	 was	 42.3±9	 jaar	 en	 25.4%	 waren	 man.	
Musculoskeletale	klachten	kwamen	erg	veel	voor	met	een	prevalentie	van	81.1%,	met	een	hogere	
prevalentie	bij	CD	dan	bij	UC.	In	het	algemeen	gaven	patienten	met	IBD	and	musculoskeletal	klachten	
een	significant	lagere	kwaliteit	van	leven	aan	op	zowel	de	IBDW	als	de	SF36	vragenlijsten.	Er	werden	
ook	 verschullen	 gezien	 in	 werken	 en	 werkproductiviteit,	 waar	 bleek	 dat	 IBD	 patienten	 met	 ook	
msuculoskeletale	klachten	vaker	werkeloos	of	arbeidsongeschikt	waren	en	een	lagere	productiviteit	
tijdens	het	werk	hadden.	Met	deze	studie	hebben	we	aangetoond	dat	musculoskeletale	klachten	een	
veel	voorkomende	extraintestinale	manifestatie	zijn	met	significante	invloed	op	kwaliteit	van	leven	en	
het	werkend	leven.	Interessant	was	dat	bleek	da	teen	verminderde	kwaliteit	van	leven	bijna	geheel	
werd	beinvloed	door	musculoskeletale	klachten.	
	
In	 het	 eerste	 gedeelte	 van	 dit	 proefschrift	 hebben	 we	 de	 prevalentie	 van	 SpA	 in	 risicogroepen	
vastgesteld	en	de	impact	hiervan.	We	weten	dat	vroegherkenning	van	deze	patienten	leidt	tot	eerdere	
behandeling	en	daarmee	tot	betere	uitkomsten	op	de	 lange	 termijn.	Om	deze	vroegherkenning	 te	
verbeteren,	moet	er	awareness	komen	voor	SpA.	In	hoofdstuk	6	beschrijven	we	de	resultaten	van	de	
AppSpA	studie	welke	opgezet	is	om	de	huidige	awarenesss	voor	SpA	bij	huisartsen	en	patienten	met	
psoriasis	 of	 IBD	 in	 kaart	 te	 brengen.	 We	 ontwikkelden	 een	 enquete	 voor	 huisartsen,	 gericht	 op	
herkenning	 van	 inflammatoire	 symptomen	 en	 symptomen	 specifiek	 voor	 SpA.	 We	 hebben	 949	
huisartsen	uitgenodigd	om	deel	te	nemen,	van	wie	312	de	enquete	teruggestuurd	hebben	(response	
32.9%),	 van	wie	op	hen	beurt	181	huisartsen	de	enquete	 ingevuld	hadden.	ALs	we	kijken	naar	de	
herkenning	van	symptomen	van	inflammatoire	klachten,	bleek	dat	met	name	de	klassieke	symptomen	
zoals	 ochtendstijfheid	 en	 verbetering	 van	 de	 klachten	 door	 NSAIDs	 herkend	 werden.	 Andere	
symptomen	 zoals	 verbetering	 van	 de	 pijn	 bij	 beweging	werden	 slecht	 herkend.	 Bijna	 60%	 van	 de	
huisartsen	 herkenden	minder	 dan	 de	 helft	 van	 de	 kenmerken	 duidend	 op	 inflammatoire	 perifere	
gewrichtsklachten.	Voor	 inflammatoire	axiale	klachten	 lag	dit	percentage	op	40%.	De	meerderheid	
van	de	huisarts	associeerden	SpA	alleen	met	axiale	SpA.	In	het	patientendeel	van	deze	studie	zagen	
we	dat	minder	dan	de	helft	(42.6%)	van	de	patienten	met	psoriasis	of	IBD	op	de	hoogte	was	van	hun	
verhoogde	risico	op	het	ontwikkelen	van	SpA.	Als	patienten	hiervan	wel	op	de	hoogte	waren,	had	het	
merendeel	ditz	elf	opgezocht	en	was	niet	geinformeerd	door	een	arts.	De	resultaten	van	deze	studie	
laten	zien	dat	er	ruimte	is	voor	verbetering	in	de	awareness	voor	SpA	bij	zowle	huisartsen	als	patienten	
met	een	verhoogd	risico.	
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een	 ingangscriteria,	 wat	 er	 toe	 leidt	 dat	 patienten	 met	 enthesitis	 geclassificeerd	 zouden	 kunnen	
worden	als	PsA.	Het	problem	is	echter	dat	er	geen	duidelijke	definitie	is	van	enthesitis.	In	deze	studie	
hebben	we	daarom	een	echo	gemaakt	van	de	entheses	van	patienten	die	klinisch	verdacht	werden	
van	enthesitis,	zoals	gedefineerd	met	de	LEI	en	MASES	scores.	In	total	waren	er	111	patienten	met	
een	pijnlijke	enthesis	die	een	echo	kregen	van	7	entheses	zoals	omschreven	in	de	MASEI	score.	Onze	
definitie	 van	klinisch	 relevante	enthesitis	was	een	combinatie	 van	actieve	 inflammatie	op	de	echo	
(positief	power	Doppler	signaal	of	in	het	geval	van	de	fascia	plantaris	verdikking)	in	combinatie	met	
een	pijnlijke	enthesis	op	dezelfde	plek.	Volgens	deze	definitie	hadden	40	patienten	(36%)	een	klinisch	
relevante	 ontsteking	 van	 de	 enthesis.	 De	 meest	 voorkomende	 plekken	 waren	 de	 knie	 en	 de	
aponeurosis	plantaris.	Structurele	afwijkingen	werden	gevonden	bij	95%	van	de	psoriasis	patienten,	
onafhankelijk	van	hun	klinische	presentatie.	
	
Naast	patienten	met	psoriasis	hebben	patienten	met	IBD	ook	een	verhoogd	risico	op	het	ontwikkelen	
van	SpA.	Om	de	grootte	van	dit	problem	in	kaart	te	brengen,	hebben	we	een	systematic	review	en	
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werd	 een	 uitgebreide	 zoekstrategie	 opgezet,	 die	 leidde	 tot	 een	 total	 aantal	 van	 4845	 potentieel	
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We	 weten	 nu	 dat	 SpA	 relatief	 vaak	 voorkomt	 bij	 patienten	 met	 IBD.	 Het	 meerendeel	 van	 deze	
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Een	 van	 de	 mogelijkheden	 om	 vroegherkenning	 in	 de	 hand	 te	 werken	 is	 het	 inzetten	 van	
screeningtools.	Voor	PsA	zijn	er	diverse	screeningtools	ontwikkeld,	het	meerendeel	in	de	tweede	lijn.	
In	Nederland	hebben	we	echter	een	uitgebreid	eerstelijnszorg	system,	waardoor	deze	hulpmiddelen	
het	 beste	 in	 de	 eerste	 lijn	 ingezet	 kunnen	worden.	 In	hoofdstuk	7	 hebben	we	de	werking	 van	de	
bestaande	screeningtools	onderzocht	in	een	eerstelijns	populatie.	Voor	dit	gedeelte	hebben	we	data	
van	 de	 SENSOR	 studie	 gebruikt	 en	 473	 patienten	 zonder	 diagnose	 van	 PsA	 geincludeerd.	 Deze	
patienten	hebben	de	PEST,	PASE	en	EARP	vragenlijsten	 ingevuld	voordat	ze	een	klinische	evaluatie	
ondergingen.	Bij	53	van	deze	patienten	is	een	diagnose	van	PsA	gesteld	door	de	reumatoloog.	De	PEST	
had	in	deze	stduie	een	sensitiviteit	van	0.68	en	een	specificiteit	van	0.71.	De	PASE	is	gevalideerd	voor	
twee	verschillende	afkapwaarden.	De	afkapwaarde	van	47	leidde	tot	een	sensitiviteit	van	0.59	en	een	
specificiteit	van	0.66,	waar	de	lagere	afkapwaarde	van	44	leidde	tot	een	sensitiviteit	van	0.66	en	een	
specificiteit	van	0.57.	De	EARP	had	een	sensitiviteit	van	0.87	met	een	specificiteit	van	0.34.	In	deze	
studie	lijkt	de	PEST	de	beste	balans	te	hebben	tussen	sensitiviteit	en	specificiteit	om	te	screenen	op	
PsA.	Vanwege	de	relatief	lage	prevalentie	van	PsA	in	de	eerstelijn	zou	het	zinvol	kunnen	zijn	om	alleen	
de	patienten	met	musculoskeletale	klachten	te	screenen.	
	
Zoals	 uit	 hoofdstuk	 7	 blijkt,	 hebben	 de	 bestaande	 screeningtools	 geen	 ideale	 sensitiviteit	 en	
specificiteit.	 Om	 deze	 reden	 heeft	 de	 CONTEST	 studiegroep	 een	 nieuwe	 screeningtool	 opgezet	
gebaseerd	uit	de	best	onderscheidende	vragen	van	bestaande	screeningtools.	In	hoofdstuk	8	hebben	
we	bekeken	of	deze	nieuwe	vragenlijst	meerwaarde	heeft	ten	opzichte	van	de	eerder	ontwikkelde	
vragenlijsten	 in	 de	 eerste	 lijn.	 Data	 van	 de	 SENSOR	 studie	 werd	 gebruikt	 en	 we	 berekenden	
sensitiviteit,	 specificiteit	 en	 area	 under	 the	 curve	 (AUC)	 voor	 de	 diverse	 versies	 van	 de	 CONTEST	
vragenlijst.	Voor	deze	analyse	hadden	we	473	patienten	 zonder	PsA	beschikbaar.	De	AUC	voor	de	
CONTEST	versies	varieerde	 tussen	de	0.67	en	0.69.	De	 sensitiviteit	 in	onze	eerstelijnspopulatie	 lag	
tussen	de	0.30	en	0.51,	met	een	specificiteit	tussen	de	0.74	en	0.86.	Als	we	kijken	naar	sensitiviteit,	
doen	zowel	de	PEST	(0.68)	als	de	PASE	(0.66)	en	de	EARP	(0.87)	het	beter	dan	de	CONTEST,	maar	qua	
specificiteit	 doet	 de	 CONTEST	 het	 beter	 dan	 de	 PEST	 (0.71),	 PASE	 (0.57)	 en	 EARP	 (0.34).	 In	 onze	
eerstelijnspopulatie	zijn	we	tot	de	conclusie	gekomen	dat	de	CONTEST	geen	meerwaarde	heeft	boven	
de	al	bestaande	PEST,	PASE	of	EARP.	
	
Het	laatste	hoofdstuk	van	dit	proefschrift,	hoofdstuk	9,	is	een	algemene	discussie	van	de	resultaten	
beschreven	in	dit	proefschrift.	De	discussie	richt	zich	op	de	generaliseerbaarheid	en	aanbelevlingen	
voor	toekomstig	onderzoek.	In	dit	hoofdstuk	worden	ook	manieren	beschreven	om	de	awareness	voor	
SpA	te	vergroten	en	ideeen	om	dit	in	de	praktijk	te	onderzoeken.	
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In	Nederland	hebben	we	echter	een	uitgebreid	eerstelijnszorg	system,	waardoor	deze	hulpmiddelen	
het	 beste	 in	 de	 eerste	 lijn	 ingezet	 kunnen	worden.	 In	hoofdstuk	7	 hebben	we	de	werking	 van	de	
bestaande	screeningtools	onderzocht	in	een	eerstelijns	populatie.	Voor	dit	gedeelte	hebben	we	data	
van	 de	 SENSOR	 studie	 gebruikt	 en	 473	 patienten	 zonder	 diagnose	 van	 PsA	 geincludeerd.	 Deze	
patienten	hebben	de	PEST,	PASE	en	EARP	vragenlijsten	 ingevuld	voordat	ze	een	klinische	evaluatie	
ondergingen.	Bij	53	van	deze	patienten	is	een	diagnose	van	PsA	gesteld	door	de	reumatoloog.	De	PEST	
had	in	deze	stduie	een	sensitiviteit	van	0.68	en	een	specificiteit	van	0.71.	De	PASE	is	gevalideerd	voor	
twee	verschillende	afkapwaarden.	De	afkapwaarde	van	47	leidde	tot	een	sensitiviteit	van	0.59	en	een	
specificiteit	van	0.66,	waar	de	lagere	afkapwaarde	van	44	leidde	tot	een	sensitiviteit	van	0.66	en	een	
specificiteit	van	0.57.	De	EARP	had	een	sensitiviteit	van	0.87	met	een	specificiteit	van	0.34.	In	deze	
studie	lijkt	de	PEST	de	beste	balans	te	hebben	tussen	sensitiviteit	en	specificiteit	om	te	screenen	op	
PsA.	Vanwege	de	relatief	lage	prevalentie	van	PsA	in	de	eerstelijn	zou	het	zinvol	kunnen	zijn	om	alleen	
de	patienten	met	musculoskeletale	klachten	te	screenen.	
	
Zoals	 uit	 hoofdstuk	 7	 blijkt,	 hebben	 de	 bestaande	 screeningtools	 geen	 ideale	 sensitiviteit	 en	
specificiteit.	 Om	 deze	 reden	 heeft	 de	 CONTEST	 studiegroep	 een	 nieuwe	 screeningtool	 opgezet	
gebaseerd	uit	de	best	onderscheidende	vragen	van	bestaande	screeningtools.	In	hoofdstuk	8	hebben	
we	bekeken	of	deze	nieuwe	vragenlijst	meerwaarde	heeft	ten	opzichte	van	de	eerder	ontwikkelde	
vragenlijsten	 in	 de	 eerste	 lijn.	 Data	 van	 de	 SENSOR	 studie	 werd	 gebruikt	 en	 we	 berekenden	
sensitiviteit,	 specificiteit	 en	 area	 under	 the	 curve	 (AUC)	 voor	 de	 diverse	 versies	 van	 de	 CONTEST	
vragenlijst.	Voor	deze	analyse	hadden	we	473	patienten	 zonder	PsA	beschikbaar.	De	AUC	voor	de	
CONTEST	versies	varieerde	 tussen	de	0.67	en	0.69.	De	 sensitiviteit	 in	onze	eerstelijnspopulatie	 lag	
tussen	de	0.30	en	0.51,	met	een	specificiteit	tussen	de	0.74	en	0.86.	Als	we	kijken	naar	sensitiviteit,	
doen	zowel	de	PEST	(0.68)	als	de	PASE	(0.66)	en	de	EARP	(0.87)	het	beter	dan	de	CONTEST,	maar	qua	
specificiteit	 doet	 de	 CONTEST	 het	 beter	 dan	 de	 PEST	 (0.71),	 PASE	 (0.57)	 en	 EARP	 (0.34).	 In	 onze	
eerstelijnspopulatie	zijn	we	tot	de	conclusie	gekomen	dat	de	CONTEST	geen	meerwaarde	heeft	boven	
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Het	laatste	hoofdstuk	van	dit	proefschrift,	hoofdstuk	9,	is	een	algemene	discussie	van	de	resultaten	
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voor	toekomstig	onderzoek.	In	dit	hoofdstuk	worden	ook	manieren	beschreven	om	de	awareness	voor	
SpA	te	vergroten	en	ideeen	om	dit	in	de	praktijk	te	onderzoeken.	
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geneeskunde	van	het	Maasstad	Ziekenhuis.		
	
Gedurende	dit	oudste	co-schap	bleek	er	een	plek	als	onderzoeker	vrij	te	komen	voor	een	jaar	in	het	
Erasmus	MC	om	de	SENSOR	studie	op	te	zetten.	Onder	begeleiding	van	dr.	J.J.	Luime	en	dr.	A.E.A.M.	
Weel	heeft	zij	toen	gedurende	een	jaar	de	SENSOR	studie	opgezet	en	uitgevoerd.	Dit	project	bleek	
een	mooie	opstap	naar	een	volledig	promotie	traject,	gebaseerd	op	de	data	uit	de	SENSOR	studie	en	
de	nieuw	op	te	zetten	AppSpA	studie.	Het	promotietraject	werd	uitgevoerd	onder	begeleiding	van	
dr.	J.J.	Luime,	dr.	A.E.A.M.	Weel	en	prof.	dr.	J.M.W.	Hazes	en	was	een	samenwerking	tussen	het	
Erasmus	MC,	het	Maasstadziekenhuis	en	The	Dutch	Institute	of	Rheumatology	(TDIOR	BV).	
	
Sinds	1	november	2016	is	zij	begonnen	aan	haar	opleiding	tot	reumatoloog	(opleider	dr.	R.J.E.M.	
Dolhain),	startend	met	de	vooropleiding	interne	geneeskunde	in	het	Maasstad	Ziekenhuis	te	
Rotterdam	(opleider	dr.	M.A.	van	den	Dorpel).	
	
Maren	is	op	4	september	2015	getrouwd	met	Remco	Hof	en	op	15	maart	2017	zijn	zij	ouders	
geworden	van	hun	dochter	Maeve.	
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Eindelijk	kun	je	dan	beginnen	aan	het	schrijven	van	het	dankwoord.	Een	dankwoord	wat	ik	nooit	
verwacht	had	te	schrijven,	aangezien	ik	altijd	heel	hard	geroepen	heb	nooit	te	zullen	gaan	
promoveren.	Wat	ben	ik	blij	dat	ik	deze	stap	toch	genomen	heb	en	dat	er	nu	na	een	mooi	traject	een	
boekje	ligt.	Graag	wil	ik	diegene	die	een	bijdrage	geleverd	hebben	aan	dit	traject	bedanken.	
	
Allereerst	mijn	promotor,	professor	Hazes.	Beste	Mieke,	bedankt	voor	alle	begeleiding	de	afgelopen	
jaren.	Ondanks	de	altijd	drukke	agenda,	was	er	altijd	tijd	in	te	plannen	voor	overleg	en	tijd	voor	
waardevolle	feedback	op	de	artikelen.	Na	elk	overleg	waren	de	grote	lijnen	weer	duidelijk	en	kon	ik	
met	frisse	moed	weer	verder.	
	
Ik	had	de	eer	om	begeleid	te	worden	door	twee	co-promotoren,	met	een	hele	goede	mix	tussen	
wetenschap	en	kliniek.	
Angelique,	ik	herinner	me	nog	een	gesprek	tijdens	mijn	oudste	co-schap	waarin	je	zei	het	is	gelukt	je	
enthousiast	te	maken	voor	het	vak	als	reumatoloog,	nu	nog	voor	het	onderzoek.	Toen	zei	ik	dat	dat	
waarschijnlijk	niet	ging	lukken,	maar	nu	ligt	er	toch	een	boekje.	Iets	wat	begon	met	een	project	van	
een	jaar,	is	uitgegroeid	tot	een	volledig	promotietraject.	Bij	elk	overleg	keek	jij	altijd	weer	naar	het	
verband	met	de	kliniek,	wat	heel	waardevol	geweest	is	voor	mijn	stukken.	Bedankt	voor	dit	alles.	
Jolanda,	ik	heb	ontzettend	veel	van	je	geleerd	qua	epidemiologie	en	statistiek.	Toen	ik	begon	wist	ik	
nog	net	wat	een	p-waarde	was,	maar	mede	dankzij	jou	is	mijn	kennis	op	dit	vlak	wel	groter	
geworden.	Ik	heb	bewondering	voor	de	manier	waarop	jij	dingen	altijd	weer	vanuit	een	andere	hoek	
kunt	bekijken,	waardoor	er	altijd	weer	iets	leuks	uit	kwam	om	toe	te	voegen	aan	een	artikel.	Bedankt	
voor	al	je	uitleg	en	begeleiding.	
	
Geachte	professor	Bindels,	professor	Prens	en	dr.	Van	der	Horst-Bruinsma;	hartelijk	dank	voor	het	
plaatsnemen	in	de	kleine	commissie.	Ook	de	leden	van	de	grote	commissie	wil	ik	hartelijk	danken	
voor	hun	aanwezigheid.	
	
Klinisch	onderzoek	doen	is	niet	mogelijk	zonder	patiënten.	Ik	wil	daarom	alle	patiënten	die	
deelgenomen	hebben	aan	zowel	de	SENSOR	als	de	AppSpA	studie	hartelijk	bedanken.	Ook	de	
huisartsen	die	bereid	waren	hun	patiënten	voor	ons	onderzoek	uit	te	nodigen	wil	ik	hiervoor	
bedanken.	Tot	slot	wil	ik	de	Psoriasis	Vereniging	Nederland	(PVN)	en	de	Crohn	en	Colitis	Ulcerosa	
Vereniging	Nederland	(CCUVN)	bedanken	voor	hun	medewerking	aan	de	AppSpA	studie.	
	
Voor	de	studies	moesten	er	heel	veel	huisartsen	gebeld	worden,	brieven	verstuurd	worden	en	
vragenlijsten	ingevoerd	worden.	Zonder	een	team	van	fijne	studenten	had	dit	een	stuk	meer	tijd	
gekost.	Ilse,	Bart,	Jacqueline,	Marije,	Lisa	en	Pauline,	heel	veel	dank	voor	jullie	hulp.	
	
Beste	Michael,	een	groot	deel	van	dit	traject	ben	jij	mijn	baas	geweest.	Wat	was	het	fijn	om	op	die	
manier	toch	de	mogelijkheid	te	hebben	dit	onderzoek	te	doen.	Bijna	alles	was	altijd	mogelijk	en	door	
de	kleinschaligheid	van	jouw	bedrijf	ook	vaak	eenvoudig	te	regelen.	Dank	je	wel	voor	alle	
mogelijkheden!	
	
Beste	co-auteurs,	bedankt	voor	jullie	waardevolle	feedback	op	mijn	artikelen.	Hierdoor	werd	elk	
artikel	vanuit	meerdere	hoeken	en	ook	specialismen	bekeken	en	hierdoor	zijn	ze	zeker	beter	
geworden.	
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mogelijkheden!	
	
Beste	co-auteurs,	bedankt	voor	jullie	waardevolle	feedback	op	mijn	artikelen.	Hierdoor	werd	elk	
artikel	vanuit	meerdere	hoeken	en	ook	specialismen	bekeken	en	hierdoor	zijn	ze	zeker	beter	
geworden.	
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Naast	patiënten	heb	je	ook	zeker	collega’s	nodig	tijdens	een	promotietraject.	
Marie-Louise,	toen	ik	begon	aan	de	SENSOR	studie	wist	ik	niks	van	onderzoek	doen.	Jij	hebt	mij	
hierin	wegwijs	gemaakt	en	ik	heb	veel	van	je	geleerd,	dank	daarvoor.	Bedankt	ook	voor	de	prettige	
samenwerking	tijdens	de	rest	van	de	SENSOR	studie	
Esther,	bedankt	voor	de	prettige	samenwerking	in	de	SENSOR	studie.	We	hebben	veel	patienten	
gezien,	maar	er	was	altijd	tijd	voor	een	gezellig	praatje.	
	
 “It is more fun to talk with someone who doesn't use long, difficult words but rather short, easy 
words like "What about lunch?” - Winnie the Pooh 
 
Ik	denk	dat	er	geen	zin	is	die	meer	van	toepassing	is	op	de	club	promovendi	van	de	reumatologie	
destijds.	We	hebben	hard	gewerkt,	maar	het	was	ook	altijd	gezellig.	Gewoon	even	lunchen	in	het	
park,	high-tea-en	of	sushi	eten	en	even	niet	over	het	onderzoek	praten.		
Annelieke,	altijd	nuchter	en	altijd	in	de	hoop	dat	het	computerscherm	ooit	wat	terug	gaat	zeggen.	Ik	
vind	het	heel	leuk	voor	je	dat	je	toch	weer	een	baan	gevonden	hebt	op	de	afdeling	en	nog	leuker	dat	
je	binnenkort	nog	zo’n	heerlijk	mannetje	mag	verwelkomen.	
Hilal,	wat	heb	ik	veel	om	en	met	jou	gelachen.Van	hoe	we	je	toen	je	zwanger	was	moesten	uitleggen	
waar	een	romper	goed	voor	is	tot	het	aantrekken	van	precies	de	juiste	outfit	voor	de	foto’s	in	het	
coloseum.	Nog	even	en	jij	mag	ook	weer	de	kliniek	in.	Het	zal	even	wennen	zijn,	maar	ik	weet	zeker	
dat	je	het	kan!	
Jenny,	soms	op	de	fertiliteit,	soms	op	de	reumatologie	maar	altijd	bereid	om	een	vraag	te	
beantwoorden.	Ook	als	we	samen	NIHES	hadden,	was	je	altijd	bereid	om	even	wat	extra	uit	te	
leggen,	dank	je	wel	daarvoor!	
Martijn,	de	statistiek-vraagbak	van	de	afdeling.	Ik	vind	het	zo	knap	hoe	jij	na	een	halve	uitleg	over	
een	bepaald	onderzoek	precies	weet	hoe	je	het	statistisch	gezien	moet	aanpakken	en	waar	de	
valkuilen	zitten.	Ik	ben	blij	dat	je	nu	zo	op	je	plek	zit	in	het	Maasstad.	
Kim,	eerst	als	keuze-onderzoek	student	en	later	als	college	promovenda.	Je	bleef	altijd	vrolijk	en	
positief,	ondanks	dat	het	instromen	in	zo’n	groot	onderzoek	niet	altijd	makkelijk	was.		
Esther,	wat	was	het	fijn	om	zo’n	ervaren	iemand	op	ons	fijne	Na607	te	hebben.	Ervaren	qua	
onderzoekster,	qua	moeder	en	als	persoon.	Je	had	altijd	een	luisterend	oor	en	vaak	nog	een	
oplossing	ook.	Ik	hoop	dat	je	helemaal	op	je	plek	zit	in	je	nieuwe	functie.	
Florentien,	als	collega-promovendi	hebben	we	elkaar	niet	heel	lang	meegemaakt,	maar	nu	als	
collega’s	in	de	voorlopleiding	een	stuk	meer.	Ik	vind	het	knap	hoe	je	je	met	twee	kleine	kindjes	door	
de	vooropleiding	heen	slaat.	Hou	vol,	je	bent	er	bijna!	
Ook	alle	andere	collega’s	op	de	afdeling	Reumatologie	bedankt	voor	alle	gezelligheid.		
	
Joyce,	zonder	jou	valt	heel	de	afdeling	in	duigen.	Dank	je	wel	voor	al	het	regelwerk	om	toch	altijd	
een	gaatje	te	vinden	in	de	agenda	van	Mieke.	Ook	bedankt	voor	het	oppassen	op	Maeve,	zodat	ik	
rustig	even	met	Mieke	kon	overleggen	op	mijn	parttime	dag.	
Ron,	bedankt	voor	al	het	werk	wat	je	doet	om	alle	data	goed	bij	elkaar	te	houden.	Hierdoor	was	je	
de	reddende	engel	toen	mijn	harde	schijf	er	mee	ophield	en	ik	een	groot	stuk	van	mijn	promotie	
kwijt	leek	te	zijn,	dank	je	wel	hiervoor!	
	
	
	
Dan	nog	twee	hele	speciale	collega’s	en	vriendinnen,	ofwel	mijn	paranimfen.	
Lonneke,	ooit	begonnen	we	samen	in	hetzelfde	Eureka	week	groepje.	Vervolgens	gingen	we	tijdens	
de	studie	ieder	onze	eigen	weg	om	uiteindelijk	weer	samen	in	hetzelfde	co-groepje	te	belanden.	Je	
hebt	altijd	een	beetje	op	me	voorgelopen	en	bent	daarom	ook	altijd	een	voorbeeld	voor	me	
geweest.	Mede	dankzij	jou	durfde	ik	te	kiezen	voor	een	promotieonderzoek	en	hebben	we	heel	wat	
jaar	gezellig	op	Na607	doorgebracht.	Van	vrijgezellenfeest	tot	trouwen	en	een	eerste	huis	kopen,	
alles	kwam	voorbij	tussen	het	werken	door.	Ook	de	angst	die	we	allebei	hadden	om	weer	terug	de	
kliniek	in	te	gaan.	Ook	daar	liep	jij	op	me	voor	en	was	het	voor	mij	een	hele	geruststelling	dat	jij	er	al	
was	toen	ik	in	het	Maasstad	begon.	Ondertussen	hebben	we	allebei	onze	plek	weer	gevonden	in	de	
kliniek.	Ik	heb	veel	bewondering	voor	het	feit	dat	je	uiteindelijk	je	gevoel	gevolgd	hebt	en	naar	de	
Interne	Geneeskunde	bent	overgestapt,	die	keuze	was	niet	makkelijk.		
Myrthe,	wij	zijn	pas	echt	gaan	samenwerken	voor	het	SENSOR	echo	onderzoek.	Jouw	brabantse	
gezelligheid	werkte	gelijk	aanstekelijk.	Ik	denk	ook	oprecht	dat	ik	jou	nog	nooit	in	de	stress	heb	
gezien,	zelf	vlak	voor	je	eigen	promotie	leek	je	de	rust	zelve.	Naast	het	onderzoek,	kwam	jij	vaak	
meerdere	keren	per	dag	even	langs	bij	ons	op	de	kamer	ernaast	voor	een	praatje.	Ook	hebben	we	
heel	veel	leuke	reisjes	gemaakt	naar	congressen,	maar	altijd	nog	een	paar	dagen	erbij	als	
minivakantie.	Wat	is	het	dan	een	geluk	dat	je	een	collega	hebt	waarmee	het	zo	goed	klikt	dat	dit	
gewoon	altijd	een	feestje	was.	Ik	heb	bewondering	voor	hoe	je	elke	dag	maar	weer	in	die	trein	heen	
en	weer	vanuit	Eindhoven	naar	Rotterdam	kwam,	ik	was	het	allang	zat	geweest.	Ik	hoop	dat	je	je	
plek	gaat	vinden	in	je	nieuwe	functie.	Ondanks	de	afstand,	hoop	ik	dat	we	elkaar	nog	vaak	blijven	
zien,	Tijmen	en	Maeve	moeten	elkaar	natuurlijk	wel	een	beetje	leren	kennen	voor	ze	gaan	trouwen	
;-).	
	
Na	bijna	4	jaar	onderzoek	doen,	komt	daar	dan	ook	de	tijd	dat	je	terug	de	kliniek	in	gaat.	In	mijn	
geval	mocht	ik	aan	de	opleiding	beginnen	in	het	Maasstad	Ziekenhuis.	Ondanks	dat	ik	er	wel	een	
beetje	tegen	op	zag,	had	ik	me	geen	betere	plek	kunnen	wensen.	Bedankt	dat	jullie	mij	weer	wegwijs	
gemaakt	hebben	in	de	kliniek	en	voor	de	fijne	samenwerking.	
	
Lieve	meiden	van	Schravenlant;	Myrthe,	Carmen,	Laura,	Julia,	Joanne,	Jessie,	Merel,	Sanne,	Sanne,	
Nina	&	Nouchka,	hoe	bijzonder	dat	we	elkaar	na	al	die	jaren	nog	zo	veel	zien!	We	kennen	elkaar	al	
vanaf	de	eerste	klas	middelbare	school	en	ondanks	dat	we	daarna	allemaal	onze	eigen	weg	gegaan	
zijn,	hebben	we	nog	veel	contact.	Ik	hoop	dat	onze	jaarlijkse	weekendjes	weg	nog	lang	stand	
houden.	Laten	we	ook	het	MMD	weer	meer	leven	inblazen!	
Manon,	wij	kennen	elkaar	nog	vanaf	de	basisschool	in	het	altijd	fijne	Overschie!	We	zien	elkaar	niet	
meer	zo	veel	als	vroeger,	maar	toch	is	het	altijd	gezellig.	Snel	weer	een	keertje	sushi	en	bioscoop!	
	
Lieve	Toos,	Chris	&	Mara,	jullie	ken	ik	ondertussen	al	meer	dan	de	helft	van	mijn	leven.	Ondertussen	
dus	meer	familie	dan	schoonfamilie.	Bedankt	voor	alle	gezelligheid	altijd	en	ook	voor	het	oppassen	
op	Maeve.	
	
Lieve	papa	en	mama,	bedankt	voor	alles.	Er	komt	geen	eind	aan	de	lijst	met	dingen	waar	ik	jullie	
dankbaar	voor	ben.	Jullie	hebben	ons	alle	mogelijkheden	gegeven	om	uit	te	groeien	tot	wie	we	nu	
zijn.	Ook	nu	staan	jullie	altijd	voor	ons	klaar	om	op	Maeve	te	passen,	een	muurtje	te	verven	of	een	
traphekje	op	te	hangen.	Ik	hou	van	jullie.	
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Naast	patiënten	heb	je	ook	zeker	collega’s	nodig	tijdens	een	promotietraject.	
Marie-Louise,	toen	ik	begon	aan	de	SENSOR	studie	wist	ik	niks	van	onderzoek	doen.	Jij	hebt	mij	
hierin	wegwijs	gemaakt	en	ik	heb	veel	van	je	geleerd,	dank	daarvoor.	Bedankt	ook	voor	de	prettige	
samenwerking	tijdens	de	rest	van	de	SENSOR	studie	
Esther,	bedankt	voor	de	prettige	samenwerking	in	de	SENSOR	studie.	We	hebben	veel	patienten	
gezien,	maar	er	was	altijd	tijd	voor	een	gezellig	praatje.	
	
 “It is more fun to talk with someone who doesn't use long, difficult words but rather short, easy 
words like "What about lunch?” - Winnie the Pooh 
 
Ik	denk	dat	er	geen	zin	is	die	meer	van	toepassing	is	op	de	club	promovendi	van	de	reumatologie	
destijds.	We	hebben	hard	gewerkt,	maar	het	was	ook	altijd	gezellig.	Gewoon	even	lunchen	in	het	
park,	high-tea-en	of	sushi	eten	en	even	niet	over	het	onderzoek	praten.		
Annelieke,	altijd	nuchter	en	altijd	in	de	hoop	dat	het	computerscherm	ooit	wat	terug	gaat	zeggen.	Ik	
vind	het	heel	leuk	voor	je	dat	je	toch	weer	een	baan	gevonden	hebt	op	de	afdeling	en	nog	leuker	dat	
je	binnenkort	nog	zo’n	heerlijk	mannetje	mag	verwelkomen.	
Hilal,	wat	heb	ik	veel	om	en	met	jou	gelachen.Van	hoe	we	je	toen	je	zwanger	was	moesten	uitleggen	
waar	een	romper	goed	voor	is	tot	het	aantrekken	van	precies	de	juiste	outfit	voor	de	foto’s	in	het	
coloseum.	Nog	even	en	jij	mag	ook	weer	de	kliniek	in.	Het	zal	even	wennen	zijn,	maar	ik	weet	zeker	
dat	je	het	kan!	
Jenny,	soms	op	de	fertiliteit,	soms	op	de	reumatologie	maar	altijd	bereid	om	een	vraag	te	
beantwoorden.	Ook	als	we	samen	NIHES	hadden,	was	je	altijd	bereid	om	even	wat	extra	uit	te	
leggen,	dank	je	wel	daarvoor!	
Martijn,	de	statistiek-vraagbak	van	de	afdeling.	Ik	vind	het	zo	knap	hoe	jij	na	een	halve	uitleg	over	
een	bepaald	onderzoek	precies	weet	hoe	je	het	statistisch	gezien	moet	aanpakken	en	waar	de	
valkuilen	zitten.	Ik	ben	blij	dat	je	nu	zo	op	je	plek	zit	in	het	Maasstad.	
Kim,	eerst	als	keuze-onderzoek	student	en	later	als	college	promovenda.	Je	bleef	altijd	vrolijk	en	
positief,	ondanks	dat	het	instromen	in	zo’n	groot	onderzoek	niet	altijd	makkelijk	was.		
Esther,	wat	was	het	fijn	om	zo’n	ervaren	iemand	op	ons	fijne	Na607	te	hebben.	Ervaren	qua	
onderzoekster,	qua	moeder	en	als	persoon.	Je	had	altijd	een	luisterend	oor	en	vaak	nog	een	
oplossing	ook.	Ik	hoop	dat	je	helemaal	op	je	plek	zit	in	je	nieuwe	functie.	
Florentien,	als	collega-promovendi	hebben	we	elkaar	niet	heel	lang	meegemaakt,	maar	nu	als	
collega’s	in	de	voorlopleiding	een	stuk	meer.	Ik	vind	het	knap	hoe	je	je	met	twee	kleine	kindjes	door	
de	vooropleiding	heen	slaat.	Hou	vol,	je	bent	er	bijna!	
Ook	alle	andere	collega’s	op	de	afdeling	Reumatologie	bedankt	voor	alle	gezelligheid.		
	
Joyce,	zonder	jou	valt	heel	de	afdeling	in	duigen.	Dank	je	wel	voor	al	het	regelwerk	om	toch	altijd	
een	gaatje	te	vinden	in	de	agenda	van	Mieke.	Ook	bedankt	voor	het	oppassen	op	Maeve,	zodat	ik	
rustig	even	met	Mieke	kon	overleggen	op	mijn	parttime	dag.	
Ron,	bedankt	voor	al	het	werk	wat	je	doet	om	alle	data	goed	bij	elkaar	te	houden.	Hierdoor	was	je	
de	reddende	engel	toen	mijn	harde	schijf	er	mee	ophield	en	ik	een	groot	stuk	van	mijn	promotie	
kwijt	leek	te	zijn,	dank	je	wel	hiervoor!	
	
	
	
Dan	nog	twee	hele	speciale	collega’s	en	vriendinnen,	ofwel	mijn	paranimfen.	
Lonneke,	ooit	begonnen	we	samen	in	hetzelfde	Eureka	week	groepje.	Vervolgens	gingen	we	tijdens	
de	studie	ieder	onze	eigen	weg	om	uiteindelijk	weer	samen	in	hetzelfde	co-groepje	te	belanden.	Je	
hebt	altijd	een	beetje	op	me	voorgelopen	en	bent	daarom	ook	altijd	een	voorbeeld	voor	me	
geweest.	Mede	dankzij	jou	durfde	ik	te	kiezen	voor	een	promotieonderzoek	en	hebben	we	heel	wat	
jaar	gezellig	op	Na607	doorgebracht.	Van	vrijgezellenfeest	tot	trouwen	en	een	eerste	huis	kopen,	
alles	kwam	voorbij	tussen	het	werken	door.	Ook	de	angst	die	we	allebei	hadden	om	weer	terug	de	
kliniek	in	te	gaan.	Ook	daar	liep	jij	op	me	voor	en	was	het	voor	mij	een	hele	geruststelling	dat	jij	er	al	
was	toen	ik	in	het	Maasstad	begon.	Ondertussen	hebben	we	allebei	onze	plek	weer	gevonden	in	de	
kliniek.	Ik	heb	veel	bewondering	voor	het	feit	dat	je	uiteindelijk	je	gevoel	gevolgd	hebt	en	naar	de	
Interne	Geneeskunde	bent	overgestapt,	die	keuze	was	niet	makkelijk.		
Myrthe,	wij	zijn	pas	echt	gaan	samenwerken	voor	het	SENSOR	echo	onderzoek.	Jouw	brabantse	
gezelligheid	werkte	gelijk	aanstekelijk.	Ik	denk	ook	oprecht	dat	ik	jou	nog	nooit	in	de	stress	heb	
gezien,	zelf	vlak	voor	je	eigen	promotie	leek	je	de	rust	zelve.	Naast	het	onderzoek,	kwam	jij	vaak	
meerdere	keren	per	dag	even	langs	bij	ons	op	de	kamer	ernaast	voor	een	praatje.	Ook	hebben	we	
heel	veel	leuke	reisjes	gemaakt	naar	congressen,	maar	altijd	nog	een	paar	dagen	erbij	als	
minivakantie.	Wat	is	het	dan	een	geluk	dat	je	een	collega	hebt	waarmee	het	zo	goed	klikt	dat	dit	
gewoon	altijd	een	feestje	was.	Ik	heb	bewondering	voor	hoe	je	elke	dag	maar	weer	in	die	trein	heen	
en	weer	vanuit	Eindhoven	naar	Rotterdam	kwam,	ik	was	het	allang	zat	geweest.	Ik	hoop	dat	je	je	
plek	gaat	vinden	in	je	nieuwe	functie.	Ondanks	de	afstand,	hoop	ik	dat	we	elkaar	nog	vaak	blijven	
zien,	Tijmen	en	Maeve	moeten	elkaar	natuurlijk	wel	een	beetje	leren	kennen	voor	ze	gaan	trouwen	
;-).	
	
Na	bijna	4	jaar	onderzoek	doen,	komt	daar	dan	ook	de	tijd	dat	je	terug	de	kliniek	in	gaat.	In	mijn	
geval	mocht	ik	aan	de	opleiding	beginnen	in	het	Maasstad	Ziekenhuis.	Ondanks	dat	ik	er	wel	een	
beetje	tegen	op	zag,	had	ik	me	geen	betere	plek	kunnen	wensen.	Bedankt	dat	jullie	mij	weer	wegwijs	
gemaakt	hebben	in	de	kliniek	en	voor	de	fijne	samenwerking.	
	
Lieve	meiden	van	Schravenlant;	Myrthe,	Carmen,	Laura,	Julia,	Joanne,	Jessie,	Merel,	Sanne,	Sanne,	
Nina	&	Nouchka,	hoe	bijzonder	dat	we	elkaar	na	al	die	jaren	nog	zo	veel	zien!	We	kennen	elkaar	al	
vanaf	de	eerste	klas	middelbare	school	en	ondanks	dat	we	daarna	allemaal	onze	eigen	weg	gegaan	
zijn,	hebben	we	nog	veel	contact.	Ik	hoop	dat	onze	jaarlijkse	weekendjes	weg	nog	lang	stand	
houden.	Laten	we	ook	het	MMD	weer	meer	leven	inblazen!	
Manon,	wij	kennen	elkaar	nog	vanaf	de	basisschool	in	het	altijd	fijne	Overschie!	We	zien	elkaar	niet	
meer	zo	veel	als	vroeger,	maar	toch	is	het	altijd	gezellig.	Snel	weer	een	keertje	sushi	en	bioscoop!	
	
Lieve	Toos,	Chris	&	Mara,	jullie	ken	ik	ondertussen	al	meer	dan	de	helft	van	mijn	leven.	Ondertussen	
dus	meer	familie	dan	schoonfamilie.	Bedankt	voor	alle	gezelligheid	altijd	en	ook	voor	het	oppassen	
op	Maeve.	
	
Lieve	papa	en	mama,	bedankt	voor	alles.	Er	komt	geen	eind	aan	de	lijst	met	dingen	waar	ik	jullie	
dankbaar	voor	ben.	Jullie	hebben	ons	alle	mogelijkheden	gegeven	om	uit	te	groeien	tot	wie	we	nu	
zijn.	Ook	nu	staan	jullie	altijd	voor	ons	klaar	om	op	Maeve	te	passen,	een	muurtje	te	verven	of	een	
traphekje	op	te	hangen.	Ik	hou	van	jullie.	
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Lief	groot	klein	broertje,	lieve	Sven.	Ik	ben	zo	ontzettend	trots	op	je.	Na	alle	omwegen	en	diverse	
studies	die	je	hebt	geprobeerd,	heb	je	het	nu	toch	maar	mooi	voor	elkaar	daar	in	Londen.	Helaas	
zien	we	je	daardoor	wel	een	stuk	minder,	maar	des	te	meer	reden	om	wat	vaker	een	tripje	naar	
Londen	te	boeken.	
Lieve	oma,	wat	vind	ik	het	bijzonder	dat	u	hier	nog	bij	mag	zijn.	Ik	vind	het	heel	knap	hoe	u	op	uw	
leeftijd	alles	nog	zo	goed	weet	te	regelen;	een	kerstdiner	voor	12	personen,	daar	draait	u	uw	hand	
niet	voor	om.	Helaas	kan	opa	hier	niet	meer	bij	zijn,	maar	ik	zie	hem	in	gedachten	glunderen	van	
trots.	
	
Lieve	Remco,	al	zo	lang	samen	en	het	wordt	alleen	maar	leuker.	Jij	hebt	dit	traject	van	begin	tot	eind	
meegemaakt	en	mede	door	jou	is	het	stress-level	tot	nu	toe	redelijk	beperkt	gebleven.	Het	valt	niet	
altijd	mee	om	alle	ballen	in	de	lucht	te	houden	qua	privé,	opleiding	en	een	nog	lopend	
promotietraject,	maar	samen	lukt	het	ons	wel.	Ik	hou	van	je	en	kijk	uit	naar	alle	jaren	die	nog	komen	
gaan!	
Lieve	Maeve,	jij	hebt	ons	leven	nog	zoveel	mooier	gemaakt.	Je	bent	het	beste	wat	ons	is	overkomen	
en	we	genieten	volop	van	elke	nieuwe	stap	die	jij	zet.	
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